Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12587803,unbound fractions,"Protein binding was minimal in both milk and plasma, with unbound fractions of 1 and 0.84, respectively There was little partitioning into milk fat, as demonstrated by the whole milk:skim milk ratio of 0.98.",Hydromorphone transfer into breast milk after intranasal administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,1,287,DB00295,Morphine
,12587803,unbound fractions,"Protein binding was minimal in both milk and plasma, with unbound fractions of 1 and 0.84, respectively There was little partitioning into milk fat, as demonstrated by the whole milk:skim milk ratio of 0.98.",Hydromorphone transfer into breast milk after intranasal administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,0.84,288,DB00295,Morphine
,12587803,M:P ratios,"The observed and predicted M:P ratios +/- SD for hydromorphone were 2.57 +/- 0.47 and 1.11 +/- 0.28, respectively.",Hydromorphone transfer into breast milk after intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,2.57,289,DB00295,Morphine
,12587803,M:P ratios,"The observed and predicted M:P ratios +/- SD for hydromorphone were 2.57 +/- 0.47 and 1.11 +/- 0.28, respectively.",Hydromorphone transfer into breast milk after intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,1.11,290,DB00295,Morphine
,2597363,Concentration,Concentration of plasma AVP increased slightly from 3.8 +/- 1.5 pg/ml after induction and increased 3-fold after sternotomy.,Responses of vasopressin release in patients with cardiopulmonary bypass anesthetized with enflurane and morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597363/),[pg] / [ml],3.8,344,DB00295,Morphine
,29350477,Maximum systemic concentration,Maximum systemic concentration reached in a single horse was 6.98 ng/mL.,Pharmacokinetic evaluation and safety of topical 1% morphine sulfate application on the healthy equine eye. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29350477/),[ng] / [ml],6.98,498,DB00295,Morphine
,23507688,run time,Reversed-phase chromatography using a gradient elution with methanol and 0.04% formic acid solution (pH 3.5) was used for separation in a run time of 5 min.,Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),min,5,1583,DB00295,Morphine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,300.4,1584,DB00295,Morphine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,215.2,1585,DB00295,Morphine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,286.2,1586,DB00295,Morphine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,152.0,1587,DB00295,Morphine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,462.2,1588,DB00295,Morphine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,286.2,1589,DB00295,Morphine
,23507688,response,"The method has the following performance characteristics: a reliable response range of 0.05-80 ng/ml for codeine, M3G and M6G and a response range of 0.05-5.0 ng/ml for morphine with correlation coefficients (r) of >0.997 for all analytes.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),[ng] / [ml],0.05-80,1590,DB00295,Morphine
,23507688,response range,"The method has the following performance characteristics: a reliable response range of 0.05-80 ng/ml for codeine, M3G and M6G and a response range of 0.05-5.0 ng/ml for morphine with correlation coefficients (r) of >0.997 for all analytes.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),[ng] / [ml],0.05-5.0,1591,DB00295,Morphine
,9262341,total clearance,"Compared with sheep with normal kidneys (Milne et al., 1995), renal failure did not alter (P = .11) the mean total clearance of morphine (1.5 +/- 0.3 liters/min); clearance by the kidney was less (P < .001).","Influence of renal failure on the disposition of morphine, morphine-3-glucuronide and morphine-6-glucuronide in sheep during intravenous infusion with morphine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262341/),[l] / [min],1.5,1594,DB00295,Morphine
,26763764,elimination half-life,"Pharmacokinetic evaluation showed that 91% of methadone was cleared during this time, with a mean elimination half-life of 59 hours.","Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26763764/),h,59,2269,DB00295,Morphine
,8032582,half-life,"Furthermore, the similar half-life of both drugs (2-2.5 h) is advantageous for a fixed drug combination.",Pharmacokinetic evaluation of two ibuprofen-codeine combinations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032582/),h,2-2.5,2335,DB00295,Morphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,30,3433,DB00295,Morphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,54,3434,DB00295,Morphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,67,3435,DB00295,Morphine
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,82,3436,DB00295,Morphine
,2917110,elimination half-life,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),min,207,3761,DB00295,Morphine
,2917110,elimination half-life,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),min,153,3762,DB00295,Morphine
,2917110,volume of distribution at steady state,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),l,147,3763,DB00295,Morphine
,2917110,volume of distribution at steady state,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),l,128,3764,DB00295,Morphine
,2917110,volume of distribution at steady state,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),[ml] / [min],587,3765,DB00295,Morphine
,2917110,clearance,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),[ml] / [min],587,3766,DB00295,Morphine
,2917110,clearance,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),[ml] / [min],766,3767,DB00295,Morphine
,2917110,AUC,"The AUC for M3G and M6G (0-180 min) also were greater in the anaesthetized patients, presumably as a result of decreases in renal blood flow and glomerular filtration rate during halothane anaesthesia.",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),min,0,3768,DB00295,Morphine
,7205649,volume of distribution,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[l] / [kg],7.58,3860,DB00295,Morphine
,7205649,elimination T 1/2,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),min,88.6,3861,DB00295,Morphine
,7205649,plasma clearance,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[ml] / [kg·min],59.3,3862,DB00295,Morphine
,15564947,clearance,Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. placebo cotreatment).,Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564947/),[l] / [h],8.3,4294,DB00295,Morphine
,15564947,clearance,Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. placebo cotreatment).,Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564947/),[l] / [h],6.7,4295,DB00295,Morphine
,827709,binding to,"Studies on naltrexone disposition indicate that (a) binding to plasma proteins in several species varies from 20-26 per cent, (b) distribution of drug from blood is extremely rapid and extensive, (c) beta-naltrexol is a major metabolite of naltrexone in man, monkey and guinea pig among six species studied, whereas alpha-naltrexol is a minor metabolite in the monkey and guinea pig only, and (d) metabolic reduction of naltrexone occurs in the 100,000 x g supernatant of guinea pig liver.",Testing of drug delivery systems for use in the treatment of narcotic addiction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/827709/),%,20-26,4399,DB00295,Morphine
,10217341,area under the curve (AUC),The mean morphine area under the curve (AUC) value (0-8 h) was smaller (434.3 +/- 170.2 nmolL(-1)h) in the oral administration than in the rectal administration (574.8 +/- 285.0 nmolL(-1)h) (p < 0.05).,The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),1/[nmoll],434.3,4773,DB00295,Morphine
,10217341,area under the curve (AUC),The mean morphine area under the curve (AUC) value (0-8 h) was smaller (434.3 +/- 170.2 nmolL(-1)h) in the oral administration than in the rectal administration (574.8 +/- 285.0 nmolL(-1)h) (p < 0.05).,The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),1/[nmoll],574.8,4774,DB00295,Morphine
,10217341,AUC ratio,"The median AUC ratio--M3G/M and M6G/M, 12.58 and 1.85--following MSR rectal administration was smaller than following MST oral administration in 6 patients (19.97 and 2.59; p < 0.05), whereas the median AUC ratio M3G/M6G in the rectal dosing was 6.24 (range 5.2-7.6) was almost the same as the median ratio M3G/M6G in the oral dosing was 6.49 (range 5.8-8.5; p > 0.1).",The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),,12.58,4775,DB00295,Morphine
,10217341,AUC ratio,"The median AUC ratio--M3G/M and M6G/M, 12.58 and 1.85--following MSR rectal administration was smaller than following MST oral administration in 6 patients (19.97 and 2.59; p < 0.05), whereas the median AUC ratio M3G/M6G in the rectal dosing was 6.24 (range 5.2-7.6) was almost the same as the median ratio M3G/M6G in the oral dosing was 6.49 (range 5.8-8.5; p > 0.1).",The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),,1.85,4776,DB00295,Morphine
,10217341,AUC ratio,"The median AUC ratio--M3G/M and M6G/M, 12.58 and 1.85--following MSR rectal administration was smaller than following MST oral administration in 6 patients (19.97 and 2.59; p < 0.05), whereas the median AUC ratio M3G/M6G in the rectal dosing was 6.24 (range 5.2-7.6) was almost the same as the median ratio M3G/M6G in the oral dosing was 6.49 (range 5.8-8.5; p > 0.1).",The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),,19.97,4777,DB00295,Morphine
,10217341,AUC ratio,"The median AUC ratio--M3G/M and M6G/M, 12.58 and 1.85--following MSR rectal administration was smaller than following MST oral administration in 6 patients (19.97 and 2.59; p < 0.05), whereas the median AUC ratio M3G/M6G in the rectal dosing was 6.24 (range 5.2-7.6) was almost the same as the median ratio M3G/M6G in the oral dosing was 6.49 (range 5.8-8.5; p > 0.1).",The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),,2.59,4778,DB00295,Morphine
,10217341,AUC ratio,"The median AUC ratio--M3G/M and M6G/M, 12.58 and 1.85--following MSR rectal administration was smaller than following MST oral administration in 6 patients (19.97 and 2.59; p < 0.05), whereas the median AUC ratio M3G/M6G in the rectal dosing was 6.24 (range 5.2-7.6) was almost the same as the median ratio M3G/M6G in the oral dosing was 6.49 (range 5.8-8.5; p > 0.1).",The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217341/),,6.24,4779,DB00295,Morphine
,7639374,steady-state concentration (Css),The infusion led to a high steady-state concentration (Css) of 5.91 +/- 2.46 mg/mL in Group TD-.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),[mg] / [ml],5.91,6020,DB00295,Morphine
,7639374,VAS score,The VAS score was slightly reduced after the bolus (6.6 +/- 1.0 vs 8.7 +/- 0.3; P < 0.05 vs the placebo group) but the cumulative doses of morphine were similar in both groups.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),,6.6,6021,DB00295,Morphine
,7639374,VAS score,The VAS score was slightly reduced after the bolus (6.6 +/- 1.0 vs 8.7 +/- 0.3; P < 0.05 vs the placebo group) but the cumulative doses of morphine were similar in both groups.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),,8.7,6022,DB00295,Morphine
,22169470,maximum hydromorphone plasma concentration (C(max)),"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),[ng] / [ml],24.15,6633,DB00295,Morphine
,22169470,time to the C(max),"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),min,10.0,6634,DB00295,Morphine
,22169470,elimination half-life,"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),h,2.7,6635,DB00295,Morphine
,9725479,relative bioavailabilities,"The relative bioavailabilities of codeine and ibuprofen (alone or in association) were 106 +/- 24% (mean +/- sd) and 101 +/- 19%, respectively.",Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725479/),%,106,6999,DB00295,Morphine
,9725479,relative bioavailabilities,"The relative bioavailabilities of codeine and ibuprofen (alone or in association) were 106 +/- 24% (mean +/- sd) and 101 +/- 19%, respectively.",Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725479/),%,101,7000,DB00295,Morphine
,7091244,free drug,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,7.6,7006,DB00295,Morphine
,7091244,free drug,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,2.9,7007,DB00295,Morphine
,7091244,concentration ratios,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,7.6,7008,DB00295,Morphine
,7091244,concentration ratios,"At steady state after maternal infusion of the drugs, the maternal: fetal free drug concentration ratios were 7.6 +/- 0.6 for morphine and 2.9 +/- 0.6 for methadone.",A comparison of morphine and methadone disposition in the maternal-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),,2.9,7009,DB00295,Morphine
,7091244,clearance,The clearance of morphine from mother to fetus (24.9 +/- 3.0 ml/min) was fifteenfold less than that of methadone (390.3 +/- 92.8 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],24.9,7010,DB00295,Morphine
,7091244,clearance,The clearance of morphine from mother to fetus (24.9 +/- 3.0 ml/min) was fifteenfold less than that of methadone (390.3 +/- 92.8 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],390.3,7011,DB00295,Morphine
,7091244,nonplacental clearance,Fetal nonplacental clearance of methadone (381 +/- 89.1 ml/min) was higher than that of morphine (125.6 +/- 15.3 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],381,7012,DB00295,Morphine
,7091244,nonplacental clearance,Fetal nonplacental clearance of methadone (381 +/- 89.1 ml/min) was higher than that of morphine (125.6 +/- 15.3 ml/min).,A comparison of morphine and methadone disposition in the maternal-fetal unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091244/),[ml] / [min],125.6,7013,DB00295,Morphine
,23001479,latency,"In the second study, similar hyperalgesic responses were observed in mice lacking the multidrug resistance protein 3 (MRP3) transporter protein (Mrp3(-/-) mice) in the liver and their wild-type controls (FVB mice; latency reductions: 3.1 ± 0.2 s at t = 30 min, P < 0.001 versus within-strain baseline).",Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23001479/),s,3.1,8469,DB00295,Morphine
,2401756,peak codeine plasma concentrations,The mean peak codeine plasma concentrations and tmax (time to reach maximum plasma codeine concentrations) were 88.1 ng/mL and 1.2 hours.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),[ng] / [ml],88.1,8582,DB00295,Morphine
,2401756,tmax (,The mean peak codeine plasma concentrations and tmax (time to reach maximum plasma codeine concentrations) were 88.1 ng/mL and 1.2 hours.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),[ng] / [ml],88.1,8583,DB00295,Morphine
,2401756,time to reach maximum plasma codeine concentrations),The mean peak codeine plasma concentrations and tmax (time to reach maximum plasma codeine concentrations) were 88.1 ng/mL and 1.2 hours.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),h,1.2,8584,DB00295,Morphine
,2401756,maximum concentrations,Mean maximum concentrations of metabolically produced morphine was 2.7 +/- 0.6 ng/mL.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),[ng] / [ml],2.7,8585,DB00295,Morphine
,27300254,half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,50.2,8778,DB00295,Morphine
,27300254,plasma half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,24.5,8779,DB00295,Morphine
,27300254,plasma half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,3-6,8780,DB00295,Morphine
,27300254,half-life,"After cessation of dosing, the rate of urinary elimination decreased significantly (F3,23 = 247: P < 0.05, n = 6) in a predictable manner with low intersubject variability and a half-life of 16.1 ± 3.8 h (n = 10).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,16.1,8781,DB00295,Morphine
,9260872,EC50,"In saline-exposed rats, the antinociceptive response to morphine was characterized by a sigmoidal Emax model, with an EC50 of 328 ng/mL, a Hill coefficient (gamma) of 4.5, and a half-life for the offset of pharmacologic effect of 11 min.",Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260872/),[ng] / [ml],328,9992,DB00295,Morphine
,9260872,Hill coefficient (gamma),"In saline-exposed rats, the antinociceptive response to morphine was characterized by a sigmoidal Emax model, with an EC50 of 328 ng/mL, a Hill coefficient (gamma) of 4.5, and a half-life for the offset of pharmacologic effect of 11 min.",Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260872/),,4.5,9993,DB00295,Morphine
,9260872,half-life,"In saline-exposed rats, the antinociceptive response to morphine was characterized by a sigmoidal Emax model, with an EC50 of 328 ng/mL, a Hill coefficient (gamma) of 4.5, and a half-life for the offset of pharmacologic effect of 11 min.",Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260872/),min,11,9994,DB00295,Morphine
,8400092,clearance rates,"Children with TOF had significantly faster clearance rates of morphine (1.39 +/- 0.37 L/kg/h) than children following the Fontan procedure (0.86 +/- 0.31 L/kg/h, P < 0.01).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],1.39,10254,DB00295,Morphine
,8400092,clearance rates,"Children with TOF had significantly faster clearance rates of morphine (1.39 +/- 0.37 L/kg/h) than children following the Fontan procedure (0.86 +/- 0.31 L/kg/h, P < 0.01).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],0.86,10255,DB00295,Morphine
,8400092,clearance rates,"When stratifying children by their postsurgical needs for inotropic support, those needing epinephrine, dopamine, or dobutamine at more than 10 micrograms/kg/min had significantly slower clearance rates (0.73 +/- 0.3 L/kg/h) when compared to the rest of the patients (1.5 +/- 0.41 L/kg/h, P < 0.05).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],0.73,10256,DB00295,Morphine
,8400092,clearance rates,"When stratifying children by their postsurgical needs for inotropic support, those needing epinephrine, dopamine, or dobutamine at more than 10 micrograms/kg/min had significantly slower clearance rates (0.73 +/- 0.3 L/kg/h) when compared to the rest of the patients (1.5 +/- 0.41 L/kg/h, P < 0.05).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],1.5,10257,DB00295,Morphine
,24853314,time to first morphine dose,"When required, median time to first morphine dose was longer in the USGRSB group (65.5 min vs. 47.5 min, P = 0.049).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,65.5,10379,DB00295,Morphine
,24853314,time to first morphine dose,"When required, median time to first morphine dose was longer in the USGRSB group (65.5 min vs. 47.5 min, P = 0.049).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,47.5,10380,DB00295,Morphine
,24853314,Peak plasma bupivacaine concentration,"Peak plasma bupivacaine concentration was higher following USGRSB than WI (median: 631.9 ng·ml(-1) IQR: 553.9-784.1 vs. 389.7 ng·ml(-1) IQR: 250.5-502.7, P = 0.002).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),[ng] / [ml],631.9,10381,DB00295,Morphine
,24853314,Peak plasma bupivacaine concentration,"Peak plasma bupivacaine concentration was higher following USGRSB than WI (median: 631.9 ng·ml(-1) IQR: 553.9-784.1 vs. 389.7 ng·ml(-1) IQR: 250.5-502.7, P = 0.002).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),[ng] / [ml],389.7,10382,DB00295,Morphine
,24853314,Tmax,"Tmax was longer in the USGRSB group (median 45 min IQR: 30-60 vs. 20 min IQR: 20-45, P = 0.006).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,45,10383,DB00295,Morphine
,24853314,Tmax,"Tmax was longer in the USGRSB group (median 45 min IQR: 30-60 vs. 20 min IQR: 20-45, P = 0.006).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,20,10384,DB00295,Morphine
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.88,10593,DB00295,Morphine
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.73,10594,DB00295,Morphine
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.61,10595,DB00295,Morphine
,6709027,half-life,"The mean half-life of heroin (+/- S.D.) after intravenous injection or infusion was only 3.0 +/- 1.3 minutes, and the mean clearance of heroin from the blood at apparent steady state was 30.8 +/- 2.1 ml per kilogram of body weight per minute.",The pharmacokinetics of heroin in patients with chronic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6709027/),min,3.0,10667,DB00295,Morphine
,6709027,clearance of heroin from the blood at apparent steady state,"The mean half-life of heroin (+/- S.D.) after intravenous injection or infusion was only 3.0 +/- 1.3 minutes, and the mean clearance of heroin from the blood at apparent steady state was 30.8 +/- 2.1 ml per kilogram of body weight per minute.",The pharmacokinetics of heroin in patients with chronic pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6709027/),[ml] / [kg],30.8,10668,DB00295,Morphine
not exceed,9571218,recovery,We investigated the acidic hydrolysis of M6G and found that the recovery of morphine did not exceed 5%.,Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571218/),%,5,10806,DB00295,Morphine
,9571218,hepatic extraction ratio,"The hepatic extraction ratio of M6G was very low (0.04 +/- 0.02), but 88. 7 +/- 11.2% of the dose was excreted in bile.",Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571218/),,0.04,10807,DB00295,Morphine
,9571218,elimination half-life,The elimination half-life of M6G in the perfusate (66.4 +/- 20.6 min) was higher than the elimination half-life in bile (18.6 +/- 2.5 min).,Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571218/),min,66.4,10808,DB00295,Morphine
,9571218,elimination half-life,The elimination half-life of M6G in the perfusate (66.4 +/- 20.6 min) was higher than the elimination half-life in bile (18.6 +/- 2.5 min).,Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571218/),min,18.6,10809,DB00295,Morphine
,9571218,hydrolysis,"The hydrolysis of M6G was low, with only 7.7% and 0.03% of morphine in the perfusate and bile, respectively.",Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571218/),%,7.7,10810,DB00295,Morphine
,9571218,hydrolysis,"The hydrolysis of M6G was low, with only 7.7% and 0.03% of morphine in the perfusate and bile, respectively.",Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571218/),%,0.03,10811,DB00295,Morphine
,10632086,AUC ratio,"The foetal brain to maternal brain AUC ratio for morphine was 9.5, suggesting large differences in their blood-brain barrier permeability.",Disposition of morphine in tissues of the pregnant rat and foetus following single and continuous intraperitoneal administration to the mother. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632086/),,9.5,11027,DB00295,Morphine
>,11868970,extraction recoveries,The extraction recoveries were > 76% for all analytes.,LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),%,76,11390,DB00295,Morphine
,11868970,limits of detection,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),1/[nmol],7.0,11391,DB00295,Morphine
,11868970,limits of detection,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),[ng] / [ml],2.0,11392,DB00295,Morphine
,11868970,limits of detection,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),[nM] / [l],11,11393,DB00295,Morphine
,11868970,signal-to-noise ratio,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),,3. 3,11394,DB00295,Morphine
,11745739,elimination half-life,The mean elimination half-life (+/- S.D.) of M3G was 1.66 (+/- 0.47) h.,Limited phase I study of morphine-3-glucuronide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745739/),h,1.66,11593,DB00295,Morphine
,11745739,AUC,Mean AUC standardized to a dose of 1 mg/70 kg was 228 (+/- 62) etamolL(-1) x h.,Limited phase I study of morphine-3-glucuronide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745739/),[h] / [etamoll],228,11594,DB00295,Morphine
,11745739,clearance,Mean M3G clearance was 169 (+/- 48) mLmin(-1) and the mean volume of distribution was 23.1 (+/- 4.8) liters.,Limited phase I study of morphine-3-glucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745739/),1/[mlmin],169,11595,DB00295,Morphine
,11745739,volume of distribution,Mean M3G clearance was 169 (+/- 48) mLmin(-1) and the mean volume of distribution was 23.1 (+/- 4.8) liters.,Limited phase I study of morphine-3-glucuronide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745739/),l,23.1,11596,DB00295,Morphine
,1653145,tmax,The tmax was 3.3 h for the tablets compared to 1.1 h for the solution.,Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653145/),h,3.3,12183,DB00295,Morphine
,1653145,tmax,The tmax was 3.3 h for the tablets compared to 1.1 h for the solution.,Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653145/),h,1.1,12184,DB00295,Morphine
,1653145,Urinary recovery at steady state,"Urinary recovery at steady state was comparable between the two preparations, with averages of 57% and 47%, respectively.",Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653145/),%,57,12185,DB00295,Morphine
,1653145,Urinary recovery at steady state,"Urinary recovery at steady state was comparable between the two preparations, with averages of 57% and 47%, respectively.",Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653145/),%,47,12186,DB00295,Morphine
,7579032,apparent half-lives,"The mean apparent half-lives (+/- SD) of elimination were 10 min (0.165 h +/- 0.053 h) for 3,6-dinicotinoylmorphine and 1.77 h +/- 1.23 h for 6-mononicotinoylmorphine.",Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579032/),min,10,12536,DB00295,Morphine
,7579032,apparent half-lives,"The mean apparent half-lives (+/- SD) of elimination were 10 min (0.165 h +/- 0.053 h) for 3,6-dinicotinoylmorphine and 1.77 h +/- 1.23 h for 6-mononicotinoylmorphine.",Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579032/),h,0.165,12537,DB00295,Morphine
,7579032,apparent half-lives,"The mean apparent half-lives (+/- SD) of elimination were 10 min (0.165 h +/- 0.053 h) for 3,6-dinicotinoylmorphine and 1.77 h +/- 1.23 h for 6-mononicotinoylmorphine.",Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579032/),h,1.77,12538,DB00295,Morphine
,7579032,apparent half-lives,"The apparent half-lives of morphine, morphine-3-glucuronide, and morphine-6-glucuronide are similar: 3.63 h +/- 1.63 h, 4.10 h +/- 0.57 h, and 4.20 h +/- 1.64 h respectively.",Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579032/),h,3.63,12539,DB00295,Morphine
,7579032,apparent half-lives,"The apparent half-lives of morphine, morphine-3-glucuronide, and morphine-6-glucuronide are similar: 3.63 h +/- 1.63 h, 4.10 h +/- 0.57 h, and 4.20 h +/- 1.64 h respectively.",Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579032/),h,4.10,12540,DB00295,Morphine
,7579032,apparent half-lives,"The apparent half-lives of morphine, morphine-3-glucuronide, and morphine-6-glucuronide are similar: 3.63 h +/- 1.63 h, 4.10 h +/- 0.57 h, and 4.20 h +/- 1.64 h respectively.",Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579032/),h,4.20,12541,DB00295,Morphine
,1419474,elimination half-life,2. The mean elimination half-life (+/- s.d.) of morphine-6-glucuronide was 3.2 +/- 1.6 h.,The analgesic activity of morphine-6-glucuronide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1419474/),h,3.2,12926,DB00295,Morphine
,1419474,AUC,The mean AUC standardised to a dose of 1 mg 70 kg-1 was 390 +/- 263 nmol l-1 h.,The analgesic activity of morphine-6-glucuronide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1419474/),[h·nM] / [l],390,12927,DB00295,Morphine
,1419474,clearance,Mean morphine-6-glucuronide clearance was 96 +/- 38 ml min-1.,The analgesic activity of morphine-6-glucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1419474/),[ml] / [min],96,12928,DB00295,Morphine
,9248943,flow rate,The chromatographic separation of the analytes was achieved using a normal phase column and a water-methanol-acetonitrile-formic acid mobile phase at a flow rate of 230 microL/min.,"Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μl] / [min],230,13068,DB00295,Morphine
,9248943,peak concentration,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],0.93,13069,DB00295,Morphine
,9248943,peak concentrations,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],9.6,13070,DB00295,Morphine
,9248943,peak concentrations,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],2.9,13071,DB00295,Morphine
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,45.6,13185,DB00295,Morphine
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,37.2,13186,DB00295,Morphine
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,22.9,13187,DB00295,Morphine
,18945270,bioavailability,"However, morphine bioavailability was considerably higher in chronic users [diacetylmorphine 45.6% (95% confidence interval 40.0, 51.3), morphine 37.2% (30.1, 44.3)] than in naive subjects [diacetylmorphine 22.9% (16.4, 29.4), morphine 23.9% (16.5, 31.2)] after low oral doses (48.5 micromol) of either diacetylmorphine or morphine.",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,23.9,13188,DB00295,Morphine
,18945270,bioavailability,"Moreover, oral absorption of morphine from diacetylmorphine was found to be dose dependent, with bioavailability reaching 64.2% (55.3, 73.1) for high diacetylmorphine doses (1601 micromol).",Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18945270/),%,64.2,13189,DB00295,Morphine
,2445789,absolute bioavailability,"Hydromorphone has an absolute bioavailability of 51.35 +/- 29.29% and 36.33 +/- 29.60% after peroral and rectal administration, respectively.",Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445789/),%,51.35,13829,DB00295,Morphine
,2445789,absolute bioavailability,"Hydromorphone has an absolute bioavailability of 51.35 +/- 29.29% and 36.33 +/- 29.60% after peroral and rectal administration, respectively.",Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445789/),%,36.33,13830,DB00295,Morphine
,1489328,half-lives,In addition to the short half-lives of morphine and morphine-glucuronides long half-lives were found in the range of 12.6 to 20 hours in serum and urine.,[Pilot study of dose dependence in glucuronidation of morphine to morphine-3- and morphine-5-glucuronide]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489328/),h,12.6 to 20,14596,DB00295,Morphine
,18467078,k1e,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.038,14909,DB00295,Morphine
,18467078,keo,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.043,14910,DB00295,Morphine
,18467078,k1e,"Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1).",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.04 to 0.47,14911,DB00295,Morphine
,18467078,EC50,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),[ng] / [ml],1.2-451,14912,DB00295,Morphine
,18467078,alpha,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),μv,18-109,14913,DB00295,Morphine
,26309104,terminal half-life,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,1.56,15188,DB00295,Morphine
,26309104,maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],155.6,15189,DB00295,Morphine
,26309104,time to maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.90,15190,DB00295,Morphine
,26309104,maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],7.90,15191,DB00295,Morphine
,26309104,time to maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.47,15192,DB00295,Morphine
,26309104,terminal half-life,"The terminal half-life for hydrocodone was 15.85 hours, but was likely influenced by delayed drug absorption in some dogs and may not have been a robust estimate.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,15.85,15193,DB00295,Morphine
,9542560,peak plasma concentrations,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],2.2,15230,DB00295,Morphine
,9542560,peak plasma concentrations,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],1.6,15231,DB00295,Morphine
,9542560,time,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,17,15232,DB00295,Morphine
,9542560,time,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,19,15233,DB00295,Morphine
,9542560,Tmax,"The absorption of morphine was similar in both groups (Tmax 16 min), but the peak plasma concentrations were higher after deltoid injection (71 vs 49 micrograms/l).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,16,15234,DB00295,Morphine
,9542560,peak plasma concentrations,"The absorption of morphine was similar in both groups (Tmax 16 min), but the peak plasma concentrations were higher after deltoid injection (71 vs 49 micrograms/l).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],71,15235,DB00295,Morphine
,9542560,peak plasma concentrations,"The absorption of morphine was similar in both groups (Tmax 16 min), but the peak plasma concentrations were higher after deltoid injection (71 vs 49 micrograms/l).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],49,15236,DB00295,Morphine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,1.9,15237,DB00295,Morphine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,2.1,15238,DB00295,Morphine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,1.3,15239,DB00295,Morphine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,2.3,15240,DB00295,Morphine
,9542560,maximal effect,A heavy sedation and antisialogogue effect (VAS) was found in both groups with faster occurrence of maximal effect in group D (60 vs 120-180 min).,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,60,15241,DB00295,Morphine
,9542560,maximal effect,A heavy sedation and antisialogogue effect (VAS) was found in both groups with faster occurrence of maximal effect in group D (60 vs 120-180 min).,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,120-180,15242,DB00295,Morphine
,29594153,half-life (t1/2),"Following M or PM administration, it was determined that the half-life (t1/2) was significantly longer in the PM (5.5 ± 7.2 h) than M (0.7 ± 0.8 h) indicated a slow dissolution of poloxamer with morphine.",Evaluation of 25% Poloxamer As a Slow Release Carrier for Morphine in a Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29594153/),h,5.5,16086,DB00295,Morphine
,29594153,half-life (t1/2),"Following M or PM administration, it was determined that the half-life (t1/2) was significantly longer in the PM (5.5 ± 7.2 h) than M (0.7 ± 0.8 h) indicated a slow dissolution of poloxamer with morphine.",Evaluation of 25% Poloxamer As a Slow Release Carrier for Morphine in a Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29594153/),h,0.7,16087,DB00295,Morphine
within,29594153,tmax,"The tmax was within 15 min and Cmax was approximately three times higher with M than with PM, reaching 716.8 (±153.7 ng/ml) of plasma morphine concentrations.",Evaluation of 25% Poloxamer As a Slow Release Carrier for Morphine in a Rat Model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29594153/),min,15,16088,DB00295,Morphine
,29594153,Cmax,"The tmax was within 15 min and Cmax was approximately three times higher with M than with PM, reaching 716.8 (±153.7 ng/ml) of plasma morphine concentrations.",Evaluation of 25% Poloxamer As a Slow Release Carrier for Morphine in a Rat Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29594153/),[ng] / [ml],716.8,16089,DB00295,Morphine
,6653402,minimum serum morphine concentration,This concentration is well above the minimum serum morphine concentration of 50 micrograms/L for moderate analgesic effects in adults.,Pharmacokinetics of intravenous morphine in balanced anesthesia: studies in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653402/),[μg] / [l],50,16132,DB00295,Morphine
,6653402,clearance,The clearance of morphine in 8 children between 0 and 5 yr of age was 20.5 +/- 2.8 mL/kg/min (means +/- SD).,Pharmacokinetics of intravenous morphine in balanced anesthesia: studies in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653402/),[ml] / [kg·min],20.5,16133,DB00295,Morphine
,6653402,steady-state serum morphine concentration,"Having established a dosing regimen that achieves a steady-state serum morphine concentration of approximately 75 micrograms/L, we plan to investigate the relationship between morphine serum concentration and pharmacologic effect.",Pharmacokinetics of intravenous morphine in balanced anesthesia: studies in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653402/),[μg] / [l],75,16134,DB00295,Morphine
,32228262,clearance,"Mean ± SD clearance and volume of distribution for hydromorphone administered IV were 52.8 ± 13.5 mL/min/kg and 2.39 ± 0.479 L/kg, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[ml] / [kg·min],52.8,17172,DB00295,Morphine
,32228262,volume of distribution,"Mean ± SD clearance and volume of distribution for hydromorphone administered IV were 52.8 ± 13.5 mL/min/kg and 2.39 ± 0.479 L/kg, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[l] / [kg],2.39,17173,DB00295,Morphine
,32228262,Mean residence time,"Mean residence time determined for the IV and IM administration routes was 0.77 ± 0.14 hours and 0.99 ± 0.34 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),h,0.77,17174,DB00295,Morphine
,32228262,Mean residence time,"Mean residence time determined for the IV and IM administration routes was 0.77 ± 0.14 hours and 0.99 ± 0.34 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),h,0.99,17175,DB00295,Morphine
,32228262,maximum observed plasma concentration,The maximum observed plasma concentration following IM administration of hydromorphone was 171.9 ± 29.4 ng/mL.,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[ng] / [ml],171.9,17176,DB00295,Morphine
,32228262,target plasma concentration,Pharmacokinetic data indicated that hydromorphone at a dose of 0.3 mg/kg may be administered IV every 2 to 3 hours or IM every 4 to 5 hours to maintain a target plasma concentration between 2 and 4 ng/mL in guinea pigs.,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[ng] / [ml],2 and 4,17177,DB00295,Morphine
,29016880,maximum effect,"Mean maximum effect for ""at the moment"" Drug Liking was significantly (P < 0.01) lower for intranasal hydrocodone ER (72.8) compared with hydrocodone powder (80.2) and HYD-OF (83.2).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,72.8,17212,DB00295,Morphine
,29016880,maximum effect,"Mean maximum effect for ""at the moment"" Drug Liking was significantly (P < 0.01) lower for intranasal hydrocodone ER (72.8) compared with hydrocodone powder (80.2) and HYD-OF (83.2).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,80.2,17213,DB00295,Morphine
,29016880,maximum effect,"Mean maximum effect for ""at the moment"" Drug Liking was significantly (P < 0.01) lower for intranasal hydrocodone ER (72.8) compared with hydrocodone powder (80.2) and HYD-OF (83.2).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,83.2,17214,DB00295,Morphine
,29016880,Overall Drug Liking maximum effect,"Similar results were observed for Overall Drug Liking maximum effect (68.5 vs 77.1 and 79.8, respectively; P < 0.01).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,68.5,17215,DB00295,Morphine
,29016880,Overall Drug Liking maximum effect,"Similar results were observed for Overall Drug Liking maximum effect (68.5 vs 77.1 and 79.8, respectively; P < 0.01).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,77.1,17216,DB00295,Morphine
,29016880,Overall Drug Liking maximum effect,"Similar results were observed for Overall Drug Liking maximum effect (68.5 vs 77.1 and 79.8, respectively; P < 0.01).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,79.8,17217,DB00295,Morphine
,10475315,time to onset of relief,Median time to onset of relief was approximately 5 min for all groups.,The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10475315/),min,5,17298,DB00295,Morphine
,22973910,V(d),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),l,193,17347,DB00295,Morphine
,22973910,k(a),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),1/[h],0.336,17348,DB00295,Morphine
,22973910,T(lag),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),h,0.859,17349,DB00295,Morphine
,3768080,terminal half-life (t1/2),The decline of morphine serum concentration after epidural administration of 0.1 mg/kg was described by a bi- or triexponential decay equation with a mean terminal half-life (t1/2) of 134.7 +/- 107.9 min.,Pharmacokinetics of morphine after epidural administration in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768080/),min,134.7,17780,DB00295,Morphine
,3768080,clearance,"Pharmacokinetic parameters were calculated from the fit parameters mean values for clearance and apparent volume of distribution were 1.16 +/- 0.65 l/min, and 156.6 +/- 107.3 l, respectively, for free morphine and 0.19 +/- 0.09 l/min and 37.2 +/- 17.7 l, respectively, for morphine glucuronide.",Pharmacokinetics of morphine after epidural administration in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768080/),[l] / [min],1.16,17781,DB00295,Morphine
,3768080,clearance,"Pharmacokinetic parameters were calculated from the fit parameters mean values for clearance and apparent volume of distribution were 1.16 +/- 0.65 l/min, and 156.6 +/- 107.3 l, respectively, for free morphine and 0.19 +/- 0.09 l/min and 37.2 +/- 17.7 l, respectively, for morphine glucuronide.",Pharmacokinetics of morphine after epidural administration in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768080/),[l] / [min],0.19,17782,DB00295,Morphine
,3768080,apparent volume of distribution,"Pharmacokinetic parameters were calculated from the fit parameters mean values for clearance and apparent volume of distribution were 1.16 +/- 0.65 l/min, and 156.6 +/- 107.3 l, respectively, for free morphine and 0.19 +/- 0.09 l/min and 37.2 +/- 17.7 l, respectively, for morphine glucuronide.",Pharmacokinetics of morphine after epidural administration in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768080/),l,156.6,17783,DB00295,Morphine
,3768080,apparent volume of distribution,"Pharmacokinetic parameters were calculated from the fit parameters mean values for clearance and apparent volume of distribution were 1.16 +/- 0.65 l/min, and 156.6 +/- 107.3 l, respectively, for free morphine and 0.19 +/- 0.09 l/min and 37.2 +/- 17.7 l, respectively, for morphine glucuronide.",Pharmacokinetics of morphine after epidural administration in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768080/),l,37.2,17784,DB00295,Morphine
,3768080,Peak concentration,Peak concentration of morphine 79 +/- 19 ng/ml was reached within 10 min after administration.,Pharmacokinetics of morphine after epidural administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768080/),[ng] / [ml],79,17785,DB00295,Morphine
>,23100195,octanol:water partition coefficient,"It is a full agonist at μ-opioid receptors and possesses physicochemical properties, in particular a high lipophilicity (octanol:water partition coefficient >700), which allow it to cross quickly between plasma and central nervous target sites (transfer half-life of 4.7-6.6 min).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),,700,18089,DB00295,Morphine
,23100195,transfer half-life,"It is a full agonist at μ-opioid receptors and possesses physicochemical properties, in particular a high lipophilicity (octanol:water partition coefficient >700), which allow it to cross quickly between plasma and central nervous target sites (transfer half-life of 4.7-6.6 min).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,4.7-6.6,18090,DB00295,Morphine
,23100195,bioavailability,"It undergoes first-pass metabolism via cytochrome P450 3A (bioavailability ~30 % after rapid swallowing), which can be circumvented by non-intravenous formulations (bioavailability 50-90 % for oral transmucosal or intranasal formulations).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),%,30,18091,DB00295,Morphine
,23100195,bioavailability,"It undergoes first-pass metabolism via cytochrome P450 3A (bioavailability ~30 % after rapid swallowing), which can be circumvented by non-intravenous formulations (bioavailability 50-90 % for oral transmucosal or intranasal formulations).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),%,50-90,18092,DB00295,Morphine
,23100195,time to reach maximum fentanyl plasma concentrations,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,20,18093,DB00295,Morphine
,23100195,time to reach maximum fentanyl plasma concentrations,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,12,18094,DB00295,Morphine
,23100195,time to onset of analgesia,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,5,18095,DB00295,Morphine
,23100195,time to onset of analgesia,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,2,18096,DB00295,Morphine
,15212187,delivery rate,"Subcutaneous (s.c.) morphine infusions (0, 10, 30 mg/kg body weight/24 h) have been administered using implantable mini-osmotic pumps with a delivery rate of 10 microl/h.",On the role of the kidneys in the pathogenesis of edema formation during permanent morphine application/an experimental study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212187/),[μl] / [h],10,18531,DB00295,Morphine
,11139459,target plasma concentration,Two groups of rats received an exponential infusion of M3G over 4 h to reach a target plasma concentration of 65 microM on two consecutive days.,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),μM,65,18889,DB00295,Morphine
,11139459,influx clearance into the brain,"The process that appears to be mainly influenced by probenecid is influx clearance into the brain (0.11 microl min(-1) g-brain(-1) vs 0.17 microl min(-1) g-brain(-1), in the absence vs presence of probenecid, P:<0.001).",Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),[μl] / [g-brain·min],0.11,18890,DB00295,Morphine
,11139459,influx clearance into the brain,"The process that appears to be mainly influenced by probenecid is influx clearance into the brain (0.11 microl min(-1) g-brain(-1) vs 0.17 microl min(-1) g-brain(-1), in the absence vs presence of probenecid, P:<0.001).",Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),[μl] / [g-brain·min],0.17,18891,DB00295,Morphine
,11139459,efflux clearance,The efflux clearance was 1.15 microl min(-1) g-brain(-1).,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),[μl] / [g-brain·min],1.15,18892,DB00295,Morphine
,11139459,half-life,The half-life of M3G was 81+/-25 min in brain ECF vs 22+/-2 min in blood (P<0.0001).,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),min,81,18893,DB00295,Morphine
,11139459,half-life,The half-life of M3G was 81+/-25 min in brain ECF vs 22+/-2 min in blood (P<0.0001).,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),min,22,18894,DB00295,Morphine
,7841696,volume of distribution at steady state (Vd beta),"In the five term infants, median (range) volume of distribution at steady state (Vd beta) was 1758 (634-2700) ml/kg, plasma clearance (Cl) was 4.73 (1.75-6.61) ml/kg/min and terminal half-life (T1/2) was 224 (107-394) min.",Morphine pharmacokinetics in premature and mature newborn infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841696/),[ml] / [kg],1758,20790,DB00295,Morphine
,7841696,plasma clearance (Cl),"In the five term infants, median (range) volume of distribution at steady state (Vd beta) was 1758 (634-2700) ml/kg, plasma clearance (Cl) was 4.73 (1.75-6.61) ml/kg/min and terminal half-life (T1/2) was 224 (107-394) min.",Morphine pharmacokinetics in premature and mature newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841696/),[ml] / [kg·min],4.73,20791,DB00295,Morphine
,7841696,terminal half-life (T1/2),"In the five term infants, median (range) volume of distribution at steady state (Vd beta) was 1758 (634-2700) ml/kg, plasma clearance (Cl) was 4.73 (1.75-6.61) ml/kg/min and terminal half-life (T1/2) was 224 (107-394) min.",Morphine pharmacokinetics in premature and mature newborn infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841696/),min,224,20792,DB00295,Morphine
,7841696,Vd beta,"In the eight preterm infants, Vd beta was 2366 (1662-2876) ml/kg, Cl was 2.82 (1.88-6.60) ml/kg/min and T1/2 was 556 (248-834) min.",Morphine pharmacokinetics in premature and mature newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841696/),[ml] / [kg],2366,20793,DB00295,Morphine
,7841696,Cl,"In the eight preterm infants, Vd beta was 2366 (1662-2876) ml/kg, Cl was 2.82 (1.88-6.60) ml/kg/min and T1/2 was 556 (248-834) min.",Morphine pharmacokinetics in premature and mature newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841696/),[ml] / [kg·min],2.82,20794,DB00295,Morphine
,7841696,T1/2,"In the eight preterm infants, Vd beta was 2366 (1662-2876) ml/kg, Cl was 2.82 (1.88-6.60) ml/kg/min and T1/2 was 556 (248-834) min.",Morphine pharmacokinetics in premature and mature newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841696/),min,556,20795,DB00295,Morphine
,3362553,elimination half-life,"Peak levels (I) were reached in 5-15 min (30 and 60 micrograms/ml); they then fell rapidly during the 1st hour (7 and 11 micrograms/ml) with an elimination half-life of 10 and 15 min, followed by a change in slope (elimination half-life of 108 and 140 min).",CSF morphine levels after lumbar intrathecal administration of isobaric and hyperbaric solutions for cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3362553/),min,10,21471,DB00295,Morphine
,3362553,elimination half-life,"Peak levels (I) were reached in 5-15 min (30 and 60 micrograms/ml); they then fell rapidly during the 1st hour (7 and 11 micrograms/ml) with an elimination half-life of 10 and 15 min, followed by a change in slope (elimination half-life of 108 and 140 min).",CSF morphine levels after lumbar intrathecal administration of isobaric and hyperbaric solutions for cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3362553/),min,15,21472,DB00295,Morphine
,3362553,elimination half-life,"Peak levels (I) were reached in 5-15 min (30 and 60 micrograms/ml); they then fell rapidly during the 1st hour (7 and 11 micrograms/ml) with an elimination half-life of 10 and 15 min, followed by a change in slope (elimination half-life of 108 and 140 min).",CSF morphine levels after lumbar intrathecal administration of isobaric and hyperbaric solutions for cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3362553/),min,108,21473,DB00295,Morphine
,3362553,elimination half-life,"Peak levels (I) were reached in 5-15 min (30 and 60 micrograms/ml); they then fell rapidly during the 1st hour (7 and 11 micrograms/ml) with an elimination half-life of 10 and 15 min, followed by a change in slope (elimination half-life of 108 and 140 min).",CSF morphine levels after lumbar intrathecal administration of isobaric and hyperbaric solutions for cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3362553/),min,140,21474,DB00295,Morphine
,3362553,elimination half-life,Peak levels (II) were reached in 4-5 h (0.8-3.3 micrograms/ml); they then fell progressively according to a single exponential function (elimination half-life: 144-246 min).,CSF morphine levels after lumbar intrathecal administration of isobaric and hyperbaric solutions for cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3362553/),min,144-246,21475,DB00295,Morphine
,3362553,duration of anal,The duration of analgesia for a dose of 2 mg was 30 h for solution 2 and 24 h for solution 1.,CSF morphine levels after lumbar intrathecal administration of isobaric and hyperbaric solutions for cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3362553/),h,30,21476,DB00295,Morphine
,1484193,bioavailability (AUC0-24,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),[h·ng] / [ml],72.7,22568,DB00295,Morphine
,1484193,bioavailability (AUC0-24,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),[h·ng] / [ml],98.6,22569,DB00295,Morphine
,1484193,bioavailability (AUC0-24,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),[h·ng] / [ml],105.8,22570,DB00295,Morphine
,1484193,peak concentration (tmax,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),h,2.3,22571,DB00295,Morphine
,1484193,peak concentration (tmax,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),h,3.1,22572,DB00295,Morphine
,1484193,peak concentration (tmax,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),h,5.0,22573,DB00295,Morphine
,1484193,half-value duration,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),h,4.3,22574,DB00295,Morphine
,1484193,half-value duration,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),h,10.4,22575,DB00295,Morphine
,1484193,half-value duration,"Compared with oral controlled-release morphine, the high- and low-viscosity suppository formulations had significantly greater bioavailability (AUC0-24 72.7 +/- 13.2 for the oral preparation versus 98.6 +/- 35.7 and 105.8 +/- 37.3 ng.hr/mL for the suppositories, respectively, P < 0.05), later peak concentration (tmax 2.3 +/- 0.8 versus 3.1 +/- 2.3 and 5.0 +/- 1.5 hr, respectively, P < 0.05), and longer half-value duration (4.3 +/- 1.6 versus 10.4 +/- 5.5 and 9.5 +/- 4.3 hr, respectively, P < 0.05).",Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),h,9.5,22576,DB00295,Morphine
,1484193,Cmax,Peak concentration for the high-viscosity suppository formulation (Cmax 7.75 +/- 2.66 ng/mL) was significantly lower than the low-viscosity suppository (Cmax 9.23 +/- 2.85 ng/mL) and the oral tablet (Cmax 10.4 +/- 2.78 ng/mL) formulations (P < 0.05).,Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),[ng] / [ml],7.75,22577,DB00295,Morphine
,1484193,Cmax,Peak concentration for the high-viscosity suppository formulation (Cmax 7.75 +/- 2.66 ng/mL) was significantly lower than the low-viscosity suppository (Cmax 9.23 +/- 2.85 ng/mL) and the oral tablet (Cmax 10.4 +/- 2.78 ng/mL) formulations (P < 0.05).,Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),[ng] / [ml],9.23,22578,DB00295,Morphine
,1484193,Cmax,Peak concentration for the high-viscosity suppository formulation (Cmax 7.75 +/- 2.66 ng/mL) was significantly lower than the low-viscosity suppository (Cmax 9.23 +/- 2.85 ng/mL) and the oral tablet (Cmax 10.4 +/- 2.78 ng/mL) formulations (P < 0.05).,Pharmacokinetics of two novel rectal controlled-release morphine formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484193/),[ng] / [ml],10.4,22579,DB00295,Morphine
,1997044,volume of distribution,"For M6G 30 micrograms kg-1 the mean (SD) volume of distribution, elimination half-life and clearance were 29.38 (18.36) litre, 2.05 (1.2) h and 187.81 (37.41) litre h-1, respectively.",Disposition of morphine-6-glucuronide and morphine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997044/),l,29.38,23218,DB00295,Morphine
,1997044,elimination half-life,"For M6G 30 micrograms kg-1 the mean (SD) volume of distribution, elimination half-life and clearance were 29.38 (18.36) litre, 2.05 (1.2) h and 187.81 (37.41) litre h-1, respectively.",Disposition of morphine-6-glucuronide and morphine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997044/),h,2.05,23219,DB00295,Morphine
,1997044,clearance,"For M6G 30 micrograms kg-1 the mean (SD) volume of distribution, elimination half-life and clearance were 29.38 (18.36) litre, 2.05 (1.2) h and 187.81 (37.41) litre h-1, respectively.",Disposition of morphine-6-glucuronide and morphine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997044/),[l] / [h],187.81,23220,DB00295,Morphine
,6859584,peak plasma morphine concentrations,"For the three groups, peak plasma morphine concentrations (range 19-34 ng/ml) were reached within 15 min.",Pharmacokinetic aspects of epidural morphine analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859584/),[ng] / [ml],19-34,23457,DB00295,Morphine
,6859584,elimination half-life,"The plasma curves had a similar appearance as after an intramuscular injection and pharmacokinetic calculations showed an elimination half-life (mean +/- SEM) of 173 +/- 24 min, 200 +/- 60 min, and 213 +/- 57 min for the groups, respectively.",Pharmacokinetic aspects of epidural morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859584/),min,173,23458,DB00295,Morphine
,6859584,elimination half-life,"The plasma curves had a similar appearance as after an intramuscular injection and pharmacokinetic calculations showed an elimination half-life (mean +/- SEM) of 173 +/- 24 min, 200 +/- 60 min, and 213 +/- 57 min for the groups, respectively.",Pharmacokinetic aspects of epidural morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859584/),min,200,23459,DB00295,Morphine
,6859584,elimination half-life,"The plasma curves had a similar appearance as after an intramuscular injection and pharmacokinetic calculations showed an elimination half-life (mean +/- SEM) of 173 +/- 24 min, 200 +/- 60 min, and 213 +/- 57 min for the groups, respectively.",Pharmacokinetic aspects of epidural morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859584/),min,213,23460,DB00295,Morphine
,17619868,AUC(CSF)/AUC(serum) (0-120 min) concentration ratios,"The mean AUC(CSF)/AUC(serum) (0-120 min) concentration ratios were 0.18 and 0.09 after IV and IM, respectively.",Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17619868/),,0.18,24202,DB00295,Morphine
,17619868,AUC(CSF)/AUC(serum) (0-120 min) concentration ratios,"The mean AUC(CSF)/AUC(serum) (0-120 min) concentration ratios were 0.18 and 0.09 after IV and IM, respectively.",Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17619868/),,0.09,24203,DB00295,Morphine
,22595262,flow rate,"The separation was performed on LichroCART RP-18e with particle size of 5 µm (250 × 4.6 mm) with mobile phase acetonitrile-50 mM KH(2)PO(4) buffer, pH 7.1, using a gradient mode with a 1.0 mL/min flow rate.",New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),[ml] / [min],1.0,24703,DB00295,Morphine
,22595262,Recovery,Recovery values for the substances ranged between 59 and 83%.,New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),%,59 and 83,24704,DB00295,Morphine
,27633773,E max,Median Drug Liking VAS E max was significantly lower after treatment with manipulated morphine-ADER-IMT (67) compared with manipulated morphine ER (74; P = 0.007).,"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27633773/),,67,25062,DB00295,Morphine
,27633773,E max,Median Drug Liking VAS E max was significantly lower after treatment with manipulated morphine-ADER-IMT (67) compared with manipulated morphine ER (74; P = 0.007).,"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27633773/),,74,25063,DB00295,Morphine
,29849845,maximum observed plasma concentration (Cmax),"Mean maximum observed plasma concentration (Cmax) for morphine was lower with crushed intranasal Morphine ARER (26.2 ng/mL) and intact oral Morphine ARER (18.6 ng/mL), compared with crushed intranasal ER morphine (49.5 ng/mL).","Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29849845/),[ng] / [ml],26.2,25131,DB00295,Morphine
,29849845,maximum observed plasma concentration (Cmax),"Mean maximum observed plasma concentration (Cmax) for morphine was lower with crushed intranasal Morphine ARER (26.2 ng/mL) and intact oral Morphine ARER (18.6 ng/mL), compared with crushed intranasal ER morphine (49.5 ng/mL).","Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29849845/),[ng] / [ml],18.6,25132,DB00295,Morphine
,29849845,maximum observed plasma concentration (Cmax),"Mean maximum observed plasma concentration (Cmax) for morphine was lower with crushed intranasal Morphine ARER (26.2 ng/mL) and intact oral Morphine ARER (18.6 ng/mL), compared with crushed intranasal ER morphine (49.5 ng/mL).","Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29849845/),[ng] / [ml],49.5,25133,DB00295,Morphine
,29849845,time to Cmax (Tmax),The time to Cmax (Tmax) was the same for intact oral and crushed intranasal Morphine ARER (1.6 hours) and longer for crushed intranasal morphine ER (1.1 hours).,"Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29849845/),h,1.6,25134,DB00295,Morphine
,29849845,time to Cmax (Tmax),The time to Cmax (Tmax) was the same for intact oral and crushed intranasal Morphine ARER (1.6 hours) and longer for crushed intranasal morphine ER (1.1 hours).,"Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29849845/),h,1.1,25135,DB00295,Morphine
,20183965,Tmax,Morphine had a Tmax (time at which the maximum plasma concentration was measured) of 0.5 h in both species.,Pharmacokinetics of morphine after intramuscular injection in common goldfish Carassius auratus and Atlantic salmon Salmo salar. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20183965/),h,0.5,25273,DB00295,Morphine
,20183965,Cmax (maximum plasma concentration),"The Cmax (maximum plasma concentration) showed substantial inter-individual variation, with a mean (90% CI) of 187 (167 to 199) mg l(-1) in salmon and 37 (29 to 43) mg l(-1) in goldfish, as determined by bootstrap analysis.",Pharmacokinetics of morphine after intramuscular injection in common goldfish Carassius auratus and Atlantic salmon Salmo salar. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20183965/),[mg] / [l],187,25274,DB00295,Morphine
,20183965,Cmax (maximum plasma concentration),"The Cmax (maximum plasma concentration) showed substantial inter-individual variation, with a mean (90% CI) of 187 (167 to 199) mg l(-1) in salmon and 37 (29 to 43) mg l(-1) in goldfish, as determined by bootstrap analysis.",Pharmacokinetics of morphine after intramuscular injection in common goldfish Carassius auratus and Atlantic salmon Salmo salar. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20183965/),[mg] / [l],37,25275,DB00295,Morphine
,20183965,elimination half-lives,"The mean elimination half-lives were 12.5 and 13.5 h in goldfish and in salmon, respectively.",Pharmacokinetics of morphine after intramuscular injection in common goldfish Carassius auratus and Atlantic salmon Salmo salar. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20183965/),h,12.5,25276,DB00295,Morphine
,20183965,elimination half-lives,"The mean elimination half-lives were 12.5 and 13.5 h in goldfish and in salmon, respectively.",Pharmacokinetics of morphine after intramuscular injection in common goldfish Carassius auratus and Atlantic salmon Salmo salar. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20183965/),h,13.5,25277,DB00295,Morphine
,2186650,time,The corresponding time was 125 minutes in those given midazolam.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,125,25278,DB00295,Morphine
,2186650,elimination half-life,Pharmacokinetic analysis in 20 patients showed that the elimination half-life of propofol was prolonged (470 minutes) and clearance was reduced (1.14 litres/minute) compared with subjects who had not undergone cardiopulmonary bypass.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,470,25279,DB00295,Morphine
,2186650,clearance,Pharmacokinetic analysis in 20 patients showed that the elimination half-life of propofol was prolonged (470 minutes) and clearance was reduced (1.14 litres/minute) compared with subjects who had not undergone cardiopulmonary bypass.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),[l] / [min],1.14,25280,DB00295,Morphine
,2186650,redistribution half-life,"The rapid clinical recovery was reflected in a rapid redistribution half-life (13.4 minutes), but this was also longer than the redistribution time of 2-4 minutes in other patients.",Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,13.4,25281,DB00295,Morphine
,2186650,red,"The rapid clinical recovery was reflected in a rapid redistribution half-life (13.4 minutes), but this was also longer than the redistribution time of 2-4 minutes in other patients.",Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,2-4,25282,DB00295,Morphine
,731414,first-pass elimination,From the serum concentration data after intraportal administration it was calculated that the first-pass elimination of morphine in the liver amounts to 72 +/- 2% (SD).,Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/731414/),%,72,25577,DB00295,Morphine
,731414,first-pass fraction eliminated,"The first-pass fraction eliminated after oral administration was 85 +/- 7% (SD), thus yielding a contribution by the gut mucosa of 46% to the overall first-pass elimination after an oral dose.",Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/731414/),%,85,25578,DB00295,Morphine
,9585276,steady-state concentration,Infants received morphine after a loading dose of 0.05 mg/kg and continuous infusion calculated to reach a steady-state concentration of 20 ng/mL.,Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585276/),[ng] / [ml],20,25667,DB00295,Morphine
,9585276,clearance,"Morphine given to 26 infants by continuous i.v. infusion after major noncardiac surgery has rapidly increasing clearance values, from a median value of 9.2 mL x min(-1) x kg(-1) in infants 1-7 days old, 25.3 in infants 31-90 days old, and 31.0 in infants 91-180 days old to 48.9 in infants 180-380 days old.",Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585276/),[ml] / [kg·min],9.2,25668,DB00295,Morphine
,9585276,clearance,"Morphine given to 26 infants by continuous i.v. infusion after major noncardiac surgery has rapidly increasing clearance values, from a median value of 9.2 mL x min(-1) x kg(-1) in infants 1-7 days old, 25.3 in infants 31-90 days old, and 31.0 in infants 91-180 days old to 48.9 in infants 180-380 days old.",Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585276/),[ml] / [kg·min],25.3,25669,DB00295,Morphine
,9585276,clearance,"Morphine given to 26 infants by continuous i.v. infusion after major noncardiac surgery has rapidly increasing clearance values, from a median value of 9.2 mL x min(-1) x kg(-1) in infants 1-7 days old, 25.3 in infants 31-90 days old, and 31.0 in infants 91-180 days old to 48.9 in infants 180-380 days old.",Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585276/),[ml] / [kg·min],31.0,25670,DB00295,Morphine
,9585276,clearance,"Morphine given to 26 infants by continuous i.v. infusion after major noncardiac surgery has rapidly increasing clearance values, from a median value of 9.2 mL x min(-1) x kg(-1) in infants 1-7 days old, 25.3 in infants 31-90 days old, and 31.0 in infants 91-180 days old to 48.9 in infants 180-380 days old.",Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585276/),[ml] / [kg·min],48.9,25671,DB00295,Morphine
,10320184,Mini,"Minimal respiratory rates were significantly slower after the administration of diclofenac (P < 0.001), occurring at 197+/-51.9 (60-360) min; arterial desaturations occurred in two patients without oxygen therapy.",Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: potential for opioid-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320184/),min,197,25880,DB00295,Morphine
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.29,26054,DB00295,Morphine
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.90,26055,DB00295,Morphine
,1676661,percentage,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),,17,26056,DB00295,Morphine
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],4.46,26057,DB00295,Morphine
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],3.39,26058,DB00295,Morphine
,9792524,flow-rates,"The activity of the BG-IMER was followed by measurement of percent deconjugation and the parameters investigated were: substrate concentration, pH (4 to 6), temperature (r.t., 37 degrees C), enzyme-substrate contact time using flow-rates of 0.1 to 1.0 min/min (15-1.5 min).",On-line deconjugation of glucuronides using an immobilized enzyme reactor based upon beta-glucuronidase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792524/),[min] / [min],0.1 to 1.0,27522,DB00295,Morphine
,20444020,T(1/2),"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,1.22,28839,DB00295,Morphine
,20444020,clearance,"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ml] / [kg·min],29.94,28840,DB00295,Morphine
,20444020,volume of distribution,"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[l] / [kg],3.17,28841,DB00295,Morphine
,20444020,C(max),"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ng] / [ml],735.75,28842,DB00295,Morphine
,20444020,oral bioavailability,"The oral bioavailability of codeine was 4%, morphine concentrations were negligible, but large amounts of codeine-6-glucuronide (C(max) = 1952.86 ng/mL) were detected suggesting substantial first pass metabolism.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),%,4,28843,DB00295,Morphine
,20444020,C(max),"The oral bioavailability of codeine was 4%, morphine concentrations were negligible, but large amounts of codeine-6-glucuronide (C(max) = 1952.86 ng/mL) were detected suggesting substantial first pass metabolism.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ng] / [ml],1952.86,28844,DB00295,Morphine
,20444020,C(max),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[μg] / [ml],6.74,28845,DB00295,Morphine
,20444020,T(max),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,0.85,28846,DB00295,Morphine
,20444020,T(1/2),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,0.96,28847,DB00295,Morphine
,25359452,clearance (CL),"The estimated geometric mean clearance (CL) of oxycodone was 24.3 L per hour after constant intravenous infusion and 29.5 L per hour after constant subcutaneous infusion, respectively.",Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359452/),[l] / [h],24.3,29288,DB00295,Morphine
,25359452,clearance (CL),"The estimated geometric mean clearance (CL) of oxycodone was 24.3 L per hour after constant intravenous infusion and 29.5 L per hour after constant subcutaneous infusion, respectively.",Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359452/),[l] / [h],29.5,29289,DB00295,Morphine
,10866910,area under the curve,"Concerning the pharmacokinetic variables of morphine and its glucuronides, no significant difference between morphine + placebo and morphine + GBP was observed, whereas the area under the curve of GBP (43.9 +/- 5.3 vs 63.4 +/- 16.2 microg.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),μg,43.9,29884,DB00295,Morphine
,10866910,area under the curve,"Concerning the pharmacokinetic variables of morphine and its glucuronides, no significant difference between morphine + placebo and morphine + GBP was observed, whereas the area under the curve of GBP (43.9 +/- 5.3 vs 63.4 +/- 16.2 microg.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),μg,63.4,29885,DB00295,Morphine
,10866910,apparent oral clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],230.8,29886,DB00295,Morphine
,10866910,apparent oral clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],178,29887,DB00295,Morphine
,10866910,apparent renal clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],86.9,29888,DB00295,Morphine
,10866910,apparent renal clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],73.0,29889,DB00295,Morphine
,29695616,total protein content,"The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic versus control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8, vs. 51.1 ± 20.7 mg/g liver, respectively).",Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695616/),[mg] / [g],38.3,29901,DB00295,Morphine
,29695616,total protein content,"The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic versus control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8, vs. 51.1 ± 20.7 mg/g liver, respectively).",Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695616/),[mg] / [g],32.3,29902,DB00295,Morphine
,29695616,total protein content,"The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic versus control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8, vs. 51.1 ± 20.7 mg/g liver, respectively).",Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695616/),[mg] / [g],51.1,29903,DB00295,Morphine
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,0.9,30364,DB00295,Morphine
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30365,DB00295,Morphine
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,1.9,30366,DB00295,Morphine
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2.2,30367,DB00295,Morphine
,22541841,absolute bioavailability,"The absolute bioavailability of naloxone was higher following rectal administration compared with oral administration, but was still low at 15%.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,15,30368,DB00295,Morphine
≤,22541841,oral absolute bioavailability,The mean oral absolute bioavailability of naloxone in this study was ≤ 2% at doses ranging from 5 mg to 120 mg.,Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30369,DB00295,Morphine
,3670879,steady-state plasma,"In monkeys administered a constant infusion of 0.15 mg morphine sulfate/kg/h, morphine steady-state plasma and CSF concentrations were 84.4 +/- 20.0 ng/ml and 25.3 +/- 4.9 ng/ml, respectively, for a CSF:plasma ratio of 0.30 +/- 0.05.",Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670879/),[ng] / [ml],84.4,30828,DB00295,Morphine
,3670879,CSF concentrations,"In monkeys administered a constant infusion of 0.15 mg morphine sulfate/kg/h, morphine steady-state plasma and CSF concentrations were 84.4 +/- 20.0 ng/ml and 25.3 +/- 4.9 ng/ml, respectively, for a CSF:plasma ratio of 0.30 +/- 0.05.",Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670879/),[ng] / [ml],25.3,30829,DB00295,Morphine
,3670879,CSF:plasma ratio,"In monkeys administered a constant infusion of 0.15 mg morphine sulfate/kg/h, morphine steady-state plasma and CSF concentrations were 84.4 +/- 20.0 ng/ml and 25.3 +/- 4.9 ng/ml, respectively, for a CSF:plasma ratio of 0.30 +/- 0.05.",Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670879/),,0.30,30830,DB00295,Morphine
,3670879,CSF:plasma,"The CSF:plasma area under the concentration-time curve (AUC) ratio was 0.40 +/- 0.07, similar to that seen with continuous infusion.",Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670879/),,0.40,30831,DB00295,Morphine
,3670879,area under the concentration-time curve (AUC) ratio,"The CSF:plasma area under the concentration-time curve (AUC) ratio was 0.40 +/- 0.07, similar to that seen with continuous infusion.",Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670879/),,0.40,30832,DB00295,Morphine
,3670879,clearance,The average clearance value was 23 ml/min/kg which is at the upper end of the estimates reported for morphine clearance using bolus administration.,Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670879/),[ml] / [kg·min],23,30833,DB00295,Morphine
,2891328,maximum plasma concentrations,"Morphine appeared rapidly in plasma, and maximum plasma concentrations were usually detected 5 min after injection and averaged 33 ng.",Pharmacokinetics of epidural morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),ng,33,31927,DB00295,Morphine
,2891328,terminal plasma half-life,"The terminal plasma half-life averaged 91 +/- 34 min and 87 +/- 27 min, respectively (mean +/- SEM).",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,91,31928,DB00295,Morphine
,2891328,terminal plasma half-life,"The terminal plasma half-life averaged 91 +/- 34 min and 87 +/- 27 min, respectively (mean +/- SEM).",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,87,31929,DB00295,Morphine
,2891328,Maximal plasma concentrations,Maximal plasma concentrations of meperidine were usually detected 10 or 15 min post-injection and averaged 196 +/- 29 ng.,Pharmacokinetics of epidural morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),ng,196,31930,DB00295,Morphine
,2891328,terminal plasma half-life,The terminal plasma half-life averaged 124 +/- 26 min.,Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,124,31931,DB00295,Morphine
,2891328,absorption half-life,"Morphine crossed the dura relatively slowly, and the absorption half-life across the dura averaged 22 min.",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,22,31932,DB00295,Morphine
,2891328,absorption half-life,"In contrast, meperidine crossed the dura quickly, with an absorption half-life averaging 7.6 +/- 2.0 min.",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,7.6,31933,DB00295,Morphine
,2891328,early half-life in CSF,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,73.3,31934,DB00295,Morphine
,2891328,early half-life in CSF,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,71.3,31935,DB00295,Morphine
,2891328,late half-life,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,369,31936,DB00295,Morphine
,2891328,late half-life,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,982,31937,DB00295,Morphine
,8734231,plasma peak concentration,The median plasma peak concentration was 0.94 +/- 0.47 microgram.,[Analgesia after laparoscopic cholecystectomy by intraperitoneal administration of bupivacaine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8734231/),μg,0.94,32102,DB00295,Morphine
>,8734231,toxic concentrations,In one patient toxic concentrations (> 1.6 micrograms.,[Analgesia after laparoscopic cholecystectomy by intraperitoneal administration of bupivacaine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8734231/),μg,1.6,32103,DB00295,Morphine
,11195429,absolute bioavailability,A nasal spray formulation of ketorolac tromethamine showed the highest absorption with an absolute bioavailability of 91%.,Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,91,32893,DB00295,Morphine
,11195429,absolute bioavailability,The absolute bioavailability of a solution of ketorolac acid was 70%.,Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,70,32894,DB00295,Morphine
,11195429,absolute bioavailability,"Interestingly, the absolute bioavailability of ketorolac tromethamine from a powder formulation is only 38%, indicating that the drug may not be totally released from the polymer matrix before it is removed from nasal epithelium by mucociliary clearance.",Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,38,32895,DB00295,Morphine
,2012289,peak plasma level,Morphine was absorbed rapidly after caudal injection to reach a peak plasma level of 21.2 (+/- 4.8) ng.,Combined morphine-bupivacaine caudals for reconstructive penile surgery in children: systemic absorption of morphine and postoperative analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012289/),ng,21.2,33111,DB00295,Morphine
,1636668,clearances,"Morphine clearance increased with age, median clearances ranging from 5 mL/kg per minute in neonates aged 1 to 7 days to 21 mL/kg per minute in infants aged 6 months and older.",The maturation of morphine clearance and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636668/),[ml] / [kg·min],5,33564,DB00295,Morphine
,1636668,clearances,"Morphine clearance increased with age, median clearances ranging from 5 mL/kg per minute in neonates aged 1 to 7 days to 21 mL/kg per minute in infants aged 6 months and older.",The maturation of morphine clearance and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636668/),[ml] / [kg·min],21,33565,DB00295,Morphine
,3813075,elimination half-lives,Infants 1-4 days of age (newborns) showed longer elimination half-lives than the older infants (6.8 vs. 3.9 h).,Morphine pharmacokinetics in early infancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813075/),h,6.8,33657,DB00295,Morphine
,3813075,elimination half-lives,Infants 1-4 days of age (newborns) showed longer elimination half-lives than the older infants (6.8 vs. 3.9 h).,Morphine pharmacokinetics in early infancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813075/),h,3.9,33658,DB00295,Morphine
,3813075,Clearance,Clearance in the newborns is less than one-half that found in older infants (6.3 vs. 23.8 ml X min-1 X kg-1).,Morphine pharmacokinetics in early infancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813075/),[ml] / [kg·min],6.3,33659,DB00295,Morphine
,3813075,Clearance,Clearance in the newborns is less than one-half that found in older infants (6.3 vs. 23.8 ml X min-1 X kg-1).,Morphine pharmacokinetics in early infancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813075/),[ml] / [kg·min],23.8,33660,DB00295,Morphine
,3813075,elimination half-life,"The combination of lower clearance and longer elimination half-life in newborns (0-7 days) may well explain a prolonged duration of action for morphine in very young infants, but other etiologies are needed to explain the respiratory sensitivity believed to persist in older infants.",Morphine pharmacokinetics in early infancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813075/),d,0-7,33661,DB00295,Morphine
,18062845,T(max),Median T(max) values were between 12 and 16 h and ranges were similar for all treatments.,Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062845/),h,12 and 16,34454,DB00295,Morphine
,18566040,concentration ratio,"During maternal infusion of M3G to steady-state, the glucuronide metabolite readily appeared in fetal plasma achieving a mean +/- S.D. fetal-to-maternal concentration ratio of 0.79 +/- 0.04.",Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18566040/),,0.79,34542,DB00295,Morphine
,18566040,steady-state clearances,"In paired maternal and fetal infusions, steady-state clearances were 53 +/- 3 (maternal), 1.5 +/- 0.5 (maternal-to-fetal), 2.6 +/- 0.1 (fetal-to-maternal), and -0.70 +/- 0.6 ml x min(-1) (fetal).",Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18566040/),[ml] / [min],53,34543,DB00295,Morphine
,18566040,steady-state clearances,"In paired maternal and fetal infusions, steady-state clearances were 53 +/- 3 (maternal), 1.5 +/- 0.5 (maternal-to-fetal), 2.6 +/- 0.1 (fetal-to-maternal), and -0.70 +/- 0.6 ml x min(-1) (fetal).",Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18566040/),[ml] / [min],1.5,34544,DB00295,Morphine
,18566040,steady-state clearances,"In paired maternal and fetal infusions, steady-state clearances were 53 +/- 3 (maternal), 1.5 +/- 0.5 (maternal-to-fetal), 2.6 +/- 0.1 (fetal-to-maternal), and -0.70 +/- 0.6 ml x min(-1) (fetal).",Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18566040/),[ml] / [min],2.6,34545,DB00295,Morphine
,18566040,steady-state clearances,"In paired maternal and fetal infusions, steady-state clearances were 53 +/- 3 (maternal), 1.5 +/- 0.5 (maternal-to-fetal), 2.6 +/- 0.1 (fetal-to-maternal), and -0.70 +/- 0.6 ml x min(-1) (fetal).",Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18566040/),[ml] / [min],-0.70,34546,DB00295,Morphine
,3784573,steady-state plasma concentration,"The steady-state plasma concentration and CSF flux (or appearance rate) of morphine was 0.037 and 0.009 micrograms/min, respectively.",A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784573/),[μg] / [min],0.037,35141,DB00295,Morphine
,3784573,CSF flux,"The steady-state plasma concentration and CSF flux (or appearance rate) of morphine was 0.037 and 0.009 micrograms/min, respectively.",A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784573/),[μg] / [min],0.037,35142,DB00295,Morphine
,3784573,appearance rate,"The steady-state plasma concentration and CSF flux (or appearance rate) of morphine was 0.037 and 0.009 micrograms/min, respectively.",A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784573/),[μg] / [min],0.009,35143,DB00295,Morphine
,33833624,elimination half-life,"Ketorolac exhibits rapid elimination of the analgesia-producing S (-) isomer, elimination half-life of 0.83 hours.",Ketorolac in Postoperative Neonates and Infants: A Systematic Review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33833624/),h,0.83,35413,DB00295,Morphine
,9696456,pain tolerance,"Compared to placebo, 20 mg morphine caused a significant increase in pain tolerance in both phenotypes, EMs and PMs (16.2+/-27.4 vs. -0.66+/-27.4 s x h, n=18).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),h·s,16.2,35418,DB00295,Morphine
,9696456,pain tolerance,"Compared to placebo, 20 mg morphine caused a significant increase in pain tolerance in both phenotypes, EMs and PMs (16.2+/-27.4 vs. -0.66+/-27.4 s x h, n=18).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),h·s,-0.66,35419,DB00295,Morphine
,9696456,Cmax,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],44,35420,DB00295,Morphine
,9696456,AUC,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],199,35421,DB00295,Morphine
,9696456,Cmax,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],48,35422,DB00295,Morphine
,9696456,AUC,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],210,35423,DB00295,Morphine
,9696456,Cmax,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],38,35424,DB00295,Morphine
,9696456,AUC,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],173,35425,DB00295,Morphine
,9696456,Cmax,In PMs only traces of morphine could be detected in plasma (Cmax: 2+/-1 nmol/l; AUC: 10+/-7 nmol x h/l).,Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],2,35426,DB00295,Morphine
,9696456,AUC,In PMs only traces of morphine could be detected in plasma (Cmax: 2+/-1 nmol/l; AUC: 10+/-7 nmol x h/l).,Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],10,35427,DB00295,Morphine
,15509185,bioavailability,"Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules.",Clinical pharmacology of tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,87-95,35613,DB00295,Morphine
,15509185,plasma protein binding,Tramadol is rapidly distributed in the body; plasma protein binding is about 20%.,Clinical pharmacology of tramadol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,20,35614,DB00295,Morphine
,15509185,elimination half-life,The mean elimination half-life is about 6 hours.,Clinical pharmacology of tramadol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),h,6,35615,DB00295,Morphine
,3387374,bioavailability,The bioavailability of morphine after rectal administration was found to be 53.3 +/- 17.8% (mean +/- S.D.).,The bioavailability of rectally administered morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3387374/),%,53.3,36839,DB00295,Morphine
,3387374,Peak concentrations,Peak concentrations of 16.3 +/- 8.7 ng ml-1 were reached after 59 +/- 16 min.,The bioavailability of rectally administered morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3387374/),[ng] / [ml],16.3,36840,DB00295,Morphine
,25807927,tmax,"Following administration of the ER tablet, plasma concentrations of hydromorphone slowly increased with a median tmax of 5.0 h and the Cmax decreased to 37% of the IR tablet, while the AUC0-inf was comparable with that of the IR tablet when administered at the same dose.","Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25807927/),h,5.0,36948,DB00295,Morphine
,26712409,first-order absorption rate constant,"The estimated first-order absorption rate constant and bioavailability were 0.751 hour(-1) and 48.5%, respectively.",Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26712409/),1/[hour],0.751,36957,DB00295,Morphine
,26712409,bioavailability,"The estimated first-order absorption rate constant and bioavailability were 0.751 hour(-1) and 48.5%, respectively.",Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26712409/),%,48.5,36958,DB00295,Morphine
,8971830,Lumbar CSF levels,Lumbar CSF levels were in the range of 44 to 1230 ng/ml.,Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971830/),[ng] / [ml],44 to 1230,37003,DB00295,Morphine
,23936895,peak effect (Emax),"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,69.6,37015,DB00295,Morphine
,23936895,peak effect (Emax),"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,55.2,37016,DB00295,Morphine
,23936895,area under the effect curve,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,86.3,37017,DB00295,Morphine
,23936895,area under the effect curve,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,66.7,37018,DB00295,Morphine
,23936895,Emax,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,87.6,37019,DB00295,Morphine
,23936895,Emax,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,86.6,37020,DB00295,Morphine
,23936895,area under the curve over 2 h,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,120.6,37021,DB00295,Morphine
,23936895,area under the curve over 2 h,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,132.9,37022,DB00295,Morphine
,23936895,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),ng⁄ml,27.3,37023,DB00295,Morphine
,23936895,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),ng⁄ml,27.7,37024,DB00295,Morphine
,23936895,time to Cmax,"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.57,37025,DB00295,Morphine
,23936895,time to Cmax,"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.6,37026,DB00295,Morphine
,23936895,Cmax,Naltrexone mean Cmax was 1497 pg⁄mL after MSN and median time to Cmax was 0.55 h.,Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),pg⁄ml,1497,37027,DB00295,Morphine
,23936895,time to Cmax,Naltrexone mean Cmax was 1497 pg⁄mL after MSN and median time to Cmax was 0.55 h.,Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.55,37028,DB00295,Morphine
,8504624,total urinary recovery,"The mean total urinary recovery as morphine, M3G and M6G was 74.6 +/- 26.5% of the dose.","Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504624/),%,74.6,37131,DB00295,Morphine
,15505457,potency,The integrated NONMEM analysis yielded a potency parameter of 32 +/- 1.4 nm (typical value +/- SE) and a blood-effect site equilibration half-life of 4.4 +/- 0.3 h.,Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505457/),nm,32,37222,DB00295,Morphine
,15505457,half-life,The integrated NONMEM analysis yielded a potency parameter of 32 +/- 1.4 nm (typical value +/- SE) and a blood-effect site equilibration half-life of 4.4 +/- 0.3 h.,Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505457/),h,4.4,37223,DB00295,Morphine
,25315409,steady-state morphine concentration,"The models indicate that a steady-state morphine concentration of 21ng/ml causes 33% and 0.84% increases in stimulus intensity from baseline for muscle pressure and skin heat, respectively.",Modelling concentration-analgesia relationships for morphine to evaluate experimental pain models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315409/),[ng] / [ml],21,38049,DB00295,Morphine
,33177323,oral bioavailability,"The maximum concentration of oral hydromorphone was reduced by 37% (ratio to control: 0.63, 90% CI, 0.55-0.72), and oral bioavailability decreased from 33% to 26% (ratio to control: 0.78, 90% CI, 0.67-0.91) in the rifampin phase compared with placebo.",Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33177323/),%,33,38402,DB00295,Morphine
,33177323,oral bioavailability,"The maximum concentration of oral hydromorphone was reduced by 37% (ratio to control: 0.63, 90% CI, 0.55-0.72), and oral bioavailability decreased from 33% to 26% (ratio to control: 0.78, 90% CI, 0.67-0.91) in the rifampin phase compared with placebo.",Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33177323/),%,26,38403,DB00295,Morphine
,2249372,terminal half-life,"Morphine terminal half-life was 92 +/- 9 minutes, total body clearance was 1260 ml.min-1, and the hepatic extraction ratio was 0.65 +/- 0.11.",Extrahepatic metabolism of morphine occurs in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249372/),min,92,38875,DB00295,Morphine
,2249372,total body clearance,"Morphine terminal half-life was 92 +/- 9 minutes, total body clearance was 1260 ml.min-1, and the hepatic extraction ratio was 0.65 +/- 0.11.",Extrahepatic metabolism of morphine occurs in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249372/),[ml] / [min],1260,38876,DB00295,Morphine
,2249372,hepatic extraction ratio,"Morphine terminal half-life was 92 +/- 9 minutes, total body clearance was 1260 ml.min-1, and the hepatic extraction ratio was 0.65 +/- 0.11.",Extrahepatic metabolism of morphine occurs in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249372/),,0.65,38877,DB00295,Morphine
,26218586,clearance (CL/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],75,38897,DB00295,Morphine
,26218586,volume of distribution (V/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,756,38898,DB00295,Morphine
,26218586,absorption rate constant (Ka ),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),1/[h],0.581,38899,DB00295,Morphine
,26218586,CL/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38900,DB00295,Morphine
,26218586,V/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,119,38901,DB00295,Morphine
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38902,DB00295,Morphine
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],21,38903,DB00295,Morphine
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,193,38904,DB00295,Morphine
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,174,38905,DB00295,Morphine
,1389934,Cmax,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[ng] / [ml],34 to 38,38910,DB00295,Morphine
,1389934,AUC,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[h·ng] / [ml],208 to 245,38911,DB00295,Morphine
,1389934,tmax,The median tmax of oxycodone was 1 h in all groups.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),h,1,38912,DB00295,Morphine
,1389934,bioavailability,The bioavailability of oral relative to i.m. oxycodone was 60%.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),%,60,38913,DB00295,Morphine
,1389934,renal clearance,The mean renal clearance of oxycodone was 0.07-0.08 l min-1.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[l] / [min],0.07-0.08,38914,DB00295,Morphine
,30965021,limits of detection,"The method was validated following SWGTOX guidelines, and both analytes displayed limits of detection and quantification at 7.5 and 15 pg/mL, respectively.","Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30965021/),[pg] / [ml],7.5,38968,DB00295,Morphine
,30965021,limits of detection,"The method was validated following SWGTOX guidelines, and both analytes displayed limits of detection and quantification at 7.5 and 15 pg/mL, respectively.","Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30965021/),[pg] / [ml],15,38969,DB00295,Morphine
,7482686,initial distribution phase t1/2 pi,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,2.22,39406,DB00295,Morphine
,7482686,intermediate distribution phase t1/2 alpha,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,42.9,39407,DB00295,Morphine
,7482686,elimination phase t1/2 beta,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,370,39408,DB00295,Morphine
,7482686,clearance,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[l] / [min],1.31,39409,DB00295,Morphine
,7482686,blood concentration,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),mg,2.2,39410,DB00295,Morphine
,7482686,apparent Css,The mean calculated apparent Css was 3.9 (1.5) mg/L.,Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[mg] / [l],3.9,39411,DB00295,Morphine
,11996900,Oral bioavailability,Oral bioavailability of M6G was 2.1%; 13% of oral M6G was deglucuronidated to morphine.,Verapamil decreases glucuronidase activity in the gut. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),%,2.1,40433,DB00295,Morphine
,11996900,Oral bioavailability,Oral bioavailability of M6G was 2.1%; 13% of oral M6G was deglucuronidated to morphine.,Verapamil decreases glucuronidase activity in the gut. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),%,13,40434,DB00295,Morphine
,11996900,IC(50),"In vitro experiments provided evidence that verapamil inhibits beta-glucuronidase from E. coli with an IC(50) of 30 microM, whereas no inhibition of the rat beta-glucuronidase from small intestine was seen.",Verapamil decreases glucuronidase activity in the gut. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),μM,30,40435,DB00295,Morphine
,9034277,clearance,The mean value for morphine clearance was 11.7 +/- 9.3 (SD) ml/min/kg (range 2.6 to 34.5).,Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034277/),[ml] / [kg·min],11.7,40504,DB00295,Morphine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of morphine in the normal liver was 0.67 +/- 0.18 and fell to 0.48 +/- 0.03 (p < 0.001) in the acutely damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.67,40601,DB00295,Morphine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of morphine in the normal liver was 0.67 +/- 0.18 and fell to 0.48 +/- 0.03 (p < 0.001) in the acutely damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.48,40602,DB00295,Morphine
,7930474,hepatic clearance,The hepatic clearance of morphine fell from 6.7 +/- 0.2 ml/min in controls to 4.7 +/- 0.3 (p < 0.005) in the treated livers.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),[ml] / [min],6.7,40603,DB00295,Morphine
,7930474,hepatic clearance,The hepatic clearance of morphine fell from 6.7 +/- 0.2 ml/min in controls to 4.7 +/- 0.3 (p < 0.005) in the treated livers.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,4.7,40604,DB00295,Morphine
,7930474,perfusion rates,Similar changes were seen at perfusion rates of 7 and 12 ml/min.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),[ml] / [min],7,40605,DB00295,Morphine
,7930474,perfusion rates,Similar changes were seen at perfusion rates of 7 and 12 ml/min.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),[ml] / [min],12,40606,DB00295,Morphine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of pethidine was 0.97 +/- 0.01 in control livers and was reduced to 0.91 +/- 0.02 (p < 0.005) in damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.97,40607,DB00295,Morphine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of pethidine was 0.97 +/- 0.01 in control livers and was reduced to 0.91 +/- 0.02 (p < 0.005) in damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.91,40608,DB00295,Morphine
,19793724,Peak plasma morphine concentrations,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],109,40849,DB00295,Morphine
,19793724,Peak plasma morphine concentrations,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],36,40850,DB00295,Morphine
,19793724,area under the curve,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [h·l],3761,40851,DB00295,Morphine
,19793724,area under the curve,"Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [h·l],1794,40852,DB00295,Morphine
,19793724,plasma concentrations,"Higher plasma concentrations at 60 min (47 vs 32 nmol/l) were also observed following intravenous diamorphine (p = 0.01, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],47,40853,DB00295,Morphine
,19793724,plasma concentrations,"Higher plasma concentrations at 60 min (47 vs 32 nmol/l) were also observed following intravenous diamorphine (p = 0.01, Mann-Whitney U test).",Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19793724/),[nM] / [l],32,40854,DB00295,Morphine
,27779356,CMAX,A single-dose morphine 100 mcg·kg-1 achieved a mean CMAX 10 mcg·l-1 .,Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779356/),[mcg] / [l],10,40886,DB00295,Morphine
,27779356,steady-state concentration,Repeat 4-hourly dosing achieved mean steady-state concentration 13-18 mcg·l-1 ; concentrations associated with good analgesia after intravenous administration.,Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779356/),[mcg] / [l],13-18,40887,DB00295,Morphine
,7742159,minimum plasma concentration,There was a nine-fold variation in the minimum plasma concentration of codeine consistent with pain relief (40-350 ng ml-1).,Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742159/),[ng] / [ml],40-350,41394,DB00295,Morphine
,8556223,half-life,The half-life of nicomorphine was 0.32 +/- 0.20 h (mean +/- SD) and is governed by the absorption-rather than the elimination rate.,The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556223/),h,0.32,41610,DB00295,Morphine
,8556223,half-life,"The half-life of 6-mononicotinoylmorphine (0.39 +/- 0.09 h) was identical to that of the parent compound (p = 0.29), suggesting it is directly related to the absorption rate of nicomorphine.",The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556223/),h,0.39,41611,DB00295,Morphine
,8556223,half-life,Morphine had a half-life of 1.38 +/- 0.31 h.,The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556223/),h,1.38,41612,DB00295,Morphine
,8556223,half-life,The half-life of these 2 glucuronide conjugates was about 2.6 h (p = 0.07).,The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556223/),h,2.6,41613,DB00295,Morphine
,8556223,renal clearance,"In urine only morphine and its glucuronides are found, with renal clearance values of 214 ml.min-1 for morphine and 132 ml.min-1 for the glucuronides.",The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556223/),[ml] / [min],214,41614,DB00295,Morphine
,8556223,renal clearance,"In urine only morphine and its glucuronides are found, with renal clearance values of 214 ml.min-1 for morphine and 132 ml.min-1 for the glucuronides.",The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556223/),[ml] / [min],132,41615,DB00295,Morphine
,9342447,Bioavailability,Bioavailability of both OSRMS and NSRMS was low (15%-17%).,Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342447/),%,15,41780,DB00295,Morphine
,9342447,Bioavailability,Bioavailability of both OSRMS and NSRMS was low (15%-17%).,Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342447/),%,17,41781,DB00295,Morphine
,15667599,volume of distribution for the central compartment,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),l,45.7,41945,DB00295,Morphine
,15667599,apparent elimination rate constant,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),1/[hr],0.150,41946,DB00295,Morphine
,15667599,bioavailability,The bioavailability was approximately 60%.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41947,DB00295,Morphine
,15667599,bioavailability,The bioavailability of inhaled caffeine is approximately 60% in experienced smokers.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41948,DB00295,Morphine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.0,42982,DB00295,Morphine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,5.5,42983,DB00295,Morphine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42984,DB00295,Morphine
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.61,42985,DB00295,Morphine
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,2.04,42986,DB00295,Morphine
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42987,DB00295,Morphine
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.88,42988,DB00295,Morphine
,27815868,area under the plasma concentration-time curve (AUC) ratios,Estimated mean area under the plasma concentration-time curve (AUC) ratios following oral versus subcutaneous administration were: M3G/morphine 29.7:1 vs. 11.1:1; M6G/morphine 5.26:1 vs. 1.95:1; and M3G/M6G 5.65:1 vs. 5.70:1.,A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815868/),:1,29.7,43275,DB00295,Morphine
,27815868,area under the plasma concentration-time curve (AUC) ratios,Estimated mean area under the plasma concentration-time curve (AUC) ratios following oral versus subcutaneous administration were: M3G/morphine 29.7:1 vs. 11.1:1; M6G/morphine 5.26:1 vs. 1.95:1; and M3G/M6G 5.65:1 vs. 5.70:1.,A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815868/),:1,11.1,43276,DB00295,Morphine
,27815868,area under the plasma concentration-time curve (AUC) ratios,Estimated mean area under the plasma concentration-time curve (AUC) ratios following oral versus subcutaneous administration were: M3G/morphine 29.7:1 vs. 11.1:1; M6G/morphine 5.26:1 vs. 1.95:1; and M3G/M6G 5.65:1 vs. 5.70:1.,A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815868/),:1,5.26,43277,DB00295,Morphine
,27815868,area under the plasma concentration-time curve (AUC) ratios,Estimated mean area under the plasma concentration-time curve (AUC) ratios following oral versus subcutaneous administration were: M3G/morphine 29.7:1 vs. 11.1:1; M6G/morphine 5.26:1 vs. 1.95:1; and M3G/M6G 5.65:1 vs. 5.70:1.,A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815868/),:1,1.95,43278,DB00295,Morphine
,27815868,area under the plasma concentration-time curve (AUC) ratios,Estimated mean area under the plasma concentration-time curve (AUC) ratios following oral versus subcutaneous administration were: M3G/morphine 29.7:1 vs. 11.1:1; M6G/morphine 5.26:1 vs. 1.95:1; and M3G/M6G 5.65:1 vs. 5.70:1.,A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815868/),:1,5.65,43279,DB00295,Morphine
,27815868,area under the plasma concentration-time curve (AUC) ratios,Estimated mean area under the plasma concentration-time curve (AUC) ratios following oral versus subcutaneous administration were: M3G/morphine 29.7:1 vs. 11.1:1; M6G/morphine 5.26:1 vs. 1.95:1; and M3G/M6G 5.65:1 vs. 5.70:1.,A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815868/),:1,5.70,43280,DB00295,Morphine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],49.2,44070,DB00295,Morphine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],32.6,44071,DB00295,Morphine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],28.4,44072,DB00295,Morphine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],37.3,44073,DB00295,Morphine
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,5.9,44074,DB00295,Morphine
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,8.0,44075,DB00295,Morphine
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,1.0,44076,DB00295,Morphine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],640,44077,DB00295,Morphine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],600,44078,DB00295,Morphine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],578,44079,DB00295,Morphine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],581,44080,DB00295,Morphine
,8424509,maximum concentration (Cmax),"Sufentanil appeared rapidly in lumbar CSF, reaching a maximum concentration (Cmax) of 57 ng/mL at 6.5 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],57,44567,DB00295,Morphine
,8424509,Cmax,"In cisternal CSF, a Cmax of 1.2 ng/mL was reached at 21 min, and Cmax in plasma was 0.35 ng/mL at 6 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],1.2,44568,DB00295,Morphine
,8424509,Cmax,"In cisternal CSF, a Cmax of 1.2 ng/mL was reached at 21 min, and Cmax in plasma was 0.35 ng/mL at 6 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],0.35,44569,DB00295,Morphine
,11793627,steady-state concentrations,"The steady-state concentrations of morphine, M3G, and M6G ranged from 20 to 452, 29 to 3436, and 20 to 1240 mumol/L, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[μM] / [l],20 to 452,45044,DB00295,Morphine
,11793627,steady-state concentrations,"The steady-state concentrations of morphine, M3G, and M6G ranged from 20 to 452, 29 to 3436, and 20 to 1240 mumol/L, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[μM] / [l],29 to 3436,45045,DB00295,Morphine
,11793627,steady-state concentrations,"The steady-state concentrations of morphine, M3G, and M6G ranged from 20 to 452, 29 to 3436, and 20 to 1240 mumol/L, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[μM] / [l],20 to 1240,45046,DB00295,Morphine
,11793627,systemic clearance (Cls),The systemic clearance (Cls) of morphine ranged from 14.8 to 40.3 mL/min/kg and did not change over time.,Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[ml] / [kg·min],14.8 to 40.3,45047,DB00295,Morphine
,11793627,recovery,"Mean recovery of morphine, M3G, and M6G in urine was 1.7 +/- 1.0%, 42.0 +/- 16.8%, and 11.8 +/- 3.2%, respectively, and renal clearance ranged from 8 to 64, 26 to 325, and 59 to 589 mL/min, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),%,1.7,45048,DB00295,Morphine
,11793627,recovery,"Mean recovery of morphine, M3G, and M6G in urine was 1.7 +/- 1.0%, 42.0 +/- 16.8%, and 11.8 +/- 3.2%, respectively, and renal clearance ranged from 8 to 64, 26 to 325, and 59 to 589 mL/min, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),%,42.0,45049,DB00295,Morphine
,11793627,recovery,"Mean recovery of morphine, M3G, and M6G in urine was 1.7 +/- 1.0%, 42.0 +/- 16.8%, and 11.8 +/- 3.2%, respectively, and renal clearance ranged from 8 to 64, 26 to 325, and 59 to 589 mL/min, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),%,11.8,45050,DB00295,Morphine
,11793627,renal clearance,"Mean recovery of morphine, M3G, and M6G in urine was 1.7 +/- 1.0%, 42.0 +/- 16.8%, and 11.8 +/- 3.2%, respectively, and renal clearance ranged from 8 to 64, 26 to 325, and 59 to 589 mL/min, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[ml] / [min],8 to 64,45051,DB00295,Morphine
,11793627,renal clearance,"Mean recovery of morphine, M3G, and M6G in urine was 1.7 +/- 1.0%, 42.0 +/- 16.8%, and 11.8 +/- 3.2%, respectively, and renal clearance ranged from 8 to 64, 26 to 325, and 59 to 589 mL/min, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[ml] / [min],26 to 325,45052,DB00295,Morphine
,11793627,renal clearance,"Mean recovery of morphine, M3G, and M6G in urine was 1.7 +/- 1.0%, 42.0 +/- 16.8%, and 11.8 +/- 3.2%, respectively, and renal clearance ranged from 8 to 64, 26 to 325, and 59 to 589 mL/min, respectively.",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),[ml] / [min],59 to 589,45053,DB00295,Morphine
,11793627,pain intensity ratings,"Mean pain intensity ratings at rest remained low and stable (0.7 +/- 0.9 on day 7, 0.4 +/- 0.3 on day 14, 0 +/- 0 on day 21).",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),,0.7,45054,DB00295,Morphine
,11793627,pain intensity ratings,"Mean pain intensity ratings at rest remained low and stable (0.7 +/- 0.9 on day 7, 0.4 +/- 0.3 on day 14, 0 +/- 0 on day 21).",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),,0.4,45055,DB00295,Morphine
,11793627,pain intensity ratings,"Mean pain intensity ratings at rest remained low and stable (0.7 +/- 0.9 on day 7, 0.4 +/- 0.3 on day 14, 0 +/- 0 on day 21).",Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793627/),,0,45056,DB00295,Morphine
,7869211,Plasma morphine clearances,"Plasma morphine clearances ranged from 6.2 to 59.1 ml min-1 kg-1 (35.5 +/- 12.4, mean +/- SD) during steady-state infusions.",Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7869211/),[ml] / [kg·min],35.5,46291,DB00295,Morphine
,7869211,clearance,A significant difference (p = 0.042) was also observed in clearance values between patients who had serious adverse symptoms (23.4 +/- 10.7 ml min-1 kg-1) and those who had less serious symptoms (36.3 +/- 6.4 ml min-1 kg-1) when morphine was given at high dosage rates (> or = 0.15 mg kg-1 hr-1).,Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7869211/),[ml] / [kg·min],23.4,46292,DB00295,Morphine
,7869211,clearance,A significant difference (p = 0.042) was also observed in clearance values between patients who had serious adverse symptoms (23.4 +/- 10.7 ml min-1 kg-1) and those who had less serious symptoms (36.3 +/- 6.4 ml min-1 kg-1) when morphine was given at high dosage rates (> or = 0.15 mg kg-1 hr-1).,Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7869211/),[ml] / [kg·min],36.3,46293,DB00295,Morphine
,7869211,half-life,Pharmacokinetic modeling of plasma morphine concentrations adequately fit a two-compartment model with a short initial distribution phase (mean half-life = 4.5 minutes) and a rapid terminal elimination half-life (77.6 +/- 19.2 minutes).,Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7869211/),min,4.5,46294,DB00295,Morphine
,7869211,terminal elimination half-life,Pharmacokinetic modeling of plasma morphine concentrations adequately fit a two-compartment model with a short initial distribution phase (mean half-life = 4.5 minutes) and a rapid terminal elimination half-life (77.6 +/- 19.2 minutes).,Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7869211/),min,77.6,46295,DB00295,Morphine
,26223568,peak synovial morphine concentrations,Mean ± SD peak synovial morphine concentrations over 12 perfusions were 3903 ± 4881 ng/mL.,Morphine Synovial Fluid Concentrations After Intravenous Regional Limb Perfusion in Standing Horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26223568/),[ng] / [ml],3903,46574,DB00295,Morphine
,26223568,peak gentamicin concentrations,"Mean peak gentamicin concentrations in synovial fluid were 76,315 ± 39,809 ng/mL.",Morphine Synovial Fluid Concentrations After Intravenous Regional Limb Perfusion in Standing Horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26223568/),[ng] / [ml],"76,315",46575,DB00295,Morphine
,3530119,elimination half-lives,"Following bolus injection, the mean CSF elimination half-lives for morphine sulfate and DADL were 94 and 115 minutes, respectively.",Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530119/),min,94,46841,DB00295,Morphine
,3530119,elimination half-lives,"Following bolus injection, the mean CSF elimination half-lives for morphine sulfate and DADL were 94 and 115 minutes, respectively.",Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530119/),min,115,46842,DB00295,Morphine
,3530119,L/C ratios,"With the catheter tip at L2, the ratio of lumbar to cisternal (L/C) concentrations of morphine sulfate was about 7:1, and with the catheter tip at T10, the L/C ratios of morphine sulfate and DADL were approximately 2:1, indicating that this ratio is dependent in part on the level of intrathecal drug administration.",Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530119/),,2,46843,DB00295,Morphine
,7823539,elimination half-lives,"Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route.",Pharmacokinetics and pharmacodynamics of smoked heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7823539/),min,3.3,46890,DB00295,Morphine
,7823539,elimination half-lives,"Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route.",Pharmacokinetics and pharmacodynamics of smoked heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7823539/),min,5.4,46891,DB00295,Morphine
,7823539,elimination half-lives,"Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route.",Pharmacokinetics and pharmacodynamics of smoked heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7823539/),min,18.8,46892,DB00295,Morphine
,28864105,oral,"Morphine oral area under the curve (for time 0-12 hr; 115.8 ± 108.0 nmol.hr/L and 86.9 ± 38.8 nmol.hr/L for RYGB group and control group, respectively, P = .71), morphine at maximal concentration, metabolites oral area under the curve (for time 0-12 hr), and other PK parameters were similar between groups.",Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28864105/),[h·nM] / [l],115.8,47380,DB00295,Morphine
,28864105,area under the curve,"Morphine oral area under the curve (for time 0-12 hr; 115.8 ± 108.0 nmol.hr/L and 86.9 ± 38.8 nmol.hr/L for RYGB group and control group, respectively, P = .71), morphine at maximal concentration, metabolites oral area under the curve (for time 0-12 hr), and other PK parameters were similar between groups.",Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28864105/),[h·nM] / [l],115.8,47381,DB00295,Morphine
,28864105,area under the curve,"Morphine oral area under the curve (for time 0-12 hr; 115.8 ± 108.0 nmol.hr/L and 86.9 ± 38.8 nmol.hr/L for RYGB group and control group, respectively, P = .71), morphine at maximal concentration, metabolites oral area under the curve (for time 0-12 hr), and other PK parameters were similar between groups.",Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28864105/),[h·nM] / [l],86.9,47382,DB00295,Morphine
,10325847,area under the time-response curves (AUC),"The area under the time-response curves (AUC) of groups I and III were mean 34,556 (SD 5607) and 32,548 (9783), respectively, which were significantly different from that of group V (18,759 (8225)) (P < 0.01).",Surgical pain attenuates acute morphine tolerance in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325847/),,"34,556",47577,DB00295,Morphine
,10325847,area under the time-response curves (AUC),"The area under the time-response curves (AUC) of groups I and III were mean 34,556 (SD 5607) and 32,548 (9783), respectively, which were significantly different from that of group V (18,759 (8225)) (P < 0.01).",Surgical pain attenuates acute morphine tolerance in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325847/),,"32,548",47578,DB00295,Morphine
,10325847,area under the time-response curves (AUC),"The area under the time-response curves (AUC) of groups I and III were mean 34,556 (SD 5607) and 32,548 (9783), respectively, which were significantly different from that of group V (18,759 (8225)) (P < 0.01).",Surgical pain attenuates acute morphine tolerance in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325847/),,"18,759",47579,DB00295,Morphine
,3060191,Plasma concentrations,"4. Plasma concentrations of nalbuphine expressed as morphine equivalents ranged from 5 to 52 ng ml-1, indicating considerable mu-opiate affinity.","Psychomotor, respiratory and neuroendocrinological effects of nalbuphine and haloperidol, alone and in combination, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3060191/),[ng] / [ml],5 to 52,48419,DB00295,Morphine
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],7.73,48497,DB00295,Morphine
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],4.54,48498,DB00295,Morphine
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],3.26,48499,DB00295,Morphine
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],1.78,48500,DB00295,Morphine
,3377944,Volume of distribution at steady-state (VDss),Volume of distribution at steady-state (VDss) was smaller in elderly patients (1.36 +/- 0.44 v. 2.27 +/- 0.82 litre kg-1).,Pharmacokinetics of fentanyl in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[l] / [kg],1.36,48501,DB00295,Morphine
,3377944,Volume of distribution at steady-state (VDss),Volume of distribution at steady-state (VDss) was smaller in elderly patients (1.36 +/- 0.44 v. 2.27 +/- 0.82 litre kg-1).,Pharmacokinetics of fentanyl in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[l] / [kg],2.27,48502,DB00295,Morphine
,17199415,Total body clearance,"Total body clearance was similar between IV administration of morphine sulfate at 0.25 and 0.5 mg/kg (mean +/- SD, 25.3 +/- 6.9 mL/min/kg and 27.3 +/- 5.9 mL/min/kg, respectively), and linearity was demonstrated between these doses.",Pharmacokinetics and pharmacodynamics of morphine in llamas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199415/),[ml] / [kg·min],25.3,48980,DB00295,Morphine
,17199415,Total body clearance,"Total body clearance was similar between IV administration of morphine sulfate at 0.25 and 0.5 mg/kg (mean +/- SD, 25.3 +/- 6.9 mL/min/kg and 27.3 +/- 5.9 mL/min/kg, respectively), and linearity was demonstrated between these doses.",Pharmacokinetics and pharmacodynamics of morphine in llamas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199415/),[ml] / [kg·min],27.3,48981,DB00295,Morphine
,17199415,Bioavailability,Bioavailability of morphine following IM administration at 0.5 mg/kg was 120 +/- 30%.,Pharmacokinetics and pharmacodynamics of morphine in llamas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199415/),%,120,48982,DB00295,Morphine
,8841095,molar potency ratio,After intraperitoneal administration the molar potency ratio of morphine-6-glucuronide/morphine was 1.7 estimated by the paw lick latency on the hot plate utilizing a linked pharmacokinetic-pharmacodynamic model.,"Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),,1.7,49192,DB00295,Morphine
,8841095,potency ratio,The potency ratio of morphine-6-glucuronide/morphine utilizing the spinal nociceptive reflex depression after intravenous administration was estimated to be within the earlier reported range of 1-4 after systemic administration of the drugs.,"Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),,1-4,49193,DB00295,Morphine
,8841095,molar AUC ratio,The molar AUC ratio of morphine-3-glucuronide/morphine was 1.8 +/- 0.5 and the corresponding ratio for normorphine/morphine was 0.2 +/- 0.06.,"Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),,1.8,49194,DB00295,Morphine
,8841095,molar AUC ratio,The molar AUC ratio of morphine-3-glucuronide/morphine was 1.8 +/- 0.5 and the corresponding ratio for normorphine/morphine was 0.2 +/- 0.06.,"Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),,0.2,49195,DB00295,Morphine
,8841095,systemic clearance,"After intraperitoneal administration of morphine, morphine-6-glucuronide and normorphine mean systemic clearance values of 413 +/- 95, 50 +/- 11 and 187 +/- 54 ml.min.kg-1 respectively were observed.","Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),[min·ml] / [kg],413,49196,DB00295,Morphine
,8841095,systemic clearance,"After intraperitoneal administration of morphine, morphine-6-glucuronide and normorphine mean systemic clearance values of 413 +/- 95, 50 +/- 11 and 187 +/- 54 ml.min.kg-1 respectively were observed.","Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),[min·ml] / [kg],50,49197,DB00295,Morphine
,8841095,systemic clearance,"After intraperitoneal administration of morphine, morphine-6-glucuronide and normorphine mean systemic clearance values of 413 +/- 95, 50 +/- 11 and 187 +/- 54 ml.min.kg-1 respectively were observed.","Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),[min·ml] / [kg],187,49198,DB00295,Morphine
,8841095,Varea,"Varea was 9.0 +/- 2.1, 0.8 +/- 0.2 and 4.9 +/- 1.4 L.kg-1 respectively.","Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),[l] / [kg],9.0,49199,DB00295,Morphine
,8841095,Varea,"Varea was 9.0 +/- 2.1, 0.8 +/- 0.2 and 4.9 +/- 1.4 L.kg-1 respectively.","Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),[l] / [kg],0.8,49200,DB00295,Morphine
,8841095,Varea,"Varea was 9.0 +/- 2.1, 0.8 +/- 0.2 and 4.9 +/- 1.4 L.kg-1 respectively.","Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),[l] / [kg],4.9,49201,DB00295,Morphine
,8841095,Tmax,The slow absorption of morphine-6-glucuronide was illustrated by the mean Tmax-value of the 16 min.,"Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841095/),min,16,49202,DB00295,Morphine
,31028107,blood concentrations,"Steady-state maternal blood concentrations of NorBUP in dams infused with 1 or 3 mg/kg per day were comparable to values reported in pregnant humans treated with buprenorphine (1.0 and 9.6 ng/ml, respectively), suggesting a clinically relevant dosing regimen.","In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028107/),[ng] / [ml],1.0,49281,DB00295,Morphine
,31028107,blood concentrations,"Steady-state maternal blood concentrations of NorBUP in dams infused with 1 or 3 mg/kg per day were comparable to values reported in pregnant humans treated with buprenorphine (1.0 and 9.6 ng/ml, respectively), suggesting a clinically relevant dosing regimen.","In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028107/),[ng] / [ml],9.6,49282,DB00295,Morphine
,26445559,Pain scores,Pain scores were higher in the remifentanil group on postoperative day 2 (2.9 vs 3.8).,Intrathecal morphine attenuates acute opioid tolerance secondary to remifentanil infusions during spinal surgery in adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445559/),,2.9,49769,DB00295,Morphine
,26445559,Pain scores,Pain scores were higher in the remifentanil group on postoperative day 2 (2.9 vs 3.8).,Intrathecal morphine attenuates acute opioid tolerance secondary to remifentanil infusions during spinal surgery in adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445559/),,3.8,49770,DB00295,Morphine
,1811505,half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,2-4,50213,DB00295,Morphine
,1811505,final half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,9-11,50214,DB00295,Morphine
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,1-6,50215,DB00295,Morphine
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,7-12,50216,DB00295,Morphine
,24479785,beta,"The beta and gamma half-life for morphine ranged from 0.675 to 2.09 and 6.70 to 18.1 h, respectively, following administration of the four different IV doses.",Preliminary pharmacokinetics of morphine and its major metabolites following intravenous administration of four doses to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479785/),h,0.675 to 2.09,50293,DB00295,Morphine
,24479785,gamma half-life,"The beta and gamma half-life for morphine ranged from 0.675 to 2.09 and 6.70 to 18.1 h, respectively, following administration of the four different IV doses.",Preliminary pharmacokinetics of morphine and its major metabolites following intravenous administration of four doses to horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479785/),h,6.70 to 18.1,50294,DB00295,Morphine
,24479785,volume of distribution at steady-state,"The volume of distribution at steady-state and systemic clearance ranged from 6.95 to 15.8 L/kg and 28.3 to 35.7 mL · min/kg, respectively.",Preliminary pharmacokinetics of morphine and its major metabolites following intravenous administration of four doses to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479785/),[l] / [kg],6.95 to 15.8,50295,DB00295,Morphine
,24479785,systemic clearance,"The volume of distribution at steady-state and systemic clearance ranged from 6.95 to 15.8 L/kg and 28.3 to 35.7 mL · min/kg, respectively.",Preliminary pharmacokinetics of morphine and its major metabolites following intravenous administration of four doses to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479785/),[min·ml] / [kg],28.3 to 35.7,50296,DB00295,Morphine
,2877817,terminal half-life,"In sham-operated dogs, morphine is rapidly distributed and eliminated, with a terminal half-life of 65 +/- 30 min.",Extrahepatic glucuronidation of morphine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877817/),min,65,50408,DB00295,Morphine
,10630779,elimination half-life,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),min,54,50507,DB00295,Morphine
,10630779,half-life of distribution,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),min,3.5,50508,DB00295,Morphine
,10630779,volume of distribution,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),[ml] / [kg],"2,038",50509,DB00295,Morphine
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,5,50874,DB00295,Morphine
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,8,50875,DB00295,Morphine
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,14,50876,DB00295,Morphine
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,20,50877,DB00295,Morphine
,22381713,precision,"Sparse sampling using NPAG achieved similar values of predictive performance as mean parameter values from the more intensively sampled, with an ME of -1.0 ng/mL and precision of 26.2 ng/mL compared with 0.76 ng/mL and 25.8 ng/mL, respectively.",The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381713/),ng,26.2,50980,DB00295,Morphine
,22381713,precision,"Sparse sampling using NPAG achieved similar values of predictive performance as mean parameter values from the more intensively sampled, with an ME of -1.0 ng/mL and precision of 26.2 ng/mL compared with 0.76 ng/mL and 25.8 ng/mL, respectively.",The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381713/),[ng] / [ml],0.76,50981,DB00295,Morphine
,22381713,precision,"Sparse sampling using NPAG achieved similar values of predictive performance as mean parameter values from the more intensively sampled, with an ME of -1.0 ng/mL and precision of 26.2 ng/mL compared with 0.76 ng/mL and 25.8 ng/mL, respectively.",The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381713/),[ng] / [ml],25.8,50982,DB00295,Morphine
,22381713,ME,"Traditional (STS) modeling techniques resulted in the greatest degree of underprediction within the validation group (ME = 4.43 versus 0.76 ng/mL, STS and NPAG-9, respectively; P < 0.0001).",The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381713/),[ng] / [ml],4.43,50983,DB00295,Morphine
,22381713,ME,"Traditional (STS) modeling techniques resulted in the greatest degree of underprediction within the validation group (ME = 4.43 versus 0.76 ng/mL, STS and NPAG-9, respectively; P < 0.0001).",The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381713/),[ng] / [ml],0.76,50984,DB00295,Morphine
,25392115,Cmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng] / [ml],14.40,52417,DB00295,Morphine
,25392115,Cmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng] / [ml],11.54,52418,DB00295,Morphine
,25392115,AUC0-∞,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng´h] / [ml],157.87,52419,DB00295,Morphine
,25392115,AUC0-∞,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng´h] / [ml],106.44,52420,DB00295,Morphine
,25392115,tmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),h,2.18,52421,DB00295,Morphine
,25392115,tmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),h,2.15,52422,DB00295,Morphine
,7894664,recoveries,The recoveries ranged from 92 to 99%.,"Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894664/),%,92 to 99,52603,DB00295,Morphine
,7894664,determination limits,The determination limits were 1 ng/ml for morphine and 4 ng/ml for 6-monoacetylmorphine.,"Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894664/),[ng] / [ml],1,52604,DB00295,Morphine
,7894664,determination limits,The determination limits were 1 ng/ml for morphine and 4 ng/ml for 6-monoacetylmorphine.,"Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894664/),[ng] / [ml],4,52605,DB00295,Morphine
,9004187,bioavailability,The mean (+/- s.d.) bioavailability of the sublingual aerosol morphine was 19.7 +/- 6.7%.,A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004187/),%,19.7,52617,DB00295,Morphine
,18447799,half-life,Morphine was rapidly eliminated with a half-life of 1.28 hours and a plasma clearance of 32.55 mL/min/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),h,1.28,52879,DB00295,Morphine
,18447799,plasma clearance,Morphine was rapidly eliminated with a half-life of 1.28 hours and a plasma clearance of 32.55 mL/min/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),[ml] / [kg·min],32.55,52880,DB00295,Morphine
,18447799,volume of distribution,The volume of distribution was 3.6 L/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),[l] / [kg],3.6,52881,DB00295,Morphine
,1474160,relative bioavailability,The relative bioavailability of OSR administered after meals was 90.2% of that administered in the fasted state.,An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (ORAMORPH SR) after multiple doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474160/),%,90.2,53584,DB00295,Morphine
,33107746,bioavailability,"After IM administration, mean bioavailability was 97.6%, and mean maximum plasma concentration was 179.1 ng/mL 17 minutes after injection.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),%,97.6,54242,DB00295,Morphine
,33107746,maximum plasma concentration,"After IM administration, mean bioavailability was 97.6%, and mean maximum plasma concentration was 179.1 ng/mL 17 minutes after injection.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),[ng] / [ml],179.1,54243,DB00295,Morphine
,33107746,volume of distribution,"Mean volume of distribution and plasma drug clearance were 4.24 L/kg and 64.2 mL/min/kg, respectively, after IV administration.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),[l] / [kg],4.24,54244,DB00295,Morphine
,33107746,plasma drug clearance,"Mean volume of distribution and plasma drug clearance were 4.24 L/kg and 64.2 mL/min/kg, respectively, after IV administration.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),[ml] / [kg·min],64.2,54245,DB00295,Morphine
,33107746,elimination half-lives,"Mean elimination half-lives were 1.74 and 1.45 hours after IM and IV administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),h,1.74,54246,DB00295,Morphine
,33107746,elimination half-lives,"Mean elimination half-lives were 1.74 and 1.45 hours after IM and IV administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),h,1.45,54247,DB00295,Morphine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],3534,54386,DB00295,Morphine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],"20,580",54387,DB00295,Morphine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),,6,54388,DB00295,Morphine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],30,54389,DB00295,Morphine
,8926729,detection times,Heroin concentrations in saliva after smoking declined slowly; detection times ranged from 4 to 24 h.,Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),h,4 to 24,54390,DB00295,Morphine
,8926729,Peak saliva cocaine concentrations,"Peak saliva cocaine concentrations after intravenous administration ranged from 428 to 1927 ng/mL (N = 7); after smoking, they ranged from 15,852 to 504,880 ng/mL (N = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],428 to 1927,54391,DB00295,Morphine
,8926729,Peak saliva cocaine concentrations,"Peak saliva cocaine concentrations after intravenous administration ranged from 428 to 1927 ng/mL (N = 7); after smoking, they ranged from 15,852 to 504,880 ng/mL (N = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],"15,852 to 504,880",54392,DB00295,Morphine
,8926729,Peak plasma cocaine concentrations,"Peak plasma cocaine concentrations after intravenous administration ranged from 122 to 442 ng/mL A = 7), and after smoking, concentrations ranged from 46 to 291 ng/mL A = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],122 to 442,54393,DB00295,Morphine
,8926729,Peak plasma cocaine concentrations,"Peak plasma cocaine concentrations after intravenous administration ranged from 122 to 442 ng/mL A = 7), and after smoking, concentrations ranged from 46 to 291 ng/mL A = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],46 to 291,54394,DB00295,Morphine
,8926729,Peak saliva AEME concentrations,Peak saliva AEME concentrations were achieved at 2 min and ranged from 558 to 4374 ng/mL (N = 7).,Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],558 to 4374,54395,DB00295,Morphine
,2354092,alpha,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,13.2,54439,DB00295,Morphine
,2354092,beta,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,54.9,54440,DB00295,Morphine
,2354092,beta,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,11.2,54441,DB00295,Morphine
,2354092,gamma half-lives,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,222.5,54442,DB00295,Morphine
,26095480,C0-1havg,A 4 μg/mL C0-1havg of acetaminophen (dose: 1.5 g) may be used as cutoff point in future clinical investigations of acetaminophen to clarify the role of gastric emptying.,Acetaminophen absorption kinetics in altered gastric emptying: establishing a relevant pharmacokinetic surrogate using published data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26095480/),[μg] / [ml],4,54536,DB00295,Morphine
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,94,54576,DB00295,Morphine
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,420,54577,DB00295,Morphine
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,265,54578,DB00295,Morphine
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,80,54579,DB00295,Morphine
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,125,54580,DB00295,Morphine
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,340,54581,DB00295,Morphine
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,58.4,55481,DB00295,Morphine
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,57.4,55482,DB00295,Morphine
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,50.2,55483,DB00295,Morphine
,21404039,MRT(0-INF),LE-hydro (MRT(0-INF) = 105.9 h) demonstrated extended-release pharmacokinetics compared to hydro when administered by either i.v. (MRT(0-INF) =1.1 h) or s.c. (MRT(0-INF) =1.3 h) routes.,Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404039/),h,105.9,55735,DB00295,Morphine
,21404039,MRT(0-INF),LE-hydro (MRT(0-INF) = 105.9 h) demonstrated extended-release pharmacokinetics compared to hydro when administered by either i.v. (MRT(0-INF) =1.1 h) or s.c. (MRT(0-INF) =1.3 h) routes.,Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404039/),h,1.1,55736,DB00295,Morphine
,21404039,MRT(0-INF),LE-hydro (MRT(0-INF) = 105.9 h) demonstrated extended-release pharmacokinetics compared to hydro when administered by either i.v. (MRT(0-INF) =1.1 h) or s.c. (MRT(0-INF) =1.3 h) routes.,Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404039/),h,1.3,55737,DB00295,Morphine
,29124988,volume of distribution,"Butalbital is a small molecule (approximately 220 Da), with 26% protein binding, a 0.8 L/kg volume of distribution, and is eliminated nearly 80% unchanged in the urine.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[l] / [kg],0.8,56164,DB00295,Morphine
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mg] / [dl],46.4,56165,DB00295,Morphine
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mM] / [l],3.4,56166,DB00295,Morphine
,29124988,total body elimination,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),%,60,56167,DB00295,Morphine
,29124988,clearance,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[ml] / [min],233-300,56168,DB00295,Morphine
,1923705,relative AUC,"The relative AUC values are 15.3% for nicomorphine, 23.9% for 6-nicotinoylmorphine and 60.8% for morphine.",Pharmacokinetics of nicomorphine and its metabolites in man after epidural administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923705/),%,15.3,57256,DB00295,Morphine
,1923705,relative AUC,"The relative AUC values are 15.3% for nicomorphine, 23.9% for 6-nicotinoylmorphine and 60.8% for morphine.",Pharmacokinetics of nicomorphine and its metabolites in man after epidural administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923705/),%,23.9,57257,DB00295,Morphine
,1923705,relative AUC,"The relative AUC values are 15.3% for nicomorphine, 23.9% for 6-nicotinoylmorphine and 60.8% for morphine.",Pharmacokinetics of nicomorphine and its metabolites in man after epidural administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923705/),%,60.8,57258,DB00295,Morphine
,1704089,bioavailability,Plasma hydromorphone concentrations measured at 24 h and 48 h of infusion showed stable steady-state pharmacokinetics; the mean bioavailability from subcutaneous infusion was 78% of that with intravenous infusion.,Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704089/),%,78,57307,DB00295,Morphine
,16489488,AUC ratios,"The brain hemispheres/plasma morphine AUC ratios for the 0-5 min period were thus approximately 3 and 0.1 after nasal and i.v. administration, respectively, demonstrating a statistically significant early distribution advantage of morphine to the brain hemispheres via the nasal route.",Direct nose-to-brain transfer of morphine after nasal administration to rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16489488/),,3,58408,DB00295,Morphine
,16489488,AUC ratios,"The brain hemispheres/plasma morphine AUC ratios for the 0-5 min period were thus approximately 3 and 0.1 after nasal and i.v. administration, respectively, demonstrating a statistically significant early distribution advantage of morphine to the brain hemispheres via the nasal route.",Direct nose-to-brain transfer of morphine after nasal administration to rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16489488/),,0.1,58409,DB00295,Morphine
,2340348,sensitivities,Specific and sensitive reverse-phase HPLC assays of buprenorphine and its metabolite in biological fluids were developed with sensitivities of 2-6 ng ml-1 using fluorimetric detection.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ng] / [ml],2-6,58734,DB00295,Morphine
,2340348,terminal rate constants,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,41.6,58735,DB00295,Morphine
,2340348,total body clearance,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ml] / [min],191,58736,DB00295,Morphine
less,2340348,half-life,"This terminal rate constant was in contrast to the less than 100 min half-life of the second exponential fitting of the less lipophilic morphine, naloxone, and naltrexone.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),min,100,58737,DB00295,Morphine
,2340348,apparent volumes of distribution,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58738,DB00295,Morphine
,2340348,Vc,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58739,DB00295,Morphine
,2340348,Vd,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,663,58740,DB00295,Morphine
,2340348,terminal half-life,"Direct IV administration of the metabolite, buprenorphine glucuronide, gave a terminal half-life of 6 h and more than 90 per cent of the systemically circulating metabolite was excreted in bile; only 10 per cent in urine.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,6,58741,DB00295,Morphine
,2340348,oral bioavailability,"The oral bioavailability, estimated from the areas under the buprenorphine plasma concentration-time curve following IV and oral administration of buprenorphine in the dogs, was 3-6 per cent.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),%,3-6,58742,DB00295,Morphine
,1424423,elimination half-life,"The mean +/- SD elimination half-life after single-dose administration of intravenous (4.6 mg to 9.1 mg) and oral (9.1 mg) oxycodone was 3.01 +/- 1.37 hours and 3.51 +/- 1.43 hours, respectively.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),h,3.01,58931,DB00295,Morphine
,1424423,elimination half-life,"The mean +/- SD elimination half-life after single-dose administration of intravenous (4.6 mg to 9.1 mg) and oral (9.1 mg) oxycodone was 3.01 +/- 1.37 hours and 3.51 +/- 1.43 hours, respectively.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),h,3.51,58932,DB00295,Morphine
,1424423,volume of distribution,"After intravenous administration, the mean +/- SD volume of distribution was 211.9 +/- 186.6 L, and the mean +/- SD total plasma clearance was 48.6 +/- 26.5 L/hr.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),l,211.9,58933,DB00295,Morphine
,1424423,total plasma clearance,"After intravenous administration, the mean +/- SD volume of distribution was 211.9 +/- 186.6 L, and the mean +/- SD total plasma clearance was 48.6 +/- 26.5 L/hr.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),[l] / [h],48.6,58934,DB00295,Morphine
,1424423,absolute oral bioavailability,"The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249.1 +/- 204.3 L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),%,87,58935,DB00295,Morphine
,1424423,volume of distribution,"The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249.1 +/- 204.3 L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),l,249.1,58936,DB00295,Morphine
,1424423,steady-state concentration,"When administered orally as 10 mg oxycodone hydrochloride every 4 hours, there was no accumulation of oxycodone at steady state and the mean +/- SD steady-state concentration was 34.6 +/- 10.3 micrograms/L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),[μg] / [l],34.6,58937,DB00295,Morphine
,10383558,area under the curve to infinity (AUC,"Using a two-compartment model for plasma morphine, the area under the curve to infinity (AUC, 7143 ng ml-1 min), volume of distribution (3.6 l kg-1 ) and elimination half-life (88 min) were comparable with those reported in adults.",Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383558/),[min·ng] / [ml],7143,59232,DB00295,Morphine
,10383558,volume of distribution,"Using a two-compartment model for plasma morphine, the area under the curve to infinity (AUC, 7143 ng ml-1 min), volume of distribution (3.6 l kg-1 ) and elimination half-life (88 min) were comparable with those reported in adults.",Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383558/),[l] / [kg],3.6,59233,DB00295,Morphine
,10383558,elimination half-life,"Using a two-compartment model for plasma morphine, the area under the curve to infinity (AUC, 7143 ng ml-1 min), volume of distribution (3.6 l kg-1 ) and elimination half-life (88 min) were comparable with those reported in adults.",Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383558/),min,88,59234,DB00295,Morphine
,10383558,Clearance,Clearance (35 ml min-1 ) was higher than that in adults.,Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383558/),[ml] / [min],35,59235,DB00295,Morphine
,10383558,elimination half-life,The elimination half-life (321 min) and AUC (35507 ng ml-1 min) of plasma M6G were much greater than those of morphine.,Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383558/),min,321,59236,DB00295,Morphine
,10383558,AUC,The elimination half-life (321 min) and AUC (35507 ng ml-1 min) of plasma M6G were much greater than those of morphine.,Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383558/),[min·ng] / [ml],35507,59237,DB00295,Morphine
,8226400,renal clearance,"The mean renal clearance for rats pre-treated with MS, Pb and NS was 0.61 +/- 0.07.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),,0.61,59238,DB00295,Morphine
,8226400,non-renal clearance,"mL/min/kg, 0.60 +/- 0.13 mL/min/kg, and 0.46 +/- 0.02 mL/min/kg, respectively; the mean non-renal clearance was 0.33 +/- 0.18 mL/min/kg, 0.17 +/- 0.15 mL/min/kg, and 0.08 +/- 0.03 mL/min/kg, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),[ml] / [kg·min],0.33,59239,DB00295,Morphine
,8226400,non-renal clearance,"mL/min/kg, 0.60 +/- 0.13 mL/min/kg, and 0.46 +/- 0.02 mL/min/kg, respectively; the mean non-renal clearance was 0.33 +/- 0.18 mL/min/kg, 0.17 +/- 0.15 mL/min/kg, and 0.08 +/- 0.03 mL/min/kg, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),[ml] / [kg·min],0.17,59240,DB00295,Morphine
,8226400,non-renal clearance,"mL/min/kg, 0.60 +/- 0.13 mL/min/kg, and 0.46 +/- 0.02 mL/min/kg, respectively; the mean non-renal clearance was 0.33 +/- 0.18 mL/min/kg, 0.17 +/- 0.15 mL/min/kg, and 0.08 +/- 0.03 mL/min/kg, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),[ml] / [kg·min],0.08,59241,DB00295,Morphine
,8226400,half-life,"The mean half-life for MS-, Pb-, and NS pre-treated groups was 8.1 +/- 3.1 h, 5.9 +/- 3.3 h, and 34.6 +/- 20.7 h, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),h,8.1,59242,DB00295,Morphine
,8226400,half-life,"The mean half-life for MS-, Pb-, and NS pre-treated groups was 8.1 +/- 3.1 h, 5.9 +/- 3.3 h, and 34.6 +/- 20.7 h, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),h,5.9,59243,DB00295,Morphine
,8226400,half-life,"The mean half-life for MS-, Pb-, and NS pre-treated groups was 8.1 +/- 3.1 h, 5.9 +/- 3.3 h, and 34.6 +/- 20.7 h, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),h,34.6,59244,DB00295,Morphine
,24866507,fraction of,The fraction of the hydromorphone dose absorbed after IM administration was 0.75.,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),,0,59485,DB00295,Morphine
,24866507,maximum observed plasma concentration,The maximum observed plasma concentration was 112.1 ng/mL (5 minutes after administration).,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),[ng] / [ml],112.1,59486,DB00295,Morphine
,24866507,terminal half-life,"The terminal half-life was 1.25 and 1.26 hours after IV and IM administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),h,1.25,59487,DB00295,Morphine
,24866507,terminal half-life,"The terminal half-life was 1.25 and 1.26 hours after IV and IM administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),h,1.26,59488,DB00295,Morphine
<,21551257,IC(50),"However, IC(50) values were <100 μM only for UGT2B4, UGT2B7, and UGT2B15.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,100,59703,DB00295,Morphine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,5.8,59704,DB00295,Morphine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,4.6,59705,DB00295,Morphine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,3.5,59706,DB00295,Morphine
,8346956,plasma concentrations,"Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12.9) and 96.4 (3.2) ng/ml, and 184.2 (37.7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively.",Pharmacokinetics of morphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),[ng] / [ml],99,59869,DB00295,Morphine
,8346956,plasma concentrations,"Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12.9) and 96.4 (3.2) ng/ml, and 184.2 (37.7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively.",Pharmacokinetics of morphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),[ng] / [ml],96.4,59870,DB00295,Morphine
,8346956,plasma concentrations,"Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12.9) and 96.4 (3.2) ng/ml, and 184.2 (37.7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively.",Pharmacokinetics of morphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),[ng] / [ml],184.2,59871,DB00295,Morphine
,8346956,plasma concentrations,"Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12.9) and 96.4 (3.2) ng/ml, and 184.2 (37.7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively.",Pharmacokinetics of morphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),[ng] / [ml],319,59872,DB00295,Morphine
,8346956,clearance,"The population mean morphine clearance was 2.4 ml/min/kg, the elimination half life was 8.75 hours and the volume of distribution was 1.82 1/kg.",Pharmacokinetics of morphine infusion in premature neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),[ml] / [kg·min],2.4,59873,DB00295,Morphine
,8346956,elimination half life,"The population mean morphine clearance was 2.4 ml/min/kg, the elimination half life was 8.75 hours and the volume of distribution was 1.82 1/kg.",Pharmacokinetics of morphine infusion in premature neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),h,8.75,59874,DB00295,Morphine
,8346956,volume of distribution,"The population mean morphine clearance was 2.4 ml/min/kg, the elimination half life was 8.75 hours and the volume of distribution was 1.82 1/kg.",Pharmacokinetics of morphine infusion in premature neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346956/),[1] / [kg],1.82,59875,DB00295,Morphine
,26655109,flow rate,"The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.",Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[μl] / [min],300,60351,DB00295,Morphine
,26655109,limit of detection,The limit of detection was 30pg/mL for all analytes.,Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[pg] / [ml],30,60352,DB00295,Morphine
,23851346,area under the plasma morphine concentration versus time curve,"Cyclosporine minimally altered morphine disposition, increasing the area under the plasma morphine concentration versus time curve to 100 ± 21 versus 85 ± 24 ng/ml·h (P < 0.05) without changing maximum plasma concentration.",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [h·ml],100,60952,DB00295,Morphine
,23851346,area under the plasma morphine concentration versus time curve,"Cyclosporine minimally altered morphine disposition, increasing the area under the plasma morphine concentration versus time curve to 100 ± 21 versus 85 ± 24 ng/ml·h (P < 0.05) without changing maximum plasma concentration.",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [h·ml],85,60953,DB00295,Morphine
,23851346,area under the miosis-time curve,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),h·mm,18,60954,DB00295,Morphine
,23851346,area under the miosis-time curve,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),h·mm,11,60955,DB00295,Morphine
,23851346,plasma effect-site transfer rate constant (k(e0),"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),1/[h],0.27,60956,DB00295,Morphine
,23851346,plasma effect-site transfer rate constant (k(e0),"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),1/[h],0.17,60957,DB00295,Morphine
,23851346,maximum calculated effect-site morphine concentration,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [ml],11.5,60958,DB00295,Morphine
,23851346,maximum calculated effect-site morphine concentration,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [ml],7.6,60959,DB00295,Morphine
,11446167,plasma half-life,"The mean (+/- S.E.) plasma half-life of morphine was 0.9 +/- 0.2 h, 2.5 +/- 0.6 h and 3.5 +/- 3.5 h after the administration of A, B and C, respectively, compared to 0.9 +/- 0.2 h as estimated after the administration of non-esterified morphine.",Pharmacokinetics of morphine 3-esters after oral administration in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11446167/),h,0.9,61605,DB00295,Morphine
,11446167,plasma half-life,"The mean (+/- S.E.) plasma half-life of morphine was 0.9 +/- 0.2 h, 2.5 +/- 0.6 h and 3.5 +/- 3.5 h after the administration of A, B and C, respectively, compared to 0.9 +/- 0.2 h as estimated after the administration of non-esterified morphine.",Pharmacokinetics of morphine 3-esters after oral administration in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11446167/),h,2.5,61606,DB00295,Morphine
,11446167,plasma half-life,"The mean (+/- S.E.) plasma half-life of morphine was 0.9 +/- 0.2 h, 2.5 +/- 0.6 h and 3.5 +/- 3.5 h after the administration of A, B and C, respectively, compared to 0.9 +/- 0.2 h as estimated after the administration of non-esterified morphine.",Pharmacokinetics of morphine 3-esters after oral administration in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11446167/),h,3.5,61607,DB00295,Morphine
,7889023,lag-time,Morphine appeared almost instantaneously with a lag-time of 8 min and had a final elimination half-life of 1.48 +/- 0.48 h.,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),min,8,61682,DB00295,Morphine
,7889023,final elimination half-life,Morphine appeared almost instantaneously with a lag-time of 8 min and had a final elimination half-life of 1.48 +/- 0.48 h.,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),h,1.48,61683,DB00295,Morphine
,7889023,lag-time,These glucuronide conjugates appeared after a lag-time of 12 min and the half-life of these two glucuronide conjugates was similar: about 2.8 h (P > 0.8).,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),min,12,61684,DB00295,Morphine
,7889023,half-life,These glucuronide conjugates appeared after a lag-time of 12 min and the half-life of these two glucuronide conjugates was similar: about 2.8 h (P > 0.8).,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),h,2.8,61685,DB00295,Morphine
,7889023,renal clearance,The renal clearance value for morphine was 162 ml.min-1 and for the glucuronides 81 ml.min-1.,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),[ml] / [min],162,61686,DB00295,Morphine
,7889023,renal clearance,The renal clearance value for morphine was 162 ml.min-1 and for the glucuronides 81 ml.min-1.,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),[ml] / [min],81,61687,DB00295,Morphine
,7889023,absolute bioavailability,This study shows that administration of a suppository with 30 mg nicomorphine gives an excellent absolute bioavailability of morphine and its metabolites of 88%.,Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7889023/),%,88,61688,DB00295,Morphine
,12357147,absolute bioavailability,"The mean absolute bioavailability for the 8-mg OROS formulation was significantly larger ( = 0.025) than for the 8-mg IR formulation: 0.24 (SD 0.059) versus 0.19 (SD 0.054), respectively.",Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357147/),,0,62317,DB00295,Morphine
,12357147,absolute bioavailability,"The mean absolute bioavailability for the 8-mg OROS formulation was significantly larger ( = 0.025) than for the 8-mg IR formulation: 0.24 (SD 0.059) versus 0.19 (SD 0.054), respectively.",Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357147/),,0.24,62318,DB00295,Morphine
,12357147,absolute bioavailability,"The mean absolute bioavailability for the 8-mg OROS formulation was significantly larger ( = 0.025) than for the 8-mg IR formulation: 0.24 (SD 0.059) versus 0.19 (SD 0.054), respectively.",Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357147/),,0.19,62319,DB00295,Morphine
,2882701,elimination half-lives,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,3 to 4,62367,DB00295,Morphine
,2882701,steady-state volumes of distribution,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],2 to 4,62368,DB00295,Morphine
,2882701,hepatic clearances,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[ml] / [kg·min],10 to 20,62369,DB00295,Morphine
,2882701,terminal elimination half-life,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,1 1/2,62370,DB00295,Morphine
,2882701,steady-state volume of distribution,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],0.5 to 1,62371,DB00295,Morphine
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,140,63189,DB00295,Morphine
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,15,63190,DB00295,Morphine
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,0.92,63191,DB00295,Morphine
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,6.8,63192,DB00295,Morphine
,1671323,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),[ml] / [kg],1.54,63193,DB00295,Morphine
,1671323,clearance from the CSF,"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),μl,27,63194,DB00295,Morphine
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,2.54,64365,DB00295,Morphine
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,3.05,64366,DB00295,Morphine
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,2.67,64367,DB00295,Morphine
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,2.01,64368,DB00295,Morphine
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],142,64369,DB00295,Morphine
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],369,64370,DB00295,Morphine
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],1610,64371,DB00295,Morphine
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],5142,64372,DB00295,Morphine
,8866928,systemic bioavailabilities,The systemic bioavailabilities of morphine (mean +/- s.d.) were 5 +/- 3% and 24 +/- 13% for the nebulized and oral routes respectively.,Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866928/),%,5,64421,DB00295,Morphine
,8866928,systemic bioavailabilities,The systemic bioavailabilities of morphine (mean +/- s.d.) were 5 +/- 3% and 24 +/- 13% for the nebulized and oral routes respectively.,Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866928/),%,24,64422,DB00295,Morphine
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65144,DB00295,Morphine
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65145,DB00295,Morphine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65146,DB00295,Morphine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65147,DB00295,Morphine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.5,65148,DB00295,Morphine
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.4,65149,DB00295,Morphine
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65150,DB00295,Morphine
,26350273,AUC0-t,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],342.9,65151,DB00295,Morphine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],325.3,65152,DB00295,Morphine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],346.3,65153,DB00295,Morphine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],328.5,65154,DB00295,Morphine
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],0.64,65155,DB00295,Morphine
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65156,DB00295,Morphine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65157,DB00295,Morphine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.06,65158,DB00295,Morphine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.19,65159,DB00295,Morphine
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65160,DB00295,Morphine
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,16.1,65161,DB00295,Morphine
,23166450,AUC(0-24),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[h·ng] / [ml],41.1,66022,DB00295,Morphine
,23166450,C(max),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[ng] / [ml],2.6,66023,DB00295,Morphine
,23166450,C(min),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[ng] / [ml],1.1,66024,DB00295,Morphine
,23166450,C(avg),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[ng] / [ml],1.7,66025,DB00295,Morphine
,19438510,"K(p,uu)","Morphine K(p,uu) was 1.19 and 1.89 for the sheep and premature lambs, respectively, indicating that active influx into the brain decreases with age.",The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438510/),,1.19,67330,DB00295,Morphine
,19438510,"K(p,uu)","Morphine K(p,uu) was 1.19 and 1.89 for the sheep and premature lambs, respectively, indicating that active influx into the brain decreases with age.",The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438510/),,1.89,67331,DB00295,Morphine
,19438510,"K(p,uu)","The M3G K(p,uu) values were 0.27 and 0.17 in sheep and premature lambs, indicating a net efflux from the brain in both groups.",The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438510/),,0.27,67332,DB00295,Morphine
,19438510,"K(p,uu)","The M3G K(p,uu) values were 0.27 and 0.17 in sheep and premature lambs, indicating a net efflux from the brain in both groups.",The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438510/),,0.17,67333,DB00295,Morphine
,18381513,Serum morphine concentrations,"Serum morphine concentrations at 24 to 72 hours after birth were (median [range]) 292 ng/mL (137-767 ng/mL) in the hypothermia-treated infants and 206 ng/mL (88-327 ng/mL) in the infants on normothermia, despite similar morphine infusion rates and cumulative doses.",Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381513/),[ng] / [ml],292,68100,DB00295,Morphine
,18381513,Serum morphine concentrations,"Serum morphine concentrations at 24 to 72 hours after birth were (median [range]) 292 ng/mL (137-767 ng/mL) in the hypothermia-treated infants and 206 ng/mL (88-327 ng/mL) in the infants on normothermia, despite similar morphine infusion rates and cumulative doses.",Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381513/),[ng] / [ml],206,68101,DB00295,Morphine
,18381513,clearance,Morphine clearance was low in both groups: (median [range]) morphine clearance estimated from area under the curve was 0.69 mL/min per kg (0.58-1.21 mL/min per kg) in hypothermic group and 0.89 mL/min per kg (0.65-1.33 mL/min per kg) in infants on normothermia.,Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381513/),[ml] / [kg·min],0.69,68102,DB00295,Morphine
,18381513,clearance,Morphine clearance was low in both groups: (median [range]) morphine clearance estimated from area under the curve was 0.69 mL/min per kg (0.58-1.21 mL/min per kg) in hypothermic group and 0.89 mL/min per kg (0.65-1.33 mL/min per kg) in infants on normothermia.,Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381513/),[ml] / [kg·min],0.89,68103,DB00295,Morphine
,18381513,area under the curve,Morphine clearance was low in both groups: (median [range]) morphine clearance estimated from area under the curve was 0.69 mL/min per kg (0.58-1.21 mL/min per kg) in hypothermic group and 0.89 mL/min per kg (0.65-1.33 mL/min per kg) in infants on normothermia.,Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381513/),[ml] / [kg·min],0.69,68104,DB00295,Morphine
,18381513,area under the curve,Morphine clearance was low in both groups: (median [range]) morphine clearance estimated from area under the curve was 0.69 mL/min per kg (0.58-1.21 mL/min per kg) in hypothermic group and 0.89 mL/min per kg (0.65-1.33 mL/min per kg) in infants on normothermia.,Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381513/),[ml] / [kg·min],0.89,68105,DB00295,Morphine
,24277335,clearance,Concomitant morphine administration resulted in a 55 % reduction in theophylline clearance (0.14 ± 0.04 vs. 0.31 ± 0.061 · h(-1) kg(-1); p. < 0.0005).,Morphine inhibition of theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),1/[h·kg],0.14,68209,DB00295,Morphine
,24277335,clearance,Concomitant morphine administration resulted in a 55 % reduction in theophylline clearance (0.14 ± 0.04 vs. 0.31 ± 0.061 · h(-1) kg(-1); p. < 0.0005).,Morphine inhibition of theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),1/[h·kg],0.31,68210,DB00295,Morphine
,24277335,half-life,The reduction in theophylline clearance with morphine administration was accompanied by a significant prolongation in theophylline half-life (3.5 ± 1.5 vs. 1.4 ± 0.35 h; p < 0.02).,Morphine inhibition of theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),h,3.5,68211,DB00295,Morphine
,24277335,half-life,The reduction in theophylline clearance with morphine administration was accompanied by a significant prolongation in theophylline half-life (3.5 ± 1.5 vs. 1.4 ± 0.35 h; p < 0.02).,Morphine inhibition of theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277335/),h,1.4,68212,DB00295,Morphine
,17613029,flow rate,"Ethylcellulose with di-n-butyl-phthalate in ethanol and methylene chloride mixture for the coating of drug resinate beads was performed in Glatt fluidized bed coater, where the coating solution flow rate was 8-12 g/min, the inlet air temperature was 50-60 degrees C, the outlet air temperature was 32-38 degrees C, the atomizing air pressure was 2.0 bar and the fluidized air pressure was adjusted as required.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),[g] / [min],8-12,68225,DB00295,Morphine
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,103.6,68226,DB00295,Morphine
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,98.1,68227,DB00295,Morphine
,9784932,bioavailability,The morphine pharmacokinetics following administration of a specifically formulated controlled release suppository showed less variability (rectal bioavailability was 42%).,Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784932/),%,42,68347,DB00295,Morphine
,32856114,maximum plasma concentration (Cpmax),"While one directly compressed tablet formula (S6) was selected based on the in vitro release profile to represent the sustained core, the outcome was 2 core in cup tablets, namely B1 and B2 which were evaluated for their in vivo absorption and showed a maximum plasma concentration (Cpmax) of 354.12 ± 17.55 ng/mL and 350.82 ± 12.15 ng/mL respectively attained after 3.0 h which were twofolds significantly higher in comparison to the market tablet with Cpmax of only 172.05 ± 12.53 ng/mL attained after 2.20 ± 0.24 h.","Core in Cup Ethylmorphine Hydrochloride Tablet for Dual Fast and Sustained Pain Relief: Formulation, Characterization, and Pharmacokinetic Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856114/),[ng] / [ml],354.12,69100,DB00295,Morphine
,32856114,maximum plasma concentration (Cpmax),"While one directly compressed tablet formula (S6) was selected based on the in vitro release profile to represent the sustained core, the outcome was 2 core in cup tablets, namely B1 and B2 which were evaluated for their in vivo absorption and showed a maximum plasma concentration (Cpmax) of 354.12 ± 17.55 ng/mL and 350.82 ± 12.15 ng/mL respectively attained after 3.0 h which were twofolds significantly higher in comparison to the market tablet with Cpmax of only 172.05 ± 12.53 ng/mL attained after 2.20 ± 0.24 h.","Core in Cup Ethylmorphine Hydrochloride Tablet for Dual Fast and Sustained Pain Relief: Formulation, Characterization, and Pharmacokinetic Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856114/),[ng] / [ml],350.82,69101,DB00295,Morphine
,32856114,Cpmax,"While one directly compressed tablet formula (S6) was selected based on the in vitro release profile to represent the sustained core, the outcome was 2 core in cup tablets, namely B1 and B2 which were evaluated for their in vivo absorption and showed a maximum plasma concentration (Cpmax) of 354.12 ± 17.55 ng/mL and 350.82 ± 12.15 ng/mL respectively attained after 3.0 h which were twofolds significantly higher in comparison to the market tablet with Cpmax of only 172.05 ± 12.53 ng/mL attained after 2.20 ± 0.24 h.","Core in Cup Ethylmorphine Hydrochloride Tablet for Dual Fast and Sustained Pain Relief: Formulation, Characterization, and Pharmacokinetic Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856114/),[ng] / [ml],172.05,69102,DB00295,Morphine
,29772054,clearance,"After 0.1 mg·kg-1 oxycodone intravenously, the median clearance was 5.2 L·h-1 ·kg-1 (range 4.6-6.2), but the volume of distribution varied between 1.5 and 4.7 L·kg-1 .",Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[l] / [h·kg],5.2,69115,DB00295,Morphine
,29772054,volume of distribution,"After 0.1 mg·kg-1 oxycodone intravenously, the median clearance was 5.2 L·h-1 ·kg-1 (range 4.6-6.2), but the volume of distribution varied between 1.5 and 4.7 L·kg-1 .",Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[l] / [kg],1.5 and 4.7,69116,DB00295,Morphine
,29772054,area under the curve,The area under the curve was 17 h·ng·mL-1 (range 14-19) and the plasma concentration at 2 minutes 60 ng·mL-1 (range 50-74).,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[h·ng] / [ml],17,69117,DB00295,Morphine
,29772054,plasma concentration at 2 minutes,The area under the curve was 17 h·ng·mL-1 (range 14-19) and the plasma concentration at 2 minutes 60 ng·mL-1 (range 50-74).,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[ng] / [ml],60,69118,DB00295,Morphine
,29772054,fetal-to-maternal ratios,Accumulation of oxymorphone in the fetus occurred; fetal-to-maternal ratios were 1.3-3.5 (median 2.1) in the i.v.-group and 0.9-3.0 (1.3) in the Epidural-group.,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),,1.3-3.5,69119,DB00295,Morphine
,29772054,fetal-to-maternal ratios,Accumulation of oxymorphone in the fetus occurred; fetal-to-maternal ratios were 1.3-3.5 (median 2.1) in the i.v.-group and 0.9-3.0 (1.3) in the Epidural-group.,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),,2.1,69120,DB00295,Morphine
,2878076,duration of action,"Alftentanil reaches its peak effect within 1 min after injection, and its duration of action is very short; at 2 times its MED50, 9r has a duration of action of 11 min.","Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878076/),min,11,70928,DB00295,Morphine
,20230569,terminal half-life,The terminal half-life of morphine in SF was estimated to be 2.6 hours.,Pharmacokinetics of intra-articular morphine in horses with lipopolysaccharide-induced synovitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230569/),h,2.6,71671,DB00295,Morphine
below,20230569,serum concentrations,IA administration of morphine resulted in mean serum concentrations of morphine below 5 ng mL(-1) from 2 to 28 hours after treatment.,Pharmacokinetics of intra-articular morphine in horses with lipopolysaccharide-induced synovitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230569/),[ng] / [ml],5,71672,DB00295,Morphine
below,19247757,Total plasma concentrations,Total plasma concentrations of lidocaine remained below 4 microg ml(-1) throughout the study period.,Intranasal lidocaine plus naphazoline nitrate improves surgical conditions and perioperative analgesia in septorhinoplasty surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247757/),[μg] / [ml],4,71699,DB00295,Morphine
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,12,72602,DB00295,Morphine
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,8,72603,DB00295,Morphine
,2644963,elimination half-life,"There were no differences between the two groups for morphine elimination half-life (renal failure: 290 min; anaesthetized controls: 286 min), or clearance (renal failure: 533 ml min-1; controls 741 ml min-1).",Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644963/),min,290,72989,DB00295,Morphine
,2644963,elimination half-life,"There were no differences between the two groups for morphine elimination half-life (renal failure: 290 min; anaesthetized controls: 286 min), or clearance (renal failure: 533 ml min-1; controls 741 ml min-1).",Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644963/),min,286,72990,DB00295,Morphine
,2644963,clearance,"There were no differences between the two groups for morphine elimination half-life (renal failure: 290 min; anaesthetized controls: 286 min), or clearance (renal failure: 533 ml min-1; controls 741 ml min-1).",Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644963/),[ml] / [min],533,72991,DB00295,Morphine
,2644963,clearance,"There were no differences between the two groups for morphine elimination half-life (renal failure: 290 min; anaesthetized controls: 286 min), or clearance (renal failure: 533 ml min-1; controls 741 ml min-1).",Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644963/),[ml] / [min],741,72992,DB00295,Morphine
,2644963,volume of distribution at steady state,"However, the volume of distribution at steady state was greater in the control group (241 litre v. 141 litre; P = 0.002).",Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644963/),l,241,72993,DB00295,Morphine
,2644963,volume of distribution at steady state,"However, the volume of distribution at steady state was greater in the control group (241 litre v. 141 litre; P = 0.002).",Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644963/),l,141,72994,DB00295,Morphine
,712585,sensitivity,Liquid scintillation spectrometric analysis of 14C-morphine had a sensitivity of 1.5 ng/ml of plasma at double the background.,Pharmacokinetics of morphine and its surrogates I: comparisons of sensitive assays of morphine in biological fluids and application to morphine pharmacokinetics in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712585/),[ng] / [ml],1.5,73198,DB00295,Morphine
,34268884,absorption fraction,The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake.,Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),,0.31,73655,DB00295,Morphine
,34268884,time to maximum concentration ( T max ),"The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06).",Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),h,2,73656,DB00295,Morphine
,34268884,time to maximum concentration ( T max ),"The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06).",Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),h,3,73657,DB00295,Morphine
,21233498,clearance,"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[ml] / [kg·min],1.49,74618,DB00295,Morphine
,21233498,Vss (volume of distribution at steady state),"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[l] / [kg],0.31,74619,DB00295,Morphine
,21233498,half-life,"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),min,236,74620,DB00295,Morphine
,21233498,clearance,Estimated population pharmacokinetic parameters were clearance 1.52 mL/min/kg and Vss 0.29 L/kg.,Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[ml] / [kg·min],1.52,74621,DB00295,Morphine
,21233498,Vss,Estimated population pharmacokinetic parameters were clearance 1.52 mL/min/kg and Vss 0.29 L/kg.,Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[l] / [kg],0.29,74622,DB00295,Morphine
,1544290,Elimination half-life,"Elimination half-life, total plasma clearance, and volume of distribution (mean +/- SD) were 9.6 +/- 3.0 hours, 2.55 +/- 1.65 ml/min/kg (area analysis) or 2.09 +/- 1.19 ml/min/kg (steady-state data), and 2.05 +/- 1.05 L/kg, respectively, and were not significantly different in preterm and term neonates.",Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544290/),h,9.6,74828,DB00295,Morphine
,1544290,total plasma clearance,"Elimination half-life, total plasma clearance, and volume of distribution (mean +/- SD) were 9.6 +/- 3.0 hours, 2.55 +/- 1.65 ml/min/kg (area analysis) or 2.09 +/- 1.19 ml/min/kg (steady-state data), and 2.05 +/- 1.05 L/kg, respectively, and were not significantly different in preterm and term neonates.",Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544290/),[ml] / [kg·min],2.55,74829,DB00295,Morphine
,1544290,steady-state,"Elimination half-life, total plasma clearance, and volume of distribution (mean +/- SD) were 9.6 +/- 3.0 hours, 2.55 +/- 1.65 ml/min/kg (area analysis) or 2.09 +/- 1.19 ml/min/kg (steady-state data), and 2.05 +/- 1.05 L/kg, respectively, and were not significantly different in preterm and term neonates.",Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544290/),[ml] / [kg·min],2.09,74830,DB00295,Morphine
,10680103,clearance,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],2.5 to 10,74847,DB00295,Morphine
,10680103,clearance,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],6,74848,DB00295,Morphine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.28 to 3.30,74849,DB00295,Morphine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),,1.4,74850,DB00295,Morphine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],5.16,74851,DB00295,Morphine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],5,74852,DB00295,Morphine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.9,74853,DB00295,Morphine
,10680103,clearance,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],4.5 to 9.4,74854,DB00295,Morphine
,10680103,clearance,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],6.7,74855,DB00295,Morphine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.39 to 1.20,74856,DB00295,Morphine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.72,74857,DB00295,Morphine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],10,74858,DB00295,Morphine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],1.32,74859,DB00295,Morphine
,3437070,AUC24,"However, accumulation of morphine during multiple dosing was significant (AUC24 = 102 +/- 33 ng/mL/hr after single dose versus 212 +/- 118 ng/mL/hr after the last multiple dose).",Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437070/),[ng] / [h·ml],102,74930,DB00295,Morphine
,3437070,AUC24,"However, accumulation of morphine during multiple dosing was significant (AUC24 = 102 +/- 33 ng/mL/hr after single dose versus 212 +/- 118 ng/mL/hr after the last multiple dose).",Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437070/),[ng] / [h·ml],212,74931,DB00295,Morphine
,1623909,total plasma clearance,Codeine had a medium to high extraction ratio and a total plasma clearance of 10.8 (4.3) ml.min-1.kg-1.,The postoperative pharmacokinetics of codeine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),[ml] / [kg·min],10.8,75152,DB00295,Morphine
,1623909,systemic availability,The systemic availability of codeine varied extensively between subjects (range 12-84%).,The postoperative pharmacokinetics of codeine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),%,12-84,75153,DB00295,Morphine
,18082778,Cmax,"No statistically significant differences were observed between intraosseous and intravenous administration of morphine sulfate for nearly all of the pharmacokinetic parameters including Cmax (235 +/- 107 vs 289 +/- 197 ng/mL, mean +/- SD, i.o. vs i.v., respectively), Tmax (1.3 +/- 0.5 vs 1.4 +/- 0.5 minutes), and AUC(0-infinity) (4372 +/- 1785 vs 4410 +/- 1930 ng min(-1) mL(-1)).",Does intraosseous equal intravenous? A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082778/),[ng] / [ml],235,75229,DB00295,Morphine
,18082778,Cmax,"No statistically significant differences were observed between intraosseous and intravenous administration of morphine sulfate for nearly all of the pharmacokinetic parameters including Cmax (235 +/- 107 vs 289 +/- 197 ng/mL, mean +/- SD, i.o. vs i.v., respectively), Tmax (1.3 +/- 0.5 vs 1.4 +/- 0.5 minutes), and AUC(0-infinity) (4372 +/- 1785 vs 4410 +/- 1930 ng min(-1) mL(-1)).",Does intraosseous equal intravenous? A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082778/),[ng] / [ml],289,75230,DB00295,Morphine
,18082778,Tmax,"No statistically significant differences were observed between intraosseous and intravenous administration of morphine sulfate for nearly all of the pharmacokinetic parameters including Cmax (235 +/- 107 vs 289 +/- 197 ng/mL, mean +/- SD, i.o. vs i.v., respectively), Tmax (1.3 +/- 0.5 vs 1.4 +/- 0.5 minutes), and AUC(0-infinity) (4372 +/- 1785 vs 4410 +/- 1930 ng min(-1) mL(-1)).",Does intraosseous equal intravenous? A pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082778/),min,1.3,75231,DB00295,Morphine
,18082778,Tmax,"No statistically significant differences were observed between intraosseous and intravenous administration of morphine sulfate for nearly all of the pharmacokinetic parameters including Cmax (235 +/- 107 vs 289 +/- 197 ng/mL, mean +/- SD, i.o. vs i.v., respectively), Tmax (1.3 +/- 0.5 vs 1.4 +/- 0.5 minutes), and AUC(0-infinity) (4372 +/- 1785 vs 4410 +/- 1930 ng min(-1) mL(-1)).",Does intraosseous equal intravenous? A pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082778/),min,1.4,75232,DB00295,Morphine
,18082778,AUC(0-infinity),"No statistically significant differences were observed between intraosseous and intravenous administration of morphine sulfate for nearly all of the pharmacokinetic parameters including Cmax (235 +/- 107 vs 289 +/- 197 ng/mL, mean +/- SD, i.o. vs i.v., respectively), Tmax (1.3 +/- 0.5 vs 1.4 +/- 0.5 minutes), and AUC(0-infinity) (4372 +/- 1785 vs 4410 +/- 1930 ng min(-1) mL(-1)).",Does intraosseous equal intravenous? A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082778/),[ng] / [min·ml],4372,75233,DB00295,Morphine
,18082778,AUC(0-infinity),"No statistically significant differences were observed between intraosseous and intravenous administration of morphine sulfate for nearly all of the pharmacokinetic parameters including Cmax (235 +/- 107 vs 289 +/- 197 ng/mL, mean +/- SD, i.o. vs i.v., respectively), Tmax (1.3 +/- 0.5 vs 1.4 +/- 0.5 minutes), and AUC(0-infinity) (4372 +/- 1785 vs 4410 +/- 1930 ng min(-1) mL(-1)).",Does intraosseous equal intravenous? A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082778/),[ng] / [min·ml],4410,75234,DB00295,Morphine
,11294312,total body clearance,Mean +/- SEM total body clearance of morphine was 68 +/- 6 ml/min/kg (31 +/- 3 ml/min/lb).,Comparison of the effects of morphine administered by constant-rate intravenous infusion or intermittent intramuscular injection in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294312/),[ml] / [kg·min],68,75524,DB00295,Morphine
,11294312,total body clearance,Mean +/- SEM total body clearance of morphine was 68 +/- 6 ml/min/kg (31 +/- 3 ml/min/lb).,Comparison of the effects of morphine administered by constant-rate intravenous infusion or intermittent intramuscular injection in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294312/),[ml] / [lb·min],31,75525,DB00295,Morphine
,11294312,steady-state serum morphine concentration,Mean steady-state serum morphine concentration in dogs receiving morphine by constant-rate infusion was 30 +/- 2 ng/ml.,Comparison of the effects of morphine administered by constant-rate intravenous infusion or intermittent intramuscular injection in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294312/),[ng] / [ml],30,75526,DB00295,Morphine
,24595069,total clearance,"Expected pharmacokinetic parameters were based on a pharmacokinetic profile extrapolated from 39 patients: M total clearance varied between 1.5 and 6.42 L·h(-1)·kg(-1); the median apparent volume of M distribution was 25.0 L/kg, and the elimination half-life was 4.4 hours.",Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595069/),[l] / [h·kg],1.5 and 6.42,75680,DB00295,Morphine
,24595069,apparent volume of M distribution,"Expected pharmacokinetic parameters were based on a pharmacokinetic profile extrapolated from 39 patients: M total clearance varied between 1.5 and 6.42 L·h(-1)·kg(-1); the median apparent volume of M distribution was 25.0 L/kg, and the elimination half-life was 4.4 hours.",Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595069/),[l] / [kg],25.0,75681,DB00295,Morphine
,24595069,elimination half-life,"Expected pharmacokinetic parameters were based on a pharmacokinetic profile extrapolated from 39 patients: M total clearance varied between 1.5 and 6.42 L·h(-1)·kg(-1); the median apparent volume of M distribution was 25.0 L/kg, and the elimination half-life was 4.4 hours.",Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595069/),h,4.4,75682,DB00295,Morphine
,24595069,effective M concentration,"At the end of titration, the M6G/M ratio was significantly higher in the patients whose effective M concentration was below the median (5.2 ng/mL), than in patients in whom the concentration was above the median (M6G/M: 13.0 and 9.0, respectively).",Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595069/),[ng] / [ml],5.2,75683,DB00295,Morphine
,24595069,M6G/M,"At the end of titration, the M6G/M ratio was significantly higher in the patients whose effective M concentration was below the median (5.2 ng/mL), than in patients in whom the concentration was above the median (M6G/M: 13.0 and 9.0, respectively).",Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595069/),,13.0,75684,DB00295,Morphine
,24595069,M6G/M,"At the end of titration, the M6G/M ratio was significantly higher in the patients whose effective M concentration was below the median (5.2 ng/mL), than in patients in whom the concentration was above the median (M6G/M: 13.0 and 9.0, respectively).",Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595069/),,9.0,75685,DB00295,Morphine
,9200518,S/N ratio,"For a sample size of 1 ml, the limit of quantitation was 0.75 ng/ml (S/N ratio 10:1) and the estimated limit of detection was calculated to be 0.2 ng/ml (S/N ratio 3:1), expressed as morphine base.",Highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200518/),,10:1,75750,DB00295,Morphine
,9200518,S/N ratio,"For a sample size of 1 ml, the limit of quantitation was 0.75 ng/ml (S/N ratio 10:1) and the estimated limit of detection was calculated to be 0.2 ng/ml (S/N ratio 3:1), expressed as morphine base.",Highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200518/),,3:1,75751,DB00295,Morphine
,9200518,Precision,"Precision (n=5) was 4.9% at 0.75 ng/ml, 6.8% at 1.5 ng/ml, 3.0% at 37.5 ng/ml and 2.3% at 150 ng/ml.",Highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200518/),%,4,75752,DB00295,Morphine
,9200518,Precision,"Precision (n=5) was 4.9% at 0.75 ng/ml, 6.8% at 1.5 ng/ml, 3.0% at 37.5 ng/ml and 2.3% at 150 ng/ml.",Highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200518/),%,6,75753,DB00295,Morphine
,9200518,Precision,"Precision (n=5) was 4.9% at 0.75 ng/ml, 6.8% at 1.5 ng/ml, 3.0% at 37.5 ng/ml and 2.3% at 150 ng/ml.",Highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200518/),%,3,75754,DB00295,Morphine
,9200518,Precision,"Precision (n=5) was 4.9% at 0.75 ng/ml, 6.8% at 1.5 ng/ml, 3.0% at 37.5 ng/ml and 2.3% at 150 ng/ml.",Highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200518/),,2,75755,DB00295,Morphine
,11673751,areas under 6-hour concentration-versus-time curve,"M6G areas under 6-hour concentration-versus-time curve were as follows: Caucasians, 12,065 +/- 4354; native Indians, 8464 +/- 4809; and Latinos, 9156 +/- 3764 ng. min/mL (P =.03).",Ethnicity influences morphine pharmacokinetics and pharmacodynamics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673751/),[min·ng] / [ml],"12,065",75794,DB00295,Morphine
,11673751,areas under 6-hour concentration-versus-time curve,"M6G areas under 6-hour concentration-versus-time curve were as follows: Caucasians, 12,065 +/- 4354; native Indians, 8464 +/- 4809; and Latinos, 9156 +/- 3764 ng. min/mL (P =.03).",Ethnicity influences morphine pharmacokinetics and pharmacodynamics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673751/),[min·ng] / [ml],8464,75795,DB00295,Morphine
,11673751,areas under 6-hour concentration-versus-time curve,"M6G areas under 6-hour concentration-versus-time curve were as follows: Caucasians, 12,065 +/- 4354; native Indians, 8464 +/- 4809; and Latinos, 9156 +/- 3764 ng. min/mL (P =.03).",Ethnicity influences morphine pharmacokinetics and pharmacodynamics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673751/),[min·ng] / [ml],9156,75796,DB00295,Morphine
,8446441,steady plasma concentrations,"On the 2 test days involving morphine, the opioid was administered by a computer-pump system that used individual pharmacokinetic parameters to achieve consecutive, steady plasma concentrations near target values of 16, 32 and 64 ng morphine/ml; each morphine concentration plateau was maintained for 45 min.",Enhancement of morphine analgesia by fenfluramine in subjects receiving tailored opioid infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8446441/),[morphine·ng] / [ml],16,76414,DB00295,Morphine
,8446441,steady plasma concentrations,"On the 2 test days involving morphine, the opioid was administered by a computer-pump system that used individual pharmacokinetic parameters to achieve consecutive, steady plasma concentrations near target values of 16, 32 and 64 ng morphine/ml; each morphine concentration plateau was maintained for 45 min.",Enhancement of morphine analgesia by fenfluramine in subjects receiving tailored opioid infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8446441/),[morphine·ng] / [ml],32,76415,DB00295,Morphine
,8446441,steady plasma concentrations,"On the 2 test days involving morphine, the opioid was administered by a computer-pump system that used individual pharmacokinetic parameters to achieve consecutive, steady plasma concentrations near target values of 16, 32 and 64 ng morphine/ml; each morphine concentration plateau was maintained for 45 min.",Enhancement of morphine analgesia by fenfluramine in subjects receiving tailored opioid infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8446441/),[morphine·ng] / [ml],64,76416,DB00295,Morphine
,8809641,Tmax,"Morphine Tmax ranged from 3 h to 12 h (median 6 h), Cmax 8.0-40.0 ng/ml and AUC0-24 90.1-429.7 ng/h/ml in subjects offering blood samples over the 24-h period.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,3,76704,DB00295,Morphine
,8809641,Tmax,"Morphine Tmax ranged from 3 h to 12 h (median 6 h), Cmax 8.0-40.0 ng/ml and AUC0-24 90.1-429.7 ng/h/ml in subjects offering blood samples over the 24-h period.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,12,76705,DB00295,Morphine
,8809641,Tmax,"Morphine Tmax ranged from 3 h to 12 h (median 6 h), Cmax 8.0-40.0 ng/ml and AUC0-24 90.1-429.7 ng/h/ml in subjects offering blood samples over the 24-h period.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,6,76706,DB00295,Morphine
,8809641,Cmax,"Morphine Tmax ranged from 3 h to 12 h (median 6 h), Cmax 8.0-40.0 ng/ml and AUC0-24 90.1-429.7 ng/h/ml in subjects offering blood samples over the 24-h period.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),[ng] / [ml],8.0-40.0,76707,DB00295,Morphine
,8809641,AUC0-24,"Morphine Tmax ranged from 3 h to 12 h (median 6 h), Cmax 8.0-40.0 ng/ml and AUC0-24 90.1-429.7 ng/h/ml in subjects offering blood samples over the 24-h period.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),[ng] / [h·ml],90.1-429.7,76708,DB00295,Morphine
,8809641,Tmax,"Likewise, morphine-3-glucuronide Tmax ranged from 3 h to 24 h (median 9 h), Cmax 153-370 ng/ml and AUC0-24 2776-4390 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,3,76709,DB00295,Morphine
,8809641,Tmax,"Likewise, morphine-3-glucuronide Tmax ranged from 3 h to 24 h (median 9 h), Cmax 153-370 ng/ml and AUC0-24 2776-4390 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,24,76710,DB00295,Morphine
,8809641,Tmax,"Likewise, morphine-3-glucuronide Tmax ranged from 3 h to 24 h (median 9 h), Cmax 153-370 ng/ml and AUC0-24 2776-4390 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,9,76711,DB00295,Morphine
,8809641,Cmax,"Likewise, morphine-3-glucuronide Tmax ranged from 3 h to 24 h (median 9 h), Cmax 153-370 ng/ml and AUC0-24 2776-4390 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),[ng] / [ml],153-370,76712,DB00295,Morphine
,8809641,AUC0-24,"Likewise, morphine-3-glucuronide Tmax ranged from 3 h to 24 h (median 9 h), Cmax 153-370 ng/ml and AUC0-24 2776-4390 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),[ng] / [h·ml],2776-4390,76713,DB00295,Morphine
,8809641,Tmax,"Morphine-6-glucuronide Tmax ranged from 8 h to 12 h (median 10 h), Cmax 24-59 ng/ml and AUC0-24 137-803 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,8,76714,DB00295,Morphine
,8809641,Tmax,"Morphine-6-glucuronide Tmax ranged from 8 h to 12 h (median 10 h), Cmax 24-59 ng/ml and AUC0-24 137-803 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,12,76715,DB00295,Morphine
,8809641,Tmax,"Morphine-6-glucuronide Tmax ranged from 8 h to 12 h (median 10 h), Cmax 24-59 ng/ml and AUC0-24 137-803 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),h,10,76716,DB00295,Morphine
,8809641,Cmax,"Morphine-6-glucuronide Tmax ranged from 8 h to 12 h (median 10 h), Cmax 24-59 ng/ml and AUC0-24 137-803 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),[ng] / [ml],24-59,76717,DB00295,Morphine
,8809641,AUC0-24,"Morphine-6-glucuronide Tmax ranged from 8 h to 12 h (median 10 h), Cmax 24-59 ng/ml and AUC0-24 137-803 ng/h/ml.",Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809641/),[ng] / [h·ml],137-803,76718,DB00295,Morphine
,2390424,elimination half-life,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),h,13.1 to 44.7,76761,DB00295,Morphine
,2390424,systemic clearance,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),[l] / [h],1.02 to 1.63,76762,DB00295,Morphine
,2390424,volume of distribution,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),l,1390 to 3940,76763,DB00295,Morphine
,2390424,o,"The large volume of distribution is consistent with the high octanol/blood partition coefficient, which was found to be 72.0.",Pharmacokinetics of propofol when given by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),,72.0,76764,DB00295,Morphine
,11948846,sample recovery,The sample recovery after solid-phase extraction was 84.7% for both M3G and M6G.,Quantitative gas chromatographic/mass spectrometric analysis of morphine glucuronides in human plasma by negative ion chemical ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948846/),%,84.7,76936,DB00295,Morphine
,8213024,Total urinary excretion,"Total urinary excretion of morphine decreased significantly from 1.98 +/- 0.15 mg on day 1 to 1.6 +/- 0.2 mg and 0.19 +/- 0.002 mg on days 2 and 3, respectively (P < 0.01).",A two-dose epidural morphine regimen in cesarean section patients: pharmacokinetic profile. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213024/),mg,1.98,77321,DB00295,Morphine
,8213024,Total urinary excretion,"Total urinary excretion of morphine decreased significantly from 1.98 +/- 0.15 mg on day 1 to 1.6 +/- 0.2 mg and 0.19 +/- 0.002 mg on days 2 and 3, respectively (P < 0.01).",A two-dose epidural morphine regimen in cesarean section patients: pharmacokinetic profile. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213024/),mg,1.6,77322,DB00295,Morphine
,8213024,Total urinary excretion,"Total urinary excretion of morphine decreased significantly from 1.98 +/- 0.15 mg on day 1 to 1.6 +/- 0.2 mg and 0.19 +/- 0.002 mg on days 2 and 3, respectively (P < 0.01).",A two-dose epidural morphine regimen in cesarean section patients: pharmacokinetic profile. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213024/),mg,0.19,77323,DB00295,Morphine
,14633756,effect-site concentration,"In the sufentanil group, an effect-site concentration of 0.25 ng x ml(-1) was targeted at extubation.","Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),[ng] / [ml],0.25,77731,DB00295,Morphine
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,13,77732,DB00295,Morphine
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,14,77733,DB00295,Morphine
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,55,77734,DB00295,Morphine
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,11,77735,DB00295,Morphine
,14633756,effect-site concentration,TCI sufentanil (0.25 ng ml(-1) effect-site concentration at extubation) is more effective than the intraoperative combination of remifentanil TCI infusion with morphine bolus (0.15 mg x kg(-1)) for postoperative pain relief after major abdominal surgery and does not compromise extubation and recovery.,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),,0.25,77736,DB00295,Morphine
,16778720,conversion ratio,The mean morphine to methadone conversion ratio was 5.2 with wide interpatient variability (range 1.3 to 11).,Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),,5.2,78944,DB00295,Morphine
,16778720,steady-state concentrations,"Average steady-state concentrations were 197 (98 to 379) mug/L and 272 (55 to 378) mug/L for R- and S-methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[μg] / [l],197,78945,DB00295,Morphine
,16778720,steady-state concentrations,"Average steady-state concentrations were 197 (98 to 379) mug/L and 272 (55 to 378) mug/L for R- and S-methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[μg] / [l],272,78946,DB00295,Morphine
,16778720,apparent volume of distribution,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),l,455,78947,DB00295,Morphine
,16778720,apparent volume of distribution,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),l,338,78948,DB00295,Morphine
,16778720,half-life,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),h,53.3,78949,DB00295,Morphine
,16778720,half-life,"Mean population pharmacokinetic parameters for a 1-compartment model were 455 L and 338 L for apparent volume of distribution and 53.3 hours and 31.5 hours for half-life for R- and S- methadone, respectively.",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),h,31.5,78950,DB00295,Morphine
,16778720,apparent oral clearance,"Bayesian estimates of apparent oral clearance for individual patients were 0.082 (0.052 to 0.112) L/kg/h and 0.117 (0.061 to 0.173) L/kg/h for R- and S- methadone, respectively (mean and 95% confidence interval).",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[l] / [h·kg],0.082,78951,DB00295,Morphine
,16778720,apparent oral clearance,"Bayesian estimates of apparent oral clearance for individual patients were 0.082 (0.052 to 0.112) L/kg/h and 0.117 (0.061 to 0.173) L/kg/h for R- and S- methadone, respectively (mean and 95% confidence interval).",Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778720/),[l] / [h·kg],0.117,78952,DB00295,Morphine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.2,79157,DB00295,Morphine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.5,79158,DB00295,Morphine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,1.6,79159,DB00295,Morphine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.6,79160,DB00295,Morphine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.7,79161,DB00295,Morphine
,10097360,clearance,"Results of these parameters showed the following: clearance from 13.3 to 16.2 L.h.1, half-life of the distribution phase from 0.6 to 0.9 min, and half-life of the elimination phase from 21 to 26 min.",Morphine perfused rabbits: a tool for experiments in forensic entomotoxicology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10097360/),1·h·l,13.3 to 16.2,79553,DB00295,Morphine
,10097360,half-life of the distribution phase,"Results of these parameters showed the following: clearance from 13.3 to 16.2 L.h.1, half-life of the distribution phase from 0.6 to 0.9 min, and half-life of the elimination phase from 21 to 26 min.",Morphine perfused rabbits: a tool for experiments in forensic entomotoxicology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10097360/),min,0.6 to 0.9,79554,DB00295,Morphine
,10097360,half-life of the elimination phase,"Results of these parameters showed the following: clearance from 13.3 to 16.2 L.h.1, half-life of the distribution phase from 0.6 to 0.9 min, and half-life of the elimination phase from 21 to 26 min.",Morphine perfused rabbits: a tool for experiments in forensic entomotoxicology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10097360/),min,21 to 26,79555,DB00295,Morphine
,15920700,flow rate,"The analytes were separated using a mobile phase, consisting of acetonitrile and phosphate buffer (8:92, v/v) at a flow rate of 1 mL/min, and UV detection at 205 nm.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),[ml] / [min],1,80383,DB00295,Morphine
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,14.7,80384,DB00295,Morphine
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,13.8,80385,DB00295,Morphine
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,10.2,80386,DB00295,Morphine
,19783397,inhalation time,"Patients using the BCTS-S method inhaled a morphine dose in 6.6+/-2 minutes, whereas with the BCTS-MC method, the inhalation time was 28.8+/-8 minutes.","Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19783397/),min,28.8,80627,DB00295,Morphine
,19783397,time to maximum concentration,"In both methods, the time to maximum concentration for morphine metabolites was 20-40 minutes, much shorter than expected from oral, intranasal, or intravenous administration.","Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19783397/),min,20-40,80628,DB00295,Morphine
,16037150,arterial Pco(2),The median arterial Pco(2) level was 41 mm Hg and the interquartile range was 39-46 mm Hg.,"Preoperative ""fentanyl challenge"" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16037150/),hg·mm,41,80675,DB00295,Morphine
,33481403,peak plasma concentration,"Median total methadone peak plasma concentration was 24.7 (interquartile range [IQR], 19.2-40.8) ng/mL and the median trough was 4.09 (IQR, 2.74-6.4) ng/mL.",A Novel Perioperative Multidose Methadone-Based Multimodal Analgesic Strategy in Children Achieved Safe and Low Analgesic Blood Methadone Levels Enabling Opioid-Sparing Sustained Analgesia With Minimal Adverse Effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33481403/),[ng] / [ml],24.7,81087,DB00295,Morphine
,33481403,trough,"Median total methadone peak plasma concentration was 24.7 (interquartile range [IQR], 19.2-40.8) ng/mL and the median trough was 4.09 (IQR, 2.74-6.4) ng/mL.",A Novel Perioperative Multidose Methadone-Based Multimodal Analgesic Strategy in Children Achieved Safe and Low Analgesic Blood Methadone Levels Enabling Opioid-Sparing Sustained Analgesia With Minimal Adverse Effects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33481403/),[ng] / [ml],4.09,81088,DB00295,Morphine
,8249042,absolute bioavailability,"The absolute bioavailability of morphine in the oral solution was 21.6% (15.4-27.7%; 95% CI) and in the controlled release tablet, 17.1% (12.6-21.6%; CI).",Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249042/),%,21.6,81263,DB00295,Morphine
,8249042,absolute bioavailability,"The absolute bioavailability of morphine in the oral solution was 21.6% (15.4-27.7%; 95% CI) and in the controlled release tablet, 17.1% (12.6-21.6%; CI).",Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249042/),%,17.1,81264,DB00295,Morphine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,11.3 to 8.4,81404,DB00295,Morphine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.7 to 7.6,81405,DB00295,Morphine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,12.2 to 8.6,81406,DB00295,Morphine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.6 to 8.6,81407,DB00295,Morphine
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,266,81576,DB00295,Morphine
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,168,81577,DB00295,Morphine
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1201,81578,DB00295,Morphine
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1687,81579,DB00295,Morphine
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],726,81580,DB00295,Morphine
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1331,81581,DB00295,Morphine
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2046,81582,DB00295,Morphine
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2665,81583,DB00295,Morphine
,2891329,Maximum plasma morphine concentrations,"Maximum plasma morphine concentrations were found 5-10 min after injection, and averaged 4.5 +/- 1.1 ng.ml-1 (mean +/- SEM).",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),[ng] / [ml],4.5,81825,DB00295,Morphine
,2891329,Maximum CSF morphine concentrations,"Maximum CSF morphine concentrations were considerably higher than maximum plasma concentrations, 6410 +/- 1290 ng.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ng,6410,81826,DB00295,Morphine
,2891329,maximum plasma concentrations,"Maximum CSF morphine concentrations were considerably higher than maximum plasma concentrations, 6410 +/- 1290 ng.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ng,6410,81827,DB00295,Morphine
,2891329,Maximum plasma concentrations,Maximum plasma concentrations of meperidine were also measured 5 or 10 min after injection and were low (36 +/- 9 ng.,Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ng,36,81828,DB00295,Morphine
,2891329,maximum CSF concentrations,ml-1) compared with the maximum CSF concentrations (364 +/- 105 micrograms.ml-1).,Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),[μg] / [ml],364,81829,DB00295,Morphine
,2891329,half-life,"After a rapid initial decline for about 15 min after injection, the CSF concentrations decreased with a half-life of 89.8 +/- 16.1 min for morphine and 68.0 +/- 5.1 min for meperidine during the rest of the study period.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),min,89.8,81830,DB00295,Morphine
,2891329,half-life,"After a rapid initial decline for about 15 min after injection, the CSF concentrations decreased with a half-life of 89.8 +/- 16.1 min for morphine and 68.0 +/- 5.1 min for meperidine during the rest of the study period.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),min,68.0,81831,DB00295,Morphine
,2891329,initial volume of distribution in CSF,"The initial volume of distribution in CSF was similar for both drugs, or 22 +/- 8 ml for morphine and 18 +/- 5 ml for meperidine.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ml,22,81832,DB00295,Morphine
,2891329,initial volume of distribution in CSF,"The initial volume of distribution in CSF was similar for both drugs, or 22 +/- 8 ml for morphine and 18 +/- 5 ml for meperidine.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ml,18,81833,DB00295,Morphine
,15037665,latency of onset to clinical effect,Studies have shown the latency of onset to clinical effect after s.c. injection ranged from 7.3 to 14 minutes.,Subcutaneously administered apomorphine: pharmacokinetics and metabolism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037665/),min,7.3 to 14,82736,DB00295,Morphine
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,151.2,83339,DB00295,Morphine
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,110.0,83340,DB00295,Morphine
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,302.3,83341,DB00295,Morphine
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,199.2,83342,DB00295,Morphine
,25965875,analysis time of,The analysis time of per sample was 1.0min.,Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),min,1.0,83343,DB00295,Morphine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],30.2,83715,DB00295,Morphine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],25.6,83716,DB00295,Morphine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],11.5,83717,DB00295,Morphine
,19840530,time to Cmax (tmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,0.2,83718,DB00295,Morphine
,19840530,time to Cmax (tmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,2.0,83719,DB00295,Morphine
,19840530,Cmax,Flushing the catheter and waiting 15 minutes normalized the Cmax (11.4 +/- 6.4 ng/ml) but not the median tmax (0.5 h).,A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],11.4,83720,DB00295,Morphine
,19840530,tmax,Flushing the catheter and waiting 15 minutes normalized the Cmax (11.4 +/- 6.4 ng/ml) but not the median tmax (0.5 h).,A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,0.5,83721,DB00295,Morphine
,1394709,bioavailability (BA),"Phamacokinetics of morphine from the suppository were compared with the orally administered MST, and it was found that there was no difference in the maximum plasma concentration (Cmax) and the peak time (Tmax) between MSC and MST, but the mean residence time (MRT) of MSC was approximately three times longer than that of MST, and the extent of bioavailability (BA) of MSC was significantly larger than that of MST (71.6 +/- 14.2% and 11.9 +/- 4.0%, respectively).",Bioavailability of morphine in rabbits after rectal administration of suppository containing controlled release morphine tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394709/),%,71.6,83933,DB00295,Morphine
,1394709,bioavailability (BA),"Phamacokinetics of morphine from the suppository were compared with the orally administered MST, and it was found that there was no difference in the maximum plasma concentration (Cmax) and the peak time (Tmax) between MSC and MST, but the mean residence time (MRT) of MSC was approximately three times longer than that of MST, and the extent of bioavailability (BA) of MSC was significantly larger than that of MST (71.6 +/- 14.2% and 11.9 +/- 4.0%, respectively).",Bioavailability of morphine in rabbits after rectal administration of suppository containing controlled release morphine tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394709/),%,11.9,83934,DB00295,Morphine
,902456,peak plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],194 to 340,84173,DB00295,Morphine
,902456,peak codeine plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],102 to 140,84174,DB00295,Morphine
,902456,plasma t1/2,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),h,3.32,84175,DB00295,Morphine
,902456,volume of distribution,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[l] / [kg],5.1,84176,DB00295,Morphine
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,42,84177,DB00295,Morphine
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,53,84178,DB00295,Morphine
,3609116,terminal elimination half life,"The terminal elimination half life of morphine varied between 1.5 and 4.0 h (mean 2.4 h), the volume of distribution between 2.5 and 6.3 l X kg-1 (mean 4.4 l X kg-1) and the total plasma clearance between 13.3 and 31.3 l X min-1 X kg-1 (mean 21.1 l X kg-1).",Kinetics of morphine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),h,2.4,84309,DB00295,Morphine
,3609116,volume of distribution,"The terminal elimination half life of morphine varied between 1.5 and 4.0 h (mean 2.4 h), the volume of distribution between 2.5 and 6.3 l X kg-1 (mean 4.4 l X kg-1) and the total plasma clearance between 13.3 and 31.3 l X min-1 X kg-1 (mean 21.1 l X kg-1).",Kinetics of morphine in patients with renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),[l] / [kg],2.5 and 6.3,84310,DB00295,Morphine
,3609116,volume of distribution,"The terminal elimination half life of morphine varied between 1.5 and 4.0 h (mean 2.4 h), the volume of distribution between 2.5 and 6.3 l X kg-1 (mean 4.4 l X kg-1) and the total plasma clearance between 13.3 and 31.3 l X min-1 X kg-1 (mean 21.1 l X kg-1).",Kinetics of morphine in patients with renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),[l] / [kg],4.4,84311,DB00295,Morphine
,3609116,total plasma clearance,"The terminal elimination half life of morphine varied between 1.5 and 4.0 h (mean 2.4 h), the volume of distribution between 2.5 and 6.3 l X kg-1 (mean 4.4 l X kg-1) and the total plasma clearance between 13.3 and 31.3 l X min-1 X kg-1 (mean 21.1 l X kg-1).",Kinetics of morphine in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),[l] / [kg·min],13.3 and 31.3,84312,DB00295,Morphine
,3609116,total plasma clearance,"The terminal elimination half life of morphine varied between 1.5 and 4.0 h (mean 2.4 h), the volume of distribution between 2.5 and 6.3 l X kg-1 (mean 4.4 l X kg-1) and the total plasma clearance between 13.3 and 31.3 l X min-1 X kg-1 (mean 21.1 l X kg-1).",Kinetics of morphine in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),[l] / [kg],21.1,84313,DB00295,Morphine
,3609116,elimination half-life,"The elimination half-life of M3G varied between 14.5 and 118.8 h (mean 49.6 h) in the renal failure patients, which is distinctly different from the 2.4 to 6.7 h (mean 4.0 h) found in patients with normal kidney function.",Kinetics of morphine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),h,49.6,84314,DB00295,Morphine
,3609116,elimination half-life,"The elimination half-life of M3G varied between 14.5 and 118.8 h (mean 49.6 h) in the renal failure patients, which is distinctly different from the 2.4 to 6.7 h (mean 4.0 h) found in patients with normal kidney function.",Kinetics of morphine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609116/),h,4.0,84315,DB00295,Morphine
,29996718,rate,Median fentanyl rate of 100 µg/h was transitioned to 1 mg/h of hydromorphone.,Transition From Continuous Infusion Fentanyl to Hydromorphone in Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29996718/),[μg] / [h],100,84321,DB00295,Morphine
,15777102,area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)],"Following a single dose of 5, 10 or 20mg, the oxymorphone IR mean area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)] 4.5, 9.1 and 20.1 microg .",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),μg,4.5,84939,DB00295,Morphine
,15777102,area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)],"Following a single dose of 5, 10 or 20mg, the oxymorphone IR mean area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)] 4.5, 9.1 and 20.1 microg .",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),μg,9.1,84940,DB00295,Morphine
,15777102,area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)],"Following a single dose of 5, 10 or 20mg, the oxymorphone IR mean area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)] 4.5, 9.1 and 20.1 microg .",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),μg,20.1,84941,DB00295,Morphine
,15777102,maximum plasma concentration ([C(max)],"h/L, respectively) and maximum plasma concentration ([C(max)] 1.1, 1.9 and 4.4 microg/L, respectively) confirmed dose proportionality.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),[μg] / [l],1.1,84942,DB00295,Morphine
,15777102,maximum plasma concentration ([C(max)],"h/L, respectively) and maximum plasma concentration ([C(max)] 1.1, 1.9 and 4.4 microg/L, respectively) confirmed dose proportionality.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),[μg] / [l],1.9,84943,DB00295,Morphine
,15777102,maximum plasma concentration ([C(max)],"h/L, respectively) and maximum plasma concentration ([C(max)] 1.1, 1.9 and 4.4 microg/L, respectively) confirmed dose proportionality.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),[μg] / [l],4.4,84944,DB00295,Morphine
,15777102,t(max) (time to reach C(max)),"The median t(max) (time to reach C(max)) was 0.5 hours for all single doses of oxymorphone and at steady state, and the terminal elimination half-life (t(1/2)) was approximately 7.3-9.4 hours.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),h,0.5,84945,DB00295,Morphine
,15777102,terminal elimination half-life (t(1/2)),"The median t(max) (time to reach C(max)) was 0.5 hours for all single doses of oxymorphone and at steady state, and the terminal elimination half-life (t(1/2)) was approximately 7.3-9.4 hours.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),h,7.3-9.4,84946,DB00295,Morphine
,16433897,Bioavailability (F),Bioavailability (F) of heroin inhalation was estimated as 52% (95% CI 44-61%).,"Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),%,52,85351,DB00295,Morphine
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],930,85352,DB00295,Morphine
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],1939,85353,DB00295,Morphine
,16433897,reaction time,"After heroin administration, the reaction time was significantly prolonged with 28+/-5.3 msec.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),ms,28,85354,DB00295,Morphine
,9054254,Cp50,The propofol Cp50 with nitrous oxide was 3.85 micrograms/ ml.,Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054254/),[μg] / [ml],3.85,86430,DB00295,Morphine
,9054254,Cp50,High-dose esmolol infusion was associated with a significant reduction in the Cp50 to 2.80 micrograms/ml (P < 0.04).,Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054254/),[μg] / [ml],2.80,86431,DB00295,Morphine
,9209248,elimination half-life,"THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in patients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),h,13.9,86627,DB00295,Morphine
,9209248,elimination half-life,"THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in patients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),h,3.4,86628,DB00295,Morphine
,9209248,clearance,"Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),[l] / [min],0.26,86629,DB00295,Morphine
,9209248,clearance,"Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),[l] / [min],1.13,86630,DB00295,Morphine
,17578959,time to peak concentration,"M-6-G was 7.8 times more potent than morphine, but the average time to peak concentration in the effect compartment after a bolus injection of morphine was 4.25 h for M-6-G, when compared to 0.33 h for morphine.",Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578959/),h,4.25,86886,DB00295,Morphine
,17578959,time to peak concentration,"M-6-G was 7.8 times more potent than morphine, but the average time to peak concentration in the effect compartment after a bolus injection of morphine was 4.25 h for M-6-G, when compared to 0.33 h for morphine.",Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578959/),h,0.33,86887,DB00295,Morphine
,17578959,time to M-3-G peak concentration,The time to M-3-G peak concentration in the effect compartment after a bolus injection of morphine was 10 h.,Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578959/),h,10,86888,DB00295,Morphine
,2046334,half-life,"Following heroin administration, 6-AM was excreted rapidly with an average half-life of 0.6 h.",Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,0.6,87051,DB00295,Morphine
,2046334,half-life,The average half-life for free morphine was 3.6 h and for total morphine was 7.9 h.,Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,3.6,87052,DB00295,Morphine
,2046334,half-life,The average half-life for free morphine was 3.6 h and for total morphine was 7.9 h.,Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,7.9,87053,DB00295,Morphine
,19357842,maximal morphine concentration,Thirty subjects (group I) had a mean (standard deviation) maximal morphine concentration of 2.0 (1.0) ng/ml.,The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19357842/),[ng] / [ml],2.0,87239,DB00295,Morphine
,26751618,metabolic,"The metabolic ratios AUC0-inf M3G/morphine and AUC0-inf M6G/morphine were highly correlated (rs = 0.8, p < 0.0001) and were 73.2 ± 24.6 (34.7-137.7) and 10.9 ± 4.1 (3.8-20.6).","Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751618/),,73,88241,DB00295,Morphine
no more,3987773,availability to,The availability to spinal CSF amounted to no more than 0.005% of the administered dose.,CSF and plasma pharmacokinetics of intramuscular morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987773/),%,0.005,88575,DB00295,Morphine
,1713663,maximum blood morphine concentration,A maximum blood morphine concentration of 60 +/- 25 ng/ml (mean +/- S.D.) was obtained at 11 +/- 6 min (mean +/- S.D.).,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],60,88846,DB00295,Morphine
,1713663,peak,The blood hydromorphone peak of 14 +/- 13 ng/ml (mean +/- S.D.) occurred 8 +/- 6 min (mean +/- S.D.).,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],14,88847,DB00295,Morphine
,1713663,peak CSF opioid concentrations,The mean peak CSF opioid concentrations of 1581 ng/ml for morphine and 309 ng/ml for hydromorphone occurred 60 min after epidural administration.,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],1581,88848,DB00295,Morphine
,1713663,peak CSF opioid concentrations,The mean peak CSF opioid concentrations of 1581 ng/ml for morphine and 309 ng/ml for hydromorphone occurred 60 min after epidural administration.,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],309,88849,DB00295,Morphine
,25451468,K1,"(125)I-LinS had the highest blood-brain clearance (K1=3.46μL/gmin), followed by (125)I-LinNMe, (125)I-CycNMe, and (125)I-CycS (K1=1.64, 0.31, and 0.11μL/gmin, respectively).",Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25451468/),[μl] / [gmin],3.46,88866,DB00295,Morphine
,25451468,K1,"(125)I-LinS had the highest blood-brain clearance (K1=3.46μL/gmin), followed by (125)I-LinNMe, (125)I-CycNMe, and (125)I-CycS (K1=1.64, 0.31, and 0.11μL/gmin, respectively).",Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25451468/),[μl] / [gmin],1.64,88867,DB00295,Morphine
,25451468,K1,"(125)I-LinS had the highest blood-brain clearance (K1=3.46μL/gmin), followed by (125)I-LinNMe, (125)I-CycNMe, and (125)I-CycS (K1=1.64, 0.31, and 0.11μL/gmin, respectively).",Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25451468/),[μl] / [gmin],0.31,88868,DB00295,Morphine
,25451468,K1,"(125)I-LinS had the highest blood-brain clearance (K1=3.46μL/gmin), followed by (125)I-LinNMe, (125)I-CycNMe, and (125)I-CycS (K1=1.64, 0.31, and 0.11μL/gmin, respectively).",Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25451468/),[μl] / [gmin],0.11,88869,DB00295,Morphine
>,25451468,t1/2,"Also, these peptides had a high metabolic stability (t1/2>1h) in mouse serum and brain homogenate, and half-inhibition constant (Ki) values in the nanomolar range with predominantly μ-opioid receptor selectivity.",Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25451468/),h,1,88870,DB00295,Morphine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],28.6,89264,DB00295,Morphine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],33.4,89265,DB00295,Morphine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],42.4,89266,DB00295,Morphine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],36.5,89267,DB00295,Morphine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],31.6,89268,DB00295,Morphine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],565,89269,DB00295,Morphine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],660,89270,DB00295,Morphine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],973,89271,DB00295,Morphine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],983,89272,DB00295,Morphine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],638,89273,DB00295,Morphine
,27138027,Cmax,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],10.1,89274,DB00295,Morphine
,27138027,Cmax,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],13.0,89275,DB00295,Morphine
,27138027,AUC0-∞,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],155,89276,DB00295,Morphine
,27138027,AUC0-∞,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],269,89277,DB00295,Morphine
>,8996221,T1/2,"CTAP was also stable in the blood and serum of rats (T1/2 > 500 min), showing that the structure of this peptide offers enzymatic resistance.","Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996221/),min,500,90577,DB00295,Morphine
,18723857,Clearance,Clearance was 50% that of the mature value at 54.2 weeks PMA (CLmat(50)) and increased from 2.05 litre h(-1) 70 kg(-1) at 24 weeks PMA to 6.04 litre h(-1) 70 kg(-1) at 32 weeks PMA.,Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723857/),[l] / [70·h·kg],2.05,90711,DB00295,Morphine
,18723857,Clearance,Clearance was 50% that of the mature value at 54.2 weeks PMA (CLmat(50)) and increased from 2.05 litre h(-1) 70 kg(-1) at 24 weeks PMA to 6.04 litre h(-1) 70 kg(-1) at 32 weeks PMA.,Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723857/),[l] / [70·h·kg],6.04,90712,DB00295,Morphine
,18723857,CLmat(50),Clearance was 50% that of the mature value at 54.2 weeks PMA (CLmat(50)) and increased from 2.05 litre h(-1) 70 kg(-1) at 24 weeks PMA to 6.04 litre h(-1) 70 kg(-1) at 32 weeks PMA.,Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723857/),[l] / [70·h·kg],2.05,90713,DB00295,Morphine
,18723857,CLmat(50),Clearance was 50% that of the mature value at 54.2 weeks PMA (CLmat(50)) and increased from 2.05 litre h(-1) 70 kg(-1) at 24 weeks PMA to 6.04 litre h(-1) 70 kg(-1) at 32 weeks PMA.,Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723857/),[l] / [70·h·kg],6.04,90714,DB00295,Morphine
,18723857,volume of distribution,The volume of distribution in preterm neonates was 190 litre 70 kg(-1) (CV 51%) and did not change with age.,Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723857/),[l] / [70·kg],190,90715,DB00295,Morphine
,17973932,clearance,"3. The mean (+/-SEM) clearance of intravenous oxycodone was significantly higher in male than female SD rats (4.9 +/- 0.3 vs 3.1 +/- 0.3 L/h per kg, respectively; P < 0.01).","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),[l] / [h·kg],4.9,90976,DB00295,Morphine
,17973932,clearance,"3. The mean (+/-SEM) clearance of intravenous oxycodone was significantly higher in male than female SD rats (4.9 +/- 0.3 vs 3.1 +/- 0.3 L/h per kg, respectively; P < 0.01).","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),[l] / [h·kg],3.1,90977,DB00295,Morphine
,17973932,oral bioavailability,"4. The oral bioavailability of oxycodone was low (at 1.2 and 5.0%, respectively) in male and female SD rats, a finding consistent with high first-pass metabolism.","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),%,1.2,90978,DB00295,Morphine
,17973932,oral bioavailability,"4. The oral bioavailability of oxycodone was low (at 1.2 and 5.0%, respectively) in male and female SD rats, a finding consistent with high first-pass metabolism.","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),%,5.0,90979,DB00295,Morphine
,1570227,time to peak plasma level,"Rectal MSC had a significantly delayed time to peak plasma level (5.4 vs 1.07 and 2.5 hrs for rectal MSC vs RMS and oral MSC, respectively) and a significantly attenuated time to maximum concentration (6.1 vs 25.4 and 9.7 ng/ml, respectively).",The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570227/),h,5.4,90999,DB00295,Morphine
,1570227,time to peak plasma level,"Rectal MSC had a significantly delayed time to peak plasma level (5.4 vs 1.07 and 2.5 hrs for rectal MSC vs RMS and oral MSC, respectively) and a significantly attenuated time to maximum concentration (6.1 vs 25.4 and 9.7 ng/ml, respectively).",The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570227/),h,1.07,91000,DB00295,Morphine
,1570227,time to peak plasma level,"Rectal MSC had a significantly delayed time to peak plasma level (5.4 vs 1.07 and 2.5 hrs for rectal MSC vs RMS and oral MSC, respectively) and a significantly attenuated time to maximum concentration (6.1 vs 25.4 and 9.7 ng/ml, respectively).",The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570227/),h,2.5,91001,DB00295,Morphine
,1570227,time to maximum concentration,"Rectal MSC had a significantly delayed time to peak plasma level (5.4 vs 1.07 and 2.5 hrs for rectal MSC vs RMS and oral MSC, respectively) and a significantly attenuated time to maximum concentration (6.1 vs 25.4 and 9.7 ng/ml, respectively).",The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570227/),[ng] / [ml],6.1,91002,DB00295,Morphine
,1570227,time to maximum concentration,"Rectal MSC had a significantly delayed time to peak plasma level (5.4 vs 1.07 and 2.5 hrs for rectal MSC vs RMS and oral MSC, respectively) and a significantly attenuated time to maximum concentration (6.1 vs 25.4 and 9.7 ng/ml, respectively).",The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570227/),[ng] / [ml],25.4,91003,DB00295,Morphine
,1570227,time to maximum concentration,"Rectal MSC had a significantly delayed time to peak plasma level (5.4 vs 1.07 and 2.5 hrs for rectal MSC vs RMS and oral MSC, respectively) and a significantly attenuated time to maximum concentration (6.1 vs 25.4 and 9.7 ng/ml, respectively).",The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570227/),[ng] / [ml],9.7,91004,DB00295,Morphine
,3766095,body clearance,"After administration of intravenous morphine the plasma concentration-time curve fitted a 3-compartment model (body clearance = 84 +/- 23 ml/min/kg, mean +/- s.d., N = 5), while after fentanyl the plasma concentration-time curve was best described by a 2-compartment model (body clearance = 3.9-5.8 ml/min/kg, N = 3].","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [kg·min],84,91626,DB00295,Morphine
,3766095,body clearance,"After administration of intravenous morphine the plasma concentration-time curve fitted a 3-compartment model (body clearance = 84 +/- 23 ml/min/kg, mean +/- s.d., N = 5), while after fentanyl the plasma concentration-time curve was best described by a 2-compartment model (body clearance = 3.9-5.8 ml/min/kg, N = 3].","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [kg·min],3.9-5.8,91627,DB00295,Morphine
,3766095,elimination rates,"After intrathecal injection the elimination rates of the opioids from CSF were 0.3 to 2.0 and 0.6 to 2.4 ml/h/kg for morphine and fentanyl, respectively (N = 3).","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [h·kg],0.3 to 2.0,91628,DB00295,Morphine
,3766095,elimination rates,"After intrathecal injection the elimination rates of the opioids from CSF were 0.3 to 2.0 and 0.6 to 2.4 ml/h/kg for morphine and fentanyl, respectively (N = 3).","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [h·kg],0.6 to 2.4,91629,DB00295,Morphine
,3766095,time to reach maximum CSF concentration,The time to reach maximum CSF concentration after epidural administration was 0.22 +/- 0.14 h for morphine (N = 6) and 0.22 +/- 0.13 h for fentanyl (N = 8).,"Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),h,0.22,91630,DB00295,Morphine
,3766095,time to reach maximum CSF concentration,The time to reach maximum CSF concentration after epidural administration was 0.22 +/- 0.14 h for morphine (N = 6) and 0.22 +/- 0.13 h for fentanyl (N = 8).,"Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),h,0.22,91631,DB00295,Morphine
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,2.3,91632,DB00295,Morphine
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,11.3,91633,DB00295,Morphine
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,0.8,91634,DB00295,Morphine
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,3.3,91635,DB00295,Morphine
,17541571,K(,The K(M6G_abs)/K(M6G_M6G) ratio was found to be 10.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92595,DB00295,Morphine
,17541571,K,The K(M6G_abs)/K(M6G_M6G) ratio was found to be 10.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92596,DB00295,Morphine
,17541571,K,The K(M6G_abs)/K(M6G_M6G) ratio of 10 indicates that the second absorption peak of M6G consists of approximately 10 times more absorbed M6G than reglucuronidated M6G.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92597,DB00295,Morphine
,8263765,maximal plasma concentrations,"Three treatment groups received morphine hydrochloride over 10, 60 and 180 min, targeting maximal plasma concentrations of 25 microM at the end of the infusion.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),μM,25,93190,DB00295,Morphine
,8263765,maximal concentrations,"The maximal concentrations of morphine obtained for the three groups were 29.4 +/- 3.7, 26.7 +/- 4.7 and 28.9 +/- 7.3 microM, respectively.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),μM,29.4,93191,DB00295,Morphine
,8263765,maximal concentrations,"The maximal concentrations of morphine obtained for the three groups were 29.4 +/- 3.7, 26.7 +/- 4.7 and 28.9 +/- 7.3 microM, respectively.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),μM,26.7,93192,DB00295,Morphine
,8263765,maximal concentrations,"The maximal concentrations of morphine obtained for the three groups were 29.4 +/- 3.7, 26.7 +/- 4.7 and 28.9 +/- 7.3 microM, respectively.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),μM,28.9,93193,DB00295,Morphine
,8263765,peak effects,"For each group, the peak effects were 248 +/- 82, 337 +/- 116 and 303 +/- 49% above base line, at 35, 65 and 90 min after the start of the infusions.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),%,248,93194,DB00295,Morphine
,8263765,peak effects,"For each group, the peak effects were 248 +/- 82, 337 +/- 116 and 303 +/- 49% above base line, at 35, 65 and 90 min after the start of the infusions.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),%,337,93195,DB00295,Morphine
,8263765,peak effects,"For each group, the peak effects were 248 +/- 82, 337 +/- 116 and 303 +/- 49% above base line, at 35, 65 and 90 min after the start of the infusions.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),%,303,93196,DB00295,Morphine
,8263765,half-lives,"The rates of drug equilibration between the plasma and the effect compartment (ke0) and the plasma and the tolerance compartment (kt0), expressed as half-lives, were 34 +/- 2 and 48 +/- 4 min, respectively.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),min,34,93197,DB00295,Morphine
,8263765,half-lives,"The rates of drug equilibration between the plasma and the effect compartment (ke0) and the plasma and the tolerance compartment (kt0), expressed as half-lives, were 34 +/- 2 and 48 +/- 4 min, respectively.",Quantification of effect delay and acute tolerance development to morphine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),min,48,93198,DB00295,Morphine
,8263765,TC50,High concentrations were required for the acute tolerance to develop (TC50 of 17 microM).,Quantification of effect delay and acute tolerance development to morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263765/),μM,17,93199,DB00295,Morphine
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,2,93414,DB00295,Morphine
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.55,93415,DB00295,Morphine
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.75,93416,DB00295,Morphine
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,0.85,93417,DB00295,Morphine
,8195267,apparent terminal half-life,"The apparent terminal half-life for MS-OS was 3 hours, which is similar to that of patients without burns, but the apparent terminal half-life for the MS-CR in patients with burns was substantially longer at 14.7 hours.",Pharmacokinetics of morphine sulfate in patients with burns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),h,3,93484,DB00295,Morphine
,8195267,apparent terminal half-life,"The apparent terminal half-life for MS-OS was 3 hours, which is similar to that of patients without burns, but the apparent terminal half-life for the MS-CR in patients with burns was substantially longer at 14.7 hours.",Pharmacokinetics of morphine sulfate in patients with burns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),h,14.7,93485,DB00295,Morphine
,8195267,time to reach peak concentration,"The mean time to reach peak concentration for MS-CR was delayed relative to MS-OS 1.4 versus 0.5 hours, and the peak concentration was attenuated.",Pharmacokinetics of morphine sulfate in patients with burns. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),h,1.4,93486,DB00295,Morphine
,8195267,time to reach peak concentration,"The mean time to reach peak concentration for MS-CR was delayed relative to MS-OS 1.4 versus 0.5 hours, and the peak concentration was attenuated.",Pharmacokinetics of morphine sulfate in patients with burns. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),h,0.5,93487,DB00295,Morphine
,8195267,mean release time,The mean release time of the MS for the CR tablet is about 15 hours.,Pharmacokinetics of morphine sulfate in patients with burns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),h,15,93488,DB00295,Morphine
,8195267,renal clearances,The renal clearances of the MS-CR (114 ml/min) and MS-OS (147 ml/min) were less than the measured creatinine clearance (177 ml/min) but greater than the creatinine clearance (106 ml/min) predicted for a healthy individual.,Pharmacokinetics of morphine sulfate in patients with burns. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),[ml] / [min],114,93489,DB00295,Morphine
,8195267,renal clearances,The renal clearances of the MS-CR (114 ml/min) and MS-OS (147 ml/min) were less than the measured creatinine clearance (177 ml/min) but greater than the creatinine clearance (106 ml/min) predicted for a healthy individual.,Pharmacokinetics of morphine sulfate in patients with burns. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195267/),[ml] / [min],147,93490,DB00295,Morphine
,1981579,half-life of elimination,"A single dose of activated charcoal (10 g) significantly reduced the half-life of elimination (1.02 +/- 0.10 and 0.70 +/- 0.04 h for the control and treated groups, respectively) and mean residence time (1.01 +/- 0.12 and 0.76 +/- 0.05 h for the control and treated groups, respectively) of morphine in rabbits.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),h,1.02,93493,DB00295,Morphine
,1981579,half-life of elimination,"A single dose of activated charcoal (10 g) significantly reduced the half-life of elimination (1.02 +/- 0.10 and 0.70 +/- 0.04 h for the control and treated groups, respectively) and mean residence time (1.01 +/- 0.12 and 0.76 +/- 0.05 h for the control and treated groups, respectively) of morphine in rabbits.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),h,0.70,93494,DB00295,Morphine
,1981579,mean residence time,"A single dose of activated charcoal (10 g) significantly reduced the half-life of elimination (1.02 +/- 0.10 and 0.70 +/- 0.04 h for the control and treated groups, respectively) and mean residence time (1.01 +/- 0.12 and 0.76 +/- 0.05 h for the control and treated groups, respectively) of morphine in rabbits.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),h,1.01,93495,DB00295,Morphine
,1981579,mean residence time,"A single dose of activated charcoal (10 g) significantly reduced the half-life of elimination (1.02 +/- 0.10 and 0.70 +/- 0.04 h for the control and treated groups, respectively) and mean residence time (1.01 +/- 0.12 and 0.76 +/- 0.05 h for the control and treated groups, respectively) of morphine in rabbits.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),h,0.76,93496,DB00295,Morphine
,1981579,systemic clearance,"A 40% increase in the systemic clearance (85.73 +/- 7.72 and 122.64 +/- 16.32 mL min-1 kg-1 for the control and treated groups, respectively) and a 30% decrease in AUC (204.38 +/- 22.20 and 140.03 +/- 19.32 micrograms h L-1 in the control and treated groups, respectively) were also noted.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),[ml] / [kg·min],85.73,93497,DB00295,Morphine
,1981579,systemic clearance,"A 40% increase in the systemic clearance (85.73 +/- 7.72 and 122.64 +/- 16.32 mL min-1 kg-1 for the control and treated groups, respectively) and a 30% decrease in AUC (204.38 +/- 22.20 and 140.03 +/- 19.32 micrograms h L-1 in the control and treated groups, respectively) were also noted.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),[ml] / [kg·min],122.64,93498,DB00295,Morphine
,1981579,AUC,"A 40% increase in the systemic clearance (85.73 +/- 7.72 and 122.64 +/- 16.32 mL min-1 kg-1 for the control and treated groups, respectively) and a 30% decrease in AUC (204.38 +/- 22.20 and 140.03 +/- 19.32 micrograms h L-1 in the control and treated groups, respectively) were also noted.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),[h·μg] / [l],204.38,93499,DB00295,Morphine
,1981579,AUC,"A 40% increase in the systemic clearance (85.73 +/- 7.72 and 122.64 +/- 16.32 mL min-1 kg-1 for the control and treated groups, respectively) and a 30% decrease in AUC (204.38 +/- 22.20 and 140.03 +/- 19.32 micrograms h L-1 in the control and treated groups, respectively) were also noted.",Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981579/),[h·μg] / [l],140.03,93500,DB00295,Morphine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],12.6,93666,DB00295,Morphine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],20.7,93667,DB00295,Morphine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],30.3,93668,DB00295,Morphine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],41.2,93669,DB00295,Morphine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],62.5,93670,DB00295,Morphine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],199,93671,DB00295,Morphine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],38,93672,DB00295,Morphine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],2,93673,DB00295,Morphine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],592,93674,DB00295,Morphine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],766,93675,DB00295,Morphine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],1189,93676,DB00295,Morphine
,18205962,Plasma concentrations,"Plasma concentrations of unbound ropivacaine were stable throughout the epidural infusion (mean 0.021 range 0.011-0.068 and mean 0.016 range 0.009-0.023 mg L(-1) at 16-31 and 59-72 h, respectively) and were well below threshold levels associated with central nervous system toxicity in adults (0.35 mg L(-1)).",Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205962/),[mg] / [l],0.021,93715,DB00295,Morphine
,18205962,Plasma concentrations,"Plasma concentrations of unbound ropivacaine were stable throughout the epidural infusion (mean 0.021 range 0.011-0.068 and mean 0.016 range 0.009-0.023 mg L(-1) at 16-31 and 59-72 h, respectively) and were well below threshold levels associated with central nervous system toxicity in adults (0.35 mg L(-1)).",Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205962/),[mg] / [l],0.016,93716,DB00295,Morphine
,18205962,Plasma concentrations,"Plasma concentrations of unbound ropivacaine were stable throughout the epidural infusion (mean 0.021 range 0.011-0.068 and mean 0.016 range 0.009-0.023 mg L(-1) at 16-31 and 59-72 h, respectively) and were well below threshold levels associated with central nervous system toxicity in adults (0.35 mg L(-1)).",Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205962/),[mg] / [l],0.35,93717,DB00295,Morphine
,18205962,Apparent unbound clearance,"Apparent unbound clearance (mean 346, range 86-555 mL min(-1) kg(-1)) showed no age-dependency.",Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205962/),[ml] / [kg·min],346,93718,DB00295,Morphine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],57-110,93726,DB00295,Morphine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],23-54,93727,DB00295,Morphine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],3.9-14,93728,DB00295,Morphine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],1.7-15,93729,DB00295,Morphine
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,2-30,93730,DB00295,Morphine
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,30-480,93731,DB00295,Morphine
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,60-360,93732,DB00295,Morphine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,124-208,93733,DB00295,Morphine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,162-227,93734,DB00295,Morphine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,73-234,93735,DB00295,Morphine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,80-246,93736,DB00295,Morphine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],5037-8954,93737,DB00295,Morphine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],3084-5524,93738,DB00295,Morphine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],1444-5560,93739,DB00295,Morphine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],692-3843,93740,DB00295,Morphine
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.47-0.84,93741,DB00295,Morphine
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.22-0.84,93742,DB00295,Morphine
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.10-0.58,93743,DB00295,Morphine
,22070527,MRT,"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),min,59,93821,DB00295,Morphine
,22070527,MRT,"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),min,19,93822,DB00295,Morphine
,22070527,T(1/2),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),min,21.9,93823,DB00295,Morphine
,22070527,T(1/2),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),min,3.3,93824,DB00295,Morphine
,22070527,T(max),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),min,23.0,93825,DB00295,Morphine
,22070527,T(max),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),min,8.8,93826,DB00295,Morphine
,22070527,C(max),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),l⁻¹·mg,0.245,93827,DB00295,Morphine
,22070527,C(max),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),l⁻¹·mg,1.09,93828,DB00295,Morphine
,22070527,AUC(0-∞),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),l⁻¹·mg·min,9.7,93829,DB00295,Morphine
,22070527,AUC(0-∞),"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),l⁻¹·mg·min,15.2,93830,DB00295,Morphine
,22070527,CL,"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),kg⁻¹·l·min⁻¹,0.069,93831,DB00295,Morphine
,22070527,CL,"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),kg⁻¹·l·min⁻¹,0.063,93832,DB00295,Morphine
,22070527,absolute bioavailability,"The main pharmacokinetic parameters of morphine by inhaled and intravenous administration were: MRT 59±14 min versus 19±4 min, T(1/2) 21.9±5.1 min versus 3.3±1.0 min, T(max) 23.0±2.7 min versus 8.8±2.4 min, C(max) 0.245±0.09 mg·L⁻¹ versus 1.09±0.32 mg·L⁻¹, AUC(0-∞) 9.7±1.1 mg·min·L⁻¹ versus 15.2±7.2 mg·min·L⁻¹, CL 0.069±0.019 L·min⁻¹·kg⁻¹ versus 0.063±0.028 L·min⁻¹·kg⁻¹, and the absolute bioavailability of inhaled morphine was 35.5±10%.",The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22070527/),%,35.5,93833,DB00295,Morphine
,3741728,elimination t1/2,Codeine was absorbed and eliminated relatively rapidly [elimination t1/2 = 2.3 +/- 0.4 h (mean +/- s.d.)].,Comparative disposition of codeine and pholcodine in man after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741728/),h,2.3,94225,DB00295,Morphine
,3741728,"t1/2,z","While codeine kinetics were adequately described by a one-compartment open model with first-order absorption, a two-compartment model was required to describe pholcodine elimination from plasma (t1/2,z = 37.0 +/- 4.2 h).",Comparative disposition of codeine and pholcodine in man after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741728/),h,37.0,94226,DB00295,Morphine
,9605377,initial plasma concentrations,"The initial plasma concentrations of morphine, M3G and M6G were 2160, 13100 and 2330 nM, respectively, compatible with a lethal dose in an opioid-naive patient.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),nM,2160,94817,DB00295,Morphine
,9605377,initial plasma concentrations,"The initial plasma concentrations of morphine, M3G and M6G were 2160, 13100 and 2330 nM, respectively, compatible with a lethal dose in an opioid-naive patient.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),nM,13100,94818,DB00295,Morphine
,9605377,initial plasma concentrations,"The initial plasma concentrations of morphine, M3G and M6G were 2160, 13100 and 2330 nM, respectively, compatible with a lethal dose in an opioid-naive patient.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),nM,2330,94819,DB00295,Morphine
,9605377,urinary recovery,"The urinary recovery of morphine, M3G and M6G corresponded to 6.8 mmol, equivalent to an oral intake of at least 2500 mg.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),mM,6.8,94820,DB00295,Morphine
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,41,94855,DB00295,Morphine
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,45.5,94856,DB00295,Morphine
,17472654,terminal half-life,"For the high and low doses, respectively, mean+/-SD terminal half-life was 38+/-5 and 27+/-14 min, apparent volumes of distribution at steady-state were 1.9+/-0.5 and 1.3+/-0.8 L/kg, with clearances of 50+/-15 and 67+/-20 mL/kg/min.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),min,38,95390,DB00295,Morphine
,17472654,terminal half-life,"For the high and low doses, respectively, mean+/-SD terminal half-life was 38+/-5 and 27+/-14 min, apparent volumes of distribution at steady-state were 1.9+/-0.5 and 1.3+/-0.8 L/kg, with clearances of 50+/-15 and 67+/-20 mL/kg/min.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),min,27,95391,DB00295,Morphine
,17472654,apparent volumes of distribution at steady-state,"For the high and low doses, respectively, mean+/-SD terminal half-life was 38+/-5 and 27+/-14 min, apparent volumes of distribution at steady-state were 1.9+/-0.5 and 1.3+/-0.8 L/kg, with clearances of 50+/-15 and 67+/-20 mL/kg/min.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),[l] / [kg],1.9,95392,DB00295,Morphine
,17472654,apparent volumes of distribution at steady-state,"For the high and low doses, respectively, mean+/-SD terminal half-life was 38+/-5 and 27+/-14 min, apparent volumes of distribution at steady-state were 1.9+/-0.5 and 1.3+/-0.8 L/kg, with clearances of 50+/-15 and 67+/-20 mL/kg/min.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),[l] / [kg],1.3,95393,DB00295,Morphine
,17472654,clearances,"For the high and low doses, respectively, mean+/-SD terminal half-life was 38+/-5 and 27+/-14 min, apparent volumes of distribution at steady-state were 1.9+/-0.5 and 1.3+/-0.8 L/kg, with clearances of 50+/-15 and 67+/-20 mL/kg/min.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),[ml] / [kg·min],50,95394,DB00295,Morphine
,17472654,clearances,"For the high and low doses, respectively, mean+/-SD terminal half-life was 38+/-5 and 27+/-14 min, apparent volumes of distribution at steady-state were 1.9+/-0.5 and 1.3+/-0.8 L/kg, with clearances of 50+/-15 and 67+/-20 mL/kg/min.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),[ml] / [kg·min],67,95395,DB00295,Morphine
,17472654,Steady-state plasma concentrations,"Steady-state plasma concentrations ranged from 93 to 180 ng/mL and 45 to 80 ng/mL in the high and low doses, respectively.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),[ng] / [ml],93 to 180,95396,DB00295,Morphine
,17472654,Steady-state plasma concentrations,"Steady-state plasma concentrations ranged from 93 to 180 ng/mL and 45 to 80 ng/mL in the high and low doses, respectively.",Pharmacokinetics and physiological effects of two intravenous infusion rates of morphine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472654/),[ng] / [ml],45 to 80,95397,DB00295,Morphine
,7917776,absolute bioavailability,The absolute bioavailability of transdermal morphine was 75% (65-85%; 95% CI).,Transdermal administration of morphine to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917776/),%,75,95734,DB00295,Morphine
,8971431,t1/2abs,The absorption profile of the CR tablets was characterized by a rapid absorption component (t1/2abs = 37 min) accounting for 38% of the available dose and a slow absorption phase (t1/2abs = 6.2 h) accounting for 62% of the available dose.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),min,37,96178,DB00295,Morphine
,8971431,t1/2abs,The absorption profile of the CR tablets was characterized by a rapid absorption component (t1/2abs = 37 min) accounting for 38% of the available dose and a slow absorption phase (t1/2abs = 6.2 h) accounting for 62% of the available dose.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),h,6.2,96179,DB00295,Morphine
,8971431,bioavailable,Two 10 mg tablets of oral CR oxycodone hydrochloride were 102.7% bioavailable relative to 20 mg of IR oxycodone hydrochloride oral solution.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),%,102.7,96180,DB00295,Morphine
,19260034,serum C(max),"The serum C(max) of morphine and M6G after i.v. morphine administration was 560.5 and 309.0 nM and the T(max) was 61 and 65 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),nM,560.5,96331,DB00295,Morphine
,19260034,serum C(max),"The serum C(max) of morphine and M6G after i.v. morphine administration was 560.5 and 309.0 nM and the T(max) was 61 and 65 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),nM,309.0,96332,DB00295,Morphine
,19260034,T(max),"The serum C(max) of morphine and M6G after i.v. morphine administration was 560.5 and 309.0 nM and the T(max) was 61 and 65 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,61,96333,DB00295,Morphine
,19260034,T(max),"The serum C(max) of morphine and M6G after i.v. morphine administration was 560.5 and 309.0 nM and the T(max) was 61 and 65 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,65,96334,DB00295,Morphine
,19260034,elimination half-life,"The elimination half-life was 140.0 and 328.7 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,140.0,96335,DB00295,Morphine
,19260034,elimination half-life,"The elimination half-life was 140.0 and 328.7 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,328.7,96336,DB00295,Morphine
,19260034,serum C(max),"After oral administration of morphine, the serum C(max) of morphine and M6G was 408.34 and 256.3 nM and the T(max) was 40.0 and 60 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),nM,408.34,96337,DB00295,Morphine
,19260034,serum C(max),"After oral administration of morphine, the serum C(max) of morphine and M6G was 408.34 and 256.3 nM and the T(max) was 40.0 and 60 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),nM,256.3,96338,DB00295,Morphine
,19260034,T(max),"After oral administration of morphine, the serum C(max) of morphine and M6G was 408.34 and 256.3 nM and the T(max) was 40.0 and 60 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,40.0,96339,DB00295,Morphine
,19260034,T(max),"After oral administration of morphine, the serum C(max) of morphine and M6G was 408.34 and 256.3 nM and the T(max) was 40.0 and 60 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,60,96340,DB00295,Morphine
,19260034,half-life,"The half-life was 131.0 and 325.8 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,131.0,96341,DB00295,Morphine
,19260034,half-life,"The half-life was 131.0 and 325.8 min, respectively.",Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260034/),min,325.8,96342,DB00295,Morphine
,8491060,Systemic plasma clearance,"Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),[ml] / [kg·min],21.1,96636,DB00295,Morphine
,8491060,Systemic plasma clearance,"Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),[l] / [h·kg],1.27,96637,DB00295,Morphine
,8491060,volume of distribution,"Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),[l] / [kg],2.9,96638,DB00295,Morphine
,8491060,oral bioavailability,"Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),%,29.2,96639,DB00295,Morphine
,8491060,half-lives,"A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),h,15.1,96640,DB00295,Morphine
,8491060,half-lives,"A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),h,11.2,96641,DB00295,Morphine
,8491060,half-lives,"A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively.",Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),h,12.9,96642,DB00295,Morphine
,8491060,terminal half-life,The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration.,Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491060/),h,23.9,96643,DB00295,Morphine
,1473873,Time of peak plasma morphine concentration (tmax),"Time of peak plasma morphine concentration (tmax) was similar for both preparations (1.8 +/- 1.6 h and 1.2 +/- 0.5 h, respectively; p > 0.05), showing that the MHP suppository was rapidly absorbed.",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),h,1.8,97088,DB00295,Morphine
,1473873,Time of peak plasma morphine concentration (tmax),"Time of peak plasma morphine concentration (tmax) was similar for both preparations (1.8 +/- 1.6 h and 1.2 +/- 0.5 h, respectively; p > 0.05), showing that the MHP suppository was rapidly absorbed.",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),h,1.2,97089,DB00295,Morphine
,1473873,tmax,Prolonged release of morphine from the MAN suppository was also evident in vivo as tmax (2.5 +/- 1.4 h) was significantly greater than that for the morphine hydrochloride/PEG suppository (0.7 +/- 0.3 h; p < 0.002).,Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),h,2.5,97090,DB00295,Morphine
,1473873,tmax,Prolonged release of morphine from the MAN suppository was also evident in vivo as tmax (2.5 +/- 1.4 h) was significantly greater than that for the morphine hydrochloride/PEG suppository (0.7 +/- 0.3 h; p < 0.002).,Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),h,0.7,97091,DB00295,Morphine
,1473873,AUC (0-7 h),"There was no significant difference in AUC (0-7 h) (34.5 +/- 19.2 versus 38.9 +/- 16.1 ng.h/ml, respectively; p > 0.05) indicating a similar amount of morphine absorbed.",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),[h·ng] / [ml],34.5,97092,DB00295,Morphine
,1473873,AUC (0-7 h),"There was no significant difference in AUC (0-7 h) (34.5 +/- 19.2 versus 38.9 +/- 16.1 ng.h/ml, respectively; p > 0.05) indicating a similar amount of morphine absorbed.",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),[h·ng] / [ml],38.9,97093,DB00295,Morphine
,1473873,peak,"Plasma morphine concentrations were more sustained for 7 h after dosage with the MAN suppository, with lower peak (8.3 +/- 4.9 and 12.3 +/- 6.6 ng/ml, respectively) and higher 6 h plasma morphine concentrations (5.81 +/- 4.85 and 3.30 +/- 1.0 ng/ml, respectively; p < 0.05).",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),[ng] / [ml],8.3,97094,DB00295,Morphine
,1473873,peak,"Plasma morphine concentrations were more sustained for 7 h after dosage with the MAN suppository, with lower peak (8.3 +/- 4.9 and 12.3 +/- 6.6 ng/ml, respectively) and higher 6 h plasma morphine concentrations (5.81 +/- 4.85 and 3.30 +/- 1.0 ng/ml, respectively; p < 0.05).",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),[ng] / [ml],12.3,97095,DB00295,Morphine
,1473873,concentrations,"Plasma morphine concentrations were more sustained for 7 h after dosage with the MAN suppository, with lower peak (8.3 +/- 4.9 and 12.3 +/- 6.6 ng/ml, respectively) and higher 6 h plasma morphine concentrations (5.81 +/- 4.85 and 3.30 +/- 1.0 ng/ml, respectively; p < 0.05).",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),[ng] / [ml],5.81,97096,DB00295,Morphine
,1473873,concentrations,"Plasma morphine concentrations were more sustained for 7 h after dosage with the MAN suppository, with lower peak (8.3 +/- 4.9 and 12.3 +/- 6.6 ng/ml, respectively) and higher 6 h plasma morphine concentrations (5.81 +/- 4.85 and 3.30 +/- 1.0 ng/ml, respectively; p < 0.05).",Prolonged release of morphine alkaloid from a lipophilic suppository base in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473873/),[ng] / [ml],3.30,97097,DB00295,Morphine
,2310653,terminal elimination half-life,2. The mean terminal elimination half-life of morphine was 4.2 h (95% CI 3.6-4.8) the mean volume of distribution was 4.1 l kg-1 (95% CI 2.9-5.4) and the mean plasma clearance was 11.4 ml min-1 kg-1 (95% CI 8.1-14.7).,The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310653/),h,4.2,97431,DB00295,Morphine
,2310653,volume of distribution,2. The mean terminal elimination half-life of morphine was 4.2 h (95% CI 3.6-4.8) the mean volume of distribution was 4.1 l kg-1 (95% CI 2.9-5.4) and the mean plasma clearance was 11.4 ml min-1 kg-1 (95% CI 8.1-14.7).,The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310653/),[l] / [kg],4.1,97432,DB00295,Morphine
,2310653,plasma clearance,2. The mean terminal elimination half-life of morphine was 4.2 h (95% CI 3.6-4.8) the mean volume of distribution was 4.1 l kg-1 (95% CI 2.9-5.4) and the mean plasma clearance was 11.4 ml min-1 kg-1 (95% CI 8.1-14.7).,The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310653/),[ml] / [kg·min],11.4,97433,DB00295,Morphine
,2310653,oral bioavailability,The mean oral bioavailability was 101% (95% CI 56-147).,The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310653/),%,101,97434,DB00295,Morphine
,2310653,urinary recoveries,4. The average urinary recoveries of morphine plus M3G and M6G were 49.9% after i.v. and 57.7% after oral administration.,The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310653/),%,49.9,97435,DB00295,Morphine
,2310653,urinary recoveries,4. The average urinary recoveries of morphine plus M3G and M6G were 49.9% after i.v. and 57.7% after oral administration.,The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310653/),%,57.7,97436,DB00295,Morphine
,7128673,peak plasma level,In most patients the peak plasma concentration was reached after 30 min; the mean peak plasma level of morphine was 18 ng/ml (range 8.5-57 ng/ml).,Absorption and bioavailability of rectally administered morphine in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128673/),[ng] / [ml],18,98018,DB00295,Morphine
,7128673,bioavailability,The mean bioavailability of rectal morphine was 31% (range 12%-61%).,Absorption and bioavailability of rectally administered morphine in women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128673/),%,31,98019,DB00295,Morphine
,3958962,terminal elimination half-life,Pharmacokinetic analysis indicated that naltrexone has a terminal elimination half-life of 4.6 hr.,Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958962/),h,4.6,98302,DB00295,Morphine
,3958962,plasma ED50,Probit analysis revealed a linear plasma level-response relationship for naltrexone antagonism of morphine analgesia with a plasma ED50 of 2.1 ng/ml when plasma morphine levels average 1126 ng/ml.,Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958962/),[ng] / [ml],2.1,98303,DB00295,Morphine
,3559921,sensitivities,"Reversed-phase HPLC assays with electrochemical detection, developed to quantify naloxone, 6 beta-naloxol, and their hydrolyzed conjugates in biological fluids provided assay sensitivities of 10 to 20 ng/mL in plasma, urine, and bile.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ng] / [ml],10 to 20,98374,DB00295,Morphine
,3559921,sequential half-lives,Plasma concentration-time data were well fitted by the sums of two exponentials with two sequential half-lives of 11 +/- 1 (SEM) and 56 +/- 3 min.,Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),min,11,98375,DB00295,Morphine
,3559921,sequential half-lives,Plasma concentration-time data were well fitted by the sums of two exponentials with two sequential half-lives of 11 +/- 1 (SEM) and 56 +/- 3 min.,Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),min,56,98376,DB00295,Morphine
,3559921,total,"Pharmacokinetics were dose-independent; total and renal clearances were 1334 +/- 133 mL/min and 42 +/- 9 mL/min, respectively, with a renal clearance of 65 +/- 5 mL/min for the conjugate.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ml] / [min],1334,98377,DB00295,Morphine
,3559921,renal clearances,"Pharmacokinetics were dose-independent; total and renal clearances were 1334 +/- 133 mL/min and 42 +/- 9 mL/min, respectively, with a renal clearance of 65 +/- 5 mL/min for the conjugate.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ml] / [min],42,98378,DB00295,Morphine
,3559921,renal clearance,"Pharmacokinetics were dose-independent; total and renal clearances were 1334 +/- 133 mL/min and 42 +/- 9 mL/min, respectively, with a renal clearance of 65 +/- 5 mL/min for the conjugate.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ml] / [min],65,98379,DB00295,Morphine
,26032168,plasma Tmax,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼2,98635,DB00295,Morphine
,26032168,t1/2,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼10,98636,DB00295,Morphine
,26032168,elimination t1/2,"During washout, quinine urinary concentrations steadily declined (elimination t1/2 ∼16 hours), with a 94% decrease observed 72 hours postdose.",Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼16,98637,DB00295,Morphine
,8227477,time to reach maximum peak plasma concentration (tmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,1.0,98872,DB00295,Morphine
,8227477,time to reach maximum peak plasma concentration (tmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,1.4,98873,DB00295,Morphine
,8227477,maximum peak plasma concentration (Cmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[ng] / [ml],172,98874,DB00295,Morphine
,8227477,maximum peak plasma concentration (Cmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[ng] / [ml],225,98875,DB00295,Morphine
,8227477,area under the curve (AUC infinity),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[h·ng] / [ml],590,98876,DB00295,Morphine
,8227477,area under the curve (AUC infinity),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[h·ng] / [ml],779,98877,DB00295,Morphine
,8227477,Cl/F,"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[l] / [h],104,98878,DB00295,Morphine
,8227477,Cl/F,"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[l] / [h],89,98879,DB00295,Morphine
,8227477,mean residence time (MRT),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,3.7,98880,DB00295,Morphine
,8227477,mean residence time (MRT),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,4.7,98881,DB00295,Morphine
,8227477,half-life (t1/2),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,1.7,98882,DB00295,Morphine
,8227477,half-life (t1/2),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,2.8,98883,DB00295,Morphine
,8227477,plasma protein binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,66.0,98884,DB00295,Morphine
,8227477,plasma protein binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,30.5,98885,DB00295,Morphine
,8227477,binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,68.4,98886,DB00295,Morphine
,8227477,binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,29.2,98887,DB00295,Morphine
,18810393,blood serum concentration,"After administration via drinking water in saline-injected control animals, the hal blood serum concentration was 2.6 +/- 0.45 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],2.6,99177,DB00295,Morphine
,18810393,serum concentration,"In ket-injected animals, the mean serum concentration of hal amounted to 1.2 +/- 0.44 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],1.2,99178,DB00295,Morphine
,7657850,bioavailable,"Compared with two 100-mg MSC tablets, the 200-mg tablet was 96% bioavailable (90% confidence interval, 88.14-105.74%).",A bioequivalence study of oral controlled-release morphine using naltrexone blockade. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657850/),%,96,99193,DB00295,Morphine
,22448718,half-life,"Maternal plasma oxycodone concentration decreased with a median half-life of 2.6 hr (range, 1.8-2.8).",Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22448718/),h,2.6,99803,DB00295,Morphine
,10051088,clearance (Cl),"The clearance (Cl) was found to be 5.7+/-2.3 ml/kg per min, volume of distribution of the central compartment (Vc) 0.16+/-0.12 l/kg and volume of distribution at steady state (Vss) 1.08+/-0.69 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[ml] / [kg·min],5.7,100220,DB00295,Morphine
,10051088,volume of distribution of the central compartment (Vc),"The clearance (Cl) was found to be 5.7+/-2.3 ml/kg per min, volume of distribution of the central compartment (Vc) 0.16+/-0.12 l/kg and volume of distribution at steady state (Vss) 1.08+/-0.69 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],0.16,100221,DB00295,Morphine
,10051088,volume of distribution at steady state (Vss),"The clearance (Cl) was found to be 5.7+/-2.3 ml/kg per min, volume of distribution of the central compartment (Vc) 0.16+/-0.12 l/kg and volume of distribution at steady state (Vss) 1.08+/-0.69 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],1.08,100222,DB00295,Morphine
,10051088,Cl,"The Cl was 6.9+/-3.8 ml/kg per min, Vc 0.25+/-0.1 l/kg and Vss 0.78+/-0.26 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[ml] / [kg·min],6.9,100223,DB00295,Morphine
,10051088,Vc,"The Cl was 6.9+/-3.8 ml/kg per min, Vc 0.25+/-0.1 l/kg and Vss 0.78+/-0.26 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],0.25,100224,DB00295,Morphine
,10051088,Vss,"The Cl was 6.9+/-3.8 ml/kg per min, Vc 0.25+/-0.1 l/kg and Vss 0.78+/-0.26 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],0.78,100225,DB00295,Morphine
,833759,plasma half-life,Route of administration had no affect on plasma half-life (about 115 minutes) of unchanged morphine.,First-pass effect of morphine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833759/),min,115,100491,DB00295,Morphine
,9694907,ED50,ED50 of morphine was elevated to 7.0 mg/kg in the morphine-infused rats compared to 2.4 mg/kg in saline-infused rats.,Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9694907/),[mg] / [kg],7.0,101096,DB00295,Morphine
,9694907,ED50,ED50 of morphine was elevated to 7.0 mg/kg in the morphine-infused rats compared to 2.4 mg/kg in saline-infused rats.,Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9694907/),[mg] / [kg],2.4,101097,DB00295,Morphine
,9694907,ED50,Coinfusion of fenfluramine increased ED50 to only 3.7 mg/kg.,Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9694907/),[mg] / [kg],3.7,101098,DB00295,Morphine
,9766863,flow-rate,A flow-rate of 1.2 ml/min at 20 degrees C was used.,Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),[ml] / [min],1.2,101441,DB00295,Morphine
,9766863,limit of detection,The limit of detection of morphine was 100 pg/ml of plasma.,Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),[pg] / [ml],100,101442,DB00295,Morphine
,9766863,absolute recoveries,The absolute recoveries of morphine and nalbuphine (internal standard) were between 86 and 89% and independent of morphine concentration.,Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),%,86 and 89,101443,DB00295,Morphine
,9766863,absorption,"The absorption and elimination half-lives were 2.46 and 1.80 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,2.46,101444,DB00295,Morphine
,9766863,elimination half-lives,"The absorption and elimination half-lives were 2.46 and 1.80 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,1.80,101445,DB00295,Morphine
,9766863,distribution,"The distribution and elimination half-lives were 0.5 and 33.8 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,0.5,101446,DB00295,Morphine
,9766863,elimination half-lives,"The distribution and elimination half-lives were 0.5 and 33.8 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,33.8,101447,DB00295,Morphine
,11145227,half-life of unbound,The half-life of unbound morphine in striatum was 44 min compared to 30 min in venous and arterial blood (p<0.05).,Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145227/),min,44,101882,DB00295,Morphine
,11145227,half-life of unbound,The half-life of unbound morphine in striatum was 44 min compared to 30 min in venous and arterial blood (p<0.05).,Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145227/),min,30,101883,DB00295,Morphine
,11145227,effect delay half-life,"The concentration-effect relationship exhibited a clear hysterisis with an effect delay half-life of 32 and 5 min based on arterial blood and brain ECF concentrations, respectively.",Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145227/),min,32,101884,DB00295,Morphine
,11145227,effect delay half-life,"The concentration-effect relationship exhibited a clear hysterisis with an effect delay half-life of 32 and 5 min based on arterial blood and brain ECF concentrations, respectively.",Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145227/),min,5,101885,DB00295,Morphine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,8.5,101982,DB00295,Morphine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,7.0,101983,DB00295,Morphine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,11.5,101984,DB00295,Morphine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,15.5,101985,DB00295,Morphine
,9010701,peak change,"Codeine only reduced these pain measures significantly in EMs, with a median peak change of 5.5 mm for peak pain and 10.5 mm for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,5.5,101986,DB00295,Morphine
,9010701,peak change,"Codeine only reduced these pain measures significantly in EMs, with a median peak change of 5.5 mm for peak pain and 10.5 mm for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,10,101987,DB00295,Morphine
,2907583,AUC,"The AUC value after oral administration (15 micrograms min mL-1), which was normalized by the dose, was only one-tenth of that after i.v. dosing (151 micrograms min mL-1).",Enhanced bioavailability of morphine after rectal administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907583/),[min·μg] / [ml],15,102484,DB00295,Morphine
,2907583,AUC,"The AUC value after oral administration (15 micrograms min mL-1), which was normalized by the dose, was only one-tenth of that after i.v. dosing (151 micrograms min mL-1).",Enhanced bioavailability of morphine after rectal administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907583/),[min·μg] / [ml],151,102485,DB00295,Morphine
,2907583,AUC,"In contrast, the AUC after rectal administration (unrestricted, 133 micrograms min mL-1; restricted, 142 micrograms min mL-1) was almost comparable with that after i.v. administration.",Enhanced bioavailability of morphine after rectal administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907583/),[min·μg] / [ml],133,102486,DB00295,Morphine
,2907583,AUC,"In contrast, the AUC after rectal administration (unrestricted, 133 micrograms min mL-1; restricted, 142 micrograms min mL-1) was almost comparable with that after i.v. administration.",Enhanced bioavailability of morphine after rectal administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907583/),[min·μg] / [ml],142,102487,DB00295,Morphine
,2907583,systemic availability,"From the comparison of these AUC values, the extent of systemic availability of morphine after rectal (unrestricted or restricted) and p.o. administration was estimated to be approximately 90 and 10%, respectively.",Enhanced bioavailability of morphine after rectal administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907583/),%,90,102488,DB00295,Morphine
,2907583,systemic availability,"From the comparison of these AUC values, the extent of systemic availability of morphine after rectal (unrestricted or restricted) and p.o. administration was estimated to be approximately 90 and 10%, respectively.",Enhanced bioavailability of morphine after rectal administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907583/),%,10,102489,DB00295,Morphine
,19637105,half-life,The average half-life obtained from all profiles was 12.1 +/- 6.3 hr.,Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19637105/),h,12.1,103143,DB00295,Morphine
,19637105,Fe,Fe values ranged between .01% and 34% with high variability within the same dosing regimen.,Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19637105/),%,.01,103144,DB00295,Morphine
,19637105,Fe,Fe values ranged between .01% and 34% with high variability within the same dosing regimen.,Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19637105/),%,34,103145,DB00295,Morphine
,24887324,peak concentration,"For the 19 subjects who completed the study, morphine concentrations ranged from <300 to 7522 μg/L with a median peak concentration of 5239 μg/L.",Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887324/),[μg] / [l],5239,103153,DB00295,Morphine
,24887324,peak concentrations,"No specimens were positive for codeine at a cutoff concentration of 2000 μg/L, but 20.2% exceeded 300 μg/L, with peak concentrations of 658 μg/L (284-1540).",Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887324/),[μg] / [l],658,103154,DB00295,Morphine
,9587953,AUC ratios of brain to blood,"The AUC ratios of brain to blood were 0.99 +/- 0.25 and 0.95 +/- 0.16 for Dose 1 and 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,0.99,103215,DB00295,Morphine
,9587953,AUC ratios of brain to blood,"The AUC ratios of brain to blood were 0.99 +/- 0.25 and 0.95 +/- 0.16 for Dose 1 and 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,0.95,103216,DB00295,Morphine
,9587953,Css ratio of brain to blood,The Css ratio of brain to blood was 1.06 +/- 0.12 for the exponential infusion.,Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,1.06,103217,DB00295,Morphine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,25,103218,DB00295,Morphine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,22,103219,DB00295,Morphine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,27,103220,DB00295,Morphine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,25,103221,DB00295,Morphine
,9587953,unbound AUCblood,"Codeine was demethylated to morphine with an unbound AUCblood,morphine/AUCblood,codeine ratio of 7.7 +/- 5.1% in blood.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,7,103222,DB00295,Morphine
,9587953,"morphine/AUCblood,","Codeine was demethylated to morphine with an unbound AUCblood,morphine/AUCblood,codeine ratio of 7.7 +/- 5.1% in blood.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,7,103223,DB00295,Morphine
,2337965,bioavailability,"The extent of bioavailability of morphine by rectal administration varied with the bases used (30.5-97.5%), but every value was higher than that in the case of oral administration (13.5%).",Studies on sustained-release suppositories. Rectal absorption of morphine in rabbits and prolongation of its absorption by alginic acid addition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337965/),%,30.5-97.5,103569,DB00295,Morphine
,2337965,bioavailability,"The extent of bioavailability of morphine by rectal administration varied with the bases used (30.5-97.5%), but every value was higher than that in the case of oral administration (13.5%).",Studies on sustained-release suppositories. Rectal absorption of morphine in rabbits and prolongation of its absorption by alginic acid addition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337965/),%,13.5,103570,DB00295,Morphine
,15494471,clearances,"Mean +/- S.D. clearances of morphine, M3G, and M6G from the fetus were 69 +/- 17, 2.3 +/- 0.60, and 1.6 +/- 0.24 ml x min(-1), respectively.",The contribution of fetal metabolism to the disposition of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15494471/),[ml] / [min],69,103610,DB00295,Morphine
,15494471,clearances,"Mean +/- S.D. clearances of morphine, M3G, and M6G from the fetus were 69 +/- 17, 2.3 +/- 0.60, and 1.6 +/- 0.24 ml x min(-1), respectively.",The contribution of fetal metabolism to the disposition of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15494471/),[ml] / [min],2.3,103611,DB00295,Morphine
,15494471,clearances,"Mean +/- S.D. clearances of morphine, M3G, and M6G from the fetus were 69 +/- 17, 2.3 +/- 0.60, and 1.6 +/- 0.24 ml x min(-1), respectively.",The contribution of fetal metabolism to the disposition of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15494471/),[ml] / [min],1.6,103612,DB00295,Morphine
,15494471,metabolic clearance,This converts to a fetal metabolic clearance of 22 +/- 6.5 ml x min(-1).,The contribution of fetal metabolism to the disposition of morphine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15494471/),[ml] / [min],22,103613,DB00295,Morphine
,17978495,V(d),"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),l,226.7,103671,DB00295,Morphine
,17978495,CL,"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),[l] / [h],37.9,103672,DB00295,Morphine
,17978495,t(1/2),"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),h,4.1,103673,DB00295,Morphine
,17978495,V(d),"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),l,276.8,103674,DB00295,Morphine
,17978495,CL,"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),[l] / [h],95.1,103675,DB00295,Morphine
,17978495,t(1/2),"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),h,2.0,103676,DB00295,Morphine
,18671713,E,5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),mg,8.,104108,DB00295,Morphine
,18671713,EC(50),5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],1.8,104109,DB00295,Morphine
,18671713,ED(50),5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[mg] / [kg],10.6,104110,DB00295,Morphine
,18671713,EC(50),5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],3.7,104111,DB00295,Morphine
,18671713,ED(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[mg] / [kg],1.8,104112,DB00295,Morphine
,18671713,ED(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[mg] / [kg],1.4,104113,DB00295,Morphine
,18671713,EC(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],0.5,104114,DB00295,Morphine
,18671713,EC(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],0.4,104115,DB00295,Morphine
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,39.8,104196,DB00295,Morphine
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,12.3,104197,DB00295,Morphine
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,35.0,104198,DB00295,Morphine
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,15.5,104199,DB00295,Morphine
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,7.5,104200,DB00295,Morphine
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,3.0,104201,DB00295,Morphine
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,5.9,104202,DB00295,Morphine
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,4.4,104203,DB00295,Morphine
,21199130,central volume of distribution,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),ml,1130,104745,DB00295,Morphine
,21199130,peripheral volume of distribution,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),ml,626,104746,DB00295,Morphine
,21199130,clearance from the central compartment,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),[ml] / [min],7.40,104747,DB00295,Morphine
,21199130,elimination half-lives,"Typical elimination half-lives were 191 and 33 min, respectively.",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),min,191,104748,DB00295,Morphine
,21199130,elimination half-lives,"Typical elimination half-lives were 191 and 33 min, respectively.",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),min,33,104749,DB00295,Morphine
,14982561,unbound area under the concentration-time curve (AUCu) ratio,"The unbound area under the concentration-time curve (AUCu) ratio of morphine in brain to blood was 0.47 (0.19) during the control period, and 0.95 (0.20) (P < 0.001) during meningitis.",Altered brain exposure of morphine in experimental meningitis studied with microdialysis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982561/),,0.47,104775,DB00295,Morphine
,14982561,unbound area under the concentration-time curve (AUCu) ratio,"The unbound area under the concentration-time curve (AUCu) ratio of morphine in brain to blood was 0.47 (0.19) during the control period, and 0.95 (0.20) (P < 0.001) during meningitis.",Altered brain exposure of morphine in experimental meningitis studied with microdialysis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982561/),,0.95,104776,DB00295,Morphine
,1638557,peak serum levels,The peak serum levels of mAb 14.G2a ranged from 28 micrograms/ml to 61 micrograms/ml.,A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1638557/),[μg] / [ml],28,105186,DB00295,Morphine
,1638557,peak serum levels,The peak serum levels of mAb 14.G2a ranged from 28 micrograms/ml to 61 micrograms/ml.,A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1638557/),[μg] / [ml],61,105187,DB00295,Morphine
,1638557,alpha-half-time (t1/2 alpha),"G2a fits a two-compartment model, with an alpha-half-time (t1/2 alpha) between 0.66 h and 1.98 h and a beta-half-time (t1/2 beta) between 30.13 h and 53.33 h.",A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1638557/),h,0.66,105188,DB00295,Morphine
,1638557,alpha-half-time (t1/2 alpha),"G2a fits a two-compartment model, with an alpha-half-time (t1/2 alpha) between 0.66 h and 1.98 h and a beta-half-time (t1/2 beta) between 30.13 h and 53.33 h.",A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1638557/),h,1.98,105189,DB00295,Morphine
,1638557,beta-half-time (t1/2 beta),"G2a fits a two-compartment model, with an alpha-half-time (t1/2 alpha) between 0.66 h and 1.98 h and a beta-half-time (t1/2 beta) between 30.13 h and 53.33 h.",A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1638557/),h,30.13,105190,DB00295,Morphine
,1638557,beta-half-time (t1/2 beta),"G2a fits a two-compartment model, with an alpha-half-time (t1/2 alpha) between 0.66 h and 1.98 h and a beta-half-time (t1/2 beta) between 30.13 h and 53.33 h.",A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1638557/),h,53.33,105191,DB00295,Morphine
,20487213,elimination half-life,"Plasma morphine concentrations were lower in the STZ-diabetic rats than controls although the elimination half-life of morphine was similar in the two groups (47.9 +/- 10.7 min and 47.2 +/- 8.6 min, respectively).","The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487213/),min,47.9,105419,DB00295,Morphine
,20487213,elimination half-life,"Plasma morphine concentrations were lower in the STZ-diabetic rats than controls although the elimination half-life of morphine was similar in the two groups (47.9 +/- 10.7 min and 47.2 +/- 8.6 min, respectively).","The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487213/),min,47.2,105420,DB00295,Morphine
,20487213,biliary excretion,"The concentration of M3G in plasma was higher in STZ-diabetic than control rats, and the biliary excretion of M3G was lower in the STZ-diabetic rats (7.4 +/- 2.3% vs 13.3 +/- 2.0%).","The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487213/),%,7.4,105421,DB00295,Morphine
,20487213,biliary excretion,"The concentration of M3G in plasma was higher in STZ-diabetic than control rats, and the biliary excretion of M3G was lower in the STZ-diabetic rats (7.4 +/- 2.3% vs 13.3 +/- 2.0%).","The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487213/),%,13.3,105422,DB00295,Morphine
,20487213,urinary excretion,The urinary excretion of M3G was similar in the two groups (10.1 +/- 6.8% vs 10.9 +/- 4.9%).,"The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487213/),%,10.1,105423,DB00295,Morphine
,20487213,urinary excretion,The urinary excretion of M3G was similar in the two groups (10.1 +/- 6.8% vs 10.9 +/- 4.9%).,"The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487213/),%,10.9,105424,DB00295,Morphine
,30290794,ED50,The ED50 of hydromorphone in our population was 10.9 μg (95% confidence interval 5.6-16.2 μg).,Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),μg,10.9,105843,DB00295,Morphine
,30290794,time to pain relief,"Amongst patients for whom the dose was effective, the median time to pain relief was 24 min.",Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),min,24,105844,DB00295,Morphine
,16102253,Plasma clearance,"Plasma clearance at one week (4.5, 3.8-8.6 mL min(-1) kg(-1)) was significantly lower than at three weeks (30.0, 19.1- 39.0 mL min(-1) kg(-1)) and six weeks (37.0, 29.7-82.8 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],4.5,106016,DB00295,Morphine
,16102253,Plasma clearance,"Plasma clearance at one week (4.5, 3.8-8.6 mL min(-1) kg(-1)) was significantly lower than at three weeks (30.0, 19.1- 39.0 mL min(-1) kg(-1)) and six weeks (37.0, 29.7-82.8 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],30.0,106017,DB00295,Morphine
,16102253,Plasma clearance,"Plasma clearance at one week (4.5, 3.8-8.6 mL min(-1) kg(-1)) was significantly lower than at three weeks (30.0, 19.1- 39.0 mL min(-1) kg(-1)) and six weeks (37.0, 29.7-82.8 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],37.0,106018,DB00295,Morphine
,16102253,peak morphine concentration in CSF,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ng] / [ml],59.84,106019,DB00295,Morphine
,16102253,peak morphine concentration in CSF,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ng] / [ml],18.8,106020,DB00295,Morphine
,16102253,peak morphine concentration in CSF,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ng] / [ml],24.51,106021,DB00295,Morphine
,16102253,CSF,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],1.0,106022,DB00295,Morphine
,16102253,CSF,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],6.2,106023,DB00295,Morphine
,16102253,CSF,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],3.95,106024,DB00295,Morphine
,16102253,clearance,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],1.0,106025,DB00295,Morphine
,16102253,clearance,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],6.2,106026,DB00295,Morphine
,16102253,clearance,"The peak morphine concentration in CSF at one week (59.84, 31-67 ng mL(-1)) was higher than at three weeks (18.8, 17.7-25 ng mL(-1)) and six weeks (24.51, 16.5-84 ng mL(-1)), while CSF clearance was lower at one week (1.0, 0.18-9 mL min(-1) kg(-1)) compared with three weeks (6.2, 2.3-9.3 mL min(-1) kg(-1)) and six weeks (3.95, 1.3-85.7 mL min(-1) kg(-1)).",Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102253/),[ml] / [kg·min],3.95,106027,DB00295,Morphine
,1981718,weight normalized volume of distribution of (Vdarea),"The weight normalized volume of distribution of (Vdarea) and total body clearance (CL) were 5.1 +/- 1.7 liters/kg and 6.2 +/- 1.5 liters/kg/hr, respectively.",Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),[l] / [kg],5.1,106293,DB00295,Morphine
,1981718,total body clearance (CL),"The weight normalized volume of distribution of (Vdarea) and total body clearance (CL) were 5.1 +/- 1.7 liters/kg and 6.2 +/- 1.5 liters/kg/hr, respectively.",Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),[l] / [h·kg],6.2,106294,DB00295,Morphine
,1981718,Mean residence time,Mean residence time of codeine averaged 34.1 +/- 6.9 minutes.,Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),min,34.1,106295,DB00295,Morphine
,1981718,ratio of AUCmorphine/AUCcodeine,The ratio of AUCmorphine/AUCcodeine was 0.05 +/- 0.02.,Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),,0.05,106296,DB00295,Morphine
,1981718,absolute bioavailability,"The absolute bioavailability of codeine calculated was 8.3 +/- 3.2%, indicating extensive first pass metabolism of codeine.",Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),%,8.3,106297,DB00295,Morphine
,19084595,extended to immediate release bioavailability,The relative extended to immediate release bioavailability was calculated to be 86% by non-compartmental analysis and 93% by deconvolution analysis.,Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19084595/),%,86,107149,DB00295,Morphine
,19084595,extended to immediate release bioavailability,The relative extended to immediate release bioavailability was calculated to be 86% by non-compartmental analysis and 93% by deconvolution analysis.,Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19084595/),%,93,107150,DB00295,Morphine
,7562582,t1/2,"The median t1/2 from serum was 36 and 32 min for morphine and M6G, respectively.","Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562582/),min,36,107329,DB00295,Morphine
,7562582,t1/2,"The median t1/2 from serum was 36 and 32 min for morphine and M6G, respectively.","Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562582/),min,32,107330,DB00295,Morphine
,7562582,t1/2,"Dialysate tmax was delayed approximately 40 min relatie to serum tmax for both drugs, and the median t1/2 from the dialysate was 82 and 48 min for M6G and morphine, respectively.","Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562582/),min,82,107331,DB00295,Morphine
,7562582,t1/2,"Dialysate tmax was delayed approximately 40 min relatie to serum tmax for both drugs, and the median t1/2 from the dialysate was 82 and 48 min for M6G and morphine, respectively.","Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562582/),min,48,107332,DB00295,Morphine
,30393871,half-life (T1/2 ),"Using this approach, we identified a long half-life (T1/2 ) of 9.78 hr and a volume of distribution (Vss ) of 0.26 L/kg.",Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393871/),h,9.78,108171,DB00295,Morphine
,30393871,volume of distribution (Vss ),"Using this approach, we identified a long half-life (T1/2 ) of 9.78 hr and a volume of distribution (Vss ) of 0.26 L/kg.",Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393871/),[l] / [kg],0.26,108172,DB00295,Morphine
,33547559,clearance (CL),"Mean (±SD) population estimates for morphine were: clearance (CL) = 1.35±0.40 L/min, central volume of distribution (V1) = 8.1±2.2 L, steady-state volume of distribution (Vss) = 207±83 L, terminal elimination half-life (T1/2γ) = 177±50 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),[l] / [min],1.35,108807,DB00295,Morphine
,33547559,central volume of distribution (V1),"Mean (±SD) population estimates for morphine were: clearance (CL) = 1.35±0.40 L/min, central volume of distribution (V1) = 8.1±2.2 L, steady-state volume of distribution (Vss) = 207±83 L, terminal elimination half-life (T1/2γ) = 177±50 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),l,8.1,108808,DB00295,Morphine
,33547559,steady-state volume of distribution (Vss),"Mean (±SD) population estimates for morphine were: clearance (CL) = 1.35±0.40 L/min, central volume of distribution (V1) = 8.1±2.2 L, steady-state volume of distribution (Vss) = 207±83 L, terminal elimination half-life (T1/2γ) = 177±50 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),l,207,108809,DB00295,Morphine
,33547559,terminal elimination half-life (T1/2γ),"Mean (±SD) population estimates for morphine were: clearance (CL) = 1.35±0.40 L/min, central volume of distribution (V1) = 8.1±2.2 L, steady-state volume of distribution (Vss) = 207±83 L, terminal elimination half-life (T1/2γ) = 177±50 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),min,177,108810,DB00295,Morphine
,33547559,CL,"Mean (±SD) population estimates for M6G were: CL = 0.098±0.037 L/min, V1 = 5.5±0.8 L, Vss = 15.8±0.8 L, T1/2β = 227±74 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),[l] / [min],0.098,108811,DB00295,Morphine
,33547559,V1,"Mean (±SD) population estimates for M6G were: CL = 0.098±0.037 L/min, V1 = 5.5±0.8 L, Vss = 15.8±0.8 L, T1/2β = 227±74 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),l,5.5,108812,DB00295,Morphine
,33547559,Vss,"Mean (±SD) population estimates for M6G were: CL = 0.098±0.037 L/min, V1 = 5.5±0.8 L, Vss = 15.8±0.8 L, T1/2β = 227±74 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),l,15.8,108813,DB00295,Morphine
,33547559,T1/2β,"Mean (±SD) population estimates for M6G were: CL = 0.098±0.037 L/min, V1 = 5.5±0.8 L, Vss = 15.8±0.8 L, T1/2β = 227±74 min.",Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),min,227,108814,DB00295,Morphine
,33547559,time to peak concentration,The time to peak concentration of M6G after a bolus dose of morphine was 53±20 min.,Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547559/),min,53,108815,DB00295,Morphine
,8427941,clearance (Cl),"After the bolus dose, the clearance (Cl) was 12.1 +/- 0.6 ml min-1*kg, the volume of distribution at steady state (Vss) 1.68 +/- 0.89 l kg-1, the half-life of the first phase 13.2 +/- 1.8 min and the half-life of the second phase 11.6 +/- 7.7 h.",Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427941/),[kg·ml] / [min],12.1,109348,DB00295,Morphine
,8427941,volume of distribution at steady state (Vss),"After the bolus dose, the clearance (Cl) was 12.1 +/- 0.6 ml min-1*kg, the volume of distribution at steady state (Vss) 1.68 +/- 0.89 l kg-1, the half-life of the first phase 13.2 +/- 1.8 min and the half-life of the second phase 11.6 +/- 7.7 h.",Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427941/),[l] / [kg],1.68,109349,DB00295,Morphine
,8427941,half-life of the first phase,"After the bolus dose, the clearance (Cl) was 12.1 +/- 0.6 ml min-1*kg, the volume of distribution at steady state (Vss) 1.68 +/- 0.89 l kg-1, the half-life of the first phase 13.2 +/- 1.8 min and the half-life of the second phase 11.6 +/- 7.7 h.",Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427941/),min,13.2,109350,DB00295,Morphine
,8427941,half-life of the second phase,"After the bolus dose, the clearance (Cl) was 12.1 +/- 0.6 ml min-1*kg, the volume of distribution at steady state (Vss) 1.68 +/- 0.89 l kg-1, the half-life of the first phase 13.2 +/- 1.8 min and the half-life of the second phase 11.6 +/- 7.7 h.",Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427941/),h,11.6,109351,DB00295,Morphine
,8427941,Cl,"After the constant rate infusion, Cl was 10.5 +/- 1.7 ml min-1*kg.",Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427941/),[kg·ml] / [min],10.5,109352,DB00295,Morphine
,19655294,C(max),"Pharmacokinetic results following p.o. administrations are C(max) 290.24 ng/mL, T(max) 4 h, relative clearance 62.17 L/h/kg and T(1/2) 10.3 h.",Pharmacokinetics of vanillin and its effects on mechanical hypersensitivity in a rat model of neuropathic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655294/),[ng] / [ml],290.24,109500,DB00295,Morphine
,19655294,T(max),"Pharmacokinetic results following p.o. administrations are C(max) 290.24 ng/mL, T(max) 4 h, relative clearance 62.17 L/h/kg and T(1/2) 10.3 h.",Pharmacokinetics of vanillin and its effects on mechanical hypersensitivity in a rat model of neuropathic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655294/),h,4,109501,DB00295,Morphine
,19655294,relative clearance,"Pharmacokinetic results following p.o. administrations are C(max) 290.24 ng/mL, T(max) 4 h, relative clearance 62.17 L/h/kg and T(1/2) 10.3 h.",Pharmacokinetics of vanillin and its effects on mechanical hypersensitivity in a rat model of neuropathic pain. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655294/),[l] / [h·kg],62.17,109502,DB00295,Morphine
,19655294,T(1/2),"Pharmacokinetic results following p.o. administrations are C(max) 290.24 ng/mL, T(max) 4 h, relative clearance 62.17 L/h/kg and T(1/2) 10.3 h.",Pharmacokinetics of vanillin and its effects on mechanical hypersensitivity in a rat model of neuropathic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655294/),h,10.3,109503,DB00295,Morphine
,19655294,bioavailability,The bioavailability is 7.6%.,Pharmacokinetics of vanillin and its effects on mechanical hypersensitivity in a rat model of neuropathic pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655294/),%,7.6,109504,DB00295,Morphine
,9720327,Tmax,"PF-402 administration produced a Tmax of 7.4 hr, and an MRT of 9.8 hr, all longer than those with MSC.","[Pharmacokinetics of PF-402, sustained-release morphine capsule, in cancer patients with pain]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9720327/),h,7.4,109960,DB00295,Morphine
,9720327,MRT,"PF-402 administration produced a Tmax of 7.4 hr, and an MRT of 9.8 hr, all longer than those with MSC.","[Pharmacokinetics of PF-402, sustained-release morphine capsule, in cancer patients with pain]. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9720327/),h,9.8,109961,DB00295,Morphine
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],33.2,110008,DB00295,Morphine
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],61.3,110009,DB00295,Morphine
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],33.6,110010,DB00295,Morphine
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],20.0,110011,DB00295,Morphine
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],436,110012,DB00295,Morphine
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],925,110013,DB00295,Morphine
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],4064,110014,DB00295,Morphine
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],7195,110015,DB00295,Morphine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110784,DB00295,Morphine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,28,110785,DB00295,Morphine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110786,DB00295,Morphine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),,23,110787,DB00295,Morphine
,1711119,limit of quant,The limit of quantitation was 0.3 ng/mL of plasma for morphine and 50 pg/mL of plasma for hydromorphone.,Sensitive and specific radioimmunoassays for opiates using commercially available materials. I: Methods for the determinations of morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711119/),[ng] / [ml],0.3,111133,DB00295,Morphine
,1711119,limit of quant,The limit of quantitation was 0.3 ng/mL of plasma for morphine and 50 pg/mL of plasma for hydromorphone.,Sensitive and specific radioimmunoassays for opiates using commercially available materials. I: Methods for the determinations of morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711119/),p,50,111134,DB00295,Morphine
,6165742,half-life of elimination,"In a relatively small pilot study, the half-life of elimination of hydromorphone in six subjects was 2.64 +/- 0.88 hours and the drug had a high volume of distribution, 1.22 l./kg.",Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165742/),h,2.64,111760,DB00295,Morphine
,6165742,volume of distribution,"In a relatively small pilot study, the half-life of elimination of hydromorphone in six subjects was 2.64 +/- 0.88 hours and the drug had a high volume of distribution, 1.22 l./kg.",Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165742/),[l] / [kg],1.22,111761,DB00295,Morphine
,9187531,maximum daily dosage,"The maximum daily dosage is 90mg, and the maximum duration of treatment is 48 hours.",Ketorolac for postoperative pain management in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187531/),,90,112027,DB00295,Morphine
,8706777,Free concentrations,"Free concentrations of quinidine were 11-times lower in cerebrospinal fluid than in plasma, and ranged from 9-15 nmol.l-1.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],9-15,112338,DB00295,Morphine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],1.45,112339,DB00295,Morphine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],9.86,112340,DB00295,Morphine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],0.23,112341,DB00295,Morphine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],3.63,112342,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,3.07 x 10 (,112343,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,1.68-3.68 x 10 (-3,112344,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,19.87 x 10 (-3),112345,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,9.87-66.22 x 10 (,112346,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),-3·10·d,0.83,112347,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,0.58-1.45 x 10 (,112348,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,7.19 x 10 (-3),112349,DB00295,Morphine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,2.03-17.7 x 10 (-3,112350,DB00295,Morphine
,12739770,steady-state ratio,The steady-state ratio of 0.29 +/- 0.07 of unbound morphine concentration in brain to that in blood indicates that morphine is actively effluxed at the BBB.,Morphine blood-brain barrier transport is influenced by probenecid co-administration. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739770/),,0.29,112404,DB00295,Morphine
,12739770,half-life in brain,The half-life in brain increased from 58 +/- 9 min to 115 +/- 25 min when probenecid was co-administered.,Morphine blood-brain barrier transport is influenced by probenecid co-administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739770/),min,58,112405,DB00295,Morphine
,12739770,half-life in brain,The half-life in brain increased from 58 +/- 9 min to 115 +/- 25 min when probenecid was co-administered.,Morphine blood-brain barrier transport is influenced by probenecid co-administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739770/),min,115,112406,DB00295,Morphine
,3697811,volume of distribution at steady-state,"The volume of distribution at steady-state (2.43 +/- 0.48 L X kg-1), beta elimination rate constant (0.700 +/- 0.162/h) and plasma clearance (1.66 +/- 0.33 L X kg-1 X h-1) were similar to values previously determined in young healthy subjects receiving a single bolus infusion.",Kinetic disposition of morphine in young males after intravenous loading and maintenance infusions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697811/),[l] / [kg],2.43,113032,DB00295,Morphine
,3697811,beta elimination rate constant,"The volume of distribution at steady-state (2.43 +/- 0.48 L X kg-1), beta elimination rate constant (0.700 +/- 0.162/h) and plasma clearance (1.66 +/- 0.33 L X kg-1 X h-1) were similar to values previously determined in young healthy subjects receiving a single bolus infusion.",Kinetic disposition of morphine in young males after intravenous loading and maintenance infusions. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697811/),1/[h],0.700,113033,DB00295,Morphine
,3697811,plasma clearance,"The volume of distribution at steady-state (2.43 +/- 0.48 L X kg-1), beta elimination rate constant (0.700 +/- 0.162/h) and plasma clearance (1.66 +/- 0.33 L X kg-1 X h-1) were similar to values previously determined in young healthy subjects receiving a single bolus infusion.",Kinetic disposition of morphine in young males after intravenous loading and maintenance infusions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697811/),[l] / [h·kg],1.66,113034,DB00295,Morphine
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],159,113220,DB00295,Morphine
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],138,113221,DB00295,Morphine
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.9,113222,DB00295,Morphine
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.4,113223,DB00295,Morphine
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],6.8,113224,DB00295,Morphine
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],7.4,113225,DB00295,Morphine
,27782940,T1/2,"Several PK parameters were significantly greater in ob/ob compared with DIO mice, including AUC150 (MD: 636.4; 95% CI: 207.4-1065.4), CMAX (MD: 5.3; 95% CI: 3.2-10.3), and T1/2 (MD: 18.3; 95% CI: 2.8-33.7).",Effects of Obesity and Leptin Deficiency on Morphine Pharmacokinetics in a Mouse Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27782940/),,18,113278,DB00295,Morphine
,9433388,Cmax,"In part 2, the mean +/- SD peak plasma concentration (Cmax) occurred at 2.7 +/- 0.8 minutes after the aerosol dose, with mean values for Cmax of 109 +/- 85, 165 +/- 22, and 273 +/- 114 ng/ml for the aerosol and 2 and 4 mg intravenous doses, respectively.",Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433388/),[ng] / [ml],109,113722,DB00295,Morphine
,9433388,Cmax,"In part 2, the mean +/- SD peak plasma concentration (Cmax) occurred at 2.7 +/- 0.8 minutes after the aerosol dose, with mean values for Cmax of 109 +/- 85, 165 +/- 22, and 273 +/- 114 ng/ml for the aerosol and 2 and 4 mg intravenous doses, respectively.",Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433388/),[ng] / [ml],165,113723,DB00295,Morphine
,9433388,Cmax,"In part 2, the mean +/- SD peak plasma concentration (Cmax) occurred at 2.7 +/- 0.8 minutes after the aerosol dose, with mean values for Cmax of 109 +/- 85, 165 +/- 22, and 273 +/- 114 ng/ml for the aerosol and 2 and 4 mg intravenous doses, respectively.",Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433388/),[ng] / [ml],273,113724,DB00295,Morphine
,9433388,bioavailability [AUC(0-360 min)],"The bioavailability [AUC(0-360 min)] of aerosol-delivered morphine was approximately 100% relative to intravenous infusion, with similar intersubject variability in AUC for both routes (coefficient of variation < 30%).",Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433388/),%,100,113725,DB00295,Morphine
,3769898,AUC,"The mean AUC at 90 min was 1,590, 642 and 159 micrograms min ml-1 after saline, morphine and meptazinol respectively.",Effect of meptazinol on drug absorption and gastric emptying. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769898/),[min·μg] / [ml],"1,590",114075,DB00295,Morphine
,3769898,AUC,"The mean AUC at 90 min was 1,590, 642 and 159 micrograms min ml-1 after saline, morphine and meptazinol respectively.",Effect of meptazinol on drug absorption and gastric emptying. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769898/),[min·μg] / [ml],642,114076,DB00295,Morphine
,3769898,AUC,"The mean AUC at 90 min was 1,590, 642 and 159 micrograms min ml-1 after saline, morphine and meptazinol respectively.",Effect of meptazinol on drug absorption and gastric emptying. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769898/),[min·μg] / [ml],159,114077,DB00295,Morphine
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.07,114342,DB00295,Morphine
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.82,114343,DB00295,Morphine
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,8,114344,DB00295,Morphine
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,4,114345,DB00295,Morphine
,30049503,peak plasma,"Both morphine ARER and ER morphine exhibited peak plasma morphine and M6G concentrations of ∼30 ng/mL and ∼200 ng/mL, respectively, at 3 hours postdose.","Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30049503/),[ng] / [ml],∼30,114639,DB00295,Morphine
,30049503,peak plasma,"Both morphine ARER and ER morphine exhibited peak plasma morphine and M6G concentrations of ∼30 ng/mL and ∼200 ng/mL, respectively, at 3 hours postdose.","Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30049503/),[ng] / [ml],∼200,114640,DB00295,Morphine
,7560246,AUC0-12,"When administered at a 2.5:1 analgesic ratio, MS-CRS given every 12 hours showed an equivalent extent of absorption compared with subcutaneous morphine given every 4 hours (AUC0-12, 132.5 +/- 30.1 versus 123.8 +/- 27.3 ng.h.mL-1, P = not significant [NS]).","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),[h·ng] / [ml],132.5,115094,DB00295,Morphine
,7560246,AUC0-12,"When administered at a 2.5:1 analgesic ratio, MS-CRS given every 12 hours showed an equivalent extent of absorption compared with subcutaneous morphine given every 4 hours (AUC0-12, 132.5 +/- 30.1 versus 123.8 +/- 27.3 ng.h.mL-1, P = not significant [NS]).","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),[h·ng] / [ml],123.8,115095,DB00295,Morphine
,7560246,Cmax,"Peak morphine concentrations were lower, time of peak was later, and percent fluctuation less after MS-CRS than after subcutaneous morphine (Cmax, 14.7 +/- 2.9 versus 29.9 +/- 5.4 ng/mL, P = .0110; tmax, 3.33 +/- 0.75 versus 2.22 +/- 0.15 hours, P = .0160; fluctuation, 122 +/- 71 versus 356 +/- 123%, P = .00160).","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),[ng] / [ml],14.7,115096,DB00295,Morphine
,7560246,Cmax,"Peak morphine concentrations were lower, time of peak was later, and percent fluctuation less after MS-CRS than after subcutaneous morphine (Cmax, 14.7 +/- 2.9 versus 29.9 +/- 5.4 ng/mL, P = .0110; tmax, 3.33 +/- 0.75 versus 2.22 +/- 0.15 hours, P = .0160; fluctuation, 122 +/- 71 versus 356 +/- 123%, P = .00160).","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),[ng] / [ml],29.9,115097,DB00295,Morphine
,7560246,tmax,"Peak morphine concentrations were lower, time of peak was later, and percent fluctuation less after MS-CRS than after subcutaneous morphine (Cmax, 14.7 +/- 2.9 versus 29.9 +/- 5.4 ng/mL, P = .0110; tmax, 3.33 +/- 0.75 versus 2.22 +/- 0.15 hours, P = .0160; fluctuation, 122 +/- 71 versus 356 +/- 123%, P = .00160).","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),h,3.33,115098,DB00295,Morphine
,7560246,tmax,"Peak morphine concentrations were lower, time of peak was later, and percent fluctuation less after MS-CRS than after subcutaneous morphine (Cmax, 14.7 +/- 2.9 versus 29.9 +/- 5.4 ng/mL, P = .0110; tmax, 3.33 +/- 0.75 versus 2.22 +/- 0.15 hours, P = .0160; fluctuation, 122 +/- 71 versus 356 +/- 123%, P = .00160).","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),h,2.22,115099,DB00295,Morphine
,7560246,Relative bioavailability,"Relative bioavailability of MS-CRS using the 2.5:1 analgesic ratio was 105%, and bioavailability from data dose normalized without regard to route specificity in metabolism was 42%.","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),%,105,115100,DB00295,Morphine
,7560246,bioavailability,"Relative bioavailability of MS-CRS using the 2.5:1 analgesic ratio was 105%, and bioavailability from data dose normalized without regard to route specificity in metabolism was 42%.","Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560246/),%,42,115101,DB00295,Morphine
,20462211,IC(50),One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC(50) = 1.2 nM) and excellent selectivity for hNET over hSERT (>1600-fold) and hDAT (>600-fold).,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462211/),nM,1.2,115266,DB00295,Morphine
,17666803,T(max),"T(max) and AUC(0-24 h) values of SPILA granules were 6 h and 191 microg.h/ml, respectively.",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),h,6,116108,DB00295,Morphine
,17666803,AUC(0-24 h),"T(max) and AUC(0-24 h) values of SPILA granules were 6 h and 191 microg.h/ml, respectively.",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),[h·μg] / [ml],191,116109,DB00295,Morphine
,17666803,T(max),"T(max) and AUC(0-24 h) values of MS Contin were 2 h and 146 microg.h/ml, respectively.",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),h,2,116110,DB00295,Morphine
,17666803,AUC(0-24 h),"T(max) and AUC(0-24 h) values of MS Contin were 2 h and 146 microg.h/ml, respectively.",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),[h·μg] / [ml],146,116111,DB00295,Morphine
,17666803,Relative bioavailability,Relative bioavailability following SPILA granules administration to twice-a-day MS Contin (30 mg) administration was 131%.,Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),%,131,116112,DB00295,Morphine
,17666803,AUC(0-24 h),"AUC(0-24 h) value for SPILA granules was 8.88 microg.h/ml, which was a little lower than that for the aqueous solution (10.1 microg.h/ml), whereas the analgesic effect after SPILA granules once-a-day administration expressed as AURC (1701% Analgesia.h) was similar to that after the aqueous solution 4 times-a-day administration (1603% Analgesia.h).",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),[h·μg] / [ml],8.88,116113,DB00295,Morphine
,17666803,AUC(0-24 h),"AUC(0-24 h) value for SPILA granules was 8.88 microg.h/ml, which was a little lower than that for the aqueous solution (10.1 microg.h/ml), whereas the analgesic effect after SPILA granules once-a-day administration expressed as AURC (1701% Analgesia.h) was similar to that after the aqueous solution 4 times-a-day administration (1603% Analgesia.h).",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),[h·μg] / [ml],10.1,116114,DB00295,Morphine
,17666803,AURC,"AUC(0-24 h) value for SPILA granules was 8.88 microg.h/ml, which was a little lower than that for the aqueous solution (10.1 microg.h/ml), whereas the analgesic effect after SPILA granules once-a-day administration expressed as AURC (1701% Analgesia.h) was similar to that after the aqueous solution 4 times-a-day administration (1603% Analgesia.h).",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),%,1701,116115,DB00295,Morphine
,17666803,AURC,"AUC(0-24 h) value for SPILA granules was 8.88 microg.h/ml, which was a little lower than that for the aqueous solution (10.1 microg.h/ml), whereas the analgesic effect after SPILA granules once-a-day administration expressed as AURC (1701% Analgesia.h) was similar to that after the aqueous solution 4 times-a-day administration (1603% Analgesia.h).",Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666803/),%,1603,116116,DB00295,Morphine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,14.98,116251,DB00295,Morphine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,11.05,116252,DB00295,Morphine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,13.93,116253,DB00295,Morphine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,6.4,116254,DB00295,Morphine
,9737821,relative bioavailability,The relative bioavailability of the buccal tablet (corrected for residual unabsorbed dose) compared with the controlled-release tablet was 98% based on the morphine AUC values.,Bioavailability of morphine after administration of a new bioadhesive buccal tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737821/),%,98,116448,DB00295,Morphine
,16584286,bioavailability,"The bioavailability of inhaled heroin was estimated to be 53% (95% CI 43.7, 62.3).",Population pharmacokinetics of heroin and its major metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),%,53,116470,DB00295,Morphine
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,7.6,116471,DB00295,Morphine
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,21.8,116472,DB00295,Morphine
,16584286,clearances,"The clearances of morphine and the morphine-glucuronides were estimated to be 73.6 L/h (95% CI 62.8, 84.4) and between 6 and 10 L/h, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),[l] / [h],73.6,116473,DB00295,Morphine
,30672747,midazolam,The estimated midazolam clearance was 0.61 L/min/70kg.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),[l] / [70kg·min],0.61,117232,DB00295,Morphine
,30672747,clearance,The estimated midazolam clearance was 0.61 L/min/70kg.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),[l] / [70kg·min],0.61,117233,DB00295,Morphine
,30672747,Time to reach 50% complete mature midaz,Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),years,1.0,117234,DB00295,Morphine
,30672747,Time to reach 50% complete mature midaz,Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),years,0.97,117235,DB00295,Morphine
,16473430,AUC,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),[h·ng] / [ml],191,118024,DB00295,Morphine
,16473430,AUC,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),[h·ng] / [ml],86.4,118025,DB00295,Morphine
,16473430,MRT,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),h,10.6,118026,DB00295,Morphine
,16473430,MRT,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),h,5.86,118027,DB00295,Morphine
,4087182,half-lives,"Plasma-time data showed two sequential half-lives of 8.3 +/- 3.4 (SEM) and 128 +/- 37 min, with apparent dose-independent pharmacokinetics in the studied dose range.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,8.3,118086,DB00295,Morphine
,4087182,half-lives,"Plasma-time data showed two sequential half-lives of 8.3 +/- 3.4 (SEM) and 128 +/- 37 min, with apparent dose-independent pharmacokinetics in the studied dose range.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,128,118087,DB00295,Morphine
,4087182,Total body clearances,Total body clearances were 899 +/- 103 (SEM) mL/min.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],899,118088,DB00295,Morphine
,4087182,Renal clearances,Renal clearances (6-82 mL/min) of methadone were highly variable within and among studies but showed no significant variation with urinary pH or flow rate.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],6-82,118089,DB00295,Morphine
,4087182,half-lives,The intravenous administration of 2 resulted in two sequential half-lives of 3 and 270 min and no apparent pharmacokinetic dose dependency.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,3,118090,DB00295,Morphine
,4087182,half-lives,The intravenous administration of 2 resulted in two sequential half-lives of 3 and 270 min and no apparent pharmacokinetic dose dependency.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),min,270,118091,DB00295,Morphine
,4087182,Amounts,"Amounts of 2 excreted unchanged in urine and bile were 23% and 5-16% of the dose, respectively.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),%,23,118092,DB00295,Morphine
,4087182,Amounts,"Amounts of 2 excreted unchanged in urine and bile were 23% and 5-16% of the dose, respectively.",Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),%,5-16,118093,DB00295,Morphine
,4087182,Renal,Renal and total body clearances were 170 and 1150 mL/min.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],170,118094,DB00295,Morphine
,4087182,total body clearances,Renal and total body clearances were 170 and 1150 mL/min.,Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087182/),[ml] / [min],1150,118095,DB00295,Morphine
,7967538,apparent plasma terminal half-life,"Both RIAs showed a first-order elimination rate after i.v. intoxication (apparent plasma terminal half-life ranged from 2.9 to 4.7 hours for unchanged morphine and from 3.2 to 4.9 hours for total opiates) and a persistent opiate concentration with rebound after oral ingestion, suggesting a slow release of opiates from the gastrointestinal tract, in dealers and bodypackers.",Morphine disposition in opiate-intoxicated patients: relevance of nonspecific opiate immunoassays. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967538/),h,2.9 to 4.7,118593,DB00295,Morphine
,7967538,apparent plasma terminal half-life,"Both RIAs showed a first-order elimination rate after i.v. intoxication (apparent plasma terminal half-life ranged from 2.9 to 4.7 hours for unchanged morphine and from 3.2 to 4.9 hours for total opiates) and a persistent opiate concentration with rebound after oral ingestion, suggesting a slow release of opiates from the gastrointestinal tract, in dealers and bodypackers.",Morphine disposition in opiate-intoxicated patients: relevance of nonspecific opiate immunoassays. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967538/),h,3.2 to 4.9,118594,DB00295,Morphine
,10516633,Unbound brain extracellular fluid concentration ratios,"Unbound brain extracellular fluid concentration ratios of (-/-)/(+/+) were 2.7 for retrodialysis and 3.6 for the dynamic-no-net-flux at 4 h, with corresponding total brain concentration ratios of (-/-)/(+/+) being 2.3 for retrodialysis and 2.6 for the dynamic-no-net-flux.",The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516633/),,2.7,119960,DB00295,Morphine
,10516633,Unbound brain extracellular fluid concentration ratios,"Unbound brain extracellular fluid concentration ratios of (-/-)/(+/+) were 2.7 for retrodialysis and 3.6 for the dynamic-no-net-flux at 4 h, with corresponding total brain concentration ratios of (-/-)/(+/+) being 2.3 for retrodialysis and 2.6 for the dynamic-no-net-flux.",The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516633/),,3.6,119961,DB00295,Morphine
,10516633,total brain concentration ratios,"Unbound brain extracellular fluid concentration ratios of (-/-)/(+/+) were 2.7 for retrodialysis and 3.6 for the dynamic-no-net-flux at 4 h, with corresponding total brain concentration ratios of (-/-)/(+/+) being 2.3 for retrodialysis and 2.6 for the dynamic-no-net-flux.",The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516633/),,2.3,119962,DB00295,Morphine
,10516633,total brain concentration ratios,"Unbound brain extracellular fluid concentration ratios of (-/-)/(+/+) were 2.7 for retrodialysis and 3.6 for the dynamic-no-net-flux at 4 h, with corresponding total brain concentration ratios of (-/-)/(+/+) being 2.3 for retrodialysis and 2.6 for the dynamic-no-net-flux.",The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516633/),,2.6,119963,DB00295,Morphine
,10516633,total concentration ratios,"The total concentration ratios of brain/plasma were 1.1 and 0.5 for mdr1a (-/-) and (+/+) mice, respectively.",The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516633/),,1.1,119964,DB00295,Morphine
,10516633,total concentration ratios,"The total concentration ratios of brain/plasma were 1.1 and 0.5 for mdr1a (-/-) and (+/+) mice, respectively.",The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516633/),,0.5,119965,DB00295,Morphine
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0.35 to 0.42,120652,DB00295,Morphine
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0.06-0.08,120653,DB00295,Morphine
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0,120654,DB00295,Morphine
,7924762,half-life,"The mean (+/- SD) half-life was 8.1 +/- 8.1 h in 10 neonates younger than 1 week, 5.4 +/- 3.4 h in 10 infants aged from 1 week to 2 months and 2.6 +/- 1.7 h in 7 infants aged from 2 to 6 months.",Age-related morphine kinetics in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924762/),h,8.1,120701,DB00295,Morphine
,7924762,half-life,"The mean (+/- SD) half-life was 8.1 +/- 8.1 h in 10 neonates younger than 1 week, 5.4 +/- 3.4 h in 10 infants aged from 1 week to 2 months and 2.6 +/- 1.7 h in 7 infants aged from 2 to 6 months.",Age-related morphine kinetics in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924762/),h,5.4,120702,DB00295,Morphine
,7924762,half-life,"The mean (+/- SD) half-life was 8.1 +/- 8.1 h in 10 neonates younger than 1 week, 5.4 +/- 3.4 h in 10 infants aged from 1 week to 2 months and 2.6 +/- 1.7 h in 7 infants aged from 2 to 6 months.",Age-related morphine kinetics in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924762/),h,2.6,120703,DB00295,Morphine
,7924762,clearance,"Mean clearance increased significantly with age, being 8.7 +/- 5.8 ml/min/kg in the youngest age group, 11.9 +/- 5.1 ml/min/kg in those aged 1 week to 2 months and 28.0 +/- 8.9 ml/min/kg in those aged 2-6 months, and was also significantly lower in the critically ill infants.",Age-related morphine kinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924762/),[ml] / [kg·min],8.7,120704,DB00295,Morphine
,7924762,clearance,"Mean clearance increased significantly with age, being 8.7 +/- 5.8 ml/min/kg in the youngest age group, 11.9 +/- 5.1 ml/min/kg in those aged 1 week to 2 months and 28.0 +/- 8.9 ml/min/kg in those aged 2-6 months, and was also significantly lower in the critically ill infants.",Age-related morphine kinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924762/),[ml] / [kg·min],11.9,120705,DB00295,Morphine
,7924762,clearance,"Mean clearance increased significantly with age, being 8.7 +/- 5.8 ml/min/kg in the youngest age group, 11.9 +/- 5.1 ml/min/kg in those aged 1 week to 2 months and 28.0 +/- 8.9 ml/min/kg in those aged 2-6 months, and was also significantly lower in the critically ill infants.",Age-related morphine kinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924762/),[ml] / [kg·min],28.0,120706,DB00295,Morphine
,7469101,elimination half-time (t1/2 beta),Morphine disposition was independent of dose in this fourfold range and was best described by a three-compartment model with a mean elimination half-time (t1/2 beta) of 104 +/- 5 min.,Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),min,104,120994,DB00295,Morphine
,7469101,apparent volumes of distribution (Vd),"The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1.",Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),[l] / [kg],3.4,120995,DB00295,Morphine
,7469101,central compartment (V1),"The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1.",Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),[l] / [kg],0.13,120996,DB00295,Morphine
,7469101,clearance (ClB),"The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1.",Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),[ml] / [kg·min],23,120997,DB00295,Morphine
,7469101,t1/2 beta,Conjugated morphine was eliminated from plasma with a t1/2 beta of 169 +/- 15 min.,Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),min,169,120998,DB00295,Morphine
,9041568,volume of distribution,"For the reported pharmacokinetics parameters a meta-analysis was made; volume of distribution, estimated to be 2.8 +/- 2.6 l.kg-1, seems to be regardless of age, while half-life and clearance were found to be related to age.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),[l] / [kg],2.8,121010,DB00295,Morphine
,9041568,Half-life,"Half-life was estimated to be 9.0 +/- 3.4 h in pre-term neonates, 6.5 +/- 2.8 h in term neonates aged 0-57 days, and 2.0 +/- 1.8 h for infants and children aged 11 days to 15 years.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),h,9.0,121011,DB00295,Morphine
,9041568,Half-life,"Half-life was estimated to be 9.0 +/- 3.4 h in pre-term neonates, 6.5 +/- 2.8 h in term neonates aged 0-57 days, and 2.0 +/- 1.8 h for infants and children aged 11 days to 15 years.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),h,6.5,121012,DB00295,Morphine
,9041568,Half-life,"Half-life was estimated to be 9.0 +/- 3.4 h in pre-term neonates, 6.5 +/- 2.8 h in term neonates aged 0-57 days, and 2.0 +/- 1.8 h for infants and children aged 11 days to 15 years.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),h,2.0,121013,DB00295,Morphine
,9041568,Clearance,"Clearance was estimated to be 2.2 +/- 0.7 ml.min-1.kg-1 for preterm neonates, 8.1 +/- 3.2 ml.min-1.kg-1 in term neonates aged 0-57 days, and 23.6 +/- 8.5 ml.min-1.kg-1 in infants and children more than 11 days old.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),[ml] / [kg·min],2.2,121014,DB00295,Morphine
,9041568,Clearance,"Clearance was estimated to be 2.2 +/- 0.7 ml.min-1.kg-1 for preterm neonates, 8.1 +/- 3.2 ml.min-1.kg-1 in term neonates aged 0-57 days, and 23.6 +/- 8.5 ml.min-1.kg-1 in infants and children more than 11 days old.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),[ml] / [kg·min],8.1,121015,DB00295,Morphine
,9041568,Clearance,"Clearance was estimated to be 2.2 +/- 0.7 ml.min-1.kg-1 for preterm neonates, 8.1 +/- 3.2 ml.min-1.kg-1 in term neonates aged 0-57 days, and 23.6 +/- 8.5 ml.min-1.kg-1 in infants and children more than 11 days old.","Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041568/),[ml] / [kg·min],23.6,121016,DB00295,Morphine
,30849683,LOD,"The LOD were 0.05 ng/mL for U-47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.",Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),[ng] / [ml],0.05,121138,DB00295,Morphine
,30849683,LOD,"The LOD were 0.05 ng/mL for U-47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.",Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),[ng] / [ml],0.1,121139,DB00295,Morphine
>,30849683,Extraction recovery,Extraction recovery was >79%.,Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),%,79,121140,DB00295,Morphine
,9062618,plasma clearance,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[l] / [min],0.83,121549,DB00295,Morphine
,9062618,volume of distribution at steady-state,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[l] / [kg],2.02,121550,DB00295,Morphine
,9062618,terminal elimination half-life,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),min,157,121551,DB00295,Morphine
,9062618,peak plasma concentration,"After intranasal administration, peak plasma concentration of oxycodone was 13 +/- 6 ng/ml and it was reached in the median time of 25 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[ng] / [ml],13,121552,DB00295,Morphine
,9062618,bioavailability,The intranasal bioavailability of oxycodone was 0.46 +/- 0.34.,Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),,0.46,121553,DB00295,Morphine
,10971308,Emax,"Compared with PSC alone, morphine elicited an increase in reaction time (Emax 48 ms, compared with the predose absolute reaction time of 644 ms), which was not detected by the alertness-drowsiness score, indicating only slight sedation.",Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971308/),ms,48,121815,DB00295,Morphine
,10971308,absolute reaction time,"Compared with PSC alone, morphine elicited an increase in reaction time (Emax 48 ms, compared with the predose absolute reaction time of 644 ms), which was not detected by the alertness-drowsiness score, indicating only slight sedation.",Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971308/),ms,644,121816,DB00295,Morphine
,10971308,Emax,"In contrast, morphine caused a significant increase in PCO2 (Emax 0.69 kPa) compared to PSC alone, indicating slight respiratory depression.",Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971308/),kpa,0.69,121817,DB00295,Morphine
above,1623695,area under the plasma concentration-time curves,Withdrawal symptoms occurred with plasma naloxone area under the plasma concentration-time curves above 550 ng.,Treatment of opioid-induced constipation with oral naloxone: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623695/),ng,550,121859,DB00295,Morphine
,8149873,Bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,10,122047,DB00295,Morphine
,8149873,Bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,25,122048,DB00295,Morphine
,8149873,Bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,8,122049,DB00295,Morphine
,8149873,bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,8,122050,DB00295,Morphine
,11772809,plasma concentrations,"Although no adverse effect occurred in any patient, the largest dose led to large plasma concentrations of ropivacaine (2.93 +/- 2.46 microg/mL and 3.76 +/- 3.01 microg/mL after the first and second injection, respectively).",The clinical efficacy and pharmacokinetics of intraperitoneal ropivacaine for laparoscopic cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772809/),μ,2,122161,DB00295,Morphine
,11772809,plasma concentrations,"Although no adverse effect occurred in any patient, the largest dose led to large plasma concentrations of ropivacaine (2.93 +/- 2.46 microg/mL and 3.76 +/- 3.01 microg/mL after the first and second injection, respectively).",The clinical efficacy and pharmacokinetics of intraperitoneal ropivacaine for laparoscopic cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772809/),μ,3,122162,DB00295,Morphine
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB00295,Morphine
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB00295,Morphine
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB00295,Morphine
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB00295,Morphine
,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,50-400,122850,DB00295,Morphine
>,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,"15,000",122851,DB00295,Morphine
≤,21036913,minimal effective dose,KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤ 10 mg/kg p.o.) and a greater potency than gabapentin.,"Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),mg,10,122852,DB00295,Morphine
,19819665,T(max),"Concomitant SC administration of rHuPH20 enhanced the absorption rate of morphine compared with SC morphine with placebo, significantly reducing the mean T(max) from 13.8 to 9.2 minutes, a 33% decrease (P=0.026).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),min,13.8,123698,DB00295,Morphine
,19819665,T(max),"Concomitant SC administration of rHuPH20 enhanced the absorption rate of morphine compared with SC morphine with placebo, significantly reducing the mean T(max) from 13.8 to 9.2 minutes, a 33% decrease (P=0.026).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),min,9.2,123699,DB00295,Morphine
,19819665,maximum plasma concentration,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[nM] / [l],94.9,123700,DB00295,Morphine
,19819665,maximum plasma concentration,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[nM] / [l],107.5,123701,DB00295,Morphine
,19819665,area under the plasma concentration vs. time curve,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[min·μM] / [l],7.7,123702,DB00295,Morphine
,19819665,area under the plasma concentration vs. time curve,"The respective values for geometric mean maximum plasma concentration were 94.9 and 107.5nmol/L, a 13% increase (P=0.024), and the area under the plasma concentration vs. time curve values were 7.7 and 7.2micromol x min/L (P=0.23).",The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819665/),[min·μM] / [l],7.2,123703,DB00295,Morphine
,3839885,peak cisternal CSF morphine concentrations,"The mean peak cisternal CSF morphine concentrations were sustained for 30-40 minutes, and averaged 148 ng/ml, representing 0.3% of the administered dose.","CSF distribution of morphine, methadone and sucrose after intrathecal injection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3839885/),[ng] / [ml],148,124853,DB00295,Morphine
,9083827,apparent terminal half-lives,The apparent terminal half-lives of morphine-3-glucuronide ranged from 2.2 to 5.2 h for intranasally administered heroin and were 3.0 and 1.7 h for the intramuscularly applied drug.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),h,2.2 to 5.2,125097,DB00295,Morphine
,9083827,apparent terminal half-lives,The apparent terminal half-lives of morphine-3-glucuronide ranged from 2.2 to 5.2 h for intranasally administered heroin and were 3.0 and 1.7 h for the intramuscularly applied drug.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),h,3.0,125098,DB00295,Morphine
,9083827,apparent terminal half-lives,The apparent terminal half-lives of morphine-3-glucuronide ranged from 2.2 to 5.2 h for intranasally administered heroin and were 3.0 and 1.7 h for the intramuscularly applied drug.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),h,1.7,125099,DB00295,Morphine
,9083827,area-under-curve ratio,A mean morphine-3-glucuronide-heroin area-under-curve ratio of 93 for the intranasal route as compared with 38 for the intramuscular route demonstrated that circulating amounts of heroin were about half the size after intranasal administration of the same dose.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),,93,125100,DB00295,Morphine
,9083827,area-under-curve ratio,A mean morphine-3-glucuronide-heroin area-under-curve ratio of 93 for the intranasal route as compared with 38 for the intramuscular route demonstrated that circulating amounts of heroin were about half the size after intranasal administration of the same dose.,Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083827/),,38,125101,DB00295,Morphine
,1467140,plasma clearance,The mean plasma clearance of morphine was 20.1 ml min-1 kg-1 in neonates and 23.4 ml min-1 kg-1 in the group as a whole.,Morphine metabolism in neonates and infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467140/),[ml] / [kg·min],20.1,125368,DB00295,Morphine
,1467140,plasma clearance,The mean plasma clearance of morphine was 20.1 ml min-1 kg-1 in neonates and 23.4 ml min-1 kg-1 in the group as a whole.,Morphine metabolism in neonates and infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467140/),[ml] / [kg·min],23.4,125369,DB00295,Morphine
,1467140,M3G/morphine ratio,The M3G/morphine ratio (7.3) was higher than that previously reported for preterm neonates (5.0) but lower than that reported for children (23.9).,Morphine metabolism in neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467140/),,7.3,125370,DB00295,Morphine
,1467140,M3G/morphine ratio,The M3G/morphine ratio (7.3) was higher than that previously reported for preterm neonates (5.0) but lower than that reported for children (23.9).,Morphine metabolism in neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467140/),,5.0,125371,DB00295,Morphine
,1467140,M3G/morphine ratio,The M3G/morphine ratio (7.3) was higher than that previously reported for preterm neonates (5.0) but lower than that reported for children (23.9).,Morphine metabolism in neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467140/),,23.9,125372,DB00295,Morphine
,3190994,tmax,"4. After the single doses, pholcodine was absorbed rapidly (tmax = 1.6 +/- 1.2 h) and eliminated slowly with a mean half-life of 50.1 +/- 4.1 h.",Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),h,1.6,125695,DB00295,Morphine
,3190994,half-life,"4. After the single doses, pholcodine was absorbed rapidly (tmax = 1.6 +/- 1.2 h) and eliminated slowly with a mean half-life of 50.1 +/- 4.1 h.",Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),h,50.1,125696,DB00295,Morphine
,3190994,renal clearance,The renal clearance of pholcodine was 137 +/- 34 ml min-1 and was inversely correlated with urine pH (r = 0.60) but not with urine flow rate.,Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),[ml] / [min],137,125697,DB00295,Morphine
,3190994,plasma protein binding,The plasma protein binding was 23.5%.,Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),%,23.5,125698,DB00295,Morphine
,3826690,central compartment,Patients with RF had a significantly smaller (P less than 0.05) central compartment (0.3 +/- 0.2 l X kg-1 versus 0.8 +/- 0.4 l X kg-1) than in the controls.,Morphine pharmacokinetics in renal failure. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826690/),[l] / [kg],0.3,125857,DB00295,Morphine
,3826690,central compartment,Patients with RF had a significantly smaller (P less than 0.05) central compartment (0.3 +/- 0.2 l X kg-1 versus 0.8 +/- 0.4 l X kg-1) than in the controls.,Morphine pharmacokinetics in renal failure. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826690/),[l] / [kg],0.8,125858,DB00295,Morphine
,3826690,Volume of distribution at steady state,Volume of distribution at steady state was also significantly (P less than 0.05) decreased in RF patients (2.8 +/- 1.0 l X kg-1) versus 3.7 +/- 1.2 l X kg-1 in the normal patients.,Morphine pharmacokinetics in renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826690/),[l] / [kg],2.8,125859,DB00295,Morphine
,3826690,Volume of distribution at steady state,Volume of distribution at steady state was also significantly (P less than 0.05) decreased in RF patients (2.8 +/- 1.0 l X kg-1) versus 3.7 +/- 1.2 l X kg-1 in the normal patients.,Morphine pharmacokinetics in renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826690/),[l] / [kg],3.7,125860,DB00295,Morphine
,11071674,ventilatory response,"At base line, the mean (+/-SD) values for the ventilatory response to hypoxia (calculated as the difference between the minute ventilation during the second full minute of hypoxia and the fifth minute of hypercapnic ventilation) were similar in the three groups: 38.3+/-23.2 liters per minute in the placebo group, 33.5+/-16.4 liters per minute in the intravenous-morphine group, and 30.2+/-11.6 liters per minute in the intrathecal-morphine group (P=0.61).",Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],38.3,126483,DB00295,Morphine
,11071674,ventilatory response,"At base line, the mean (+/-SD) values for the ventilatory response to hypoxia (calculated as the difference between the minute ventilation during the second full minute of hypoxia and the fifth minute of hypercapnic ventilation) were similar in the three groups: 38.3+/-23.2 liters per minute in the placebo group, 33.5+/-16.4 liters per minute in the intravenous-morphine group, and 30.2+/-11.6 liters per minute in the intrathecal-morphine group (P=0.61).",Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],33.5,126484,DB00295,Morphine
,11071674,ventilatory response,"At base line, the mean (+/-SD) values for the ventilatory response to hypoxia (calculated as the difference between the minute ventilation during the second full minute of hypoxia and the fifth minute of hypercapnic ventilation) were similar in the three groups: 38.3+/-23.2 liters per minute in the placebo group, 33.5+/-16.4 liters per minute in the intravenous-morphine group, and 30.2+/-11.6 liters per minute in the intrathecal-morphine group (P=0.61).",Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],30.2,126485,DB00295,Morphine
,11071674,overall ventilatory response,The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=O.003).,Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],20.2,126486,DB00295,Morphine
,11071674,overall ventilatory response,The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=O.003).,Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],14.5,126487,DB00295,Morphine
,11071674,overall ventilatory response,The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=O.003).,Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],36.8,126488,DB00295,Morphine
,11071674,area under the curve,The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=O.003).,Effects of intrathecal morphine on the ventilatory response to hypoxia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],20.2,126489,DB00295,Morphine
,11071674,area under the curve,The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=O.003).,Effects of intrathecal morphine on the ventilatory response to hypoxia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],14.5,126490,DB00295,Morphine
,11071674,area under the curve,The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=O.003).,Effects of intrathecal morphine on the ventilatory response to hypoxia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],36.8,126491,DB00295,Morphine
,11071674,ventilatory response,"Twelve hours after treatment, the ventilatory response to hypoxia in the intrathecal-morphine group (19.9+/-8.9 liters per minute), but not in the intravenous-morphine group (30+/-15.8 liters per minute), remained significantly depressed as compared with the response in the placebo group (40.9+/-19.0 liters per minute) (P= 0.02 for intrathecal morphine vs. placebo).",Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],19.9,126492,DB00295,Morphine
,11071674,ventilatory response,"Twelve hours after treatment, the ventilatory response to hypoxia in the intrathecal-morphine group (19.9+/-8.9 liters per minute), but not in the intravenous-morphine group (30+/-15.8 liters per minute), remained significantly depressed as compared with the response in the placebo group (40.9+/-19.0 liters per minute) (P= 0.02 for intrathecal morphine vs. placebo).",Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],30,126493,DB00295,Morphine
,11071674,ventilatory response,"Twelve hours after treatment, the ventilatory response to hypoxia in the intrathecal-morphine group (19.9+/-8.9 liters per minute), but not in the intravenous-morphine group (30+/-15.8 liters per minute), remained significantly depressed as compared with the response in the placebo group (40.9+/-19.0 liters per minute) (P= 0.02 for intrathecal morphine vs. placebo).",Effects of intrathecal morphine on the ventilatory response to hypoxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11071674/),[l] / [min],40.9,126494,DB00295,Morphine
,17876144,CL/F,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),[l] / [h],45.6,126541,DB00295,Morphine
,17876144,Vd/F,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),l,473.0,126542,DB00295,Morphine
,17876144,t(1/2),"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,7.2,126543,DB00295,Morphine
,17876144,kel,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),,0.103,126544,DB00295,Morphine
,17876144,kal,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),,1.082,126545,DB00295,Morphine
,17876144,Lag time,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,0.9 9,126546,DB00295,Morphine
,17876144,lag time,"Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,1,126547,DB00295,Morphine
,458581,elimination half-lives,"Dose-related effects on the total, metabolic, and biliary clearances imply saturable enzymes and/or dose-inhibited hepatic flows, accounting for the major elimination half-lives of 83 +/- 8 and 37 +/- 13 min at the high and low doses, respectively.",Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/458581/),min,83,127010,DB00295,Morphine
,458581,elimination half-lives,"Dose-related effects on the total, metabolic, and biliary clearances imply saturable enzymes and/or dose-inhibited hepatic flows, accounting for the major elimination half-lives of 83 +/- 8 and 37 +/- 13 min at the high and low doses, respectively.",Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/458581/),min,37,127011,DB00295,Morphine
,458581,clearances,"Renal morphine and morphine conjugate clearances were 85 (+/- 9 SEM) and 41 (+/- 4 SEM) ml/min, respectively, indicating glomerular filtration for the latter and glomerular filtration plus tubular secretion for the former.",Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458581/),[ml] / [min],85,127012,DB00295,Morphine
,458581,clearances,"Renal morphine and morphine conjugate clearances were 85 (+/- 9 SEM) and 41 (+/- 4 SEM) ml/min, respectively, indicating glomerular filtration for the latter and glomerular filtration plus tubular secretion for the former.",Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458581/),[ml] / [min],41,127013,DB00295,Morphine
,458581,plasma protein binding,Morphine showed dose-independent plasma protein binding of 36 (+/- 1 SEM) % and a red cell-plasma water partition coefficient of 1.11 +/- 0.04 SD.,Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458581/),%,36,127014,DB00295,Morphine
,458581,red cell-plasma water partition coefficient,Morphine showed dose-independent plasma protein binding of 36 (+/- 1 SEM) % and a red cell-plasma water partition coefficient of 1.11 +/- 0.04 SD.,Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458581/),sd,1.11,127015,DB00295,Morphine
,3438223,maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),μM,0.34,127614,DB00295,Morphine
,3438223,maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),μM,6.3,127615,DB00295,Morphine
,3438223,time to reach the maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),min,65,127616,DB00295,Morphine
,10328468,systemic clearance,"While systemic clearance of morphine (1246+/-240 ml/min) was in the range observed in patients with normal kidney function, both M3G and M6G showed substantial accumulation.",Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),[ml] / [min],1246,127731,DB00295,Morphine
,10328468,area under the concentration-time curve (AUC) ratio,The area under the concentration-time curve (AUC) ratio of M3G:Mo (33.4+/-7.1) and of M6G:Mo (12.2+/-3.2) was 5.5 and 13.5 times higher than in patients with normal kidney function.,Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),,33.4,127732,DB00295,Morphine
,10328468,area under the concentration-time curve (AUC) ratio,The area under the concentration-time curve (AUC) ratio of M3G:Mo (33.4+/-7.1) and of M6G:Mo (12.2+/-3.2) was 5.5 and 13.5 times higher than in patients with normal kidney function.,Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),,12.2,127733,DB00295,Morphine
,10328468,Renal clearances,"Renal clearances of morphine, M3G, and M6G (morphine 3.0+/-2.5 ml/min; M3G 3.9+/-2.2 ml/min; M6G 3.6+/-2.2 ml/min) and dialysate clearances (morphine 4.1+/-1.3 ml/min; M3G 3.2+/-0.7 ml/min; M6G 3.0+/-0.8 ml/min) were extremely low.",Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),[ml] / [min],3.0,127734,DB00295,Morphine
,10328468,Renal clearances,"Renal clearances of morphine, M3G, and M6G (morphine 3.0+/-2.5 ml/min; M3G 3.9+/-2.2 ml/min; M6G 3.6+/-2.2 ml/min) and dialysate clearances (morphine 4.1+/-1.3 ml/min; M3G 3.2+/-0.7 ml/min; M6G 3.0+/-0.8 ml/min) were extremely low.",Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),[ml] / [min],3.9,127735,DB00295,Morphine
,10328468,Renal clearances,"Renal clearances of morphine, M3G, and M6G (morphine 3.0+/-2.5 ml/min; M3G 3.9+/-2.2 ml/min; M6G 3.6+/-2.2 ml/min) and dialysate clearances (morphine 4.1+/-1.3 ml/min; M3G 3.2+/-0.7 ml/min; M6G 3.0+/-0.8 ml/min) were extremely low.",Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),[ml] / [min],3.6,127736,DB00295,Morphine
,10328468,dial,"Renal clearances of morphine, M3G, and M6G (morphine 3.0+/-2.5 ml/min; M3G 3.9+/-2.2 ml/min; M6G 3.6+/-2.2 ml/min) and dialysate clearances (morphine 4.1+/-1.3 ml/min; M3G 3.2+/-0.7 ml/min; M6G 3.0+/-0.8 ml/min) were extremely low.",Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328468/),[ml] / [min],4.1,127737,DB00295,Morphine
,2391609,distribution half-life,"In the 10 infants whose gestational age was less than or equal to 30 weeks, the mean (+/- SD) distribution half-life was 50 +/- 35 minutes, elimination half-life was 10 +/- 3.7 hours, and clearance was 3.39 +/- 3.28 ml/kg/min; the corresponding values for the three term infants were 19 +/- 8 minutes, 6.7 +/- 4.6 hours, and 15.5 +/- 10 ml/kg/min, respectively.",Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391609/),min,50,127911,DB00295,Morphine
,2391609,elimination half-life,"In the 10 infants whose gestational age was less than or equal to 30 weeks, the mean (+/- SD) distribution half-life was 50 +/- 35 minutes, elimination half-life was 10 +/- 3.7 hours, and clearance was 3.39 +/- 3.28 ml/kg/min; the corresponding values for the three term infants were 19 +/- 8 minutes, 6.7 +/- 4.6 hours, and 15.5 +/- 10 ml/kg/min, respectively.",Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391609/),h,10,127912,DB00295,Morphine
,2391609,clearance,"In the 10 infants whose gestational age was less than or equal to 30 weeks, the mean (+/- SD) distribution half-life was 50 +/- 35 minutes, elimination half-life was 10 +/- 3.7 hours, and clearance was 3.39 +/- 3.28 ml/kg/min; the corresponding values for the three term infants were 19 +/- 8 minutes, 6.7 +/- 4.6 hours, and 15.5 +/- 10 ml/kg/min, respectively.",Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391609/),[ml] / [kg·min],3.39,127913,DB00295,Morphine
,2391609,clearance,"In the 10 infants whose gestational age was less than or equal to 30 weeks, the mean (+/- SD) distribution half-life was 50 +/- 35 minutes, elimination half-life was 10 +/- 3.7 hours, and clearance was 3.39 +/- 3.28 ml/kg/min; the corresponding values for the three term infants were 19 +/- 8 minutes, 6.7 +/- 4.6 hours, and 15.5 +/- 10 ml/kg/min, respectively.",Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391609/),min,19,127914,DB00295,Morphine
,2391609,rate,The morphine clearance rate increased as a function of gestational age at a rate of 0.9 ml/kg/min per week of gestation.,Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391609/),[ml] / [kg·min·week],0.9,127915,DB00295,Morphine
,33603216,half-life,"In the RTTE model, the hazard of rescue morphine decreased over time (half-life 18 h; P < 0.001), while the hazard for rescue morphine (21.9% at 29.5 ng ml-1) increased at higher morphine concentrations (P < 0.001).",Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33603216/),h,18,128113,DB00295,Morphine
,8375123,Systemic bioavailability,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],377.1,128887,DB00295,Morphine
,8375123,AUC,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],377.1,128888,DB00295,Morphine
,8375123,AUC,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],236.2,128889,DB00295,Morphine
,8375123,AUC,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],2610.1,128890,DB00295,Morphine
,8375123,AUC,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],1650.2,128891,DB00295,Morphine
,8375123,maximum concentrations,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[nM] / [l],110.9,128892,DB00295,Morphine
,8375123,maximum concentrations,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[nM] / [l],64.6,128893,DB00295,Morphine
,8375123,maximum concentrations,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[nM] / [l],576.9,128894,DB00295,Morphine
,8375123,maximum concentrations,"Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377.1 +/- 124.2 versus 236.2 +/- 133.7 nmol.hr/L, p = 0.05; M3G, 2610.1 +/- 446.4 versus 1650.2 +/- 309.0 nmol.hr/L, p = 0.004; maximum concentrations: M6G, 110.9 +/- 37.5 versus 64.6 +/- 28.8 nmol/L, p = 0.002; M3G, 576.9 +/- 155.8 versus 266.8 +/- 110.5 nmol/L, p = 0.007).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[nM] / [l],266.8,128895,DB00295,Morphine
,8375123,systemic availability,"Conversely, the systemic availability of morphine was lower after oral administration, although this difference failed to achieve statistical significance (142.3 +/- 17.1 versus 176.6 +/- 69.4 nmol.hr/L, p = 0.14).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],142.3,128896,DB00295,Morphine
,8375123,systemic availability,"Conversely, the systemic availability of morphine was lower after oral administration, although this difference failed to achieve statistical significance (142.3 +/- 17.1 versus 176.6 +/- 69.4 nmol.hr/L, p = 0.14).",Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375123/),[h·nM] / [l],176.6,128897,DB00295,Morphine
,9547700,extraction recoveries,"The extraction recoveries were 100% for morphine, 84% for morphine-3-glucuronide, 64% for morphine-6-glucuronide and 88% for normorphine.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),%,100,129186,DB00295,Morphine
,9547700,extraction recoveries,"The extraction recoveries were 100% for morphine, 84% for morphine-3-glucuronide, 64% for morphine-6-glucuronide and 88% for normorphine.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),%,84,129187,DB00295,Morphine
,9547700,extraction recoveries,"The extraction recoveries were 100% for morphine, 84% for morphine-3-glucuronide, 64% for morphine-6-glucuronide and 88% for normorphine.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),%,64,129188,DB00295,Morphine
,9547700,extraction recoveries,"The extraction recoveries were 100% for morphine, 84% for morphine-3-glucuronide, 64% for morphine-6-glucuronide and 88% for normorphine.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),%,88,129189,DB00295,Morphine
,9547700,limits of detection,"Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),[nM] / [l],13,129190,DB00295,Morphine
,9547700,limits of detection,"Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),[ng] / [ml],3.8,129191,DB00295,Morphine
,9547700,limits of detection,"Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),[nM] / [l],12,129192,DB00295,Morphine
,9547700,limits of detection,"Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),[nM] / [l],26,129193,DB00295,Morphine
,9547700,limits of detection,"Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),[nM] / [l],18,129194,DB00295,Morphine
,9547700,signal-to-noise ratio,"Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3.",High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547700/),,3,129195,DB00295,Morphine
,8934303,detection time,The detection time in the EMIT screening assay was found to be 20-39 h after the 25-mg dose and 30-52 h after the 50-mg dose.,Urine and plasma pharmacokinetics of codeine in healthy volunteers: implications for drugs-of-abuse testing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8934303/),h,20-39,129236,DB00295,Morphine
,8934303,detection time,The detection time in the EMIT screening assay was found to be 20-39 h after the 25-mg dose and 30-52 h after the 50-mg dose.,Urine and plasma pharmacokinetics of codeine in healthy volunteers: implications for drugs-of-abuse testing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8934303/),h,30-52,129237,DB00295,Morphine
,23098635,CMAX,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],11.73,129788,DB00295,Morphine
,23098635,terminal half-life,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,1.60,129789,DB00295,Morphine
,23098635,CMAX,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],5.2,129790,DB00295,Morphine
,23098635,terminal half-life,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,3.07,129791,DB00295,Morphine
,9428853,bioavailability,Derived pharmacokinetic parameters were similar to those previously reported in children; bioavailability of the fentanyl in Fentanyl Oralet was 0.33.,Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428853/),,0.33,129923,DB00295,Morphine
,9428853,bio-availability,"The bio-availability of the fentanyl in Fentanyl Oralet was estimated to be 33%, which is less than that reported in adults (approximately 50%).",Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428853/),%,33,129924,DB00295,Morphine
,9428853,bio-availability,"The bio-availability of the fentanyl in Fentanyl Oralet was estimated to be 33%, which is less than that reported in adults (approximately 50%).",Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428853/),%,50,129925,DB00295,Morphine
,9520243,Clearance,Clearance and initial volume of distribution were estimated to be 27 ml/min/kg for clearance and 339 ml/kg for initial volume.,Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),[ml] / [kg·min],27,130109,DB00295,Morphine
,9520243,initial volume,Clearance and initial volume of distribution were estimated to be 27 ml/min/kg for clearance and 339 ml/kg for initial volume.,Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),[ml] / [kg],339,130110,DB00295,Morphine
,9520243,peak concentrations,"The peak concentrations of 12,000 ng/ml, 6270 ng/ml and 12,800 ng/ml in the bolus, the stepwise infusion and the two consecutive infusion groups gave corresponding maximal antinociceptive effects of 49%, 181% and 168%.",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),[ng] / [ml],"12,000",130111,DB00295,Morphine
,9520243,peak concentrations,"The peak concentrations of 12,000 ng/ml, 6270 ng/ml and 12,800 ng/ml in the bolus, the stepwise infusion and the two consecutive infusion groups gave corresponding maximal antinociceptive effects of 49%, 181% and 168%.",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),[ng] / [ml],6270,130112,DB00295,Morphine
,9520243,peak concentrations,"The peak concentrations of 12,000 ng/ml, 6270 ng/ml and 12,800 ng/ml in the bolus, the stepwise infusion and the two consecutive infusion groups gave corresponding maximal antinociceptive effects of 49%, 181% and 168%.",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),[ng] / [ml],"12,800",130113,DB00295,Morphine
,9520243,maximal anti,"The peak concentrations of 12,000 ng/ml, 6270 ng/ml and 12,800 ng/ml in the bolus, the stepwise infusion and the two consecutive infusion groups gave corresponding maximal antinociceptive effects of 49%, 181% and 168%.",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),%,49,130114,DB00295,Morphine
,9520243,maximal anti,"The peak concentrations of 12,000 ng/ml, 6270 ng/ml and 12,800 ng/ml in the bolus, the stepwise infusion and the two consecutive infusion groups gave corresponding maximal antinociceptive effects of 49%, 181% and 168%.",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),%,181,130115,DB00295,Morphine
,9520243,maximal anti,"The peak concentrations of 12,000 ng/ml, 6270 ng/ml and 12,800 ng/ml in the bolus, the stepwise infusion and the two consecutive infusion groups gave corresponding maximal antinociceptive effects of 49%, 181% and 168%.",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),%,168,130116,DB00295,Morphine
,9520243,effect delay,"A pharmacokinetic-pharmacodynamic model was applied to the data and the effect delay was estimated to be 1.4 h, which is considerably longer compared to morphine (0.5 h).",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),h,1.4,130117,DB00295,Morphine
,9520243,effect delay,"A pharmacokinetic-pharmacodynamic model was applied to the data and the effect delay was estimated to be 1.4 h, which is considerably longer compared to morphine (0.5 h).",Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520243/),h,0.5,130118,DB00295,Morphine
,7818055,maximum bupivacaine concentration,"There was no clinical evidence of bupivacaine toxicity although the maximum bupivacaine concentration ranged from 0.74-6.52 mg/l, mean 2.90 (SEM 0.44) mg/l and vascular uptake was rapid in two patients.",Pharmacokinetics of bupivacaine enantiomers during interpleural infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818055/),[mg] / [l],2.90,130154,DB00295,Morphine
,21899209,flow rate,"An isocratic mobile phase consisting of acetonitrile-0.1% trifluoroacetic acid (TFA)-water (12:40:48, v/v/v), was run at a flow rate of 1.0 mL/min.",A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899209/),[ml] / [min],1.0,130256,DB00295,Morphine
,21899209,Recoveries,Recoveries were 76.10-83.81% with coefficients of variation of 1.86-6.93%.,A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899209/),%,76.10-83.81,130257,DB00295,Morphine
,11557911,arterial clearances,"The arterial clearances of diacetylmorphine, monoacetylmorphine, and morphine-d3 were 8.7 +/- 2.6, 6.7 +/- 1.6, and 2.3 +/- 0.3 L/min, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),[l] / [min],8.7,130678,DB00295,Morphine
,11557911,arterial clearances,"The arterial clearances of diacetylmorphine, monoacetylmorphine, and morphine-d3 were 8.7 +/- 2.6, 6.7 +/- 1.6, and 2.3 +/- 0.3 L/min, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),[l] / [min],6.7,130679,DB00295,Morphine
,11557911,arterial clearances,"The arterial clearances of diacetylmorphine, monoacetylmorphine, and morphine-d3 were 8.7 +/- 2.6, 6.7 +/- 1.6, and 2.3 +/- 0.3 L/min, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),[l] / [min],2.3,130680,DB00295,Morphine
,11557911,arterial half-lives,"The arterial half-lives of diacetylmorphine and morphine-d3 were 2. 4 +/- 0.8 and 88 +/- 21 minutes, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),min,2. 4,130681,DB00295,Morphine
,11557911,arterial half-lives,"The arterial half-lives of diacetylmorphine and morphine-d3 were 2. 4 +/- 0.8 and 88 +/- 21 minutes, respectively.",Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557911/),min,88,130682,DB00295,Morphine
,1477769,length of survival,The mean length of survival was 75 days.,[Intracerebral morphine therapy in cancer patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1477769/),d,75,130700,DB00295,Morphine
,27558774,MEC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],31.5,130960,DB00295,Morphine
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],74.1,130961,DB00295,Morphine
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],63.4,130962,DB00295,Morphine
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],76.1,130963,DB00295,Morphine
,27558774,MEAC,"In major intra-abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml-1 and 60 ng ml-1 , respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],75,130964,DB00295,Morphine
,27558774,analgesic potency,"In major intra-abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml-1 and 60 ng ml-1 , respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],60,130965,DB00295,Morphine
,14508308,t1/2ke0,M6G PK/PD model parameters for Vi45 were t1/2ke0 2.1 +/- 0.2 h and C25 528 +/- 88 nm and for AHR were t1/2ke0 1.0 +/- 0.1 h and C25 873 +/- 81 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),h,2.1,131161,DB00295,Morphine
,14508308,C25,M6G PK/PD model parameters for Vi45 were t1/2ke0 2.1 +/- 0.2 h and C25 528 +/- 88 nm and for AHR were t1/2ke0 1.0 +/- 0.1 h and C25 873 +/- 81 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),nm,528,131162,DB00295,Morphine
,14508308,t1/2ke0,M6G PK/PD model parameters for Vi45 were t1/2ke0 2.1 +/- 0.2 h and C25 528 +/- 88 nm and for AHR were t1/2ke0 1.0 +/- 0.1 h and C25 873 +/- 81 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),h,1.0,131163,DB00295,Morphine
,14508308,C25,M6G PK/PD model parameters for Vi45 were t1/2ke0 2.1 +/- 0.2 h and C25 528 +/- 88 nm and for AHR were t1/2ke0 1.0 +/- 0.1 h and C25 873 +/- 81 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),nm,873,131164,DB00295,Morphine
,14508308,t1/2ke0,Morphine PK/PD model parameters for Vi45 were t1/2ke0 3.8 +/- 0.9 h and C25 28 +/- 6 nm and for AHR were t1/2ke0 4.3 +/- 0.6 h and C25 16 +/- 2 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),h,3.8,131165,DB00295,Morphine
,14508308,C25,Morphine PK/PD model parameters for Vi45 were t1/2ke0 3.8 +/- 0.9 h and C25 28 +/- 6 nm and for AHR were t1/2ke0 4.3 +/- 0.6 h and C25 16 +/- 2 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),nm,28,131166,DB00295,Morphine
,14508308,t1/2ke0,Morphine PK/PD model parameters for Vi45 were t1/2ke0 3.8 +/- 0.9 h and C25 28 +/- 6 nm and for AHR were t1/2ke0 4.3 +/- 0.6 h and C25 16 +/- 2 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),h,4.3,131167,DB00295,Morphine
,14508308,C25,Morphine PK/PD model parameters for Vi45 were t1/2ke0 3.8 +/- 0.9 h and C25 28 +/- 6 nm and for AHR were t1/2ke0 4.3 +/- 0.6 h and C25 16 +/- 2 nm.,Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508308/),nm,16,131168,DB00295,Morphine
,17016501,time to reach 50%,"The blood-brain equilibration of M6G was relatively slow (time to reach 50% equilibration of the deep compartment 5.8 min), with low membrane permeability (PS, population mean, 2.5 ml min(-1)) from the initial compartment (V1, 13.7 ml) to a small deep distribution volume (V2) of 18.4 ml.",Blood-brain distribution of morphine-6-glucuronide in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016501/),min,5.8,131273,DB00295,Morphine
,17016501,V1,"The blood-brain equilibration of M6G was relatively slow (time to reach 50% equilibration of the deep compartment 5.8 min), with low membrane permeability (PS, population mean, 2.5 ml min(-1)) from the initial compartment (V1, 13.7 ml) to a small deep distribution volume (V2) of 18.4 ml.",Blood-brain distribution of morphine-6-glucuronide in sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016501/),ml,13.7,131274,DB00295,Morphine
,17016501,deep distribution volume (V2),"The blood-brain equilibration of M6G was relatively slow (time to reach 50% equilibration of the deep compartment 5.8 min), with low membrane permeability (PS, population mean, 2.5 ml min(-1)) from the initial compartment (V1, 13.7 ml) to a small deep distribution volume (V2) of 18.4 ml.",Blood-brain distribution of morphine-6-glucuronide in sheep. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016501/),ml,18.4,131275,DB00295,Morphine
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,75.6,131358,DB00295,Morphine
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,37.4,131359,DB00295,Morphine
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,18.2,131360,DB00295,Morphine
,11073290,t 1/2 beta,With a t 1/2 beta of 1.3 - 2.2 min it was rapidly desacetylated to 6-acetylmorphine which was further metabolized to morphine and its 3- and 6-O-glucuronide.,"Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073290/),min,1.3 - 2.2,131375,DB00295,Morphine
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],5.05,131968,DB00295,Morphine
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],5.29,131969,DB00295,Morphine
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],31.51,131970,DB00295,Morphine
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],31.23,131971,DB00295,Morphine
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],50.16,131972,DB00295,Morphine
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],49.01,131973,DB00295,Morphine
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],0.38,131974,DB00295,Morphine
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],0.37,131975,DB00295,Morphine
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],2.37,131976,DB00295,Morphine
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],2.41,131977,DB00295,Morphine
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],5.87,131978,DB00295,Morphine
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],5.63,131979,DB00295,Morphine
,22162639,Ad,"Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),,25,131980,DB00295,Morphine
,22162639,Ad,"Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),,23,131981,DB00295,Morphine
,22162639,Ad,"Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),,9,131982,DB00295,Morphine
,20006596,K(i),SCH 486757 selectively binds human NOP receptor (K(i)=4.6+/-0.61nM) over classical opioid receptors.,Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006596/),nM,4.6,132212,DB00295,Morphine
,22201184,elimination clearance,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),[l] / [h],51.0,132389,DB00295,Morphine
,22201184,volume of the central compartment,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),l,134,132390,DB00295,Morphine
,22201184,volume of distribution at steady state,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),l,258,132391,DB00295,Morphine
,22201184,half-time at steady state,"The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),h,3.8,132392,DB00295,Morphine
,22201184,half-time at steady state,"The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),h,4.6,132393,DB00295,Morphine
,28814158,tmax,"For oxymorphone, median tmax was 24 h, and Cmax/Cmin ratio was approximately 2.4.","A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814158/),h,24,132865,DB00295,Morphine
,28814158,Cmax/Cmin ratio,"For oxymorphone, median tmax was 24 h, and Cmax/Cmin ratio was approximately 2.4.","A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814158/),,2.4,132866,DB00295,Morphine
,20106684,elimination half-life,Oxycodone elimination half-life shortened from a mean+/-SD 3.8+/-0.7 to 3.0+/-0.4h (p<0.001).,St John's wort greatly reduces the concentrations of oral oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20106684/),h,3.8,133621,DB00295,Morphine
,20106684,elimination half-life,Oxycodone elimination half-life shortened from a mean+/-SD 3.8+/-0.7 to 3.0+/-0.4h (p<0.001).,St John's wort greatly reduces the concentrations of oral oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20106684/),h,3.0,133622,DB00295,Morphine
,1357144,initial half-lives,"Diamorphine was rapidly and quantitatively degraded to 6-monoacetylmorphine with initial half-lives of 354, 18 and 3 min at temperatures of 4, 25 and 37 degrees C, respectively.",The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),min,354,133623,DB00295,Morphine
,1357144,initial half-lives,"Diamorphine was rapidly and quantitatively degraded to 6-monoacetylmorphine with initial half-lives of 354, 18 and 3 min at temperatures of 4, 25 and 37 degrees C, respectively.",The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),min,18,133624,DB00295,Morphine
,1357144,initial half-lives,"Diamorphine was rapidly and quantitatively degraded to 6-monoacetylmorphine with initial half-lives of 354, 18 and 3 min at temperatures of 4, 25 and 37 degrees C, respectively.",The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),min,3,133625,DB00295,Morphine
greater,1357144,half-life,At pH 4.0 and 5.6 diamorphine had a half-life of greater than 14 days at all temperatures but at alkaline pH diamorphine was rapidly deacetylated.,The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357144/),d,14,133626,DB00295,Morphine
,15166257,A(50),The calculated A(50) values for the Ser/Thr and monosaccharide combinations were all very similar with values ranging from 0.02 to 0.09 nmol.,Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166257/),nM,0.02 to 0.09,134250,DB00295,Morphine
,15166257,A (50),All compounds tested produced full antinociceptive effects with calculated A (50) values ranging from 2.2 to 46.4 micromol/kg with the disaccharides having potencies that equaled or exceeded that of morphine on a micromoles per kilogram basis.,Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166257/),[μM] / [kg],2.2 to 46.4,134251,DB00295,Morphine
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],18.5,134403,DB00295,Morphine
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],20.8,134404,DB00295,Morphine
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,20,134405,DB00295,Morphine
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,25,134406,DB00295,Morphine
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,14,134407,DB00295,Morphine
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,10.5,134408,DB00295,Morphine
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,5,134409,DB00295,Morphine
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,3,134410,DB00295,Morphine
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],165,134411,DB00295,Morphine
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],411,134412,DB00295,Morphine
,9630828,apparent volume of distribution,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[l] / [kg],1.3,135230,DB00295,Morphine
,9630828,apparent volume of distribution,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[l] / [kg],1.1,135231,DB00295,Morphine
,9630828,halflife,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),h,3.3,135232,DB00295,Morphine
,9630828,halflife,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),h,3.7,135233,DB00295,Morphine
,9630828,total body clearance,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ml] / [min],451,135234,DB00295,Morphine
,9630828,total body clearance,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ml] / [min],343,135235,DB00295,Morphine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,573,135236,DB00295,Morphine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,261,135237,DB00295,Morphine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,37.7,135238,DB00295,Morphine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,14.4,135239,DB00295,Morphine
,9630828,AUECRT/AUC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,6.3,135240,DB00295,Morphine
,9630828,AUECRT/AUC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,1.8,135241,DB00295,Morphine
,9630828,concentration at half-maximal effect,"Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ng] / [ml],20.5,135242,DB00295,Morphine
,9630828,concentration at half-maximal effect,"Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ng] / [ml],29.7,135243,DB00295,Morphine
,22834454,clearance,"The median (range) values for ketobemidone clearance, apparent volume of distribution, volume of central compartment, distribution half-life and elimination half-life were 0.46 (0.23-0.84) l/h/kg, 4.64 (3.50-7.31) l/kg, 1.71 (0.16-3.47) l/kg, 2.85 (1.04-10.78) min and 7.26 (3.5-11.3) h.",Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22834454/),[l] / [h·kg],0.46,135430,DB00295,Morphine
,22834454,elimination half-life,"The median (range) values for ketobemidone clearance, apparent volume of distribution, volume of central compartment, distribution half-life and elimination half-life were 0.46 (0.23-0.84) l/h/kg, 4.64 (3.50-7.31) l/kg, 1.71 (0.16-3.47) l/kg, 2.85 (1.04-10.78) min and 7.26 (3.5-11.3) h.",Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22834454/),h,7.26,135431,DB00295,Morphine
,1391681,half-life,"The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h.",Pharmacokinetics and metabolism of codeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),h,1.47,135547,DB00295,Morphine
,1391681,half-life,"The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h.",Pharmacokinetics and metabolism of codeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),h,2.75,135548,DB00295,Morphine
,1391681,half-life,"The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h.",Pharmacokinetics and metabolism of codeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),h,1.71,135549,DB00295,Morphine
,1391681,systemic clearance,"The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1.",Pharmacokinetics and metabolism of codeine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),[ml] / [min],2280,135550,DB00295,Morphine
,1391681,renal clearance,"The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1.",Pharmacokinetics and metabolism of codeine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),[ml] / [min],93.8,135551,DB00295,Morphine
,1391681,renal clearance,"The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1.",Pharmacokinetics and metabolism of codeine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),[ml] / [min],122,135552,DB00295,Morphine
,1391681,Protein binding,"Protein binding of codeine and codeine-6-glucuronide in vivo was 56.1 +/- 2.5 per cent and 34.0 +/- 3.6 per cent, respectively.",Pharmacokinetics and metabolism of codeine in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,56.1,135553,DB00295,Morphine
,1391681,Protein binding,"Protein binding of codeine and codeine-6-glucuronide in vivo was 56.1 +/- 2.5 per cent and 34.0 +/- 3.6 per cent, respectively.",Pharmacokinetics and metabolism of codeine in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,34.0,135554,DB00295,Morphine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,23.5,135555,DB00295,Morphine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,46.5,135556,DB00295,Morphine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,23.5,135557,DB00295,Morphine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,27.0,135558,DB00295,Morphine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,36.7,135559,DB00295,Morphine
,23879213,Pain levels,Pain levels before treatment averaged 9.5 ± 0.9 out of 10.,A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879213/),,9.5,135573,DB00295,Morphine
,9004950,flow-rate,The flow-rate in the column was 1.0 ml/min.,"Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004950/),[ml] / [min],1.0,135713,DB00295,Morphine
,9004950,m/z,The compounds were detected in the mass spectrometer by selected-ion monitoring for m/z 286.2 for morphine and 462.2 for M3G and M6G.,"Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004950/),,286.2,135714,DB00295,Morphine
,9004950,m/z,The compounds were detected in the mass spectrometer by selected-ion monitoring for m/z 286.2 for morphine and 462.2 for M3G and M6G.,"Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004950/),,462.2,135715,DB00295,Morphine
,9004950,analysis time,"The major advantage with the present LC-MS method was the shorter analysis time, 10 min per sample compared to 45 min per sample with our previous LC method with dual detectors.","Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004950/),[min] / [sample],10,135716,DB00295,Morphine
,9004950,analysis time,"The major advantage with the present LC-MS method was the shorter analysis time, 10 min per sample compared to 45 min per sample with our previous LC method with dual detectors.","Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004950/),[min] / [sample],45,135717,DB00295,Morphine
,19156643,mass-to-charge ratio (m/z),"Following a single liquid-liquid extraction with ethyl acetate, the analytes were separated using an isocratic mobile phase on a C(18 )column and analyzed by MS/MS in the selected reaction monitoring mode using the respective [M+H](+ )ions, mass-to-charge ratio (m/z) 300/165 for codeine, m/z 286/165 for morphine and m/z 380/91 for IS.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),,300/165,135797,DB00295,Morphine
,19156643,m/z,"Following a single liquid-liquid extraction with ethyl acetate, the analytes were separated using an isocratic mobile phase on a C(18 )column and analyzed by MS/MS in the selected reaction monitoring mode using the respective [M+H](+ )ions, mass-to-charge ratio (m/z) 300/165 for codeine, m/z 286/165 for morphine and m/z 380/91 for IS.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),,286,135798,DB00295,Morphine
,19156643,linear dynamic,"The method exhibited a linear dynamic range of 0.2-100/0.5-250 ng/mL for codeine/morphine in human plasma, respectively.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.2-100,135799,DB00295,Morphine
,19156643,LOQs,The lower LOQs were 0.2 and 0.5 ng/mL for codeine and its metabolite morphine using 0.5 mL of human plasma.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.2,135800,DB00295,Morphine
,19156643,LOQs,The lower LOQs were 0.2 and 0.5 ng/mL for codeine and its metabolite morphine using 0.5 mL of human plasma.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.5,135801,DB00295,Morphine
,19156643,run time,A run time of 2.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),min,2.0,135802,DB00295,Morphine
,2246307,clearance,"The clearance was 12 +/- 2 ml/min/kg, the half-life was 123 +/- 24 minutes, and the volume of distribution was 2.2 +/- 0.4 L/kg for the subjects with burns compared with 25 +/- 3 ml/min/kg, 89 +/- 18 minutes, and 3.2 +/- 0.8 L/kg for the control subjects (p less than 0.001, less than 0.02, and less than 0.02, respectively).",Morphine pharmacokinetics during anesthesia and surgery in patients with burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246307/),[ml] / [kg·min],12,136659,DB00295,Morphine
,2246307,half-life,"The clearance was 12 +/- 2 ml/min/kg, the half-life was 123 +/- 24 minutes, and the volume of distribution was 2.2 +/- 0.4 L/kg for the subjects with burns compared with 25 +/- 3 ml/min/kg, 89 +/- 18 minutes, and 3.2 +/- 0.8 L/kg for the control subjects (p less than 0.001, less than 0.02, and less than 0.02, respectively).",Morphine pharmacokinetics during anesthesia and surgery in patients with burns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246307/),min,123,136660,DB00295,Morphine
,2246307,volume of distribution,"The clearance was 12 +/- 2 ml/min/kg, the half-life was 123 +/- 24 minutes, and the volume of distribution was 2.2 +/- 0.4 L/kg for the subjects with burns compared with 25 +/- 3 ml/min/kg, 89 +/- 18 minutes, and 3.2 +/- 0.8 L/kg for the control subjects (p less than 0.001, less than 0.02, and less than 0.02, respectively).",Morphine pharmacokinetics during anesthesia and surgery in patients with burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246307/),[l] / [kg],2.2,136661,DB00295,Morphine
,9671331,plasma elimination half-life,"Unlike intravenous administration, in which peak plasma levels occur within minutes and the plasma elimination half-life is 2 to 3 hours, after initial transdermal fentanyl patch application, peak levels occur within 14 hours and the elimination half-life exceeds 24 hours.",Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9671331/),h,2 to 3,137401,DB00295,Morphine
exceeds,9671331,elimination half-life,"Unlike intravenous administration, in which peak plasma levels occur within minutes and the plasma elimination half-life is 2 to 3 hours, after initial transdermal fentanyl patch application, peak levels occur within 14 hours and the elimination half-life exceeds 24 hours.",Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9671331/),h,24,137402,DB00295,Morphine
,32375158,half-life,"MCAM plasma concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased markedly 1 day after injection.","Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32375158/),min,13.7 to 199.8,138215,DB00295,Morphine
,10700307,terminal half-life,"In this patient group, terminal half-life of unchanged morphine ranged from 0.77 to 3.22 h.",Morphine use and pharmacokinetics in patients with chest pain due to suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10700307/),h,0.77 to 3.22,140031,DB00295,Morphine
,11493236,time to patient comfort,The mean (SD) time to patient comfort was 27.6 (20.2) min for the mixture and 41.2 (18.6) min for morphine (p = 0.01).,A mixture of alfentanil and morphine for rapid postoperative loading with opioid: theoretical basis and initial clinical investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493236/),min,27.6,140705,DB00295,Morphine
,11493236,time to patient comfort,The mean (SD) time to patient comfort was 27.6 (20.2) min for the mixture and 41.2 (18.6) min for morphine (p = 0.01).,A mixture of alfentanil and morphine for rapid postoperative loading with opioid: theoretical basis and initial clinical investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493236/),min,41.2,140706,DB00295,Morphine
,6628531,half-lives,The mean half-lives varied between 3.3 h-4.5 h.,Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628531/),h,3.3,141488,DB00295,Morphine
,6628531,half-lives,The mean half-lives varied between 3.3 h-4.5 h.,Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628531/),h,4.5,141489,DB00295,Morphine
,6628531,bioavailability,"From the AUC, the mean bioavailability of orally administered drug was 21% (range 12-34%).",Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628531/),%,21,141490,DB00295,Morphine
,2039637,plasma half-life,This is consistent with sustained therapeutic plasma levels due to methadone's long plasma half-life (54 +/- 20 hours).,Postoperative pain control with methadone following lower abdominal surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039637/),h,54,141586,DB00295,Morphine
,21277838,clearance,"Morphine clearance was 2.4-3.6 L/h, half-life was .3-.7 hours, AUC(0-∞) was 27.7-42.5 ng∗h/mL, and volume of distribution was .96-3.38 L/kg.",Increased clearance of morphine in sickle cell disease: implications for pain management. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277838/),[l] / [h],2.4-3.6,142309,DB00295,Morphine
,21277838,half-life,"Morphine clearance was 2.4-3.6 L/h, half-life was .3-.7 hours, AUC(0-∞) was 27.7-42.5 ng∗h/mL, and volume of distribution was .96-3.38 L/kg.",Increased clearance of morphine in sickle cell disease: implications for pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277838/),h,.3-.7,142310,DB00295,Morphine
,21277838,AUC(0-∞),"Morphine clearance was 2.4-3.6 L/h, half-life was .3-.7 hours, AUC(0-∞) was 27.7-42.5 ng∗h/mL, and volume of distribution was .96-3.38 L/kg.",Increased clearance of morphine in sickle cell disease: implications for pain management. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277838/),[ng∗h] / [ml],27.7-42.5,142311,DB00295,Morphine
,21277838,volume of distribution,"Morphine clearance was 2.4-3.6 L/h, half-life was .3-.7 hours, AUC(0-∞) was 27.7-42.5 ng∗h/mL, and volume of distribution was .96-3.38 L/kg.",Increased clearance of morphine in sickle cell disease: implications for pain management. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277838/),[l] / [kg],.96-3.38,142312,DB00295,Morphine
,21323677,apparent volume of distribution of the central compartment,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[l] / [kg],1.1,142313,DB00295,Morphine
,21323677,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[l] / [kg],1.1,142314,DB00295,Morphine
,21323677,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[l] / [kg],2.5,142315,DB00295,Morphine
,21323677,clearance,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[l] / [kg],1.1,142316,DB00295,Morphine
,21323677,clearance,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[l] / [kg],2.5,142317,DB00295,Morphine
,21323677,terminal half-life,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[l] / [kg],2.5,142318,DB00295,Morphine
,21323677,terminal half-life,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),[ml] / [kg·min],26,142319,DB00295,Morphine
,21323677,terminal half-life,"The apparent volume of distribution of the central compartment and apparent volume of distribution at steady state [mean ± SEM (range)] and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.1 ± 0.2 (0.4-1.7) L/kg, 2.5 ± 0.4 (2.4-4.4) L/kg, 26 ± 7 (18-38) mL/min.kg, and 96 ± 49 (62-277) min, respectively.",Pharmacokinetics of oxymorphone in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323677/),min,96,142320,DB00295,Morphine
,34196257,Time of maximum concentration,Time of maximum concentration varied from 30 min to approximately 90 min.,Oral absorption of oxycodone in patients with short bowel syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196257/),min,30,142770,DB00295,Morphine
,34196257,Time of maximum concentration,Time of maximum concentration varied from 30 min to approximately 90 min.,Oral absorption of oxycodone in patients with short bowel syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196257/),min,90,142771,DB00295,Morphine
,2627383,elimination half-life,"There were no differences between the two groups for morphine elimination half-life (middle-aged patients, 129 min; elderly patients, 162 min), mean residence time (154 and 207 min), and apparent volume of distribution at steady state (116 and 107 l).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),min,129,142987,DB00295,Morphine
,2627383,elimination half-life,"There were no differences between the two groups for morphine elimination half-life (middle-aged patients, 129 min; elderly patients, 162 min), mean residence time (154 and 207 min), and apparent volume of distribution at steady state (116 and 107 l).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),min,162,142988,DB00295,Morphine
,2627383,mean residence time,"There were no differences between the two groups for morphine elimination half-life (middle-aged patients, 129 min; elderly patients, 162 min), mean residence time (154 and 207 min), and apparent volume of distribution at steady state (116 and 107 l).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),min,154,142989,DB00295,Morphine
,2627383,mean residence time,"There were no differences between the two groups for morphine elimination half-life (middle-aged patients, 129 min; elderly patients, 162 min), mean residence time (154 and 207 min), and apparent volume of distribution at steady state (116 and 107 l).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),min,207,142990,DB00295,Morphine
,2627383,apparent volume of distribution at steady state,"There were no differences between the two groups for morphine elimination half-life (middle-aged patients, 129 min; elderly patients, 162 min), mean residence time (154 and 207 min), and apparent volume of distribution at steady state (116 and 107 l).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),l,116,142991,DB00295,Morphine
,2627383,apparent volume of distribution at steady state,"There were no differences between the two groups for morphine elimination half-life (middle-aged patients, 129 min; elderly patients, 162 min), mean residence time (154 and 207 min), and apparent volume of distribution at steady state (116 and 107 l).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),l,107,142992,DB00295,Morphine
,2627383,clearance,"However, clearance was significantly greater in the younger patients (853 vs. 559 ml/min; p less than 0.02).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),[ml] / [min],853,142993,DB00295,Morphine
,2627383,clearance,"However, clearance was significantly greater in the younger patients (853 vs. 559 ml/min; p less than 0.02).",Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627383/),[ml] / [min],559,142994,DB00295,Morphine
,7173046,bioavailability,"The relative codeine bioavailability in these groups was 54.8 +/- 4.9 percent and 50.2 +/- 2.1 percent (mean +/- SE), respectively.",An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173046/),%,54.8,144079,DB00295,Morphine
,7173046,bioavailability,"The relative codeine bioavailability in these groups was 54.8 +/- 4.9 percent and 50.2 +/- 2.1 percent (mean +/- SE), respectively.",An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173046/),%,50.2,144080,DB00295,Morphine
,32622946,half the maximal effect (EC50),"The PK/PD analysis revealed that the antiemetic effect was related to the plasma naldemedine concentration, with a half maximal effective concentration that produces half the maximal effect (EC50) of 3.51 ng/mL.","Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622946/),[ng] / [ml],3.51,144318,DB00295,Morphine
,15650985,t(1/2),The median t(1/2) of oxycodone varied from 5.1 to 5.9 hours.,Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,5.1 to 5.9,144396,DB00295,Morphine
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,3.8,144397,DB00295,Morphine
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,7.0,144398,DB00295,Morphine
,21472729,K(i),Oxycodone competitively inhibited DPHM uptake with a K(i) value of 106 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,106,145692,DB00295,Morphine
,21472729,K(i),DPHM also competitively inhibited oxycodone uptake with a K(i) value of 34.7 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,34.7,145693,DB00295,Morphine
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.95,145894,DB00295,Morphine
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.75,145895,DB00295,Morphine
,9121810,half-life,"In order to take into account both the short duration of treatment (8 days), and nimodipine's pharmacokinetic characteristics (half-life of 6 h and steady state of 36 h), we compared treatment with nimodipine or placebo on the third day of use, at which time, likewise, there were no statistically significant differences on any of the scales.",Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9121810/),h,6,146211,DB00295,Morphine
,9121810,steady state,"In order to take into account both the short duration of treatment (8 days), and nimodipine's pharmacokinetic characteristics (half-life of 6 h and steady state of 36 h), we compared treatment with nimodipine or placebo on the third day of use, at which time, likewise, there were no statistically significant differences on any of the scales.",Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9121810/),h,36,146212,DB00295,Morphine
,4020627,pK'a,"Estimated buprenorphine pK'a values are 8.24 and 10 for the ammonium and phenol groups, respectively.","Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),,8.24,146721,DB00295,Morphine
,4020627,pK'a,"Estimated buprenorphine pK'a values are 8.24 and 10 for the ammonium and phenol groups, respectively.","Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),,10,146722,DB00295,Morphine
,4020627,intrinsic aqueous solubility,The intrinsic aqueous solubility of neutral buprenorphine is 12.7 +/- 1.2 micrograms/mL at 23 degrees C.,"Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),[μg] / [ml],12.7,146723,DB00295,Morphine
,4020627,red blood cell-plasma water partition coefficients,The red blood cell-plasma water partition coefficients of buprenorphine ranged between 6 and 15.,"Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),,6 and 15,146724,DB00295,Morphine
,4020627,plasma protein binding,Ultracentrifugation and the red blood cell partition methods led to an estimated 95-98% plasma protein binding.,"Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020627/),%,95-98,146725,DB00295,Morphine
,1576319,T1/2 alpha,The pharmacokinetics of ch14.18 best fit a two-compartment model with a T1/2 alpha of 24 +/- 1 hr and a T1/2 beta of 181 +/- 73 hr.,Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576319/),h,24,146726,DB00295,Morphine
,1576319,T1/2 beta,The pharmacokinetics of ch14.18 best fit a two-compartment model with a T1/2 alpha of 24 +/- 1 hr and a T1/2 beta of 181 +/- 73 hr.,Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576319/),h,181,146727,DB00295,Morphine
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,48.59,147172,DB00295,Morphine
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,49.9,147173,DB00295,Morphine
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,7.73,147174,DB00295,Morphine
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,6.6,147175,DB00295,Morphine
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.1,147176,DB00295,Morphine
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.6,147177,DB00295,Morphine
,32409257,HR,"HR and SAP were 59 ± 17 beats minute-1 and 230 ± 27 mmHg, respectively, in treatment H0.05 at 5 minutes after administration.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[beats] / [min],59,148696,DB00295,Morphine
,32409257,SAP,"HR and SAP were 59 ± 17 beats minute-1 and 230 ± 27 mmHg, respectively, in treatment H0.05 at 5 minutes after administration.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),mmhg,230,148697,DB00295,Morphine
,32409257,volume of distribution at steady state,"For hydromorphone, mean ± standard deviation for volume of distribution at steady state, total systemic clearance and area under the curve until the last measured concentration were 1.00 ± 0.29 L kg-1, 106 ± 21 mL minute-1 kg-1 and 8.0 ± 1.5 ng hour mL-1, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[l] / [kg],1.00,148698,DB00295,Morphine
,32409257,total systemic clearance,"For hydromorphone, mean ± standard deviation for volume of distribution at steady state, total systemic clearance and area under the curve until the last measured concentration were 1.00 ± 0.29 L kg-1, 106 ± 21 mL minute-1 kg-1 and 8.0 ± 1.5 ng hour mL-1, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[ml] / [kg·min],106,148699,DB00295,Morphine
,32409257,area under the curve until,"For hydromorphone, mean ± standard deviation for volume of distribution at steady state, total systemic clearance and area under the curve until the last measured concentration were 1.00 ± 0.29 L kg-1, 106 ± 21 mL minute-1 kg-1 and 8.0 ± 1.5 ng hour mL-1, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[h·ng] / [ml],8.0,148700,DB00295,Morphine
,6531079,Clearance,"Clearance, 65 +/- 6 ml.min-1.kg-1, was independent of infusion rate.",Fetal lamb clearance of morphine as determined by high performance liquid chromatography with electrochemical detection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6531079/),[ml] / [kg·min],65,148718,DB00295,Morphine
,8917240,plasma hydromorphone,"The mean plasma hydromorphone concentration was 4.7 ng/ml (range, 1.9 to 8.9 ng/ml), and the mean clearance was 51.7 ml/min per kilogram of body weight (range, 28.6 to 98.2 ml/min per kilogram).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],4.7,148893,DB00295,Morphine
,8917240,concentration,"The mean plasma hydromorphone concentration was 4.7 ng/ml (range, 1.9 to 8.9 ng/ml), and the mean clearance was 51.7 ml/min per kilogram of body weight (range, 28.6 to 98.2 ml/min per kilogram).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],4.7,148894,DB00295,Morphine
,8917240,clearance,"The mean plasma hydromorphone concentration was 4.7 ng/ml (range, 1.9 to 8.9 ng/ml), and the mean clearance was 51.7 ml/min per kilogram of body weight (range, 28.6 to 98.2 ml/min per kilogram).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ml] / [kg·min],51.7,148895,DB00295,Morphine
,8917240,concentrations,"The mean plasma morphine, morphine-6-glucuronide, and morphine-3-glucuronide concentrations were 40.0 ng/ml (range, 15 to 62.5), 168.2 ng/ml (range, 54.4 to 231.9), and 391.0 ng/ml (range, 149.4 to 921.7), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],168.2,148896,DB00295,Morphine
,8917240,concentrations,"The mean plasma morphine, morphine-6-glucuronide, and morphine-3-glucuronide concentrations were 40.0 ng/ml (range, 15 to 62.5), 168.2 ng/ml (range, 54.4 to 231.9), and 391.0 ng/ml (range, 149.4 to 921.7), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],391.0,148897,DB00295,Morphine
,8917240,clearance,"The mean morphine clearance was 34.3 ml/min per kilogram of body weight (range, 19.3 to 58.3).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ml] / [kg·min],34.3,148898,DB00295,Morphine
,8917240,molar ratios,"The mean molar ratios of morphine-6-glucuronide/morphine, morphine-3-glucoronide/morphine, and morphine-3-glucuronide/morphine-6-glucuronide were 2.48 (range, 1.4 to 3.3), 5.82 (range, 3.4 to 9.1), and 2.46 (range, 1.1 to 3.3), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),,2.48,148899,DB00295,Morphine
,8917240,molar ratios,"The mean molar ratios of morphine-6-glucuronide/morphine, morphine-3-glucoronide/morphine, and morphine-3-glucuronide/morphine-6-glucuronide were 2.48 (range, 1.4 to 3.3), 5.82 (range, 3.4 to 9.1), and 2.46 (range, 1.1 to 3.3), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),,5.82,148900,DB00295,Morphine
,8917240,molar ratios,"The mean molar ratios of morphine-6-glucuronide/morphine, morphine-3-glucoronide/morphine, and morphine-3-glucuronide/morphine-6-glucuronide were 2.48 (range, 1.4 to 3.3), 5.82 (range, 3.4 to 9.1), and 2.46 (range, 1.1 to 3.3), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),,2.46,148901,DB00295,Morphine
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.75,149218,DB00295,Morphine
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.6,149219,DB00295,Morphine
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,4.4,149220,DB00295,Morphine
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,3.73,149221,DB00295,Morphine
,3755014,peak concentration,"Significant drug concentrations appeared in plasma after intrathecal heroin (peak concentration 47.8 +/- 9.0 nmol/L, time to peak concentration 10 +/- 2.4 min); after intrathecal morphine plasma drug concentrations were significantly lower (8.1 +/- 1.0 nmol/L; P less than 0.002) and significantly later (216 +/- 39 min; P less than 0.002).",Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),[nM] / [l],47.8,149516,DB00295,Morphine
,3755014,time to peak concentration,"Significant drug concentrations appeared in plasma after intrathecal heroin (peak concentration 47.8 +/- 9.0 nmol/L, time to peak concentration 10 +/- 2.4 min); after intrathecal morphine plasma drug concentrations were significantly lower (8.1 +/- 1.0 nmol/L; P less than 0.002) and significantly later (216 +/- 39 min; P less than 0.002).",Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),min,10,149517,DB00295,Morphine
,3755014,Elimination half-life,Elimination half-life of heroin from spinal fluid (43 +/- 5 min) was significantly shorter than for morphine (73 +/- 5 min; P less than 0.02).,Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),min,43,149518,DB00295,Morphine
,3755014,Elimination half-life,Elimination half-life of heroin from spinal fluid (43 +/- 5 min) was significantly shorter than for morphine (73 +/- 5 min; P less than 0.02).,Intrathecal morphine and heroin in humans: six-hour drug levels in spinal fluid and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755014/),min,73,149519,DB00295,Morphine
,7654478,urinary recovery,2. The median urinary recovery of ethylmorphine and measured metabolites was 77% over 48 h.,Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),%,77,150959,DB00295,Morphine
,7654478,tmax,"The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h.",Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),min,45,150960,DB00295,Morphine
,7654478,terminal elimination t1/2,"The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h.",Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),h,2,150961,DB00295,Morphine
,7654478,urinary recovery,3. Two subjects had significantly lower urinary recovery (0.48 h) of morphine and morphine-glucuronides than the remainder.,Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),h,0.48,150962,DB00295,Morphine
,8851456,maximum plasma oxycodone concentrations,"The mean (+/- SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 +/- 4.7 ng/mL and 15.6 +/- 4.4 ng/mL, respectively.",Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[ng] / [ml],15.1,151088,DB00295,Morphine
,8851456,maximum plasma oxycodone concentrations,"The mean (+/- SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 +/- 4.7 ng/mL and 15.6 +/- 4.4 ng/mL, respectively.",Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[ng] / [ml],15.6,151089,DB00295,Morphine
,8851456,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 +/- 2.2 hours) as for IR oxycodone (1.4 +/- 0.7 hours) (P = 0.005).,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),h,3.2,151090,DB00295,Morphine
,8851456,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 +/- 2.2 hours) as for IR oxycodone (1.4 +/- 0.7 hours) (P = 0.005).,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),h,1.4,151091,DB00295,Morphine
,8851456,area under the plasma concentration-time curve from 0 to 12 hours at steady state,The area under the plasma concentration-time curve from 0 to 12 hours at steady state was 103.6 +/- 40.0 ng.h/mL for CR oxycodone and 99.0 +/- 35.8 ng.h/mL for IR oxycodone.,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[h·ng] / [ml],103.6,151092,DB00295,Morphine
,8851456,area under the plasma concentration-time curve from 0 to 12 hours at steady state,The area under the plasma concentration-time curve from 0 to 12 hours at steady state was 103.6 +/- 40.0 ng.h/mL for CR oxycodone and 99.0 +/- 35.8 ng.h/mL for IR oxycodone.,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[h·ng] / [ml],99.0,151093,DB00295,Morphine
,3802690,bioavailability,Controlled release tablets had 86% the bioavailability of the solution.,Steady-state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802690/),%,86,151204,DB00295,Morphine
,19944650,score at pain flare,Mean score at pain flare was 7.1.,"ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19944650/),,7.1,151241,DB00295,Morphine
,3670877,CSF/plasma concentration gradient,The CSF/plasma concentration gradient of morphine at CSSmin was 132 +/- 31 (mean +/- S.E.M.).,CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3670877/),,132,151774,DB00295,Morphine
,3135138,plasma clearance,Their mean plasma clearance of morphine was 5.2 ml/min/kg and volume of the central compartment was 0.36 L/kg.,Kinetics and dynamics of postoperative intravenous morphine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135138/),[ml] / [kg·min],5.2,154102,DB00295,Morphine
,3135138,volume of the central compartment,Their mean plasma clearance of morphine was 5.2 ml/min/kg and volume of the central compartment was 0.36 L/kg.,Kinetics and dynamics of postoperative intravenous morphine in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135138/),[l] / [kg],0.36,154103,DB00295,Morphine
,3135138,clearance,"In the other patients the clearance ranged from 25.8 to 75.6 ml/min/kg and volume of central compartment from 0.67 to 2.07 L/kg, respectively.",Kinetics and dynamics of postoperative intravenous morphine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135138/),[ml] / [kg·min],25.8 to 75.6,154104,DB00295,Morphine
,3135138,volume of central compartment,"In the other patients the clearance ranged from 25.8 to 75.6 ml/min/kg and volume of central compartment from 0.67 to 2.07 L/kg, respectively.",Kinetics and dynamics of postoperative intravenous morphine in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135138/),[l] / [kg],0.67 to 2.07,154105,DB00295,Morphine
,3135138,analgetic concentration,The mean analgetic concentration of morphine was 26.2 micrograms/L in the youngest group and 3.8 micrograms/L in the other patients.,Kinetics and dynamics of postoperative intravenous morphine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135138/),[μg] / [l],26.2,154106,DB00295,Morphine
,3135138,analgetic concentration,The mean analgetic concentration of morphine was 26.2 micrograms/L in the youngest group and 3.8 micrograms/L in the other patients.,Kinetics and dynamics of postoperative intravenous morphine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135138/),[μg] / [l],3.8,154107,DB00295,Morphine
,25080430,Cmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[ng] / [ml],0.15 to 1.55,154363,DB00295,Morphine
,25080430,Cmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[ng] / [ml],0.73,154364,DB00295,Morphine
,25080430,Tmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),min,12 to 478,154365,DB00295,Morphine
,25080430,Tmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),min,190,154366,DB00295,Morphine
,25080430,clearance,Population pharmacokinetic parameter estimation yielded results similar to previous paediatric studies: clearance 13.7 litre h(-1) 70 kg(-1) and Vd 181 litre 70 kg(-1).,Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[l] / [70·h·kg],13.7,154367,DB00295,Morphine
,25080430,Vd,Population pharmacokinetic parameter estimation yielded results similar to previous paediatric studies: clearance 13.7 litre h(-1) 70 kg(-1) and Vd 181 litre 70 kg(-1).,Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[l] / [70·kg],181,154368,DB00295,Morphine
,18184441,area under the curve,"There were no significant differences between the two age groups for pain intensity at the onset of titration (numerical rating scale, 7.4 +/- 1.7 in young vs. 7.5 +/- 1.7 in elderly patients), area under the curve of numerical rating scale vs. morphine boluses (97.7 +/- 59.6 vs. 98.2 +/- 62), number of boluses required to obtain pain relief (3 +/- 1.3 vs. 3 +/- 1.3), percentage of titration failures (10% vs. 9%) and incidence of excessive sedation (18% vs. 21%).",Age-adapted morphine titration produces equivalent analgesia and adverse effects in younger and older patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184441/),,97.7,155050,DB00295,Morphine
,18184441,area under the curve,"There were no significant differences between the two age groups for pain intensity at the onset of titration (numerical rating scale, 7.4 +/- 1.7 in young vs. 7.5 +/- 1.7 in elderly patients), area under the curve of numerical rating scale vs. morphine boluses (97.7 +/- 59.6 vs. 98.2 +/- 62), number of boluses required to obtain pain relief (3 +/- 1.3 vs. 3 +/- 1.3), percentage of titration failures (10% vs. 9%) and incidence of excessive sedation (18% vs. 21%).",Age-adapted morphine titration produces equivalent analgesia and adverse effects in younger and older patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184441/),,98.2,155051,DB00295,Morphine
,18184441,number,"There were no significant differences between the two age groups for pain intensity at the onset of titration (numerical rating scale, 7.4 +/- 1.7 in young vs. 7.5 +/- 1.7 in elderly patients), area under the curve of numerical rating scale vs. morphine boluses (97.7 +/- 59.6 vs. 98.2 +/- 62), number of boluses required to obtain pain relief (3 +/- 1.3 vs. 3 +/- 1.3), percentage of titration failures (10% vs. 9%) and incidence of excessive sedation (18% vs. 21%).",Age-adapted morphine titration produces equivalent analgesia and adverse effects in younger and older patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184441/),,3,155052,DB00295,Morphine
,18184441,Renal clearance,Renal clearance was significantly reduced in elderly compared with young patients (55 +/- 21 vs. 85 +/- 15 mL min(-1); P < 0.0001).,Age-adapted morphine titration produces equivalent analgesia and adverse effects in younger and older patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184441/),[ml] / [min],55,155053,DB00295,Morphine
,18184441,Renal clearance,Renal clearance was significantly reduced in elderly compared with young patients (55 +/- 21 vs. 85 +/- 15 mL min(-1); P < 0.0001).,Age-adapted morphine titration produces equivalent analgesia and adverse effects in younger and older patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184441/),[ml] / [min],85,155054,DB00295,Morphine
,22123184,terminal plasma elimination half-life,The mean terminal plasma elimination half-life of 6β-naltrexol was 11.1±2.4 hours.,"6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123184/),h,11.1,155698,DB00295,Morphine
,22123184,effective dose (ED(50) ),"6β-Naltrexol potently blocked morphine-induced slowing of gastrointestinal transit, with a median effective dose (ED(50) ) of ~3 mg.","6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123184/),mg,3,155699,DB00295,Morphine
,17319252,ratios,"Ml3G:M6G ratios fell within a narrow range, with a median value of 4.39 (interquartile range, 3.78 to 6.96; range, 2.18 to 14.95).",Morphine analgesia in cancer pain: role of the glucuronides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319252/),,4,156043,DB00295,Morphine
,2719903,Absolute bioavailability,"Absolute bioavailability for morphine was estimated to be 23.9% after oral solution, 22.4% after MST-Continus and 18.7% after the buccal tablet.","The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719903/),%,23.9,156548,DB00295,Morphine
,2719903,Absolute bioavailability,"Absolute bioavailability for morphine was estimated to be 23.9% after oral solution, 22.4% after MST-Continus and 18.7% after the buccal tablet.","The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719903/),%,22.4,156549,DB00295,Morphine
,2719903,Absolute bioavailability,"Absolute bioavailability for morphine was estimated to be 23.9% after oral solution, 22.4% after MST-Continus and 18.7% after the buccal tablet.","The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719903/),%,18.7,156550,DB00295,Morphine
,2719903,ratio of AUCs,"3. There was no difference in the amount of M6G appearing in plasma after intravenous, oral or buccal administration but the mean ratio of AUCs for M6G: morphine in plasma after intravenous morphine was 2 : 1 compared with 11 : 1 after oral and buccal morphine.","The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719903/),,2 : 1,156551,DB00295,Morphine
,2719903,ratio of AUCs,"3. There was no difference in the amount of M6G appearing in plasma after intravenous, oral or buccal administration but the mean ratio of AUCs for M6G: morphine in plasma after intravenous morphine was 2 : 1 compared with 11 : 1 after oral and buccal morphine.","The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719903/),,11 : 1,156552,DB00295,Morphine
,18473019,elimination half-lives,"The estimated elimination half-lives for morphine and oxycodone were (mean +/- SD) 2.7 +/- 3.6 (range 0.8-11.6) and 3.1 +/- 1.3 (range 1.1-4.8) hr, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),h,2.7,156692,DB00295,Morphine
,18473019,elimination half-lives,"The estimated elimination half-lives for morphine and oxycodone were (mean +/- SD) 2.7 +/- 3.6 (range 0.8-11.6) and 3.1 +/- 1.3 (range 1.1-4.8) hr, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),h,3.1,156693,DB00295,Morphine
,18473019,Volume of distribution at steady state,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),l,243,156694,DB00295,Morphine
,18473019,Volume of distribution at steady state,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),l,277,156695,DB00295,Morphine
,18473019,clearance,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),[ml] / [min],1748,156696,DB00295,Morphine
,18473019,clearance,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),[ml] / [min],1206,156697,DB00295,Morphine
,2918477,half-life,"Acute and chronic (i.e., every half-life of 130 min for five half-lives) administration of CMI (10 or 20 mg/kg i.p.) had opposite effects; the former potentiated morphine analgesia and the latter inhibited it.",Pharmacokinetic patterns of repeated administration of antidepressants in animals. Their relevance in a study of the influence of clomipramine on morphine analgesia in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2918477/),min,130,156808,DB00295,Morphine
,7420276,Metabolic clearance,Metabolic clearance of 2916 +/- 321 ml/min are largely extrahepatic and are sixfold greater than hepatic blood flow.,Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),[ml] / [min],2916,157034,DB00295,Morphine
,7420276,terminal half-life,"Nevertheless, the terminal half-life of 60-90 min resembles that of morphine and is maintained by the rate-determining return of distributed heroin from esterase-free tissues.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),min,60-90,157035,DB00295,Morphine
,7420276,renal clearances,Normal renal clearances of 43 +/- 6 ml/min result in 1.6 +/- 0.2% of the dose being renally excreted unchanged.,Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),[ml] / [min],43,157036,DB00295,Morphine
,7420276,overall volume of distribution,"The large overall volume of distribution, 344 +/- 60 liters, is indicative of heroin's wide distribution and lipophilicity, which rapidly equilibrates heroin in the plasma with the cerebrospinal fluid.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),l,344,157037,DB00295,Morphine
,7420276,total clearance,"Its time course is close to that of heroin, although the total clearance (2200 ml/min) and overall volumes of distribution (90-170 liters) were less.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),[ml] / [min],2200,157038,DB00295,Morphine
,7420276,overall volumes of distribution,"Its time course is close to that of heroin, although the total clearance (2200 ml/min) and overall volumes of distribution (90-170 liters) were less.",Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420276/),l,90-170,157039,DB00295,Morphine
,14663457,maximum plasma concentration,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),[ng] / [ml],31.8,157589,DB00295,Morphine
,14663457,maximum plasma concentration,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),[ng] / [ml],16.9,157590,DB00295,Morphine
,14663457,AUC,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),ng,65.1,157591,DB00295,Morphine
,14663457,AUC,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),ng,40.8,157592,DB00295,Morphine
,14663457,AUC,"Differences in oral morphine miosis (AUC, 16.8 +/- 9.3 mm.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),mm,16.8,157593,DB00295,Morphine
better,9234868,recovery,After addition of ethylmorphine as internal standard the plasma samples were extracted using C18 ODS-2 solid-phase columns with a recovery better than 80%.,High-performance liquid chromatographic monitoring of intravenously administered diacetylmorphine and morphine and their metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234868/),%,80,158273,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),ng,0.57,158407,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),ng,0.96,158408,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),ng,1.93,158409,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.15,158410,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.28,158411,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.49,158412,DB00295,Morphine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.79,158413,DB00295,Morphine
,8820417,Peak plasma codeine concentrations,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [ml·plasma],"1,441",158414,DB00295,Morphine
,8820417,Peak plasma codeine concentrations,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [ml·plasma],"2,452",158415,DB00295,Morphine
,8820417,areas under the plasma concentration vs. time curve,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng-hr] / [ml],699,158416,DB00295,Morphine
,8820417,areas under the plasma concentration vs. time curve,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng-hr] / [ml],"1,581",158417,DB00295,Morphine
,18418582,detection limits,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],3,158705,DB00295,Morphine
,18418582,detection limits,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.4,158706,DB00295,Morphine
,18418582,detection limits,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.6,158707,DB00295,Morphine
,18418582,signal-to-noise ratio,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],3,158708,DB00295,Morphine
,18418582,signal-to-noise ratio,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.4,158709,DB00295,Morphine
,18418582,signal-to-noise ratio,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.6,158710,DB00295,Morphine
,12818953,bioavailabilities,"Mean hydromorphone bioavailabilities and percent coefficient of variation of 52.4% (22.7) and 57.5% (18.6) were seen after the 1.0- and 2.0-mg IN doses, respectively.",Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),%,52.4,159413,DB00295,Morphine
,12818953,percent coefficient,"Mean hydromorphone bioavailabilities and percent coefficient of variation of 52.4% (22.7) and 57.5% (18.6) were seen after the 1.0- and 2.0-mg IN doses, respectively.",Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),%,52.4,159414,DB00295,Morphine
,12818953,percent coefficient,"Mean hydromorphone bioavailabilities and percent coefficient of variation of 52.4% (22.7) and 57.5% (18.6) were seen after the 1.0- and 2.0-mg IN doses, respectively.",Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),%,57.5,159415,DB00295,Morphine
,12818953,times to maximum concentration,Median times to maximum concentration were 20 and 25 min for IN doses.,Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),min,20,159416,DB00295,Morphine
,12818953,times to maximum concentration,Median times to maximum concentration were 20 and 25 min for IN doses.,Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),min,25,159417,DB00295,Morphine
,18638294,elimination half-life,"Mean elimination half-life was 80 +/- 52.7 and 57.7 +/- 30.4 min for the high and low dose, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),min,80,159873,DB00295,Morphine
,18638294,elimination half-life,"Mean elimination half-life was 80 +/- 52.7 and 57.7 +/- 30.4 min for the high and low dose, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),min,57.7,159874,DB00295,Morphine
,18638294,apparent mean volumes of distribution at steady-state,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[l] / [kg],7.2,159875,DB00295,Morphine
,18638294,apparent mean volumes of distribution at steady-state,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[l] / [kg],4.5,159876,DB00295,Morphine
,18638294,clearance,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[ml] / [kg·min],74.7,159877,DB00295,Morphine
,18638294,clearance,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[ml] / [kg·min],68.1,159878,DB00295,Morphine
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00295,Morphine
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00295,Morphine
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00295,Morphine
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00295,Morphine
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00295,Morphine
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00295,Morphine
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00295,Morphine
,15031301,BBB,"The in vivo BBB permeation influx rates of 125I-ADAB and 125I-ADAMB after an i.v. bolus injection into mice were determined to be 0.0515 +/- 0.0284 microl/(min.g of brain) and 0.0290 +/- 0.0059 microl/(min.g of brain), respectively, both rates being slower than that of 125I-Tyr-D-Arg-Phe-betaAla-OH (125I-TAPA), a [D-Arg2]dermorphin tetrapeptide analog.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),[μl] / [g·min],0.0515,161317,DB00295,Morphine
,15031301,permeation influx rates,"The in vivo BBB permeation influx rates of 125I-ADAB and 125I-ADAMB after an i.v. bolus injection into mice were determined to be 0.0515 +/- 0.0284 microl/(min.g of brain) and 0.0290 +/- 0.0059 microl/(min.g of brain), respectively, both rates being slower than that of 125I-Tyr-D-Arg-Phe-betaAla-OH (125I-TAPA), a [D-Arg2]dermorphin tetrapeptide analog.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),[μl] / [g·min],0.0515,161318,DB00295,Morphine
,15031301,permeation influx rates,"The in vivo BBB permeation influx rates of 125I-ADAB and 125I-ADAMB after an i.v. bolus injection into mice were determined to be 0.0515 +/- 0.0284 microl/(min.g of brain) and 0.0290 +/- 0.0059 microl/(min.g of brain), respectively, both rates being slower than that of 125I-Tyr-D-Arg-Phe-betaAla-OH (125I-TAPA), a [D-Arg2]dermorphin tetrapeptide analog.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),[μl] / [brain·g·min],0.0290,161319,DB00295,Morphine
,15031301,half-saturation constant (Kd),"The internalization of both 125I-ADAB and 125I-ADAMB into cells was concentration-dependent with half-saturation constant (Kd) values of 3.76 +/- 0.83 and 5.68 +/- 1.75 microM, respectively.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),μM,3.76,161320,DB00295,Morphine
,15031301,half-saturation constant (Kd),"The internalization of both 125I-ADAB and 125I-ADAMB into cells was concentration-dependent with half-saturation constant (Kd) values of 3.76 +/- 0.83 and 5.68 +/- 1.75 microM, respectively.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),μM,5.68,161321,DB00295,Morphine
,9681326,beta e,"In contrast to the morphine conjugates, morphine was highly bound to or partitioned into red blood cells (beta e = 55.9).",A preliminary study on the distribution of morphine and its glucuronides in the subcompartments of blood. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681326/),,55.9,161865,DB00295,Morphine
more,18520605,extraction recoveries,"The extraction recoveries were more than 85%, the intraday and interday coefficients of variation were <15%, and the accuracy was >90% for all analytes at relevant plasma concentrations.","Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520605/),%,85,162078,DB00295,Morphine
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],11.25,162701,DB00295,Morphine
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],9.6,162702,DB00295,Morphine
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],9.53,162703,DB00295,Morphine
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,2.83,162704,DB00295,Morphine
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,1.92,162705,DB00295,Morphine
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,2.49,162706,DB00295,Morphine
,2414066,Peak codeine plasma concentrations,Peak codeine plasma concentrations after the standard formulation were 42.1 +/- 9.4 ng/ml at 0.75 hours compared with 36.9 +/- 3.4 ng/ml at 1.5 hours after the combination without docusate.,"The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[ng] / [ml],42.1,162707,DB00295,Morphine
,2414066,Peak codeine plasma concentrations,Peak codeine plasma concentrations after the standard formulation were 42.1 +/- 9.4 ng/ml at 0.75 hours compared with 36.9 +/- 3.4 ng/ml at 1.5 hours after the combination without docusate.,"The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[ng] / [ml],36.9,162708,DB00295,Morphine
,1815073,systemic clearance,"In addition, a statistically significant (p less than 0.05) decrease in the systemic clearance of morphine was observed in the BC-RL rats compared with the BC animals (55.2 +/- 17.2 versus 31.4 +/- 8.5 mL/min/kg).",Enterohepatic recirculation and renal metabolism of morphine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815073/),[ml] / [kg·min],55.2,162820,DB00295,Morphine
,1815073,systemic clearance,"In addition, a statistically significant (p less than 0.05) decrease in the systemic clearance of morphine was observed in the BC-RL rats compared with the BC animals (55.2 +/- 17.2 versus 31.4 +/- 8.5 mL/min/kg).",Enterohepatic recirculation and renal metabolism of morphine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815073/),[ml] / [kg·min],31.4,162821,DB00295,Morphine
,1815073,formation clearance,This decrement in systemic clearance appeared to be the result of a significant decrease in the formation clearance of morphine glucuronide after ligation of the renal pedicles (23.2 +/- 4.8 versus 10.9 +/- 5.0 mL/min/kg).,Enterohepatic recirculation and renal metabolism of morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815073/),[ml] / [kg·min],23.2,162822,DB00295,Morphine
,1815073,formation clearance,This decrement in systemic clearance appeared to be the result of a significant decrease in the formation clearance of morphine glucuronide after ligation of the renal pedicles (23.2 +/- 4.8 versus 10.9 +/- 5.0 mL/min/kg).,Enterohepatic recirculation and renal metabolism of morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815073/),[ml] / [kg·min],10.9,162823,DB00295,Morphine
,1815073,Renal metabolic clearance,"Renal metabolic clearance was calculated as 15.7 mL/min/kg, accounting for 28.5% of the systemic clearance of morphine.",Enterohepatic recirculation and renal metabolism of morphine in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815073/),[ml] / [kg·min],15.7,162824,DB00295,Morphine
,1815073,Hepatic clearance,Hepatic clearance (31.4 +/- 8.5 mL/min/kg) accounted for 56.8% of total systemic clearance.,Enterohepatic recirculation and renal metabolism of morphine in the rat. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815073/),[ml] / [kg·min],31.4,162825,DB00295,Morphine
,7791108,ED50,The ED50 for morphine analgesia in 10-day-old pups was 0.35 mg/kg and increased with age to 5.3 mg/kg on day 27.,Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),[mg] / [kg],0.35,163091,DB00295,Morphine
,7791108,ED50,The ED50 for morphine analgesia in 10-day-old pups was 0.35 mg/kg and increased with age to 5.3 mg/kg on day 27.,Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),,5,163092,DB00295,Morphine
,7791108,ED50,"Similarly, sufentanil was more potent in pups than in weanlings, the ED50 increasing from 1.7 to 7.6 micrograms/kg.",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),[μg] / [kg],1.7,163093,DB00295,Morphine
,7791108,ED50,"Similarly, sufentanil was more potent in pups than in weanlings, the ED50 increasing from 1.7 to 7.6 micrograms/kg.",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),[μg] / [kg],7.6,163094,DB00295,Morphine
,7791108,T1/2,"Serum and brain morphine levels after 5 mg/kg of morphine were higher in neonates (day 10) than weanlings (day 27), largely due to a more rapid redistribution phase in weanlings (T1/2 = 26 min.) than in pups (T1/2 = 2.5 hr).",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),min,26,163095,DB00295,Morphine
,7791108,T1/2,"Serum and brain morphine levels after 5 mg/kg of morphine were higher in neonates (day 10) than weanlings (day 27), largely due to a more rapid redistribution phase in weanlings (T1/2 = 26 min.) than in pups (T1/2 = 2.5 hr).",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),h,2.5,163096,DB00295,Morphine
,23473380,minimal alveolar concentration,"During surgery, mean minimal alveolar concentration of isoflurane was 1.69 ± 0.11%, and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),%,1.69,163499,DB00295,Morphine
,23473380,elimination half-life (t½λz ),"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,10.95,163500,DB00295,Morphine
,23473380,ClB,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [h·kg],92.66,163501,DB00295,Morphine
,23473380,Vdss,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1030.09,163502,DB00295,Morphine
,23473380,Vz,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1512.25,163503,DB00295,Morphine
,23473380,AUC(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[h·μg] / [ml],6.08,163504,DB00295,Morphine
,23473380,MRT(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,5.59,163505,DB00295,Morphine
>,33427316,bioavailability,"The bioavailability of M6S was >93% and about 5% after i.p. and oral dosing, respectively.",A pharmacokinetic study of morphine-6-O-sulfate in rat plasma and brain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33427316/),%,93,163556,DB00295,Morphine
,33427316,bioavailability,"The bioavailability of M6S was >93% and about 5% after i.p. and oral dosing, respectively.",A pharmacokinetic study of morphine-6-O-sulfate in rat plasma and brain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33427316/),%,5,163557,DB00295,Morphine
,12459664,infusion rate,A propofol infusion rate of 4 mg.,"Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459664/),mg,4,163755,DB00295,Morphine
,11207479,half-life,"The half-life of morphine in uninjured and injured brain tissue of 178 min and 169 min, respectively, were comparable but were longer than in blood (64 min) and adipose tissue (63 min).",Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207479/),min,178,163847,DB00295,Morphine
,11207479,half-life,"The half-life of morphine in uninjured and injured brain tissue of 178 min and 169 min, respectively, were comparable but were longer than in blood (64 min) and adipose tissue (63 min).",Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207479/),min,169,163848,DB00295,Morphine
,11207479,half-life,"The half-life of morphine in uninjured and injured brain tissue of 178 min and 169 min, respectively, were comparable but were longer than in blood (64 min) and adipose tissue (63 min).",Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207479/),min,64,163849,DB00295,Morphine
,11207479,half-life,"The half-life of morphine in uninjured and injured brain tissue of 178 min and 169 min, respectively, were comparable but were longer than in blood (64 min) and adipose tissue (63 min).",Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207479/),min,63,163850,DB00295,Morphine
,14740785,absolute bioavailability,"Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51.9% (28.2) and 46.9% (30.3) in patients with allergic rhinitis with and without treatment with fluticasone propionate, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,51.9,163996,DB00295,Morphine
,14740785,absolute bioavailability,"Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51.9% (28.2) and 46.9% (30.3) in patients with allergic rhinitis with and without treatment with fluticasone propionate, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,46.9,163997,DB00295,Morphine
,14740785,maximum concentration (Cmax),"Mean maximum concentration (Cmax) values were 3.02 and 3.56 ng/ml, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),[ng] / [ml],3.02,163998,DB00295,Morphine
,14740785,maximum concentration (Cmax),"Mean maximum concentration (Cmax) values were 3.02 and 3.56 ng/ml, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),[ng] / [ml],3.56,163999,DB00295,Morphine
,14740785,Bioavailability,Bioavailability values for both intranasal treatments were lower than those in healthy volunteers (57%).,Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,57,164000,DB00295,Morphine
,14740785,time to Cmax (Tmax),"Median time to Cmax (Tmax) values were significantly different (p=0.02) for treatments B and C (15 and 30 min, respectively) using rank-transformed Tmax for ANOVA.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),min,15,164001,DB00295,Morphine
,14740785,time to Cmax (Tmax),"Median time to Cmax (Tmax) values were significantly different (p=0.02) for treatments B and C (15 and 30 min, respectively) using rank-transformed Tmax for ANOVA.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),min,30,164002,DB00295,Morphine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,3.8,164029,DB00295,Morphine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,6,164030,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],17.6,164365,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],21.9,164366,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],25.9,164367,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],31.6,164368,DB00295,Morphine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],210.7,164369,DB00295,Morphine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],271.6,164370,DB00295,Morphine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],299.5,164371,DB00295,Morphine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],493.5,164372,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],7.6,164373,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],7.8,164374,DB00295,Morphine
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],13.1,164375,DB00295,Morphine
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],105.7,164376,DB00295,Morphine
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],134.7,164377,DB00295,Morphine
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],218.0,164378,DB00295,Morphine
,8247914,half-life,The mean +/- standard deviation for the half-life of morphine was 2.8 +/- 1.4 hours.,The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),h,2.8,164592,DB00295,Morphine
,8247914,apparent half-lives,"The apparent half-lives of M6G and M3G were 5.7 +/- 3.1 and 6.3 +/- 2.2 hours, respectively, and were inversely related to the estimated creatinine clearance (r = -0.61, p < 0.007 and r = -0.69, p < 0.002, respectively).",The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),h,5.7,164593,DB00295,Morphine
,8247914,apparent half-lives,"The apparent half-lives of M6G and M3G were 5.7 +/- 3.1 and 6.3 +/- 2.2 hours, respectively, and were inversely related to the estimated creatinine clearance (r = -0.61, p < 0.007 and r = -0.69, p < 0.002, respectively).",The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),h,6.3,164594,DB00295,Morphine
,8247914,collection time,"The mean concentrations of morphine, M6G, and M3G in the CSF (collection time 1.5 +/- 0.32 hrs, n = 19) were 3.1 +/- 3.7, 12.5 +/- 17.6, and 19.6 +/- 16.1 nmol/L, respectively.",The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),h,1.5,164595,DB00295,Morphine
,8247914,collection time,"The mean concentrations of morphine, M6G, and M3G in the CSF (collection time 1.5 +/- 0.32 hrs, n = 19) were 3.1 +/- 3.7, 12.5 +/- 17.6, and 19.6 +/- 16.1 nmol/L, respectively.",The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),[nM] / [l],3,164596,DB00295,Morphine
,8247914,collection time,"The mean concentrations of morphine, M6G, and M3G in the CSF (collection time 1.5 +/- 0.32 hrs, n = 19) were 3.1 +/- 3.7, 12.5 +/- 17.6, and 19.6 +/- 16.1 nmol/L, respectively.",The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),[nM] / [l],12.5,164597,DB00295,Morphine
,8247914,collection time,"The mean concentrations of morphine, M6G, and M3G in the CSF (collection time 1.5 +/- 0.32 hrs, n = 19) were 3.1 +/- 3.7, 12.5 +/- 17.6, and 19.6 +/- 16.1 nmol/L, respectively.",The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247914/),[nM] / [l],19.6,164598,DB00295,Morphine
,15120772,bioavailability,"The calculated morphine and M6G bioavailability in this patient were 20% and 21%, respectively.",The bioavailability of morphine applied topically to cutaneous ulcers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120772/),%,20,164860,DB00295,Morphine
,15120772,bioavailability,"The calculated morphine and M6G bioavailability in this patient were 20% and 21%, respectively.",The bioavailability of morphine applied topically to cutaneous ulcers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120772/),%,21,164861,DB00295,Morphine
,2470073,steady-state plasma concentration,The transdermal permeation of hydromorphone was also evaluated for 24 hr and a steady-state plasma concentration (0.135 micrograms/ml) was achieved during the 6- to 24-hr periods following the application of a transdermal patch on the inner pinna of the rabbit's ear.,Pharmacokinetics and bioavailability of hydromorphone: effect of various routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2470073/),[μg] / [ml],0.135,165306,DB00295,Morphine
,26689716,flow rate,"The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) with the mobile phase of acetonitrile and 1% formic acid in water with gradient elution at a flow rate of 0.4 mL/min.",UPLC-MS-MS Determination of Dihydrocodeine in Human Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26689716/),[ml] / [min],0.4,165624,DB00295,Morphine
,26689716,overall run time,The overall run time was 4.0 min.,UPLC-MS-MS Determination of Dihydrocodeine in Human Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26689716/),min,4.0,165625,DB00295,Morphine
,22780566,rate,"Morphine rate reached 90% of its mean final rate of 22.5 (CV 167%) μg · kg(-1) per h, observed in teenagers, at approximately 5 years of age.",The relationship between age and morphine infusion rate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22780566/),[μg] / [h·kg],22.5,165786,DB00295,Morphine
,22780566,final rate,"Morphine rate reached 90% of its mean final rate of 22.5 (CV 167%) μg · kg(-1) per h, observed in teenagers, at approximately 5 years of age.",The relationship between age and morphine infusion rate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22780566/),[μg] / [h·kg],22.5,165787,DB00295,Morphine
,22780566,maturation half-life,"There was considerable uncertainty of this age-morphine rate profile, and the maturation half-life of this profile was 20 months of age (CV 632%).",The relationship between age and morphine infusion rate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22780566/),month,20,165788,DB00295,Morphine
,22780566,initial infusion rates,"We suggest that initial infusion rates in children are started at 10 μg · kg(-1) per h in neonates, 15 μg · kg(-1) per h in toddlers and 25 μg · kg(-1) per h in children above the age of 5 years.",The relationship between age and morphine infusion rate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22780566/),[μg] / [h·kg],10,165789,DB00295,Morphine
,22780566,initial infusion rates,"We suggest that initial infusion rates in children are started at 10 μg · kg(-1) per h in neonates, 15 μg · kg(-1) per h in toddlers and 25 μg · kg(-1) per h in children above the age of 5 years.",The relationship between age and morphine infusion rate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22780566/),[μg] / [h·kg],15,165790,DB00295,Morphine
,22780566,initial infusion rates,"We suggest that initial infusion rates in children are started at 10 μg · kg(-1) per h in neonates, 15 μg · kg(-1) per h in toddlers and 25 μg · kg(-1) per h in children above the age of 5 years.",The relationship between age and morphine infusion rate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22780566/),[μg] / [h·kg],25,165791,DB00295,Morphine
,4024663,t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,0.6,166114,DB00295,Morphine
,4024663,t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,2.3,166115,DB00295,Morphine
,4024663,t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,7.2,166116,DB00295,Morphine
,4024663,plasma t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,0.5,166117,DB00295,Morphine
,4024663,plasma t1/2,"After the i.v. injection, the tri-exponential decay of drug from brain occurred with t1/2 values of 0.6, 2.3 and 7.2 h, respectively (plasma t1/2 0.5, 1.4 h, third phase not estimated due to sustained concn.)",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,1.4,166118,DB00295,Morphine
,4024663,t1/2,"Decay of drug from another high-affinity binding site in brain occurred with t1/2 values of 1.1 and 68.7 h, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,1.1,166119,DB00295,Morphine
,4024663,t1/2,"Decay of drug from another high-affinity binding site in brain occurred with t1/2 values of 1.1 and 68.7 h, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),h,68.7,166120,DB00295,Morphine
,4024663,apparent dissociation half-lives,"Peak plasma concn. of buprenorphine occurred four weeks after s.c. implantation of a long-acting 10 mg 3H-buprenorphine pellet, and apparent dissociation half-lives of drug from low- and high-affinity binding sites in brain were 4.6 and 6.8 weeks, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),weeks,4.6,166121,DB00295,Morphine
,4024663,apparent dissociation half-lives,"Peak plasma concn. of buprenorphine occurred four weeks after s.c. implantation of a long-acting 10 mg 3H-buprenorphine pellet, and apparent dissociation half-lives of drug from low- and high-affinity binding sites in brain were 4.6 and 6.8 weeks, respectively.",Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024663/),weeks,6.8,166122,DB00295,Morphine
,12701853,time required to achieve good pain control,The median time required to achieve good pain control was three days (range 1-11 days).,An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12701853/),d,three,166520,DB00295,Morphine
,1867958,Cmax,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[nM] / [l],445,166872,DB00295,Morphine
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[h·nM] / [l],1660,166873,DB00295,Morphine
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[nM] / [l],292,166874,DB00295,Morphine
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[h·nM] / [l],1010,166875,DB00295,Morphine
,1867958,Partial clearance,3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians.,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,0.79,166876,DB00295,Morphine
,1867958,Partial clearance,3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians.,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,1.42,166877,DB00295,Morphine
,1867958,total urinary recovery,4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,82.2,166878,DB00295,Morphine
,1867958,total urinary recovery,4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,84.4,166879,DB00295,Morphine
,1867958,recovery,The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,5.7,166880,DB00295,Morphine
,1867958,recovery,The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,3.3,166881,DB00295,Morphine
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,1:9,166882,DB00295,Morphine
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,35:1,166883,DB00295,Morphine
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,4:1,166884,DB00295,Morphine
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,85,167046,DB00295,Morphine
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,155,167047,DB00295,Morphine
,11752106,transit time,"After 0.1 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 110 +/- 41.0 min.",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,110,167048,DB00295,Morphine
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,98,167049,DB00295,Morphine
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,140,167050,DB00295,Morphine
,11752106,transit time,"After 0.3 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 108 +/- 59.6 min (P < 0.05 compared with placebo plus morphine).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,108,167051,DB00295,Morphine
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00295,Morphine
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00295,Morphine
,10997932,V(max),The formation of codeine-6-glucuronide exhibited single enzyme Michaelis-Menten kinetics with an average V(max) of 93.6 +/- 35.3 pmol/mg/min.,In vitro interaction of codeine and diclofenac. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997932/),[pM] / [mg·min],93.6,167800,DB00295,Morphine
,10997932,K(i),A noncompetitive inhibition of codeine-6-glucuronidation by diclofenac was observed with an average K(i) of 7.9 microM.,In vitro interaction of codeine and diclofenac. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997932/),μM,7.9,167801,DB00295,Morphine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,936.9,168270,DB00295,Morphine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,368.0,168271,DB00295,Morphine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,103.4,168272,DB00295,Morphine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,31.3,168273,DB00295,Morphine
,15197439,plasma concentrations,"Using a dose of 3-5 microg/kg every 8 h, plasma concentrations appeared to plateau at approximately 41 h giving a mean value of 1.38 ng/ml (95% confidence interval 1.0-1.8).",Use of oral clonidine for sedation in ventilated paediatric intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197439/),,1,168584,DB00295,Morphine
>,11408525,K(i)delta/K(i)mu),"H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the mu-opioid receptor (K(i)delta/K(i)mu) > 10,000) compared with H-Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO).",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),,"10,000",169074,DB00295,Morphine
,11408525,apparent volume of distribution,"When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),[ml] / [kg],50 to 80,169075,DB00295,Morphine
,11408525,Plasma clearance,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),[ml] / [h·kg],223,169076,DB00295,Morphine
,11408525,Plasma clearance,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),[ml] / [h·kg],24,169077,DB00295,Morphine
,11408525,elimination half-lives,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),h,0.24,169078,DB00295,Morphine
,11408525,elimination half-lives,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),h,1.5,169079,DB00295,Morphine
,11408525,elimination half-lives,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),h,1.8,169080,DB00295,Morphine
,18282253,serum half-life,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),h,0.57,169946,DB00295,Morphine
,18282253,clearance,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[ml] / [kg·minute],106.28,169947,DB00295,Morphine
,18282253,clearance,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[ml] / [kg·minute],60.30,169948,DB00295,Morphine
,18282253,volume of distribution,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[l] / [kg],5.35,169949,DB00295,Morphine
,18282253,volume of distribution,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[l] / [kg],5.23,169950,DB00295,Morphine
,18282253,serum half-life,"The serum half-life after SC hydromorphone at 0.1 mg kg(-1) and 0.5 mg kg(-1) was 0.66 hours and 1.11 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),h,0.66,169951,DB00295,Morphine
,18282253,serum half-life,"The serum half-life after SC hydromorphone at 0.1 mg kg(-1) and 0.5 mg kg(-1) was 0.66 hours and 1.11 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),h,1.11,169952,DB00295,Morphine
,7094501,Vd(area),Mean +/- SD for peroperative Vd(area) was 6.3 +/- 3.6 L/kg and for the terminal half-life was 3.8 +/- 2.3 h.,"Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),[l] / [kg],6.3,170019,DB00295,Morphine
,7094501,terminal half-life,Mean +/- SD for peroperative Vd(area) was 6.3 +/- 3.6 L/kg and for the terminal half-life was 3.8 +/- 2.3 h.,"Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),h,3.8,170020,DB00295,Morphine
,7094501,Vd(area),"In the postoperative period, Vd(area) decreased to 3.7 +/- 1.4L/kg and the terminal half-life to 2.2 +/- 1.1 h.","Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),[l] / [kg],3.7,170021,DB00295,Morphine
,7094501,terminal half-life,"In the postoperative period, Vd(area) decreased to 3.7 +/- 1.4L/kg and the terminal half-life to 2.2 +/- 1.1 h.","Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),h,2.2,170022,DB00295,Morphine
,7094501,Clp,"Plasma clearance (Clp) remained constant, peroperative Clp being 20 +/- 7.0 ml/min/kg and postoperative Clp 21 +/- 6.0 ml/min/kg.","Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),[ml] / [kg·min],20,170023,DB00295,Morphine
,7094501,Clp,"Plasma clearance (Clp) remained constant, peroperative Clp being 20 +/- 7.0 ml/min/kg and postoperative Clp 21 +/- 6.0 ml/min/kg.","Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),[ml] / [kg·min],21,170024,DB00295,Morphine
,7094501,plasma concentration,"The mean morphine consumption was 2.6 +/- 1.2 mg/h, which produced a mean plasma concentration of 21 +/- 12 ng/ml with a calculated mean minimum effective concentration (MEC) of 16 +/- 9 ng/ml.","Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),[ng] / [ml],21,170025,DB00295,Morphine
,7094501,minimum effective concentration (MEC),"The mean morphine consumption was 2.6 +/- 1.2 mg/h, which produced a mean plasma concentration of 21 +/- 12 ng/ml with a calculated mean minimum effective concentration (MEC) of 16 +/- 9 ng/ml.","Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094501/),[ng] / [ml],16,170026,DB00295,Morphine
,16819548,AUC,Significant differences between the EM and UM groups were detected in areas under the plasma concentration versus time curves (AUCs) of morphine with a median (range) AUC of 11 (5-17) microg h l(-1) in EMs and 16 (10-24) microg h l(-1) in UM (P=0.02).,Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),[h·μg] / [l],11,170087,DB00295,Morphine
,16819548,AUC,Significant differences between the EM and UM groups were detected in areas under the plasma concentration versus time curves (AUCs) of morphine with a median (range) AUC of 11 (5-17) microg h l(-1) in EMs and 16 (10-24) microg h l(-1) in UM (P=0.02).,Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),[h·μg] / [l],16,170088,DB00295,Morphine
,16819548,metabolic ratios,"In urine collected over 12 h, the metabolic ratios of the codeine+codeine-6-glucuronide divided by the sum of morphine+its glucuronides metabolites were 11 (6-17) in EMs and 9 (6-16) in UM (P=0.05).",Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),,11,170089,DB00295,Morphine
,16819548,metabolic ratios,"In urine collected over 12 h, the metabolic ratios of the codeine+codeine-6-glucuronide divided by the sum of morphine+its glucuronides metabolites were 11 (6-17) in EMs and 9 (6-16) in UM (P=0.05).",Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),,9,170090,DB00295,Morphine
,8442811,steady-rate serum morphine concentration,The mean (+/- SD) duration of morphine infusion was 34 +/- 15 hours and a steady-rate serum morphine concentration was 39 +/- 23 ng/ml.,Continuous intravenous morphine infusion in postoperative newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442811/),[ng] / [ml],39,170240,DB00295,Morphine
,8442811,half-life,"The respective serum morphine half-life, elimination rate, and volume of distribution were 6.6 +/- 2.9 hr, 0.126 +/- 0.056 hr-1, and 5.0 +/- 6.8 liters/kg.",Continuous intravenous morphine infusion in postoperative newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442811/),h,6.6,170241,DB00295,Morphine
,8442811,elimination rate,"The respective serum morphine half-life, elimination rate, and volume of distribution were 6.6 +/- 2.9 hr, 0.126 +/- 0.056 hr-1, and 5.0 +/- 6.8 liters/kg.",Continuous intravenous morphine infusion in postoperative newborn infants. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442811/),1/[h],0.126,170242,DB00295,Morphine
,8442811,volume of distribution,"The respective serum morphine half-life, elimination rate, and volume of distribution were 6.6 +/- 2.9 hr, 0.126 +/- 0.056 hr-1, and 5.0 +/- 6.8 liters/kg.",Continuous intravenous morphine infusion in postoperative newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442811/),[l] / [kg],5.0,170243,DB00295,Morphine
,8442811,percentage of unchanged,The mean percentage of unchanged morphine recovered in the urine was 39 +/- 19 of the dose administered over 12 hours.,Continuous intravenous morphine infusion in postoperative newborn infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442811/),,39,170244,DB00295,Morphine
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.76,170597,DB00295,Morphine
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.48,170598,DB00295,Morphine
,14576555,maximum concentration,"The plasma concentration of fentanyl also increased steadily, reaching a maximum concentration of 0.37 +/- 0.11 ng/ml by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[ng] / [ml],0.37,170599,DB00295,Morphine
,24252055,clearance,"The typical population estimates (between-subject variability) for clearance, volume of distribution, intercompartmental clearance and peripheral volume were, respectively, 17.3 l h(-1) (53.2%), 114 l (121%), 80.7 l h(-1) (79%) and 208 l (63.6%).","Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252055/),[l] / [h],17.3,170643,DB00295,Morphine
,24252055,volume of distribution,"The typical population estimates (between-subject variability) for clearance, volume of distribution, intercompartmental clearance and peripheral volume were, respectively, 17.3 l h(-1) (53.2%), 114 l (121%), 80.7 l h(-1) (79%) and 208 l (63.6%).","Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252055/),[l] / [h],80.7,170644,DB00295,Morphine
,24252055,intercompartmental clearance,"The typical population estimates (between-subject variability) for clearance, volume of distribution, intercompartmental clearance and peripheral volume were, respectively, 17.3 l h(-1) (53.2%), 114 l (121%), 80.7 l h(-1) (79%) and 208 l (63.6%).","Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252055/),[l] / [h],80.7,170645,DB00295,Morphine
,24252055,peripheral volume,"The typical population estimates (between-subject variability) for clearance, volume of distribution, intercompartmental clearance and peripheral volume were, respectively, 17.3 l h(-1) (53.2%), 114 l (121%), 80.7 l h(-1) (79%) and 208 l (63.6%).","Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252055/),l,208,170646,DB00295,Morphine
>,24252055,infusion time,"In order to maintain morphine sparing and decrease side-effects following a single dose of nefopam (20 mg), simulations suggest an infusion time of >45 min in elderly patients with or without renal impairment.","Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252055/),min,45,170647,DB00295,Morphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],6.8,171104,DB00295,Morphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.56,171105,DB00295,Morphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.30,171106,DB00295,Morphine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],18.99,171107,DB00295,Morphine
,2097341,elimination half-life,The elimination half-life of morphine was shorter (43 +/- 19 versus 84 +/- 40 min) and the plasma clearance larger (3.4 +/- 1.4 versus 2.0 +/- 0.5 l/min) in the parturients than in the non-pregnant women.,Maternal kinetics of morphine during labour. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),min,43,171553,DB00295,Morphine
,2097341,elimination half-life,The elimination half-life of morphine was shorter (43 +/- 19 versus 84 +/- 40 min) and the plasma clearance larger (3.4 +/- 1.4 versus 2.0 +/- 0.5 l/min) in the parturients than in the non-pregnant women.,Maternal kinetics of morphine during labour. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),min,84,171554,DB00295,Morphine
,2097341,plasma clearance,The elimination half-life of morphine was shorter (43 +/- 19 versus 84 +/- 40 min) and the plasma clearance larger (3.4 +/- 1.4 versus 2.0 +/- 0.5 l/min) in the parturients than in the non-pregnant women.,Maternal kinetics of morphine during labour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),[l] / [min],3.4,171555,DB00295,Morphine
,2097341,plasma clearance,The elimination half-life of morphine was shorter (43 +/- 19 versus 84 +/- 40 min) and the plasma clearance larger (3.4 +/- 1.4 versus 2.0 +/- 0.5 l/min) in the parturients than in the non-pregnant women.,Maternal kinetics of morphine during labour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),[l] / [min],2.0,171556,DB00295,Morphine
,2097341,time to peak plasma concentration,The time to peak plasma concentration of M3G was shorter (11 +/- 3 versus 21 +/- 6 min) and the M3G/morphine concentration ratio at 10 minutes higher (6.4 +/- 1.0 versus 3.4 +/- 0.6) in parturients than in non-pregnant women.,Maternal kinetics of morphine during labour. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),min,11,171557,DB00295,Morphine
,2097341,time to peak plasma concentration,The time to peak plasma concentration of M3G was shorter (11 +/- 3 versus 21 +/- 6 min) and the M3G/morphine concentration ratio at 10 minutes higher (6.4 +/- 1.0 versus 3.4 +/- 0.6) in parturients than in non-pregnant women.,Maternal kinetics of morphine during labour. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),min,21,171558,DB00295,Morphine
,2097341,concentration ratio at,The time to peak plasma concentration of M3G was shorter (11 +/- 3 versus 21 +/- 6 min) and the M3G/morphine concentration ratio at 10 minutes higher (6.4 +/- 1.0 versus 3.4 +/- 0.6) in parturients than in non-pregnant women.,Maternal kinetics of morphine during labour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),,6.4,171559,DB00295,Morphine
,2097341,concentration ratio at,The time to peak plasma concentration of M3G was shorter (11 +/- 3 versus 21 +/- 6 min) and the M3G/morphine concentration ratio at 10 minutes higher (6.4 +/- 1.0 versus 3.4 +/- 0.6) in parturients than in non-pregnant women.,Maternal kinetics of morphine during labour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097341/),,3.4,171560,DB00295,Morphine
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],3.1,171644,DB00295,Morphine
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],8.4,171645,DB00295,Morphine
,7905398,net extraction,"There was significant (p < 0.05) extraction (mean +/- SD) of morphine by the liver (0.676 +/- 0.014) and kidney (0.602 +/- 0.039), net extraction of M3G (0.106 +/- 0.046) and M6G (0.104 +/- 0.030) by the kidney, and net formation of M3G (-0.057 +/- 0.017) by the gut.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,0.106,171888,DB00295,Morphine
,7905398,net extraction,"There was significant (p < 0.05) extraction (mean +/- SD) of morphine by the liver (0.676 +/- 0.014) and kidney (0.602 +/- 0.039), net extraction of M3G (0.106 +/- 0.046) and M6G (0.104 +/- 0.030) by the kidney, and net formation of M3G (-0.057 +/- 0.017) by the gut.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,0.104,171889,DB00295,Morphine
,7905398,lambda,"The mean lambda for morphine, M3G, and M6G was 1.25 +/- 0.17, 0.80 +/- 0.03, and 0.82 +/- 0.09, respectively.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,1.25,171890,DB00295,Morphine
,7905398,lambda,"The mean lambda for morphine, M3G, and M6G was 1.25 +/- 0.17, 0.80 +/- 0.03, and 0.82 +/- 0.09, respectively.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,0.80,171891,DB00295,Morphine
,7905398,lambda,"The mean lambda for morphine, M3G, and M6G was 1.25 +/- 0.17, 0.80 +/- 0.03, and 0.82 +/- 0.09, respectively.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,0.82,171892,DB00295,Morphine
,7905398,total body clearance,The mean total body clearance of morphine with respect to blood was 1.58 +/- 0.27 liters/min.,Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),[l] / [min],1.58,171893,DB00295,Morphine
,7905398,percentage urinary recoveries,"Mean (+/-SD) percentage urinary recoveries as morphine, M3G, and M6G were 14.7 +/- 8.5, 75.4 +/- 11.1, and 0.49 +/- 0.39, respectively.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,14.7,171894,DB00295,Morphine
,7905398,percentage urinary recoveries,"Mean (+/-SD) percentage urinary recoveries as morphine, M3G, and M6G were 14.7 +/- 8.5, 75.4 +/- 11.1, and 0.49 +/- 0.39, respectively.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,75.4,171895,DB00295,Morphine
,7905398,percentage urinary recoveries,"Mean (+/-SD) percentage urinary recoveries as morphine, M3G, and M6G were 14.7 +/- 8.5, 75.4 +/- 11.1, and 0.49 +/- 0.39, respectively.",Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905398/),,0.49,171896,DB00295,Morphine
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],6.24,172847,DB00295,Morphine
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],8.60,172848,DB00295,Morphine
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],69.6,172849,DB00295,Morphine
,15366326,tmax,Mean tmax values were similar following all dose groups at approximately 1-2 minutes.,Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366326/),min,1-2,172958,DB00295,Morphine
,15366326,AUC(0-->1),"Mean AUC(0-->1) values showed dose proportionality for the first 3 dose groups (6.3, 12.3 and 24.3 ng x h x ml(-1)), the mean AUC(0-->1) for the 17.6 mg dose group was 1.6x that of the 8.8 mg dose group.",Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366326/),[h·ng] / [ml],6.3,172959,DB00295,Morphine
,15366326,AUC(0-->1),"Mean AUC(0-->1) values showed dose proportionality for the first 3 dose groups (6.3, 12.3 and 24.3 ng x h x ml(-1)), the mean AUC(0-->1) for the 17.6 mg dose group was 1.6x that of the 8.8 mg dose group.",Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366326/),[h·ng] / [ml],12.3,172960,DB00295,Morphine
,15366326,AUC(0-->1),"Mean AUC(0-->1) values showed dose proportionality for the first 3 dose groups (6.3, 12.3 and 24.3 ng x h x ml(-1)), the mean AUC(0-->1) for the 17.6 mg dose group was 1.6x that of the 8.8 mg dose group.",Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366326/),[h·ng] / [ml],24.3,172961,DB00295,Morphine
,3415896,relative bioavailabilities,"The individual relative bioavailabilities of inhaled morphine varied from 9% to 35%, with a mean of 17%.",Absorption and bioavailability of nebulized morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3415896/),%,35,173225,DB00295,Morphine
,3415896,relative bioavailabilities,"The individual relative bioavailabilities of inhaled morphine varied from 9% to 35%, with a mean of 17%.",Absorption and bioavailability of nebulized morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3415896/),%,17,173226,DB00295,Morphine
,7586903,clearance,"Remifentanil undergoes widespread extrahepatic metabolism by blood and tissue nonspecific esterases, resulting in an extremely rapid clearance of approximately 3 L/min (180 L/h).",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),[l] / [min],3,173335,DB00295,Morphine
,7586903,steady-state volume of distribution,"Like the other members of this class of drugs, remifentanil is lipophilic and is widely distributed in body tissues with a steady-state volume of distribution of approximately 30L.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),l,30,173336,DB00295,Morphine
,7586903,half-time,"Determined by computer simulation, the context-sensitive half-time of remifentanil is approximately 3 minutes, and is independent of infusion duration.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,3,173337,DB00295,Morphine
,7586903,t1/2ke0,"Speed of onset of effect is very rapid and is similar to that of alfentanil, which is reflected in a t1/2ke0 (a parameter used to characterise the delay between peak blood drug concentration and peak pharmacodynamic effect utilising a theoretical effect compartment) of approximately 1 to 2 minutes.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,1 to 2,173338,DB00295,Morphine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],2400-8000,174308,DB00295,Morphine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],4200,174309,DB00295,Morphine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],2700-7900,174310,DB00295,Morphine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],5500,174311,DB00295,Morphine
,16802855,maximum plasma concentration (Cmax),"After buccal administration, maximum plasma concentration (Cmax) was 5.4-39 ng/mL (16 ng/mL) after buccal and 5.5-42 ng/mL (22 ng/mL) after sublingual administration.",Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[ng] / [ml],5.4-39,174312,DB00295,Morphine
,16802855,maximum plasma concentration (Cmax),"After buccal administration, maximum plasma concentration (Cmax) was 5.4-39 ng/mL (16 ng/mL) after buccal and 5.5-42 ng/mL (22 ng/mL) after sublingual administration.",Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[ng] / [ml],5.5-42,174313,DB00295,Morphine
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,104-251,174314,DB00295,Morphine
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,140,174315,DB00295,Morphine
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,110-190,174316,DB00295,Morphine
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],4.54,174487,DB00295,Morphine
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],8.94,174488,DB00295,Morphine
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],17.80,174489,DB00295,Morphine
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],37.90,174490,DB00295,Morphine
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],5.60,174491,DB00295,Morphine
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],9.77,174492,DB00295,Morphine
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],19.3,174493,DB00295,Morphine
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],37.0,174494,DB00295,Morphine
,20547824,half-lifes (t(1/2)k(E0)),"M6G effect was simulated at various values for the arterial blood-effect-site equilibration half-lifes (t(1/2)k(E0)), ranging from 5 to 240 minutes.",Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20547824/),min,5 to 240,174545,DB00295,Morphine
,20547824,t(1/2)k(E0),"Assuming that the true values of M6G t(1/2)k(E0) range from 120 to 240 minutes (depending on the end point measured), we would have underestimated t(1/2)k(E0) by 30%, whereas the potency parameter would have been overestimated by about 40%, when using venous plasma samples.",Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20547824/),min,120 to 240,174546,DB00295,Morphine
,14695733,half-life,"The M6G effect site concentration causing a 25% increase in current (C25) was 275 +/- 135 nm (population estimate +/- SE), the blood effect site equilibration half-life was 6.2 +/- 3.3 h, and the steepness parameter was 0.71 +/- 0.18.",Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14695733/),h,6.2,175114,DB00295,Morphine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],473.49,175280,DB00295,Morphine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],491.22,175281,DB00295,Morphine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],488.89,175282,DB00295,Morphine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],502.28,175283,DB00295,Morphine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.91,175284,DB00295,Morphine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],35.73,175285,DB00295,Morphine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.46,175286,DB00295,Morphine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],40.45,175287,DB00295,Morphine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],539.93,175288,DB00295,Morphine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],522.45,175289,DB00295,Morphine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],520.10,175290,DB00295,Morphine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],523.37,175291,DB00295,Morphine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],62.01,175292,DB00295,Morphine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.62,175293,DB00295,Morphine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],61.95,175294,DB00295,Morphine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.55,175295,DB00295,Morphine
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],22.6,175296,DB00295,Morphine
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],24.0,175297,DB00295,Morphine
,12492606,total clearance,"While morphine was rapidly cleared from plasma (total clearance = 1838 ml min-1 (95% CI 1668, 2001 ml min-1)) the glucuronide metabolites were eliminated more slowly (clearance M3G = 44.5 ml min-1 (35.1, 53.9 ml min-1), clearance M6G = 42.1 ml min-1 (36.4, 47.7 ml min-1)) and their clearance could be described as a function of creatinine clearance.","Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492606/),[ml] / [min],1838,176379,DB00295,Morphine
,12492606,clearance M3G,"While morphine was rapidly cleared from plasma (total clearance = 1838 ml min-1 (95% CI 1668, 2001 ml min-1)) the glucuronide metabolites were eliminated more slowly (clearance M3G = 44.5 ml min-1 (35.1, 53.9 ml min-1), clearance M6G = 42.1 ml min-1 (36.4, 47.7 ml min-1)) and their clearance could be described as a function of creatinine clearance.","Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492606/),[ml] / [min],44.5,176380,DB00295,Morphine
,12492606,clearance M6G,"While morphine was rapidly cleared from plasma (total clearance = 1838 ml min-1 (95% CI 1668, 2001 ml min-1)) the glucuronide metabolites were eliminated more slowly (clearance M3G = 44.5 ml min-1 (35.1, 53.9 ml min-1), clearance M6G = 42.1 ml min-1 (36.4, 47.7 ml min-1)) and their clearance could be described as a function of creatinine clearance.","Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492606/),[ml] / [min],42.1,176381,DB00295,Morphine
,12492606,central volumes of distribution,"The central volumes of distribution were estimated to be 12.7 l (11.1, 14.3 l) for morphine.","Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492606/),l,12.7,176382,DB00295,Morphine
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.6,176468,DB00295,Morphine
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.7,176469,DB00295,Morphine
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.2,176470,DB00295,Morphine
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.0,176471,DB00295,Morphine
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,1.8,176472,DB00295,Morphine
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,4.3,176473,DB00295,Morphine
<,28035588,time to maximum plasma concentration,"Naloxegol is rapidly absorbed, with mean time to maximum plasma concentration of <2 h.","Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28035588/),h,2,177005,DB00295,Morphine
,3377942,clearance,Calculated clearance of fentanyl was 1.05 +/- 0.38 litre min-1 and was not related to weight or age.,Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[l] / [min],1.05,177042,DB00295,Morphine
,3377942,serum concentrations,"Mean serum concentrations of fentanyl in these groups were 1.42 +/- 0.14 (SD) and 1.90 +/- 0.30 ng ml-1, respectively.",Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[ng] / [ml],1.42,177043,DB00295,Morphine
,3377942,serum concentrations,"Mean serum concentrations of fentanyl in these groups were 1.42 +/- 0.14 (SD) and 1.90 +/- 0.30 ng ml-1, respectively.",Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[ng] / [ml],1.90,177044,DB00295,Morphine
,3377942,Steady-state serum concentrations,Steady-state serum concentrations in this group were 2.15 +/- 0.92 (SD) ng ml-1.,Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[ng] / [ml],2.15,177045,DB00295,Morphine
,3377942,apparent half-life,"Serum concentrations of fentanyl increased slowly (15 h to plateau) and decreased slowly (apparent half-life, 21 h).",Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),h,21,177046,DB00295,Morphine
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],40.1,177182,DB00295,Morphine
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],53.7,177183,DB00295,Morphine
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),hg·mm,42.2,177184,DB00295,Morphine
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.6,177185,DB00295,Morphine
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),h·mm,46.2,177186,DB00295,Morphine
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.3,177187,DB00295,Morphine
,34229249,Ki,"The resulting macrocyclic peptide, CR-01-64, exhibited high-affinity for NTS2 (Ki 7.0 nM), with a more than 125-fold selectivity over NTS1, as well as an improved plasma stability profile (t1/2 > 24 h) compared with NT (t1/2 ~ 2 min).",Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34229249/),nM,7.0,177500,DB00295,Morphine
>,34229249,t1/2,"The resulting macrocyclic peptide, CR-01-64, exhibited high-affinity for NTS2 (Ki 7.0 nM), with a more than 125-fold selectivity over NTS1, as well as an improved plasma stability profile (t1/2 > 24 h) compared with NT (t1/2 ~ 2 min).",Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34229249/),h,24,177501,DB00295,Morphine
~,34229249,t1/2,"The resulting macrocyclic peptide, CR-01-64, exhibited high-affinity for NTS2 (Ki 7.0 nM), with a more than 125-fold selectivity over NTS1, as well as an improved plasma stability profile (t1/2 > 24 h) compared with NT (t1/2 ~ 2 min).",Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34229249/),min,2,177502,DB00295,Morphine
,34229249,ED50,"Following intrathecal administration, CR-01-64 exerted dose-dependent and long-lasting analgesic effects in acute (ED50 = 4.6 µg/kg) and tonic (ED50 = 7.1 µg/kg) pain models as well as strong mechanical anti-allodynic effects in the CFA-induced chronic inflammatory pain model.",Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34229249/),[μg] / [kg],4.6,177503,DB00295,Morphine
,34229249,ED50,"Following intrathecal administration, CR-01-64 exerted dose-dependent and long-lasting analgesic effects in acute (ED50 = 4.6 µg/kg) and tonic (ED50 = 7.1 µg/kg) pain models as well as strong mechanical anti-allodynic effects in the CFA-induced chronic inflammatory pain model.",Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34229249/),[μg] / [kg],7.1,177504,DB00295,Morphine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),[μg] / [l],6.6,178377,DB00295,Morphine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),[μg] / [l],158,178378,DB00295,Morphine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,13.0,178379,DB00295,Morphine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,9.7,178380,DB00295,Morphine
,1874209,time,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,13.0,178381,DB00295,Morphine
,1874209,time,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,9.7,178382,DB00295,Morphine
,1874209,elimination half-life,"The elimination half-life of hyoscine in the plasma was 2.4 h, which is somewhat greater than obtained in earlier studies with young healthy patients under regional anaesthesia.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),h,2.4,178383,DB00295,Morphine
,1874209,t1/2el,Elimination of plasma morphine (t1/2el = 3.3 h) was not significantly altered by the procedure.,Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),h,3.3,178384,DB00295,Morphine
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],4.2,178518,DB00295,Morphine
,27779354,V2,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],130,178519,DB00295,Morphine
,27779354,Q,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·h·kg],6.02,178520,DB00295,Morphine
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],2.03,178521,DB00295,Morphine
,19918182,maximum concentration,"After subcutaneous bolus dose administration, the median maximum concentration of fentanyl was 0.55 ng ml(-1) (range 0.28-0.87 ng ml(-1)), reached at a median time of 15 min (range 10-30 min).",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),[ng] / [ml],0.55,181497,DB00295,Morphine
,19918182,terminal half-life,The terminal half-life was 10.00 h (range 5.48-16.37 h).,Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,10.00,181498,DB00295,Morphine
,19918182,terminal half-life,"Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer (10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes.",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,10,181499,DB00295,Morphine
,19918182,terminal half-life,"Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer (10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes.",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,2.1,181500,DB00295,Morphine
,2720576,area under the curve (AUC),"In this group, the mean area under the curve (AUC) with MSC was 443.6 +/- 348.4 ng/ml/hour, compared with 406.8 +/- 259.7 ng/ml/hour for MSS (P greater than 0.20).",Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),[ng] / [h·ml],443.6,181811,DB00295,Morphine
,2720576,area under the curve (AUC),"In this group, the mean area under the curve (AUC) with MSC was 443.6 +/- 348.4 ng/ml/hour, compared with 406.8 +/- 259.7 ng/ml/hour for MSS (P greater than 0.20).",Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),[ng] / [h·ml],406.8,181812,DB00295,Morphine
,2720576,maximum morphine concentrations (Cmax),"Mean maximum morphine concentrations (Cmax) for MSC and MSS were 67.9 +/- 42.1 and 58.8 +/- 30.3 ng/ml, respectively (P greater than 0.05).",Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),[ng] / [ml],67.9,181813,DB00295,Morphine
,2720576,maximum morphine concentrations (Cmax),"Mean maximum morphine concentrations (Cmax) for MSC and MSS were 67.9 +/- 42.1 and 58.8 +/- 30.3 ng/ml, respectively (P greater than 0.05).",Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),[ng] / [ml],58.8,181814,DB00295,Morphine
,2720576,minimum morphine concentrations (Cmin),"Mean minimum morphine concentrations (Cmin) were 17.0 +/- 17.7 and 18.3 +/- 15.0, respectively (P greater than 0.30).",Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),,17.0,181815,DB00295,Morphine
,2720576,minimum morphine concentrations (Cmin),"Mean minimum morphine concentrations (Cmin) were 17.0 +/- 17.7 and 18.3 +/- 15.0, respectively (P greater than 0.30).",Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),,18.3,181816,DB00295,Morphine
,2720576,Tmax,Mean Tmax after MSC occurred at 3.6 +/- 2.3 hours.,Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720576/),h,3.6,181817,DB00295,Morphine
,20645689,bioavailability,"Intranasal fentanyl has a bioavailability of 89%, with a short onset of action ( approximately 7 min) and duration times ( approximately 1 h).",Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20645689/),%,89,182162,DB00295,Morphine
,1704690,detection limit,Concentrations of hydromorphone in plasma from serial blood samples were measured by a high-performance liquid chromatography method specific for hydromorphone with a detection limit of 0.1 ng/mL.,Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),[ng] / [ml],0.1,183043,DB00295,Morphine
,1704690,distribution,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,1.27,183044,DB00295,Morphine
,1704690,t1/2 pi,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,1.27,183045,DB00295,Morphine
,1704690,t1/2 alpha,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,14.7,183046,DB00295,Morphine
,1704690,t1/2 beta,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,184,183047,DB00295,Morphine
,1704690,systemic clearance,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),[l] / [min],1.66,183048,DB00295,Morphine
,1704690,Cl,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),[l] / [min],1.66,183049,DB00295,Morphine
,1704690,Vc,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),l,24.4,183050,DB00295,Morphine
,1704690,Vdss,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),l,295,183051,DB00295,Morphine
,8735684,Overall relative bioavailability,"Overall relative bioavailability of the two formulations (log AUC), was within the acceptable 80-125% limits for bioequivalence both fed and fasting.",Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: Oramorph SR and MST Continus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735684/),%,80-125,183264,DB00295,Morphine
,7602474,plasma AUC ratio,"After single morphine dosage, the plasma AUC ratio of morphine-3- glucuronide/morphine was 11.1 compared with 0.14 for morphine-6-glucuronide/morphine.",Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602474/),,11.1,183267,DB00295,Morphine
,7602474,plasma AUC ratio,"After single morphine dosage, the plasma AUC ratio of morphine-3- glucuronide/morphine was 11.1 compared with 0.14 for morphine-6-glucuronide/morphine.",Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602474/),,0.14,183268,DB00295,Morphine
,7602474,elimination half-lives,"The similar elimination half-lives of morphine (107 min), morphine-3-glucuronide (122 min), and morphine-6-glucuronide (105 min) suggested the glucuronidation to be the rate-limiting step, which was substantiated by the observation that morphine-3-glucuronide becomes eliminated four times faster when applied intravenously.",Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602474/),min,107,183269,DB00295,Morphine
,7602474,elimination half-lives,"The similar elimination half-lives of morphine (107 min), morphine-3-glucuronide (122 min), and morphine-6-glucuronide (105 min) suggested the glucuronidation to be the rate-limiting step, which was substantiated by the observation that morphine-3-glucuronide becomes eliminated four times faster when applied intravenously.",Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602474/),min,122,183270,DB00295,Morphine
,7602474,elimination half-lives,"The similar elimination half-lives of morphine (107 min), morphine-3-glucuronide (122 min), and morphine-6-glucuronide (105 min) suggested the glucuronidation to be the rate-limiting step, which was substantiated by the observation that morphine-3-glucuronide becomes eliminated four times faster when applied intravenously.",Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602474/),min,105,183271,DB00295,Morphine
,9802834,ED50,"44.1 sessions, respectively), and the ED50 for U69,593 discrimination was significantly higher in females than in males (0.074 vs. 0.025 mg/kg).","Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802834/),[mg] / [kg],0.074,183292,DB00295,Morphine
,9802834,ED50,"44.1 sessions, respectively), and the ED50 for U69,593 discrimination was significantly higher in females than in males (0.074 vs. 0.025 mg/kg).","Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802834/),[mg] / [kg],0.025,183293,DB00295,Morphine
,9802834,ED50,"The ED50 for bremazocine substitution was significantly higher in females than in males (0.0039 vs. 0.0006 mg/kg), whereas ethylketazocine substituted for U69,593 in all males and five of seven females, with no sex difference in substitution ED50.","Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802834/),[mg] / [kg],0.0039,183294,DB00295,Morphine
,9802834,ED50,"The ED50 for bremazocine substitution was significantly higher in females than in males (0.0039 vs. 0.0006 mg/kg), whereas ethylketazocine substituted for U69,593 in all males and five of seven females, with no sex difference in substitution ED50.","Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802834/),[mg] / [kg],0.0006,183295,DB00295,Morphine
,9802834,urine output/dose,"U69,593 also produced significantly less urine output/dose in females compared to males (e.g., 5.92 vs. 14.83 ml urine/kg body weight after 1.0 mg/kg U69,593), but was equipotent between the sexes in producing hot-plate antinociception.","Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802834/),[ml·urine] / [body·kg·weight],5.92,183296,DB00295,Morphine
,9802834,urine output/dose,"U69,593 also produced significantly less urine output/dose in females compared to males (e.g., 5.92 vs. 14.83 ml urine/kg body weight after 1.0 mg/kg U69,593), but was equipotent between the sexes in producing hot-plate antinociception.","Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802834/),[ml·urine] / [body·kg·weight],14.83,183297,DB00295,Morphine
,8331561,Clearance (CL),Clearance (CL) was estimated as 148 +/- 58 ml/min*kg after the bolus dose and 108 +/- 32 ml/min*kg during infusion (N.S.).,Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331561/),[ml] / [kg·min],148,183428,DB00295,Morphine
,8331561,Clearance (CL),Clearance (CL) was estimated as 148 +/- 58 ml/min*kg after the bolus dose and 108 +/- 32 ml/min*kg during infusion (N.S.).,Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331561/),[ml] / [kg·min],108,183429,DB00295,Morphine
,8331561,half-lives,"The rates of equilibration of drug between the blood and effect compartment and the blood and tolerance compartment, expressed in half-lives, were estimated as 25 +/- 8 min and 26 +/- 6 hr, respectively.",Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331561/),min,25,183430,DB00295,Morphine
,8331561,half-lives,"The rates of equilibration of drug between the blood and effect compartment and the blood and tolerance compartment, expressed in half-lives, were estimated as 25 +/- 8 min and 26 +/- 6 hr, respectively.",Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331561/),h,26,183431,DB00295,Morphine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,8.6,183621,DB00295,Morphine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,13.0,183622,DB00295,Morphine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,15.6,183623,DB00295,Morphine
,6589939,CSF/plasma concentration ratio,This is to be compared with a CSF/plasma concentration ratio around 100 after E.D. administration.,Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),,100,183624,DB00295,Morphine
,19459553,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of ropivacaine and bupivacaine were 964 (282) ng ml(-1) and 638 (366) ng ml(-1), respectively.",Local anaesthetic use for the iliac crest-donor site: pharmacokinetic and pharmacodynamic evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19459553/),[ng] / [ml],964,183689,DB00295,Morphine
,19459553,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of ropivacaine and bupivacaine were 964 (282) ng ml(-1) and 638 (366) ng ml(-1), respectively.",Local anaesthetic use for the iliac crest-donor site: pharmacokinetic and pharmacodynamic evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19459553/),[ng] / [ml],638,183690,DB00295,Morphine
,8799518,steady-state plasma concentration,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ng] / [ml],86,183779,DB00295,Morphine
,8799518,steady-state plasma concentration,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ng] / [ml],703,183780,DB00295,Morphine
,8799518,steady-state plasma concentration,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ng] / [ml],48,183781,DB00295,Morphine
,8799518,clearance,"2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],4.6,183782,DB00295,Morphine
,8799518,formation clearance,"3. M3G formation clearance was estimated to be 2.5 +/- 1.8 ml min-1 kg-1, and the formation clearance of M6G was estimated to be 0.46 +/- 0.32 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],2.5,183783,DB00295,Morphine
,8799518,formation clearance,"3. M3G formation clearance was estimated to be 2.5 +/- 1.8 ml min-1 kg-1, and the formation clearance of M6G was estimated to be 0.46 +/- 0.32 ml min-1 kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],0.46,183784,DB00295,Morphine
,8799518,clearance,"4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],0.46,183785,DB00295,Morphine
,8799518,elimination half-life,"4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),h,11.1,183786,DB00295,Morphine
,8799518,volume of distribution,"4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[l] / [kg],0.55,183787,DB00295,Morphine
,8799518,clearance,"M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[ml] / [kg·min],0.71,183788,DB00295,Morphine
,8799518,elimination half-life,"M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),h,18.2,183789,DB00295,Morphine
,8799518,volume of distribution,"M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),[l] / [kg],1.03,183790,DB00295,Morphine
,8799518,steady-state plasma concentration ratios,"7. M3G: morphine and M6G: morphine steady-state plasma concentration ratios were 11.0 +/- 10.8 and 0.8 +/- 0.8, respectively.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),,11.0,183791,DB00295,Morphine
,8799518,steady-state plasma concentration ratios,"7. M3G: morphine and M6G: morphine steady-state plasma concentration ratios were 11.0 +/- 10.8 and 0.8 +/- 0.8, respectively.","Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799518/),,0.8,183792,DB00295,Morphine
,7707487,Bioavailability (F),Bioavailability (F) for both oral dosages was approximately 20%.,Pharmacokinetics of parenteral and oral sustained-release morphine sulphate in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707487/),%,20,183984,DB00295,Morphine
,15678314,Clearance,"Clearance in neonates (age <7 days) at the start of ECMO (2.2 l per hour per 70 kg) was lower than that in postoperative neonates (10.5 l per hour per 70 kg) but increased rapidly (maturation half-life 30 and 70 days, respectively) and equaled that of the postoperative group after 14 days.",Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15678314/),[l] / [70·h·kg],2.2,184008,DB00295,Morphine
,15678314,Clearance,"Clearance in neonates (age <7 days) at the start of ECMO (2.2 l per hour per 70 kg) was lower than that in postoperative neonates (10.5 l per hour per 70 kg) but increased rapidly (maturation half-life 30 and 70 days, respectively) and equaled that of the postoperative group after 14 days.",Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15678314/),[l] / [70·h·kg],10.5,184009,DB00295,Morphine
,15678314,maturation half-life,"Clearance in neonates (age <7 days) at the start of ECMO (2.2 l per hour per 70 kg) was lower than that in postoperative neonates (10.5 l per hour per 70 kg) but increased rapidly (maturation half-life 30 and 70 days, respectively) and equaled that of the postoperative group after 14 days.",Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15678314/),d,30,184010,DB00295,Morphine
,15678314,maturation half-life,"Clearance in neonates (age <7 days) at the start of ECMO (2.2 l per hour per 70 kg) was lower than that in postoperative neonates (10.5 l per hour per 70 kg) but increased rapidly (maturation half-life 30 and 70 days, respectively) and equaled that of the postoperative group after 14 days.",Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15678314/),d,70,184011,DB00295,Morphine
,16050817,half-life,"Mean +/- SE values for half-life, apparent volume of distribution, and clearance after i.v. administration were 1.16 +/- 0.15 h, 4.55 +/- 0.17 L/kg, and 62.46 +/- 10.44 mL/min/kg, respectively.",Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050817/),h,1.16,184413,DB00295,Morphine
,16050817,apparent volume of distribution,"Mean +/- SE values for half-life, apparent volume of distribution, and clearance after i.v. administration were 1.16 +/- 0.15 h, 4.55 +/- 0.17 L/kg, and 62.46 +/- 10.44 mL/min/kg, respectively.",Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050817/),[l] / [kg],4.55,184414,DB00295,Morphine
,16050817,clearance,"Mean +/- SE values for half-life, apparent volume of distribution, and clearance after i.v. administration were 1.16 +/- 0.15 h, 4.55 +/- 0.17 L/kg, and 62.46 +/- 10.44 mL/min/kg, respectively.",Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050817/),[ml] / [kg·min],62.46,184415,DB00295,Morphine
,16050817,Oral bioavailability,Oral bioavailability was 5% as determined from naïve-averaged analysis.,Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050817/),%,5,184416,DB00295,Morphine
,7538514,AUC0-12,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),[h·ng] / [ml],123.10,184924,DB00295,Morphine
,7538514,AUC0-12,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),[h·ng] / [ml],118.98,184925,DB00295,Morphine
,7538514,Cmax,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,17.76,184926,DB00295,Morphine
,7538514,Cmax,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,19.70,184927,DB00295,Morphine
,7538514,Cmin,"mL-1, P = NS, Cmin 6.04 +/- 1.01 vs. 5.28 +/- 1.000 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,6.04,184928,DB00295,Morphine
,7538514,Cmin,"mL-1, P = NS, Cmin 6.04 +/- 1.01 vs. 5.28 +/- 1.000 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,5.28,184929,DB00295,Morphine
,7538514,Tmax,"mL-1, P = NS, and Tmax 4.78 +/- 0.78 vs. 1.47 +/- 0.22 hr, P = 0.0008).",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),h,4.78,184930,DB00295,Morphine
,7538514,Tmax,"mL-1, P = NS, and Tmax 4.78 +/- 0.78 vs. 1.47 +/- 0.22 hr, P = 0.0008).",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),h,1.47,184931,DB00295,Morphine
,7538514,steady-state molar ratio,The steady-state molar ratio of H3G to hydromorphone was 27:1.,Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),,27:1,184932,DB00295,Morphine
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,77.72,185385,DB00295,Morphine
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),[ml] / [kg·min],119.41,185386,DB00295,Morphine
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,52.73,185387,DB00295,Morphine
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),,178.57,185388,DB00295,Morphine
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,50.53,185389,DB00295,Morphine
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),[ml] / [kg·min],187.24,185390,DB00295,Morphine
,14694918,relative potency ratio,These results support the commonly used oral-to-intravenous relative potency ratio of 1:2 to 1:3 in patients with cancer pain receiving chronic morphine treatment.,The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14694918/),,1,185475,DB00295,Morphine
,26416348,plasma clearance,Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg.,"Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),[ml] / [kg·min)],8.4,185580,DB00295,Morphine
,26416348,volume of distribution at steady-state,Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg.,"Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),[l] / [kg],0.77,185581,DB00295,Morphine
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,2.0,185582,DB00295,Morphine
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,2.6,185583,DB00295,Morphine
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,7.1,185584,DB00295,Morphine
,26416348,bioavailability,"The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),%,71,185585,DB00295,Morphine
,26416348,bioavailability,"The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),%,57,185586,DB00295,Morphine
,4057070,apparent steady-state level,"Mean plasma morphine concentration after two morphine pellets reached a peak at 4 to 6 hr, then declined to a mean apparent steady-state level of 210 ng/ml at 36 hr that was maintained until the pellets were removed at 72 hr.",Pharmacokinetics and pharmacodynamics of subcutaneous morphine pellets in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057070/),[ng] / [ml],210,185886,DB00295,Morphine
,4057070,terminal T1/2,"After pellet removal, the plasma elimination kinetics of morphine were biexponential with a terminal T1/2 of 8.3 hr.",Pharmacokinetics and pharmacodynamics of subcutaneous morphine pellets in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057070/),h,8.3,185887,DB00295,Morphine
,15692141,maximum APAP concentration ([APAP](max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg] / [ml],71.8,186083,DB00295,Morphine
,15692141,time to peak [APAP] (t(max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.71,186084,DB00295,Morphine
,15692141,area under the receiver operating characteristic curve (AUC(0-8)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],318.3,186085,DB00295,Morphine
,15692141,t(max),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.90,186086,DB00295,Morphine
,15692141,AUC(0-8),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],297.7,186087,DB00295,Morphine
,15692141,t(max),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,2.87,186088,DB00295,Morphine
,15692141,AUC(0-8),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],232.1,186089,DB00295,Morphine
,10190764,maximum plasma concentrations,"Under steady-state conditions in the first dosing interval, mean maximum plasma concentrations for morphine were 19.1 ng/ml (CV% 41) for Oramorph SR 30 mg and 19.1 ng/ml (CV% 33) for MST-30 Mundipharma Retardtabletten.",Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190764/),[ng] / [ml],19.1,186498,DB00295,Morphine
,10190764,maximum plasma concentrations,"Under steady-state conditions in the first dosing interval, mean maximum plasma concentrations for morphine were 19.1 ng/ml (CV% 41) for Oramorph SR 30 mg and 19.1 ng/ml (CV% 33) for MST-30 Mundipharma Retardtabletten.",Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190764/),[ng] / [ml],19.1,186499,DB00295,Morphine
,10190764,AUC(0-12),Geometric mean AUC(0-12) values were calculated as 108 ngxh/ml (CV% 40) for Oramorph SR 30 mg and as 118 ng x h/ml (CV% 30) for the reference formulation.,Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190764/),[h·ng] / [ml],108,186500,DB00295,Morphine
,10190764,AUC(0-12),Geometric mean AUC(0-12) values were calculated as 108 ngxh/ml (CV% 40) for Oramorph SR 30 mg and as 118 ng x h/ml (CV% 30) for the reference formulation.,Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190764/),[h·ng] / [ml],118,186501,DB00295,Morphine
,31597014,absorption lag,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),h,0.23,187251,DB00295,Morphine
,31597014,absorption rate constant (kaCR,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),1/[h],0.19,187252,DB00295,Morphine
,31597014,kaSOL,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),1/[h],0.94,187253,DB00295,Morphine
,31597014,half-life,Effects on pupil diameter were delayed relative to plasma (14 minutes half-life) for all formulations and were best described by a proportional Emax model.,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),min,14,187254,DB00295,Morphine
,31597014,plasma concentration of o,The plasma concentration of oxycodone at half-maximum effect was lower in males (31.1 μg/L) compared to females (52.8 μg/L; P < .001).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),[μg] / [l],31.1,187255,DB00295,Morphine
,31597014,plasma concentration of o,The plasma concentration of oxycodone at half-maximum effect was lower in males (31.1 μg/L) compared to females (52.8 μg/L; P < .001).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),[μg] / [l],52.8,187256,DB00295,Morphine
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],1.56,187947,DB00295,Morphine
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],5.40,187948,DB00295,Morphine
,17675197,Plasma half-life,"Plasma half-life was 1.0+/-0.1h and the main metabolite was morphine-3-glucuronide, whereas morphine-6-glucuronide was negligible.",Morphine reduces spinal c-fos expression dose-dependently during experimental laparotomy in pigs: a combined pharmacokinetic and surgical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17675197/),h,1.0,188235,DB00295,Morphine
,17675197,elimination half-life,"CSF morphine concentration peaked after 20-30min (2.5mg/kg) and 60-120min (10mg/kg), and elimination half-life was 3.5+/-0.3h.",Morphine reduces spinal c-fos expression dose-dependently during experimental laparotomy in pigs: a combined pharmacokinetic and surgical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17675197/),h,3.5,188236,DB00295,Morphine
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],17.1,188412,DB00295,Morphine
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],15.5,188413,DB00295,Morphine
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],22.2,188414,DB00295,Morphine
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,1.0,188415,DB00295,Morphine
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,2.0,188416,DB00295,Morphine
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,3.0,188417,DB00295,Morphine
,15502034,peak plasma concentrations,"After 7 intranasal doses of 1 and 2 mg (once every 6 h), mean +/- sd peak plasma concentrations of 2.8 +/- 0.7 ng/mL and 5.3 +/- 2.3 ng/mL, respectively, were observed.",A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502034/),[ng] / [ml],2.8,188882,DB00295,Morphine
,15502034,peak plasma concentrations,"After 7 intranasal doses of 1 and 2 mg (once every 6 h), mean +/- sd peak plasma concentrations of 2.8 +/- 0.7 ng/mL and 5.3 +/- 2.3 ng/mL, respectively, were observed.",A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502034/),[ng] / [ml],5.3,188883,DB00295,Morphine
,15502034,time to peak concentration,The median time to peak concentration was 20 min for both single and multiple doses.,A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502034/),min,20,188884,DB00295,Morphine
,22451244,Clearance,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),[l] / [h],28.9,189233,DB00295,Morphine
,22451244,volume of distribution at steady state,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),l,186,189234,DB00295,Morphine
,22451244,half-life of elimination,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),h,5.2,189235,DB00295,Morphine
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,59,189236,DB00295,Morphine
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,64,189237,DB00295,Morphine
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,55,189238,DB00295,Morphine
,1804656,AUC,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],2.2,189673,DB00295,Morphine
,1804656,AUC,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],0.81,189674,DB00295,Morphine
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],2.2,189675,DB00295,Morphine
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],0.81,189676,DB00295,Morphine
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],252,189677,DB00295,Morphine
below,18334103,Mor/Cod,The Mor/Cod in plasma were below 1 for both UMs and EMs during the first 12 h.,CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189803,DB00295,Morphine
>,18334103,ratios,"After 12 h, 9% of the 11 UM and none of the 12 EM had ratios > 1.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189804,DB00295,Morphine
below,18334103,Mor/Cod ratios,"In urine, Mor/Cod ratios were below one for all EMs and UMs during the first 12 h.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,one,189805,DB00295,Morphine
>,18334103,Mor/Cod ratios,"Thus, CYP2D6 genotyping in general will not explain Mor/Cod ratios > 1 in plasma or urine, unless the time of drug intake is more than 24 h previous.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189806,DB00295,Morphine
,1867957,area under the curve (AUC),"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),[h·nM] / [l],1020,190000,DB00295,Morphine
,1867957,half-life,"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),h,2.58,190001,DB00295,Morphine
,1867957,total plasma clearance,"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),[l] / [h·kg],2.02,190002,DB00295,Morphine
,9190324,half-life,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,5 to 7,190044,DB00295,Morphine
,9190324,time to peak plasma concentration,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,3.1,190045,DB00295,Morphine
,9190324,plasma protein binding,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),%,20,190046,DB00295,Morphine
,19000260,half-life,"Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg).",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,0.52,190088,DB00295,Morphine
,19000260,volume of distribution,"Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg).",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),[l] / [kg],12.47,190089,DB00295,Morphine
,19000260,serum clearance,"Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg).",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),[ml] / [kg·min],128.97,190090,DB00295,Morphine
,19000260,half-life,"The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively.",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,5.22,190091,DB00295,Morphine
,19000260,half-life,"The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively.",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,31.48,190092,DB00295,Morphine
,19000260,half-life,"The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively.",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,24.05,190093,DB00295,Morphine
,19000260,maximum serum concentration normalized for dose (C(MAX)/D),The maximum serum concentration normalized for dose (C(MAX)/D) ranged between 19.41-24.96 ng/mL occurring at 0.18-0.27 h.,Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),[ng] / [ml],19.41-24.96,190094,DB00295,Morphine
,22727949,area under the concentration-time curve from 0 to 72 hours (AUC(0-72)),"The area under the concentration-time curve from 0 to 72 hours (AUC(0-72)) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively.",Novel patch for transdermal administration of morphine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727949/),[h·ng] / [ml],60.4,190417,DB00295,Morphine
,22727949,area under the concentration-time curve from 0 to 72 hours (AUC(0-72)),"The area under the concentration-time curve from 0 to 72 hours (AUC(0-72)) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively.",Novel patch for transdermal administration of morphine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727949/),[h·ng] / [ml],133.7,190418,DB00295,Morphine
,22727949,area under the concentration-time curve from 0 to 72 hours (AUC(0-72)),"The area under the concentration-time curve from 0 to 72 hours (AUC(0-72)) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively.",Novel patch for transdermal administration of morphine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727949/),[h·ng] / [ml],861.5,190419,DB00295,Morphine
,22727949,plasma area under the concentration-time curve from 0 to 72 hours ratio,The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64.,Novel patch for transdermal administration of morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727949/),,2.64,190420,DB00295,Morphine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],214.2,190750,DB00295,Morphine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],474.3,190751,DB00295,Morphine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],638.4,190752,DB00295,Morphine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],1599.3,190753,DB00295,Morphine
,12194925,oral fluid-to-plasma ratio,The oral fluid-to-plasma ratio for codeine was relatively constant ( approximately 4) from 1 to 12 h.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),,4,190754,DB00295,Morphine
,12194925,half-life (t(1/2)),The mean half-life (t(1/2)) of codeine was 2.2 +/- 0.10 h in plasma and 2.2 +/- 0.16 h in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,2.2,190755,DB00295,Morphine
,12194925,half-life (t(1/2)),The mean half-life (t(1/2)) of codeine was 2.2 +/- 0.10 h in plasma and 2.2 +/- 0.16 h in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,2.2,190756,DB00295,Morphine
,12194925,oral fluid detection time,"Mean codeine oral fluid detection time was 21 h with a 2.5 microg/L cutoff, longer than that of plasma (12-16 h).",Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,21,190757,DB00295,Morphine
,12194925,oral fluid detection time,"Mean codeine oral fluid detection time was 21 h with a 2.5 microg/L cutoff, longer than that of plasma (12-16 h).",Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,12-16,190758,DB00295,Morphine
,12194925,Detection times,Detection times with the proposed Substance Abuse and Mental Health Services Administration cutoff (40 microg/L) were only 7 h.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,7,190759,DB00295,Morphine
,7735464,recoveries,"The method had good reproducibility, precision, accuracy and recoveries of 91 and 90% for codeine and nalorphine, respectively.",Determination of codeine in human plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735464/),%,91,191173,DB00295,Morphine
,7735464,recoveries,"The method had good reproducibility, precision, accuracy and recoveries of 91 and 90% for codeine and nalorphine, respectively.",Determination of codeine in human plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735464/),%,90,191174,DB00295,Morphine
,17162465,oral clearance,"Following oral administration of acetaminophen (600 mg) to chimpanzees (n=2), pharmacokinetics were comparable with previously reported human values, namely mean oral clearance 0.91 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,0.91,192203,DB00295,Morphine
,17162465,apparent volume of distribution,"0.62+/-0.05 l h-1 kg-1, apparent volume of distribution 2.29 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,2.29,192204,DB00295,Morphine
,17162465,half-life,"1.65+/-0.25 l kg-1, and half-life 1.86 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,1.86,192205,DB00295,Morphine
,17162465,Urinary excretions,"Urinary excretions (percentage of dose) of acetaminophen, acetaminophen glucuronide and acetaminophen sulfate were also similar between chimpanzees and humans, namely 2.3 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,2.3,192206,DB00295,Morphine
,3800320,elimination half-life,"Based upon total platinum plasma concentrations, the elimination half-life is 58.3 hrs and the plasma clearance is 21.2 ml/min with an apparent volume of distribution of 7.6 liters.","Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),h,58.3,192312,DB00295,Morphine
,3800320,plasma clearance,"Based upon total platinum plasma concentrations, the elimination half-life is 58.3 hrs and the plasma clearance is 21.2 ml/min with an apparent volume of distribution of 7.6 liters.","Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),[ml] / [min],21.2,192313,DB00295,Morphine
,3800320,apparent volume of distribution,"Based upon total platinum plasma concentrations, the elimination half-life is 58.3 hrs and the plasma clearance is 21.2 ml/min with an apparent volume of distribution of 7.6 liters.","Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),l,7.6,192314,DB00295,Morphine
,3800320,half-life,"However, considering both plasma concentrations and urinary excretion, we could estimate the half-life of free filterable species (60 min), the plasma clearance (125 ml/min) and the renal clearance (86 ml/min).","Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),min,60,192315,DB00295,Morphine
,3800320,plasma clearance,"However, considering both plasma concentrations and urinary excretion, we could estimate the half-life of free filterable species (60 min), the plasma clearance (125 ml/min) and the renal clearance (86 ml/min).","Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),[ml] / [min],125,192316,DB00295,Morphine
,3800320,renal clearance,"However, considering both plasma concentrations and urinary excretion, we could estimate the half-life of free filterable species (60 min), the plasma clearance (125 ml/min) and the renal clearance (86 ml/min).","Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),[ml] / [min],86,192317,DB00295,Morphine
,3800320,urinary excretion,Mean urinary excretion is 64.4% of the dose after 6 days and 53.1% at 24 hrs.,"Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),%,64.4,192318,DB00295,Morphine
,3800320,urinary excretion,Mean urinary excretion is 64.4% of the dose after 6 days and 53.1% at 24 hrs.,"Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800320/),%,53.1,192319,DB00295,Morphine
,7605420,drug clearance,2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[ml] / [kg·min],15.2,192431,DB00295,Morphine
,7605420,volume of distribution (Vss),2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[l] / [kg],2.1,192432,DB00295,Morphine
,10383928,area under the concentration-time curve ratio,"The area under the concentration-time curve ratio for unbound morphine in brain ECF versus unbound morphine in blood was significantly higher in GF120918-treated rats compared with control rats (1.21 +/- 0.34 versus 0.47 +/- 0.05, respectively; p <.05).",Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383928/),,1.21,192790,DB00295,Morphine
,10383928,area under the concentration-time curve ratio,"The area under the concentration-time curve ratio for unbound morphine in brain ECF versus unbound morphine in blood was significantly higher in GF120918-treated rats compared with control rats (1.21 +/- 0.34 versus 0.47 +/- 0.05, respectively; p <.05).",Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383928/),,0.47,192791,DB00295,Morphine
,10383928,fraction unbound,The fraction unbound of morphine in whole blood was not altered significantly in the presence of GF120918 (0.651 +/- 0.039) as compared with controls (0.662 +/- 0.035).,Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383928/),,0.651,192792,DB00295,Morphine
,10383928,fraction unbound,The fraction unbound of morphine in whole blood was not altered significantly in the presence of GF120918 (0.651 +/- 0.039) as compared with controls (0.662 +/- 0.035).,Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383928/),,0.662,192793,DB00295,Morphine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),ng,0.,193259,DB00295,Morphine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),ng,0.51,193260,DB00295,Morphine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),ng,14.46,193261,DB00295,Morphine
,8801066,glucuronide,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],0.67,193262,DB00295,Morphine
,8801066,glucuronide,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],1.04,193263,DB00295,Morphine
,8801066,glucuronide,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],13.80,193264,DB00295,Morphine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],0.67,193265,DB00295,Morphine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],1.04,193266,DB00295,Morphine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],13.80,193267,DB00295,Morphine
,11043656,t(1/2),"As a result, the t(1/2) for the acidic method was significantly less than that of the control method (1.8 vs. 3.0 h, respectively).",The effects of collection methods on oral fluid codeine concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043656/),h,1.8,193476,DB00295,Morphine
,11043656,t(1/2),"As a result, the t(1/2) for the acidic method was significantly less than that of the control method (1.8 vs. 3.0 h, respectively).",The effects of collection methods on oral fluid codeine concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043656/),h,3.0,193477,DB00295,Morphine
,2301762,clearance (CLs),"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),[ml] / [min],963,193904,DB00295,Morphine
,2301762,clearance (CLs),"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),[ml] / [min],579,193905,DB00295,Morphine
,2301762,half-life,"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),min,78,193906,DB00295,Morphine
,2301762,half-life,"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),min,106,193907,DB00295,Morphine
,1369552,minimal detectable concentrations,The minimal detectable concentrations were respectively 1 and 5 ng/ml for M and M6G.,[Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high performance liquid chromatography and colorimetric detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1369552/),[ng] / [ml],1,195097,DB00295,Morphine
,1369552,minimal detectable concentrations,The minimal detectable concentrations were respectively 1 and 5 ng/ml for M and M6G.,[Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high performance liquid chromatography and colorimetric detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1369552/),[ng] / [ml],5,195098,DB00295,Morphine
,1369552,M/M6G ratio,"However, with dosages > 1 mg/kg/d, a difference appeared and gradually rose to a M/M6G ratio of 1.3 +/- 0.04.",[Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high performance liquid chromatography and colorimetric detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1369552/),,1.3,195099,DB00295,Morphine
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],11.1,195168,DB00295,Morphine
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],8.3,195169,DB00295,Morphine
,16740093,steady-state volume of distribution,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg],244.6,195175,DB00295,Morphine
,16740093,t1/2,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),min,47.04,195176,DB00295,Morphine
,16740093,clearance,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg·min],11.43,195177,DB00295,Morphine
,3171947,urinary recovery,"With each preparation, the mean urinary recovery of dihydrocodeine was approximately 30 mg, and both had a comparable bioavailability.",Two assays for dihydrocodeine in plasma and in urine and their use to determine the bioavailability of a controlled-release product. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171947/),mg,30,195320,DB00295,Morphine
,31092024,plasma clearance,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),[l] / [h],37.4,196345,DB00295,Morphine
,31092024,apparent distribution volumes,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),l,0.035,196346,DB00295,Morphine
,31092024,apparent distribution volumes,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),l,0.039,196347,DB00295,Morphine
,32434285,EC50,The probability of oversedation as a function of morphine concentration was best described using a step function in which the EC50 was 46.3 ng/mL.,Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32434285/),[ng] / [ml],46.3,196553,DB00295,Morphine
,12017351,total clearance,"The estimates (mean +/- SEM) for morphine total clearance and steady-state volume of distribution were 1.0 +/- 0.07 L/h/kg and 1.6 +/- 0.1 L/kg, respectively.",Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017351/),[l] / [h·kg],1.0,196664,DB00295,Morphine
,12017351,steady-state volume of distribution,"The estimates (mean +/- SEM) for morphine total clearance and steady-state volume of distribution were 1.0 +/- 0.07 L/h/kg and 1.6 +/- 0.1 L/kg, respectively.",Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017351/),[l] / [kg],1.6,196665,DB00295,Morphine
,12017351,AUC ratio,The AUC ratio of M6G to morphine was 0.73 +/- 0.06.,Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017351/),,0.73,196666,DB00295,Morphine
,11453888,pain,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],91,196963,DB00295,Morphine
,11453888,AUC changes,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],91,196964,DB00295,Morphine
,11453888,AUC changes,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],-,196965,DB00295,Morphine
,11453888,AUC changes,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],17,196966,DB00295,Morphine
,11453888,AIC,"The assumption of a simple linear relationship between DHC concentration and effect provided a significantly better fit than the model containing DHM as the active moiety (AIC = 4.431 vs 4.668, respectively).",Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),,4,196967,DB00295,Morphine
,12897995,plasma concentration,"The younger neonates differed significantly from the older neonates in morphine requirement (median 10 vs. 10.8 micro g/kg per hour), morphine plasma concentration [23.0 vs. 15.3 ng/ml), and M6G/morphine ratio (0.6 vs. 1.5).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),[ng] / [ml],23.0,197077,DB00295,Morphine
,12897995,plasma concentration,"The younger neonates differed significantly from the older neonates in morphine requirement (median 10 vs. 10.8 micro g/kg per hour), morphine plasma concentration [23.0 vs. 15.3 ng/ml), and M6G/morphine ratio (0.6 vs. 1.5).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),[ng] / [ml],15.3,197078,DB00295,Morphine
,12897995,M6G/morphine,"The younger neonates differed significantly from the older neonates in morphine requirement (median 10 vs. 10.8 micro g/kg per hour), morphine plasma concentration [23.0 vs. 15.3 ng/ml), and M6G/morphine ratio (0.6 vs. 1.5).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),,0.6,197079,DB00295,Morphine
,12897995,M6G/morphine,"The younger neonates differed significantly from the older neonates in morphine requirement (median 10 vs. 10.8 micro g/kg per hour), morphine plasma concentration [23.0 vs. 15.3 ng/ml), and M6G/morphine ratio (0.6 vs. 1.5).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),,1.5,197080,DB00295,Morphine
,12897995,ratio,"The younger neonates differed significantly from the older neonates in morphine requirement (median 10 vs. 10.8 micro g/kg per hour), morphine plasma concentration [23.0 vs. 15.3 ng/ml), and M6G/morphine ratio (0.6 vs. 1.5).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),,0.6,197081,DB00295,Morphine
,12897995,ratio,"The younger neonates differed significantly from the older neonates in morphine requirement (median 10 vs. 10.8 micro g/kg per hour), morphine plasma concentration [23.0 vs. 15.3 ng/ml), and M6G/morphine ratio (0.6 vs. 1.5).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),,1.5,197082,DB00295,Morphine
,12897995,plasma concentrations,"Neonates who were mechanically ventilated longer than 24 h had significantly higher morphine plasma concentrations than the spontaneously breathing neonates 12 and 24 h after surgery (29.1 vs. 13.1 ng/ml and 26.9 vs. 12.0 ng/ml, respectively).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),[ng] / [ml],29.1,197083,DB00295,Morphine
,12897995,plasma concentrations,"Neonates who were mechanically ventilated longer than 24 h had significantly higher morphine plasma concentrations than the spontaneously breathing neonates 12 and 24 h after surgery (29.1 vs. 13.1 ng/ml and 26.9 vs. 12.0 ng/ml, respectively).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),[ng] / [ml],13.1,197084,DB00295,Morphine
,12897995,plasma concentrations,"Neonates who were mechanically ventilated longer than 24 h had significantly higher morphine plasma concentrations than the spontaneously breathing neonates 12 and 24 h after surgery (29.1 vs. 13.1 ng/ml and 26.9 vs. 12.0 ng/ml, respectively).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),[ng] / [ml],26.9,197085,DB00295,Morphine
,12897995,plasma concentrations,"Neonates who were mechanically ventilated longer than 24 h had significantly higher morphine plasma concentrations than the spontaneously breathing neonates 12 and 24 h after surgery (29.1 vs. 13.1 ng/ml and 26.9 vs. 12.0 ng/ml, respectively).",Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897995/),[ng] / [ml],12.0,197086,DB00295,Morphine
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[μg] / [ml],7.95,197087,DB00295,Morphine
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[ng] / [ml],11.0,197088,DB00295,Morphine
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[ng] / [ml],3819,197089,DB00295,Morphine
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,0.94,197090,DB00295,Morphine
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,1.71,197091,DB00295,Morphine
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,3.12,197092,DB00295,Morphine
,29214506,peak concentration (C max),"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[μg] / [ml],11,197273,DB00295,Morphine
,29214506,area under the plasma concentration-time curve over the dosing interval (AUC0-6),"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[h·μg] / [ml],31.00 to 25.51,197274,DB00295,Morphine
,29214506,C max,"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[μg] / [ml],13.5,197275,DB00295,Morphine
,29214506,AUC0-6,"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[h·μg] / [ml],52.38,197276,DB00295,Morphine
,29214506,time to peak plasma concentration (T max),There was also a significantly prolonged mean time to peak plasma concentration (T max) after the 4th dose of oral paracetamol (2.84 h) compared to the 1st dose (1.48 h).,Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),h,2.84,197277,DB00295,Morphine
,29214506,time to peak plasma concentration (T max),There was also a significantly prolonged mean time to peak plasma concentration (T max) after the 4th dose of oral paracetamol (2.84 h) compared to the 1st dose (1.48 h).,Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),h,1.48,197278,DB00295,Morphine
,6723763,Cmax,"Plasma morphine concentrations after epidural injection were similar to those found after intramuscular administration; Cmax (66 +/- 8 mg/ml: mean +/- SEM) appeared within 12 +/- 3 min, and the terminal elimination half-life in plasma was 213 +/- 24 min.",Pharmacokinetics of epidural morphine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723763/),[mg] / [ml],66,197673,DB00295,Morphine
,6723763,terminal elimination half-life,"Plasma morphine concentrations after epidural injection were similar to those found after intramuscular administration; Cmax (66 +/- 8 mg/ml: mean +/- SEM) appeared within 12 +/- 3 min, and the terminal elimination half-life in plasma was 213 +/- 24 min.",Pharmacokinetics of epidural morphine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723763/),min,213,197674,DB00295,Morphine
,6723763,peak,"In CSF, morphine reached a peak (1575 +/- 359 ng/ml) after 135 +/- 40 min.",Pharmacokinetics of epidural morphine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723763/),[ng] / [ml],1575,197675,DB00295,Morphine
,6723763,terminal elimination half-life,The terminal elimination half-life for morphine in CSF was 239 +/- 10 min.,Pharmacokinetics of epidural morphine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723763/),min,239,197676,DB00295,Morphine
,6723763,bioavailability,The CSF bioavailability of morphine after epidural administration was calculated to be 1.9 +/- 0.5%.,Pharmacokinetics of epidural morphine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723763/),%,1.9,197677,DB00295,Morphine
,27513688,infusion rate,"The median morphine infusion rate during the first 24 hours after surgery was 31.3 μg/kg/hr (interquartile range, 23.4-36.4) in the Down syndrome group versus 31.7 μg/kg/hr (interquartile range, 25.1-36.1) in the control group (p = 1.00).",Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With and Without Down Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513688/),[μg] / [h·kg],31.3,198205,DB00295,Morphine
,27513688,infusion rate,"The median morphine infusion rate during the first 24 hours after surgery was 31.3 μg/kg/hr (interquartile range, 23.4-36.4) in the Down syndrome group versus 31.7 μg/kg/hr (interquartile range, 25.1-36.1) in the control group (p = 1.00).",Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With and Without Down Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513688/),[μg] / [h·kg],31.7,198206,DB00295,Morphine
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,69,198466,DB00295,Morphine
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,21,198467,DB00295,Morphine
,1467165,duration of severe pain,"However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days).",Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),d,0.9,198696,DB00295,Morphine
,1467165,duration of severe pain,"However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days).",Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),d,2.0,198697,DB00295,Morphine
,1467165,Total body clearance (TBC),Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05).,Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),[ml] / [kg·min],40.4,198698,DB00295,Morphine
,1467165,Total body clearance (TBC),Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05).,Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),[ml] / [kg·min],28,198699,DB00295,Morphine
,25486331,absorption transit time,"The mean morphine absorption transit time was 0.6h, clearance 78 L/h [relative standard error (RSE) 12%] and absolute bioavailability 24% (RSE 11%).",Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25486331/),h,0.6,199506,DB00295,Morphine
,25486331,clearance,"The mean morphine absorption transit time was 0.6h, clearance 78 L/h [relative standard error (RSE) 12%] and absolute bioavailability 24% (RSE 11%).",Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25486331/),[l] / [h],78,199507,DB00295,Morphine
,25486331,absolute bioavailability,"The mean morphine absorption transit time was 0.6h, clearance 78 L/h [relative standard error (RSE) 12%] and absolute bioavailability 24% (RSE 11%).",Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25486331/),%,24,199508,DB00295,Morphine
,21059857,steady-state plasma concentrations,"A 10-min bolus infusion of morphine, followed by a constant-rate infusion, was given to male rats (n = 6) to achieve high (250 ng/ml), medium (50 ng/ml), and low (10 ng/ml) steady-state plasma concentrations.",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,250,199592,DB00295,Morphine
,21059857,steady-state plasma concentrations,"A 10-min bolus infusion of morphine, followed by a constant-rate infusion, was given to male rats (n = 6) to achieve high (250 ng/ml), medium (50 ng/ml), and low (10 ng/ml) steady-state plasma concentrations.",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),[ng] / [ml],50,199593,DB00295,Morphine
,21059857,steady-state plasma concentrations,"A 10-min bolus infusion of morphine, followed by a constant-rate infusion, was given to male rats (n = 6) to achieve high (250 ng/ml), medium (50 ng/ml), and low (10 ng/ml) steady-state plasma concentrations.",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),[ng] / [ml],10,199594,DB00295,Morphine
,21059857,"partition coefficient for unbound drug (K(p,uu))","The average partition coefficient for unbound drug (K(p,uu)) values for the low and medium steady-state levels were 0.22 ± 0.08 and 0.21 ± 0.05, respectively, when measured by AMS [not significant (NS); p = 0.5].",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.22,199595,DB00295,Morphine
,21059857,"partition coefficient for unbound drug (K(p,uu))","The average partition coefficient for unbound drug (K(p,uu)) values for the low and medium steady-state levels were 0.22 ± 0.08 and 0.21 ± 0.05, respectively, when measured by AMS [not significant (NS); p = 0.5].",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.21,199596,DB00295,Morphine
,21059857,"K(p,uu)","For the medium and high steady-state levels, K(p,uu) values were 0.24 ± 0.05 and 0.26 ± 0.05, respectively, when measured by LC-MS/MS (NS; p = 0.2).",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.24,199597,DB00295,Morphine
,21059857,"K(p,uu)","For the medium and high steady-state levels, K(p,uu) values were 0.24 ± 0.05 and 0.26 ± 0.05, respectively, when measured by LC-MS/MS (NS; p = 0.2).",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.26,199598,DB00295,Morphine
,21059857,"K(p,uu)","For the low, very low, and ultralow steady-state levels, K(p,uu) values were 0.16 ± 0.01, 0.16 ± 0.02, and 0.18 ± 0.03, respectively, when measured by AMS.",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.16,199599,DB00295,Morphine
,21059857,"K(p,uu)","For the low, very low, and ultralow steady-state levels, K(p,uu) values were 0.16 ± 0.01, 0.16 ± 0.02, and 0.18 ± 0.03, respectively, when measured by AMS.",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.16,199600,DB00295,Morphine
,21059857,"K(p,uu)","For the low, very low, and ultralow steady-state levels, K(p,uu) values were 0.16 ± 0.01, 0.16 ± 0.02, and 0.18 ± 0.03, respectively, when measured by AMS.",Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21059857/),,0.18,199601,DB00295,Morphine
,29389842,apparent half-life,"In contrast to the rapid clearance of dihydrocodeine from blood in the 14-year-old girl (apparent half-life of 3 hours), the 1-month-old baby boy still had high serum concentrations of dihydrocodeine (400 nmol/L) and dihydromorphine (1.9 nmol/L) 21 hours after the last oral administration of dihydrocodeine-containing cough mixture.",Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36: Comparing Developmental Ages and Drug Monitoring Data With the Results of Pharmacokinetic Modeling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389842/),h,3,199906,DB00295,Morphine
,15907650,half-lives,Alfentanil and remifentanil are very fast equilibrating opioids with equilibration half-lives between plasma and effect site of about 1 minute.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,1,199979,DB00295,Morphine
,15907650,half-lives,"They are followed by fentanyl and sufentanil, each with equilibration half-lives of about 6 min.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,6,199980,DB00295,Morphine
,15907650,half-life,Methadone equilibrates with a half-life of about 8 min.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,8,199981,DB00295,Morphine
,15907650,half-life,"Morphine, in contrast, equilibrates with a half-life of 2-3 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,2-3,199982,DB00295,Morphine
,15907650,half-life,"The slowest opioid with respect to plasma-effect site transfer is M6G, with an equilibration half-life of about 7 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,7,199983,DB00295,Morphine
,7094509,apparent plasma clearance,"There was a faster, but clinically unimportant, mean apparent plasma clearance in smokers (52.8 +/- 2.3 (SEM) ml/min/70 kg) than in nonsmokers (45.0 +/- 2.1 ml/min/70 kg) after intramuscular injection only.",Codeine disposition in smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),[ml] / [70·kg·min],52.8,200430,DB00295,Morphine
,7094509,apparent plasma clearance,"There was a faster, but clinically unimportant, mean apparent plasma clearance in smokers (52.8 +/- 2.3 (SEM) ml/min/70 kg) than in nonsmokers (45.0 +/- 2.1 ml/min/70 kg) after intramuscular injection only.",Codeine disposition in smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),[ml] / [70·kg·min],45.0,200431,DB00295,Morphine
,7094509,bioavailability,Mean oral codeine bioavailability in smokers (54.8 +/- 4.9%) and in nonsmokers (50.2 +/- 2.1%) did not offer.,Codeine disposition in smokers and nonsmokers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),%,54.8,200432,DB00295,Morphine
,7094509,bioavailability,Mean oral codeine bioavailability in smokers (54.8 +/- 4.9%) and in nonsmokers (50.2 +/- 2.1%) did not offer.,Codeine disposition in smokers and nonsmokers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),%,50.2,200433,DB00295,Morphine
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.29,200615,DB00295,Morphine
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.65,200616,DB00295,Morphine
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.40,200617,DB00295,Morphine
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],6.8,200618,DB00295,Morphine
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],14.2,200619,DB00295,Morphine
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],40.1,200620,DB00295,Morphine
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,3.7,200621,DB00295,Morphine
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,5.7,200622,DB00295,Morphine
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,22,200623,DB00295,Morphine
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],15.7,200624,DB00295,Morphine
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],12.4,200625,DB00295,Morphine
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],16.4,200626,DB00295,Morphine
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,62.6,200627,DB00295,Morphine
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,40,200628,DB00295,Morphine
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],6.2,200629,DB00295,Morphine
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],1.3,200630,DB00295,Morphine
,9695716,volume,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),l,5.0,201138,DB00295,Morphine
,9695716,volume,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),l,2,201139,DB00295,Morphine
,9695716,volume,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),l,0.80,201140,DB00295,Morphine
,9695716,volume,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),l,3,201141,DB00295,Morphine
,9695716,volume,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),l,12,201142,DB00295,Morphine
,9695716,clearance 1,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),[l] / [min],6.0,201143,DB00295,Morphine
,9695716,clearance 2,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),[l] / [min],0.054,201144,DB00295,Morphine
,9695716,clearance 3,"The pharmacokinetics of dynorphin immunoreactivity were linear over the dose range studied and were best described by a three-compartment mammillary model whose parameters were volume 1, 5.0 L; volume 2, 0.80 L; volume 3, 12 L; clearance 1, 6.0 L/min; clearance 2, 0.054 L/min; and clearance 3, 0.044 L/min.",Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695716/),[l] / [min],0.044,201145,DB00295,Morphine
,7737438,serum half-life,After a single injection with 20 mg/kg methadone a pharmacokinetic analysis revealed a serum half-life of approximately 2 hr.,The effect of methadone on the immune status of B6C3F1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737438/),h,2,202382,DB00295,Morphine
,12895198,clearance,No differences were detected between carriers and noncarriers of Gilbert's syndrome in the clearance of morphine (80.1 +/- 12 l h(-1) vs 87.9 +/- 22 l h(-1)) and in the percentage of morphine that was metabolized to M6G (10.9 +/- 1.4 vs 13 +/- 2).,Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895198/),[l] / [h],80.1,202692,DB00295,Morphine
,12895198,clearance,No differences were detected between carriers and noncarriers of Gilbert's syndrome in the clearance of morphine (80.1 +/- 12 l h(-1) vs 87.9 +/- 22 l h(-1)) and in the percentage of morphine that was metabolized to M6G (10.9 +/- 1.4 vs 13 +/- 2).,Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895198/),[l] / [h],87.9,202693,DB00295,Morphine
,12895198,percentage,No differences were detected between carriers and noncarriers of Gilbert's syndrome in the clearance of morphine (80.1 +/- 12 l h(-1) vs 87.9 +/- 22 l h(-1)) and in the percentage of morphine that was metabolized to M6G (10.9 +/- 1.4 vs 13 +/- 2).,Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895198/),,10.9,202694,DB00295,Morphine
,12895198,percentage,No differences were detected between carriers and noncarriers of Gilbert's syndrome in the clearance of morphine (80.1 +/- 12 l h(-1) vs 87.9 +/- 22 l h(-1)) and in the percentage of morphine that was metabolized to M6G (10.9 +/- 1.4 vs 13 +/- 2).,Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895198/),,13,202695,DB00295,Morphine
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,9,203445,DB00295,Morphine
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,4,203446,DB00295,Morphine
,33581736,MR,The MR of codeine O-demethylation ranged from 0.002 to 0.147 (median 0.018) among all horses.,Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.002 to 0.147,203453,DB00295,Morphine
,33581736,MR,The MR of codeine O-demethylation ranged from 0.002 to 0.147 (median 0.018) among all horses.,Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.018,203454,DB00295,Morphine
,33581736,MR,"The mean ± SD MR was 0.089 ± 0.027, 0.022 ± 0.011, and 0.0095 ± 0.001 for high-, moderate-, and low-MR groups, respectively.",Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.089,203455,DB00295,Morphine
,33581736,MR,"The mean ± SD MR was 0.089 ± 0.027, 0.022 ± 0.011, and 0.0095 ± 0.001 for high-, moderate-, and low-MR groups, respectively.",Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.022,203456,DB00295,Morphine
,33581736,MR,"The mean ± SD MR was 0.089 ± 0.027, 0.022 ± 0.011, and 0.0095 ± 0.001 for high-, moderate-, and low-MR groups, respectively.",Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.0095,203457,DB00295,Morphine
,24954166,latency,"Compared to morphine, TRV130 (3, 4.5mg) elicited higher peak analgesia (105, 116 seconds latency vs 75 seconds for morphine, P<.02), with faster onset and similar duration of action.","Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954166/),seconds,"105, 116",203647,DB00295,Morphine
,24954166,maximum latency,"More subjects doubled latency or achieved maximum latency (180 seconds) with TRV130 (3, 4.5mg).","Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954166/),seconds,180,203648,DB00295,Morphine
,16584154,C(max),"Following administration of a 0.1 mg dose, the average C(max) values were found to be 64.9 +/- 12.1 and 95.2 +/- 10.1 ng/mL, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),[ng] / [ml],64.9,204292,DB00295,Morphine
,16584154,C(max),"Following administration of a 0.1 mg dose, the average C(max) values were found to be 64.9 +/- 12.1 and 95.2 +/- 10.1 ng/mL, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),[ng] / [ml],95.2,204293,DB00295,Morphine
,16584154,area under the curve (AUC),"The area under the curve (AUC) values were found to be 5807.0, and 8965.3 ng.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),ng,5807.0,204294,DB00295,Morphine
,16584154,area under the curve (AUC),"The area under the curve (AUC) values were found to be 5807.0, and 8965.3 ng.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),ng,8965.3,204295,DB00295,Morphine
,16584154,bioavailability,"The mean sublingual bioavailability of oxycodone was 45.4% +/- 20.1% and 70.1% +/- 17.9%, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),%,45.4,204296,DB00295,Morphine
,16584154,bioavailability,"The mean sublingual bioavailability of oxycodone was 45.4% +/- 20.1% and 70.1% +/- 17.9%, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),%,70.1,204297,DB00295,Morphine
,3377150,peak concentrations,Morphine concentrations were generally higher in the gluteal group although the mean peak concentrations (62.8 ng/ml in the gluteal group and 52.3 ng/ml in the deltoid group) were similar.,Plasma morphine concentrations after intramuscular injection into the deltoid or gluteal muscles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377150/),[ng] / [ml],62.8,204331,DB00295,Morphine
,3377150,peak concentrations,Morphine concentrations were generally higher in the gluteal group although the mean peak concentrations (62.8 ng/ml in the gluteal group and 52.3 ng/ml in the deltoid group) were similar.,Plasma morphine concentrations after intramuscular injection into the deltoid or gluteal muscles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377150/),[ng] / [ml],52.3,204332,DB00295,Morphine
,3377150,Peak morphine concentrations,Peak morphine concentrations varied from 22.5-99.3 ng/ml in the gluteal group and 26.5-84.5 ng/ml in the deltoid group.,Plasma morphine concentrations after intramuscular injection into the deltoid or gluteal muscles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377150/),[ng] / [ml],22.5-99.3,204333,DB00295,Morphine
,3377150,Peak morphine concentrations,Peak morphine concentrations varied from 22.5-99.3 ng/ml in the gluteal group and 26.5-84.5 ng/ml in the deltoid group.,Plasma morphine concentrations after intramuscular injection into the deltoid or gluteal muscles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377150/),[ng] / [ml],26.5-84.5,204334,DB00295,Morphine
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,6,204674,DB00295,Morphine
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,2.9,204675,DB00295,Morphine
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,3.6,204950,DB00295,Morphine
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,5.6,204951,DB00295,Morphine
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,5.7,204952,DB00295,Morphine
,2590614,plasma clearance,"2. The mean plasma clearance of morphine was significantly higher in children than neonates (25.7 and 4.7 ml min-1 kg-1, respectively) (P less than 0.01).",Morphine metabolism in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590614/),[ml] / [kg·min],25.7,205945,DB00295,Morphine
,2590614,plasma clearance,"2. The mean plasma clearance of morphine was significantly higher in children than neonates (25.7 and 4.7 ml min-1 kg-1, respectively) (P less than 0.01).",Morphine metabolism in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590614/),[ml] / [kg·min],4.7,205946,DB00295,Morphine
,7983238,Cmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],217.8,206467,DB00295,Morphine
,7983238,Cmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],138.8,206468,DB00295,Morphine
,7983238,Tmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.3,206469,DB00295,Morphine
,7983238,Tmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,1.1,206470,DB00295,Morphine
,7983238,AUC0-inf,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1202.3,206471,DB00295,Morphine
,7983238,AUC0-inf,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1262.4,206472,DB00295,Morphine
,7983238,t1/2el,mL-1.hour-1; and t1/2el of 2.6 hours for both formulations.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.6,206473,DB00295,Morphine
,7983238,Cmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],263.8,206474,DB00295,Morphine
,7983238,Cmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],222.9,206475,DB00295,Morphine
,7983238,Tmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,3.2,206476,DB00295,Morphine
,7983238,Tmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,1.1,206477,DB00295,Morphine
,7983238,AUC0-12h,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1576.4,206478,DB00295,Morphine
,7983238,AUC0-12h,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1379.1,206479,DB00295,Morphine
,7983238,t1/2el,mL-1.hour-1; and t1/2el of 2.8 and 2.3 hours.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.8,206480,DB00295,Morphine
,7983238,t1/2el,mL-1.hour-1; and t1/2el of 2.8 and 2.3 hours.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.3,206481,DB00295,Morphine
,291954,terminal half-life,"The mean terminal half-life after intravenous administration of 5 or 10 mg of human beta-endorphin to three patients was 37 min; the mean volume of distribution was 178 ml/kg, and the metabolic clearance rate was 3.2 (ml/min)/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),min,37,206720,DB00295,Morphine
,291954,volume of distribution,"The mean terminal half-life after intravenous administration of 5 or 10 mg of human beta-endorphin to three patients was 37 min; the mean volume of distribution was 178 ml/kg, and the metabolic clearance rate was 3.2 (ml/min)/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),[ml] / [kg],178,206721,DB00295,Morphine
,291954,metabolic clearance rate,"The mean terminal half-life after intravenous administration of 5 or 10 mg of human beta-endorphin to three patients was 37 min; the mean volume of distribution was 178 ml/kg, and the metabolic clearance rate was 3.2 (ml/min)/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),[ml] / [kg·min)],3.2,206722,DB00295,Morphine
,291954,half-life,"The half-life of beta-endorphin in cerebrospinal fluid after intracerebroventricular administration was 93 min, and the volume of distribution was 0.74 ml/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),min,93,206723,DB00295,Morphine
,291954,volume of distribution,"The half-life of beta-endorphin in cerebrospinal fluid after intracerebroventricular administration was 93 min, and the volume of distribution was 0.74 ml/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),[ml] / [kg],0.74,206724,DB00295,Morphine
,8996532,plasma clearance rate,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],54 to 28,206813,DB00295,Morphine
,8996532,elimination half-life,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),min,6.9 to 12.2,206814,DB00295,Morphine
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],145,206815,DB00295,Morphine
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],94,206816,DB00295,Morphine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],6307,206850,DB00295,Morphine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],9791,206851,DB00295,Morphine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],1503,206852,DB00295,Morphine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],2388,206853,DB00295,Morphine
,26491112,maximal plasma concentration,"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),h,4,206854,DB00295,Morphine
,26491112,maximal plasma concentration,"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),h,2,206855,DB00295,Morphine
,9496218,clearance,Patients with cirrhosis had less clearance (0.586 litre h-1) than controls (0.729 litre h-1).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),[l] / [h],0.586,206968,DB00295,Morphine
,9496218,clearance,Patients with cirrhosis had less clearance (0.586 litre h-1) than controls (0.729 litre h-1).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),[l] / [h],0.729,206969,DB00295,Morphine
,9496218,Mean residence time (MRT),Mean residence time (MRT) was prolonged in cirrhotic patients (19.57 h) compared with controls (7.03 h).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),h,19.57,206970,DB00295,Morphine
,9496218,Mean residence time (MRT),Mean residence time (MRT) was prolonged in cirrhotic patients (19.57 h) compared with controls (7.03 h).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),h,7.03,206971,DB00295,Morphine
,9496218,Elimination half-life,Elimination half-life in cirrhotic patients (mean 7.36 (SEM 0.45) h) was nearly twice that of controls (4.01 (0.15) h).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),h,7.36,206972,DB00295,Morphine
,9496218,Elimination half-life,Elimination half-life in cirrhotic patients (mean 7.36 (SEM 0.45) h) was nearly twice that of controls (4.01 (0.15) h).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),h,4.01,206973,DB00295,Morphine
,9496218,peak concentration,Serum concentrations were higher at all sampling times in the cirrhotic patients (peak concentration 35.2 (3.2) ng ml-1 compared with 12.8 (0.4) ng ml-1 in controls).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),[ng] / [ml],35.2,206974,DB00295,Morphine
,9496218,peak concentration,Serum concentrations were higher at all sampling times in the cirrhotic patients (peak concentration 35.2 (3.2) ng ml-1 compared with 12.8 (0.4) ng ml-1 in controls).,Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496218/),[ng] / [ml],12.8,206975,DB00295,Morphine
,27870477,t1/2,"Noribogaine had dose-linear increases for AUC and Cmax and was slowly eliminated (mean t1/2 range, 24-30 hours).","Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27870477/),h,24-30,207699,DB00295,Morphine
,1448475,half-life,Morphine sulfate administered IV and SC had a half-life of approximately 1 h whereas delayed-release morphine alkaloid delivered SC had a half-life of 28 h.,Acute and chronic morphine administration in swine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448475/),h,1,208049,DB00295,Morphine
,1448475,half-life,Morphine sulfate administered IV and SC had a half-life of approximately 1 h whereas delayed-release morphine alkaloid delivered SC had a half-life of 28 h.,Acute and chronic morphine administration in swine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448475/),h,28,208050,DB00295,Morphine
,2053119,detection limit,"An original, highly sensitive and specific high-performance liquid chromatographic (HPLC) assay has been developed for the measurement of oxycodone in human plasma with a detection limit of 10 ng/ml using a 1.0-ml plasma sample.",Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053119/),[ng] / [ml],10,208051,DB00295,Morphine
,2088996,Tmax,Time to maximal concentration (Tmax) was similar (p greater than 0.05) in the two treatment groups; the mean Tmax for fed volunteers was 2.5 hours versus 2.4 hours for fasted volunteers.,Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088996/),h,2.5,208708,DB00295,Morphine
,2088996,Tmax,Time to maximal concentration (Tmax) was similar (p greater than 0.05) in the two treatment groups; the mean Tmax for fed volunteers was 2.5 hours versus 2.4 hours for fasted volunteers.,Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088996/),h,2.4,208709,DB00295,Morphine
,2088996,Cmax,"The two regimens did not differ significantly (p greater than 0.05) with regard to maximal morphine concentration (Cmax); mean Cmax for fed subjects was 8.22 ng/ml whereas mean Cmax for fasted subjects was 8.53 ng/ It was concluded that consumption of a high fat meal did not affect either the rate or extent of morphine absorption, or any of the other pharmacokinetic parameters tested, following administration of MSC.",Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088996/),[ng] / [ml],8.22,208710,DB00295,Morphine
,2088996,Cmax,"The two regimens did not differ significantly (p greater than 0.05) with regard to maximal morphine concentration (Cmax); mean Cmax for fed subjects was 8.22 ng/ml whereas mean Cmax for fasted subjects was 8.53 ng/ It was concluded that consumption of a high fat meal did not affect either the rate or extent of morphine absorption, or any of the other pharmacokinetic parameters tested, following administration of MSC.",Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088996/),-1·ng,8.53,208711,DB00295,Morphine
,25255074,clearance,"After intravenous administration, the median clearance and terminal half-life were 37.7 (range, 33.7 to 47.1) mL/kg/min and 142 (range, 131 to 218) min, respectively.",Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),[ml] / [kg·min],37.7,209371,DB00295,Morphine
,25255074,terminal half-life,"After intravenous administration, the median clearance and terminal half-life were 37.7 (range, 33.7 to 47.1) mL/kg/min and 142 (range, 131 to 218) min, respectively.",Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),min,142,209372,DB00295,Morphine
,25255074,elimination half-life,The median (range) elimination half-life after intramuscular administration was 81.5 (77.2 to 92.5) min.,Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),min,81.5,209373,DB00295,Morphine
,25255074,intramuscular bioavailability,"Median intramuscular bioavailability was 92% (range, 75% to 104%).",Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),%,92,209374,DB00295,Morphine
,21417617,half-life,Codeine is an important opioid anti-tussive agent whose short half-life (2.9 ± 0.7 h) requires that it be administered at 4-h intervals when formulated as a simple aqueous solution.,Pharmacokinetics of a novel liquid controlled release codeine formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417617/),h,2.9,209665,DB00295,Morphine
,21417617,apparent mean half life,"Controlled release from the suspension of beads protracted the apparent mean half life of codeine from 3.2 h to 8.2 h, while the mean AUC(0-12 h) was unchanged.",Pharmacokinetics of a novel liquid controlled release codeine formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417617/),h,3.2,209666,DB00295,Morphine
,21417617,apparent mean half life,"Controlled release from the suspension of beads protracted the apparent mean half life of codeine from 3.2 h to 8.2 h, while the mean AUC(0-12 h) was unchanged.",Pharmacokinetics of a novel liquid controlled release codeine formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417617/),h,8.2,209667,DB00295,Morphine
,3771915,apparent liver blood flow,In six patients with septic shock apparent liver blood flow was significantly reduced compared with two patients restudied on recovery from shock and a group of four matched unshocked patients undergoing intensive care (287 +/- 23 ml/min vs 870 +/- 164 ml/min; mean +/- SEM).,Profound reduction in morphine clearance and liver blood flow in shock. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3771915/),[ml] / [min],287,209889,DB00295,Morphine
,3771915,apparent liver blood flow,In six patients with septic shock apparent liver blood flow was significantly reduced compared with two patients restudied on recovery from shock and a group of four matched unshocked patients undergoing intensive care (287 +/- 23 ml/min vs 870 +/- 164 ml/min; mean +/- SEM).,Profound reduction in morphine clearance and liver blood flow in shock. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3771915/),[ml] / [min],870,209890,DB00295,Morphine
,3771915,elimination half-life,"In the shocked patients the elimination half-life of morphine was significantly prolonged (13.2 +/- 3.5 h vs 5.9 +/- 1.4 h; mean +/- SEM) and the systemic clearance of morphine reduced by 53%, in comparison with the non-shocked patients.",Profound reduction in morphine clearance and liver blood flow in shock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3771915/),h,13.2,209891,DB00295,Morphine
,3771915,elimination half-life,"In the shocked patients the elimination half-life of morphine was significantly prolonged (13.2 +/- 3.5 h vs 5.9 +/- 1.4 h; mean +/- SEM) and the systemic clearance of morphine reduced by 53%, in comparison with the non-shocked patients.",Profound reduction in morphine clearance and liver blood flow in shock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3771915/),h,5.9,209892,DB00295,Morphine
,32427759,clearance,"Among the critically ill neonates and infants, morphine clearance showed substantial variability with a 40-fold range (ie, 2.2 to 87.1, mean 23.7 L/h/70 kg).",Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32427759/),[l] / [70·h·kg],23.7,210289,DB00295,Morphine
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00295,Morphine
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00295,Morphine
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00295,Morphine
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00295,Morphine
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00295,Morphine
,22717418,C(max),"The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although C(max) was ~16.5% lower.","Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22717418/),%,16.5,210871,DB00295,Morphine
,9587957,ke0,"A pharmacokinetic/pharmacodynamic effect model accurately described the effect-concentration data for the rats that received 1-mg/kg morphine; ke0 was significantly smaller for GF120918- vs. vehicle-treated and control rats (0.060 +/- 0.028 vs. 0.228 +/- 0.101 vs. 0.274 +/- 0.026 min-1, p = 0.0023).","Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587957/),1/[min],0.060,210963,DB00295,Morphine
,9587957,ke0,"A pharmacokinetic/pharmacodynamic effect model accurately described the effect-concentration data for the rats that received 1-mg/kg morphine; ke0 was significantly smaller for GF120918- vs. vehicle-treated and control rats (0.060 +/- 0.028 vs. 0.228 +/- 0.101 vs. 0.274 +/- 0.026 min-1, p = 0.0023).","Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587957/),1/[min],0.228,210964,DB00295,Morphine
,9587957,ke0,"A pharmacokinetic/pharmacodynamic effect model accurately described the effect-concentration data for the rats that received 1-mg/kg morphine; ke0 was significantly smaller for GF120918- vs. vehicle-treated and control rats (0.060 +/- 0.028 vs. 0.228 +/- 0.101 vs. 0.274 +/- 0.026 min-1, p = 0.0023).","Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587957/),1/[min],0.274,210965,DB00295,Morphine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],21.7,211340,DB00295,Morphine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],10.1,211341,DB00295,Morphine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],29.8,211342,DB00295,Morphine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],62.12,211343,DB00295,Morphine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],182.2,211344,DB00295,Morphine
,17461710,serum concentrations,"When comparing fentanyl ITS with intravenously administered fentanyl, serum concentrations differ significantly at 10 minutes after the initial dose is administered: 0.1 ng/ml for fentanyl ITS versus 0.7 ng/ml for intravenous fentanyl.",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),ng,0.1,211555,DB00295,Morphine
,17461710,serum concentrations,"When comparing fentanyl ITS with intravenously administered fentanyl, serum concentrations differ significantly at 10 minutes after the initial dose is administered: 0.1 ng/ml for fentanyl ITS versus 0.7 ng/ml for intravenous fentanyl.",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[ng] / [ml],0.7,211556,DB00295,Morphine
,17461710,maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[μg] / [ml],1.37,211557,DB00295,Morphine
,17461710,maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[μg] / [ml],1.82,211558,DB00295,Morphine
,17461710,time to maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),h,0.65,211559,DB00295,Morphine
,17461710,time to maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),h,0.58,211560,DB00295,Morphine
,17461710,area under the concentration-time curve at 23-24 hrs,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[h·μg] / [ml],1.23,211561,DB00295,Morphine
,17461710,area under the concentration-time curve at 23-24 hrs,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[h·μg] / [ml],1.34,211562,DB00295,Morphine
,28421874,maximum plasma concentration,"Oxycodone was detected 8.0 ± 2.7-h postpatch administration, reaching a mean maximum plasma concentration of 3.41 ± 1.34 ng/ml at 49.3 ± 21.2 h.","Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421874/),[ng] / [ml],3.41,212221,DB00295,Morphine
,3402521,terminal elimination of half-life,"A relatively long terminal elimination of half-life of morphine was found in all patients (mean +/- SD: 9.2 +/- 2.5 h), irrespective of glomerular function.",Influence of renal function on the elimination of morphine and morphine glucuronides. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402521/),h,9.2,212237,DB00295,Morphine
,11599592,Excretion half-life,Excretion half-life mean +/- SD for Tmor was 3.11 +/- 0.30 h.,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,3.11,212732,DB00295,Morphine
,11599592,peak urine concentrations,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),[ng] / [ml],1392-9250,212733,DB00295,Morphine
,11599592,time to peak,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,1.2-6.2,212734,DB00295,Morphine
,11599592,time to peak,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,7.4-31.9,212735,DB00295,Morphine
,11599592,time to last positive sample,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,7.4-31.9,212736,DB00295,Morphine
,11599592,time to last positive sample,"Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (< or = 7 mg) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,0-10.1,212737,DB00295,Morphine
,11599592,peak Fmor concentrations,"Range (median) of peak Fmor concentrations and time to last positive using a cutoff of 100 ng/mL for low and high doses were, respectively, 117-1160 (415) ng/mL, 1.2-10.1 (4.5) h and 150-2580 (1400) ng/mL, 2.3-29.1 (9.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),[ng] / [ml],117-1160,212738,DB00295,Morphine
,11599592,time to last positive,"Range (median) of peak Fmor concentrations and time to last positive using a cutoff of 100 ng/mL for low and high doses were, respectively, 117-1160 (415) ng/mL, 1.2-10.1 (4.5) h and 150-2580 (1400) ng/mL, 2.3-29.1 (9.3) h.","Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),h,1.2-10.1,212739,DB00295,Morphine
,11599592,peak urine concentrations,The range (median) of peak urine concentrations for 6-AM was 6.1-568 (124) ng/mL.,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),[ng] / [ml],6.1-568,212740,DB00295,Morphine
,11599592,percent of heroin excreted into urine as,The range (median) values for percent of heroin excreted into urine as Tmor was 12.8-88.5% (51.0).,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),%,12.8-88.5,212741,DB00295,Morphine
,11599592,Tmor,The range (median) values for percent of heroin excreted into urine as Tmor was 12.8-88.5% (51.0).,"Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599592/),%,12.8-88.5,212742,DB00295,Morphine
,8950049,half-life,The mean half-life of M6G after intravenous administration was 51.0 +/- 8.2 min and that after intranasal dosing was 45.0 +/- 5.5 min.,Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950049/),min,51.0,212774,DB00295,Morphine
,8950049,half-life,The mean half-life of M6G after intravenous administration was 51.0 +/- 8.2 min and that after intranasal dosing was 45.0 +/- 5.5 min.,Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950049/),min,45.0,212775,DB00295,Morphine
,8950049,clearance,M6G clearance and volume of distribution were 5.4 +/- 1.5 mL min-1 kg-1 and 0.4 +/- 0.1 L kg-1 respectively.,Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950049/),[ml] / [kg·min],5.4,212776,DB00295,Morphine
,8950049,volume of distribution,M6G clearance and volume of distribution were 5.4 +/- 1.5 mL min-1 kg-1 and 0.4 +/- 0.1 L kg-1 respectively.,Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950049/),[l] / [kg],0.4,212777,DB00295,Morphine
,8950049,bioavailability,The bioavailability of M6G in the chitosan formulation was found to be 31.4%.,Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950049/),%,31.4,212778,DB00295,Morphine
,24122908,AUC0-inf,"TRV130 geometric mean exposure and Cmax were dose-linear, with AUC0-inf of 2.52 to 205.97 ng h/mL and Cmax of 1.04 to 102.36 ng/mL across the dose range tested, with half-life of 1.6-2.7 hours.",First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122908/),[h·ng] / [ml],2.52 to 205.97,214370,DB00295,Morphine
,24122908,Cmax,"TRV130 geometric mean exposure and Cmax were dose-linear, with AUC0-inf of 2.52 to 205.97 ng h/mL and Cmax of 1.04 to 102.36 ng/mL across the dose range tested, with half-life of 1.6-2.7 hours.",First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122908/),[ng] / [ml],1.04 to 102.36,214371,DB00295,Morphine
,24122908,half-life,"TRV130 geometric mean exposure and Cmax were dose-linear, with AUC0-inf of 2.52 to 205.97 ng h/mL and Cmax of 1.04 to 102.36 ng/mL across the dose range tested, with half-life of 1.6-2.7 hours.",First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122908/),h,1.6-2.7,214372,DB00295,Morphine
,25845657,clearance,The mean clearance was higher in children (32 and 52 ml min(-1) kg(-1)) than in neonates (2 to 16 ml min(-1) kg(-1)).,Inter-individual variation in morphine clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25845657/),[ml] / [kg·min],32,214430,DB00295,Morphine
,25845657,clearance,The mean clearance was higher in children (32 and 52 ml min(-1) kg(-1)) than in neonates (2 to 16 ml min(-1) kg(-1)).,Inter-individual variation in morphine clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25845657/),[ml] / [kg·min],52,214431,DB00295,Morphine
,25845657,clearance,The mean clearance was higher in children (32 and 52 ml min(-1) kg(-1)) than in neonates (2 to 16 ml min(-1) kg(-1)).,Inter-individual variation in morphine clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25845657/),[ml] / [kg·min],2 to 16,214432,DB00295,Morphine
,24077699,clearance,"Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively.",Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077699/),[l] / [h],73,214433,DB00295,Morphine
,24077699,oral absorption rate constant,"Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively.",Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077699/),h,0.0735,214434,DB00295,Morphine
,3565791,terminal half-life,"In cirrhotic patients as compared with normal subjects, terminal half-life of unchanged morphine was longer (201 +/- 39 vs 111 +/- 32 min (mean +/- SD), P less than 0.01) and total body clearance was slower (21 +/- 7.5 vs 33.5 +/- 8 ml X min-1 X kg-1, P less than 0.05).",Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565791/),min,201,214481,DB00295,Morphine
,3565791,terminal half-life,"In cirrhotic patients as compared with normal subjects, terminal half-life of unchanged morphine was longer (201 +/- 39 vs 111 +/- 32 min (mean +/- SD), P less than 0.01) and total body clearance was slower (21 +/- 7.5 vs 33.5 +/- 8 ml X min-1 X kg-1, P less than 0.05).",Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565791/),min,111,214482,DB00295,Morphine
,3565791,total body clearance,"In cirrhotic patients as compared with normal subjects, terminal half-life of unchanged morphine was longer (201 +/- 39 vs 111 +/- 32 min (mean +/- SD), P less than 0.01) and total body clearance was slower (21 +/- 7.5 vs 33.5 +/- 8 ml X min-1 X kg-1, P less than 0.05).",Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565791/),[ml] / [kg·min],21,214483,DB00295,Morphine
,3565791,total body clearance,"In cirrhotic patients as compared with normal subjects, terminal half-life of unchanged morphine was longer (201 +/- 39 vs 111 +/- 32 min (mean +/- SD), P less than 0.01) and total body clearance was slower (21 +/- 7.5 vs 33.5 +/- 8 ml X min-1 X kg-1, P less than 0.05).",Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565791/),[ml] / [kg·min],33.5,214484,DB00295,Morphine
,15025740,area under the concentration-time curve (AUC) ratio,"The area under the concentration-time curve (AUC) ratio of unbound morphine in brain tissue to plasma was 0.64 (95% confidence interval 0.40, 0.87) in 'better' brain tissue (P < 0.05 vs. the subcutaneous fat/plasma ratio), 0.78 (0.49, 1.07) in 'worse' brain tissue and 1.00 (0.86, 1.13) in subcutaneous fat.",Blood-brain barrier transport of morphine in patients with severe brain trauma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025740/),,0.64,214778,DB00295,Morphine
,15025740,area under the concentration-time curve (AUC) ratio,"The area under the concentration-time curve (AUC) ratio of unbound morphine in brain tissue to plasma was 0.64 (95% confidence interval 0.40, 0.87) in 'better' brain tissue (P < 0.05 vs. the subcutaneous fat/plasma ratio), 0.78 (0.49, 1.07) in 'worse' brain tissue and 1.00 (0.86, 1.13) in subcutaneous fat.",Blood-brain barrier transport of morphine in patients with severe brain trauma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025740/),,0.78,214779,DB00295,Morphine
,15025740,area under the concentration-time curve (AUC) ratio,"The area under the concentration-time curve (AUC) ratio of unbound morphine in brain tissue to plasma was 0.64 (95% confidence interval 0.40, 0.87) in 'better' brain tissue (P < 0.05 vs. the subcutaneous fat/plasma ratio), 0.78 (0.49, 1.07) in 'worse' brain tissue and 1.00 (0.86, 1.13) in subcutaneous fat.",Blood-brain barrier transport of morphine in patients with severe brain trauma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025740/),,1.,214780,DB00295,Morphine
,22119507,flow rate,"Following liquid-liquid extraction, the analytes were separated on a reversed-phase C(18) column (150 mm × 2.0 mm, 3 μm) using formic acid:10 mM ammonium acetate:methanol (0.2:62:38, v/v/v) as mobile phase at a flow rate of 0.2 mL/min and analyzed by a triple-quadrupole mass spectrometer in the selected reaction monitoring (SRM) mode.","Simultaneous determination of codeine, ephedrine, guaiphenesin and chlorpheniramine in beagle dog plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119507/),[ml] / [min],0.2,215136,DB00295,Morphine
below,6138235,absolute oral bioavailabilities,"The absolute oral bioavailabilities of morphine, codeine, ethylmorphine, and t-butylmorphine all were below 10%, whereas that of pholcodine was over 40%.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),%,10,215170,DB00295,Morphine
over,6138235,absolute oral bioavailabilities,"The absolute oral bioavailabilities of morphine, codeine, ethylmorphine, and t-butylmorphine all were below 10%, whereas that of pholcodine was over 40%.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),%,40,215171,DB00295,Morphine
less,6138235,Terminal half-lives,"Terminal half-lives of morphine, codeine, ethylmorphine, and t-butylmorphine after iv administration all were less than 45 min, while that of pholcoline was over 2 hr.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),min,45,215172,DB00295,Morphine
over,6138235,Terminal half-lives,"Terminal half-lives of morphine, codeine, ethylmorphine, and t-butylmorphine after iv administration all were less than 45 min, while that of pholcoline was over 2 hr.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),h,2,215173,DB00295,Morphine
,17270058,Tmax,Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose.,Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270058/),h,12.0-16.0,215475,DB00295,Morphine
,17270058,t1/2,Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose.,Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270058/),h,10.6-11.0,215476,DB00295,Morphine
,9587954,BBB permeability-surface area product,The brain uptake of BDNF-PEG-biotin was increased following conjugation to OX26/SA to a level of 0.144 +/- 0.004% injected dose per g brain and a BBB permeability-surface area product of 2.0 +/- 0.2 microL/min/g.,Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587954/),[μl] / [g·min],2.0,216007,DB00295,Morphine
,26814240,Cmax,"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [ml],27.5,216200,DB00295,Morphine
,26814240,Cmax,"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [ml],36.5,216201,DB00295,Morphine
,26814240,Cmax,"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [ml],105.8,216202,DB00295,Morphine
,26814240,Cmax/Tmax),"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [h·ml],9.5,216203,DB00295,Morphine
,26814240,Cmax/Tmax),"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [h·ml],13.4,216204,DB00295,Morphine
,26814240,Cmax/Tmax),"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [h·ml],82.0,216205,DB00295,Morphine
,17786418,transfer half-life,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),min,21.1,216418,DB00295,Morphine
,17786418,transfer half-life,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),min,19.8,216419,DB00295,Morphine
,17786418,EC50,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),[ng] / [ml],207,216420,DB00295,Morphine
,17786418,EC50,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),[ng] / [ml],230,216421,DB00295,Morphine
,3179150,clearance,"Mean clearance was 512 ml kg-1 h-1 and mean elimination half-lives were 3.3 h following CPB, with a tendency to a higher clearance in those children who had not undergone bypass.",A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179150/),[ml] / [h·kg],512,216492,DB00295,Morphine
,3179150,elimination half-lives,"Mean clearance was 512 ml kg-1 h-1 and mean elimination half-lives were 3.3 h following CPB, with a tendency to a higher clearance in those children who had not undergone bypass.",A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179150/),h,3.3,216493,DB00295,Morphine
,3179150,plasma midazolam concentrations,Mean plasma midazolam concentrations consistent with adequate sedation were 80-100 ng ml-1 during the infusion.,A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179150/),[ng] / [ml],80-100,216494,DB00295,Morphine
,1635423,concentrations,"The concentrations in plasma of morphine and its metabolite, morphine-3-glucuronide, were 4.2 +/- 1.4 microM and 7.7 +/- 4.0 microM, respectively, during the constant rate infusion.",Estimation of unbound concentrations of morphine from microdialysate concentrations by use of nonlinear regression analysis in vivo and in vitro during steady state conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635423/),μM,4.2,217639,DB00295,Morphine
,1635423,concentrations,"The concentrations in plasma of morphine and its metabolite, morphine-3-glucuronide, were 4.2 +/- 1.4 microM and 7.7 +/- 4.0 microM, respectively, during the constant rate infusion.",Estimation of unbound concentrations of morphine from microdialysate concentrations by use of nonlinear regression analysis in vivo and in vitro during steady state conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635423/),μM,7.7,217640,DB00295,Morphine
,1635423,unbound concentrations,The corresponding estimated unbound concentrations of morphine in striatum varied between 0.06 and 0.11 microM.,Estimation of unbound concentrations of morphine from microdialysate concentrations by use of nonlinear regression analysis in vivo and in vitro during steady state conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635423/),μM,0.06 and 0.11,217641,DB00295,Morphine
,8738689,re,The mean rectal bioavailability of morphine was 35% (range 18-59) after hydrogel administration and 27% (range 6-93) after the solution.,Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738689/),%,35,217769,DB00295,Morphine
,8738689,Cmax,"Mean values of Cmax were 76 nmol/l (25-129) and 56 nmol/1 (15-140), respectively.",Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738689/),[nM] / [l],76,217770,DB00295,Morphine
,8738689,Cmax,"Mean values of Cmax were 76 nmol/l (25-129) and 56 nmol/1 (15-140), respectively.",Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738689/),nM,56,217771,DB00295,Morphine
,23835420,transport,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218864,DB00295,Morphine
,23835420,membrane permeability,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218865,DB00295,Morphine
,23835420,KM,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),μM,3.4,218866,DB00295,Morphine
,23835420,VMAX,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[pM] / [mg·min],27,218867,DB00295,Morphine
,23835420,transporter-independent,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218868,DB00295,Morphine
,23835420,membrane permeability,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218869,DB00295,Morphine
,23601353,Cmax,Cmax for ASG-oxymorphone was 7.5 ng mL(-1) ; Cmax for ASG-hydromorphone was 5.7 ng mL(-1) .,Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23601353/),[ng] / [ml],7.5,218925,DB00295,Morphine
,23601353,Cmax,Cmax for ASG-oxymorphone was 7.5 ng mL(-1) ; Cmax for ASG-hydromorphone was 5.7 ng mL(-1) .,Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23601353/),[ng] / [ml],5.7,218926,DB00295,Morphine
,28345745,conversion to OC,Incubation at 80°C for 24 hours in vinegar or vodka produced a conversion to OC of 6 percent.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),%,6,219178,DB00295,Morphine
,28345745,half-life,Incubation with trypsin at 37°C converted PF614 approximately stoichiometric to OC with half-life of 4 hours.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),h,4,219179,DB00295,Morphine
,15626577,ratio,"The extent of BBB transport, expressed as the ratio between clearance into the brain and clearance out of the brain (CL(in)/CL(out)), was estimated as 0.29 on both days, indicating that efflux transporters act on M6G at the BBB.",Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626577/),,0.29,219750,DB00295,Morphine
,15626577,clearance into the brain,"The extent of BBB transport, expressed as the ratio between clearance into the brain and clearance out of the brain (CL(in)/CL(out)), was estimated as 0.29 on both days, indicating that efflux transporters act on M6G at the BBB.",Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626577/),,0.29,219751,DB00295,Morphine
,19839946,clearance,"The values of ketobemidone clearance (l/h/kg) given as median (range) were 0.84 (0.29-3.0) in Group A (0-90 days), 0.89 (0.55-1.35) in Group B (1-2.5 years) and 0.74 (0.50-0.99) in Group C (7-10 years).",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [h·kg],0.84,220647,DB00295,Morphine
,19839946,clearance,"The values of ketobemidone clearance (l/h/kg) given as median (range) were 0.84 (0.29-3.0) in Group A (0-90 days), 0.89 (0.55-1.35) in Group B (1-2.5 years) and 0.74 (0.50-0.99) in Group C (7-10 years).",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [h·kg],0.89,220648,DB00295,Morphine
,19839946,clearance,"The values of ketobemidone clearance (l/h/kg) given as median (range) were 0.84 (0.29-3.0) in Group A (0-90 days), 0.89 (0.55-1.35) in Group B (1-2.5 years) and 0.74 (0.50-0.99) in Group C (7-10 years).",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [h·kg],0.74,220649,DB00295,Morphine
,19839946,apparent volume of distribution,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [kg],4.4,220650,DB00295,Morphine
,19839946,apparent volume of distribution,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [kg],2.6,220651,DB00295,Morphine
,19839946,apparent volume of distribution,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [kg],3.9,220652,DB00295,Morphine
,19839946,elimination half-life,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,3.0,220653,DB00295,Morphine
,19839946,elimination half-life,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,2.0,220654,DB00295,Morphine
,19839946,elimination half-life,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,3.7,220655,DB00295,Morphine
,19839946,elimination half-life,In the two neonates the elimination half-life was almost 9 h.,Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,9,220656,DB00295,Morphine
,6869996,serum half life (t1/2(beta)),Computer analysis revealed that a 3-compartment open system was the best fitting model with a serum half life (t1/2(beta)) of 87.9 minutes and a urine t1/2(beta) of 101.1 minutes.,Pharmacokinetics and protein binding of morphine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869996/),min,87.9,220856,DB00295,Morphine
,6869996,urine t1/2(beta),Computer analysis revealed that a 3-compartment open system was the best fitting model with a serum half life (t1/2(beta)) of 87.9 minutes and a urine t1/2(beta) of 101.1 minutes.,Pharmacokinetics and protein binding of morphine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869996/),min,101.1,220857,DB00295,Morphine
,2015734,maximum concentration,"Morphine diffuses to the lumbar level, and the mean maximum concentration was 192 +/- 105 ng/ml at 4.5 +/- 1.3 hours.",Morphine pharmacokinetics and pain assessment after intracerebroventricular administration in patients with terminal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015734/),[ng] / [ml],192,221100,DB00295,Morphine
,2015734,terminal half-lives,"Ventricular and lumbar CSF morphine kinetics showed a similar decline during the elimination phase, with terminal half-lives of 3.8 +/- 0.6 hours and 4.2 +/- 1.6 hours, respectively.",Morphine pharmacokinetics and pain assessment after intracerebroventricular administration in patients with terminal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015734/),h,3.8,221101,DB00295,Morphine
,2015734,terminal half-lives,"Ventricular and lumbar CSF morphine kinetics showed a similar decline during the elimination phase, with terminal half-lives of 3.8 +/- 0.6 hours and 4.2 +/- 1.6 hours, respectively.",Morphine pharmacokinetics and pain assessment after intracerebroventricular administration in patients with terminal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015734/),h,4.2,221102,DB00295,Morphine
,4026183,Systemic clearance,"Systemic clearance of morphine was low, being about 3 ml/min/kg after both intravenous and oral administration.",Systemic availability of oral slow-release morphine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026183/),[ml] / [kg·min],3,221937,DB00295,Morphine
,17724700,AUC ratio,Presence of the -840G allele (GG and GA) was associated with lower morphine metabolites/morphine AUC ratio compared with AA genotype (1.8 +/- 0.5 vs.,UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724700/),,1.8,222497,DB00295,Morphine
,19947167,Cmax,"Both formulations presented a relatively rapid absorption of morphine with similar values of Cmax (MST: 53 ng/ml; MEC: 50 ng/ml) and Tmax (MST: 86 min; MEC: 88 min), and prolonged morphine plasma levels.",In vivo evaluation of a new sustained-release formulation of morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947167/),[ng] / [ml],53,222611,DB00295,Morphine
,19947167,Cmax,"Both formulations presented a relatively rapid absorption of morphine with similar values of Cmax (MST: 53 ng/ml; MEC: 50 ng/ml) and Tmax (MST: 86 min; MEC: 88 min), and prolonged morphine plasma levels.",In vivo evaluation of a new sustained-release formulation of morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947167/),[ng] / [ml],50,222612,DB00295,Morphine
,19947167,Tmax,"Both formulations presented a relatively rapid absorption of morphine with similar values of Cmax (MST: 53 ng/ml; MEC: 50 ng/ml) and Tmax (MST: 86 min; MEC: 88 min), and prolonged morphine plasma levels.",In vivo evaluation of a new sustained-release formulation of morphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947167/),min,86,222613,DB00295,Morphine
,19947167,Tmax,"Both formulations presented a relatively rapid absorption of morphine with similar values of Cmax (MST: 53 ng/ml; MEC: 50 ng/ml) and Tmax (MST: 86 min; MEC: 88 min), and prolonged morphine plasma levels.",In vivo evaluation of a new sustained-release formulation of morphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947167/),min,88,222614,DB00295,Morphine
,26715216,clearance,Typical morphine clearance was 48 L/h and fell exponentially by more than 10 L/h in the last week before death.,"Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26715216/),[l] / [h],48,222800,DB00295,Morphine
,3207527,relative bioavailability,"The relative bioavailability of morphine with MST was significantly less than that with MSS (mean 80%, range 50-110%) although there was no difference between the formulations in the relative availability of M3G and M6G.",Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207527/),%,80,223002,DB00295,Morphine
,3207527,tmax,Median tmax for morphine was 0.5 h with MSS and 2.5 h with MST; for M3G 1.5 h with MSS and 3.0 h with MST; and for M6G 1.5 h with MSS and 3.25 h with MST.,Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207527/),h,0.5,223003,DB00295,Morphine
,3207527,tmax,Median tmax for morphine was 0.5 h with MSS and 2.5 h with MST; for M3G 1.5 h with MSS and 3.0 h with MST; and for M6G 1.5 h with MSS and 3.25 h with MST.,Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207527/),h,2.5,223004,DB00295,Morphine
,3207527,tmax,Median tmax for morphine was 0.5 h with MSS and 2.5 h with MST; for M3G 1.5 h with MSS and 3.0 h with MST; and for M6G 1.5 h with MSS and 3.25 h with MST.,Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207527/),h,1.5,223005,DB00295,Morphine
,3207527,tmax,Median tmax for morphine was 0.5 h with MSS and 2.5 h with MST; for M3G 1.5 h with MSS and 3.0 h with MST; and for M6G 1.5 h with MSS and 3.25 h with MST.,Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207527/),h,3.0,223006,DB00295,Morphine
,3207527,tmax,Median tmax for morphine was 0.5 h with MSS and 2.5 h with MST; for M3G 1.5 h with MSS and 3.0 h with MST; and for M6G 1.5 h with MSS and 3.25 h with MST.,Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207527/),h,3.25,223007,DB00295,Morphine
,9040097,Concentrations,Concentrations of codeine and phenobarbital in SD hair samples were 0.98 +/- 0.10 and 17.01 +/- 1.40 ng/mg hair.,A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),ng,0.98,223112,DB00295,Morphine
,9040097,Concentrations,Concentrations of codeine and phenobarbital in SD hair samples were 0.98 +/- 0.10 and 17.01 +/- 1.40 ng/mg hair.,A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),ng,17.01,223113,DB00295,Morphine
,9040097,areas under the curve (AUC),"The areas under the curve (AUC) of plasma concentration versus time for codeine and phenobarbital were 1.58 and 414.50 micrograms h/microL, respectively.",A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),[h·μg] / [μl],1.58,223114,DB00295,Morphine
,9040097,areas under the curve (AUC),"The areas under the curve (AUC) of plasma concentration versus time for codeine and phenobarbital were 1.58 and 414.50 micrograms h/microL, respectively.",A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),[h·μg] / [μl],414.50,223115,DB00295,Morphine
,10381807,apparent clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],1939,223370,DB00295,Morphine
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],162.7,223371,DB00295,Morphine
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],52.7,223372,DB00295,Morphine
,10381807,O,"Codeine O-demethylation was significantly reduced after quinidine in both ethnic groups; however, the absolute decrease was greater in Caucasians (115.8 +/- 25.9 ml/min versus 46.8 +/- 10.6 ml/min, respectively, p <.03).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],115.8,223373,DB00295,Morphine
,2049245,time to achieve maximum plasma codeine concentrations,"2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,0.97,223560,DB00295,Morphine
,2049245,time to achieve maximum plasma codeine concentrations,"2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,1.28,223561,DB00295,Morphine
,2049245,elimination half-life,The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,3.2,223562,DB00295,Morphine
,2049245,elimination half-life,The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,3.2,223563,DB00295,Morphine
,2049245,renal clearance,3. The renal clearance of codeine was 183 +/- 59 ml min-1 and was inversely correlated with urine pH (r = 0.81).,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],183,223564,DB00295,Morphine
,2049245,renal clearance,"The renal clearance of codeine-6-glucuronide was 55 +/- 21 ml min-1, and was not correlated with urine pH.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],55,223565,DB00295,Morphine
less,2049245,binding,Its binding to human plasma was less than 10%.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),%,10,223566,DB00295,Morphine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],137,223567,DB00295,Morphine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],8,223568,DB00295,Morphine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],103,223569,DB00295,Morphine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],90,223570,DB00295,Morphine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],914,223571,DB00295,Morphine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],971,223572,DB00295,Morphine
,2049245,intrinsic clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],1568,223573,DB00295,Morphine
,2049245,intrinsic clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],1450,223574,DB00295,Morphine
,20465864,Recoveries,Recoveries of analytes of interest were between 81 and 109%.,Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),%,81 and 109,223783,DB00295,Morphine
,20465864,Limits of detection,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.08-0.37,223784,DB00295,Morphine
,20465864,Limits of detection,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.28-1.22,223785,DB00295,Morphine
,20465864,q,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.08-0.37,223786,DB00295,Morphine
,20465864,q,"Limits of detection and quantitation were 0.08-0.37 ng/mL and 0.28-1.22 ng/mL, respectively.",Method for the quantification of diamorphine and its metabolites in pediatric plasma samples by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465864/),[ng] / [ml],0.28-1.22,223787,DB00295,Morphine
,27330154,maximum effect (E max ),"Mean maximum effect (E max ) for ""at the moment"" drug liking was significantly lower for intact (53.9) and finely crushed hydrocodone ER (66.9) vs. hydrocodone IR (85.2; P < 0.001).","Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,53,223788,DB00295,Morphine
,27330154,maximum effect (E max ),"Mean maximum effect (E max ) for ""at the moment"" drug liking was significantly lower for intact (53.9) and finely crushed hydrocodone ER (66.9) vs. hydrocodone IR (85.2; P < 0.001).","Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,66,223789,DB00295,Morphine
,27330154,E max,Drug liking for intact hydrocodone ER was comparable to placebo (E max : 53.9 vs. 53.2).,"Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,53.9,223790,DB00295,Morphine
,27330154,E max,Drug liking for intact hydrocodone ER was comparable to placebo (E max : 53.9 vs. 53.2).,"Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,53.2,223791,DB00295,Morphine
,1267205,Serum concentration,Serum concentration of naloxone at 5 minutes was 1.45 +/- 0.1 mug/ml (mean +/- SE) and that of morphine was 1.0 +/- 0.08 mug/ml.,Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),[μg] / [ml],1.45,224375,DB00295,Morphine
,1267205,Serum concentration,Serum concentration of naloxone at 5 minutes was 1.45 +/- 0.1 mug/ml (mean +/- SE) and that of morphine was 1.0 +/- 0.08 mug/ml.,Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),[μg] / [ml],1.0,224376,DB00295,Morphine
,1267205,serum half-lives,"Their serum half-lives from one to four hours were approximately the same, 30-40 minutes.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),h,one to four,224377,DB00295,Morphine
,1267205,serum half-lives,"Their serum half-lives from one to four hours were approximately the same, 30-40 minutes.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),min,30-40,224378,DB00295,Morphine
,1267205,brain-serum concentration ratios,"With naloxone, the brain-serum concentration ratios ranged from 2.7 to 4.6.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),,2.7 to 4.6,224379,DB00295,Morphine
,1267205,initial brain concentration,"However, with morphine the initial brain concentration was approximately one tenth that in the serum (0.096 +/- 0.04 mug/ml).",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),[μg] / [ml],0.096,224380,DB00295,Morphine
,1267205,serum half-life,"From 20 minutes to two hours after injection, the calculated mean serum half-life of naloxone was 64 minutes.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),min,64,224381,DB00295,Morphine
,3758144,extraction ratio,"The extraction ratio (mean +/- SD) across the lung was 0.06 +/- 0.10, implying insignificant lung clearance.",Potential pulmonary uptake and clearance of morphine in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758144/),,0.06,224448,DB00295,Morphine
,3758144,total clearance,"On the other hand, the total clearance was similar in diabetic and nondiabetic patients (1190 and 1150 ml/min, respectively), implying that pulmonary clearance would have no significant influence on the kinetics of morphine.",Potential pulmonary uptake and clearance of morphine in postoperative patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758144/),[ml] / [min],1190,224449,DB00295,Morphine
,3758144,total clearance,"On the other hand, the total clearance was similar in diabetic and nondiabetic patients (1190 and 1150 ml/min, respectively), implying that pulmonary clearance would have no significant influence on the kinetics of morphine.",Potential pulmonary uptake and clearance of morphine in postoperative patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758144/),[ml] / [min],1150,224450,DB00295,Morphine
,7954994,Times to awakening,"Times to awakening were longer in Group H: 3.1 +/- 3.4 hr, than in Group L: 1.1 +/- 0.8 h, P < 0.05.",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,3.1,224529,DB00295,Morphine
,7954994,Times to awakening,"Times to awakening were longer in Group H: 3.1 +/- 3.4 hr, than in Group L: 1.1 +/- 0.8 h, P < 0.05.",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,1.1,224530,DB00295,Morphine
,7954994,t1/2 beta,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,4.4,224531,DB00295,Morphine
,7954994,CL,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),[ml] / [kg·min],5.94,224532,DB00295,Morphine
,7954994,Vd,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),[l] / [kg],3.13,224533,DB00295,Morphine
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],9.9,225461,DB00295,Morphine
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],20.1,225462,DB00295,Morphine
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],15.4,225463,DB00295,Morphine
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],3.3,225464,DB00295,Morphine
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],5.6,225465,DB00295,Morphine
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],3.2,225466,DB00295,Morphine
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,4.4,225467,DB00295,Morphine
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,3.6,225468,DB00295,Morphine
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,2.0,225469,DB00295,Morphine
,6204757,ED50,"Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay.",Oxymorphazone: a long-acting opiate analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6204757/),[mg] / [kg],0.3,225561,DB00295,Morphine
,33515201,half maximal inhibitory concentration (IC50),"The PK/PD model parameters were confirmed by the new data, leading to the following estimates: half maximal inhibitory concentration (IC50) of 26.5 ng/mL, maximum pupil restriction of 66.0% from baseline, and a Hill factor of 1.05.",Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515201/),[ng] / [ml],26.5,226249,DB00295,Morphine
,33515201,Hill factor,"The PK/PD model parameters were confirmed by the new data, leading to the following estimates: half maximal inhibitory concentration (IC50) of 26.5 ng/mL, maximum pupil restriction of 66.0% from baseline, and a Hill factor of 1.05.",Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515201/),,1.05,226250,DB00295,Morphine
,758459,t1/2,The inhibition of the spontaneous hydrolysis of heroin in fresh dog plasma on blood (t1/2 = 8 min) is effected by 10 mg of sodium fluoride/ml (t1/2 = 40 min) and 35 microgram of tetraethyl pyrophosphate/ml (t1/2 = 415 min).,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),min,8,226476,DB00295,Morphine
,758459,t1/2,The inhibition of the spontaneous hydrolysis of heroin in fresh dog plasma on blood (t1/2 = 8 min) is effected by 10 mg of sodium fluoride/ml (t1/2 = 40 min) and 35 microgram of tetraethyl pyrophosphate/ml (t1/2 = 415 min).,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),min,40,226477,DB00295,Morphine
,758459,t1/2,The inhibition of the spontaneous hydrolysis of heroin in fresh dog plasma on blood (t1/2 = 8 min) is effected by 10 mg of sodium fluoride/ml (t1/2 = 40 min) and 35 microgram of tetraethyl pyrophosphate/ml (t1/2 = 415 min).,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),min,415,226478,DB00295,Morphine
,758459,extraction efficiencies,Modified extraction procedures developed for enzyme-inhibited plasma at pH 4.5 have high extraction efficiencies (86--100%) and permit isolation of undergraded heroin from its metabolites.,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),%,86--100,226479,DB00295,Morphine
,758459,Efficiencies,Efficiencies of these TLC recoveries were 81 +/- 1% for heroin and 82 +/- 1% for morphine.,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),%,81,226480,DB00295,Morphine
,758459,Efficiencies,Efficiencies of these TLC recoveries were 81 +/- 1% for heroin and 82 +/- 1% for morphine.,Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),%,82,226481,DB00295,Morphine
,758459,apparent partition coefficient,"The apparent partition coefficient is 1.4 +/- 0.2 between red blood cells and plasma water, and it is 0.8 +/- 0.1 between red blood cells and dog plasma.",Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),,1.4,226482,DB00295,Morphine
,758459,apparent partition coefficient,"The apparent partition coefficient is 1.4 +/- 0.2 between red blood cells and plasma water, and it is 0.8 +/- 0.1 between red blood cells and dog plasma.",Pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758459/),,0.8,226483,DB00295,Morphine
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,15,227254,DB00295,Morphine
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,30,227255,DB00295,Morphine
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,60,227256,DB00295,Morphine
,19574865,area under the concentration-time curve,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,30,227257,DB00295,Morphine
,19574865,area under the concentration-time curve,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,60,227258,DB00295,Morphine
,7818116,terminal half-life,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),h,3.4,227635,DB00295,Morphine
,7818116,plasma clearance,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),[l] / [h],45.4,227636,DB00295,Morphine
,7818116,volume of distribution in the terminal phase,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),[l] / [kg],3.0,227637,DB00295,Morphine
,7818116,absorption lag time,"After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability was 61.6% (+/- 30.2%).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),h,0.52,227638,DB00295,Morphine
,7818116,absolute bioavailability,"After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability was 61.6% (+/- 30.2%).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),%,61.6,227639,DB00295,Morphine
,11361046,pain intensity,Mean (+/- SD) pain intensity (0 = none to 10 = severe) decreased from a baseline of 6.0 +/- 2.2 to 2.7 +/- 1.1 after titration with IR oxycodone dosed qid.,"Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361046/),,6.0,228062,DB00295,Morphine
,15516353,bioavailability,"Morphine bioavailability showed a substantial increase in patients with primary liver and secondary metastatic carcinoma than that of controls (64.8, 62.1, and 16.8%, respectively).",Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),%,64.8,228192,DB00295,Morphine
,15516353,bioavailability,"Morphine bioavailability showed a substantial increase in patients with primary liver and secondary metastatic carcinoma than that of controls (64.8, 62.1, and 16.8%, respectively).",Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),%,62.1,228193,DB00295,Morphine
,15516353,bioavailability,"Morphine bioavailability showed a substantial increase in patients with primary liver and secondary metastatic carcinoma than that of controls (64.8, 62.1, and 16.8%, respectively).",Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),%,16.8,228194,DB00295,Morphine
,15516353,area under the serum concentration-time curve,The area under the serum concentration-time curve increased 4-fold in primary carcinoma (416 [sem25] microg h(-1) litre(-1)) and 3-fold (303 [21] microg h(-1) litre(-1)) in metastatic liver patients compared with healthy control (92.5 [3] microg h(-1) litre(-1)).,Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),[μg] / [h·litre],416,228195,DB00295,Morphine
,15516353,area under the serum concentration-time curve,The area under the serum concentration-time curve increased 4-fold in primary carcinoma (416 [sem25] microg h(-1) litre(-1)) and 3-fold (303 [21] microg h(-1) litre(-1)) in metastatic liver patients compared with healthy control (92.5 [3] microg h(-1) litre(-1)).,Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),[μg] / [h·litre],303,228196,DB00295,Morphine
,15516353,area under the serum concentration-time curve,The area under the serum concentration-time curve increased 4-fold in primary carcinoma (416 [sem25] microg h(-1) litre(-1)) and 3-fold (303 [21] microg h(-1) litre(-1)) in metastatic liver patients compared with healthy control (92.5 [3] microg h(-1) litre(-1)).,Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),[μg] / [h·litre],92.5,228197,DB00295,Morphine
,15516353,t(1/2),Impaired morphine elimination was noted in primary carcinoma only (t(1/2) 5.99 [0.39] h).,Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516353/),h,5.99,228198,DB00295,Morphine
,14722170,volume of distribution,"Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1).","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),l,136,228577,DB00295,Morphine
,14722170,formation clearance,"Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1).","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [h],64.3,228578,DB00295,Morphine
,14722170,formation clearance,"Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1).","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [h],3.63,228579,DB00295,Morphine
,14722170,clearance,"Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1).","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [70·h·kg],3.12,228580,DB00295,Morphine
,14722170,elimination clearance,"Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1).","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [h],17.4,228581,DB00295,Morphine
,14722170,elimination clearance,"Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1).","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [h],5.8,228582,DB00295,Morphine
,14722170,maturation half-life,The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at birth.,"Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),d,26,228583,DB00295,Morphine
,14722170,maturation half-life,The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at birth.,"Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [70·kg],83,228584,DB00295,Morphine
,14722170,maturation half-life,The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at birth.,"Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),d,88.3,228585,DB00295,Morphine
,14722170,maturation half-life,The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at birth.,"Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [70·h·kg],10.8,228586,DB00295,Morphine
,14722170,maturation half-life,The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at birth.,"Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[l] / [70·h·kg],0.61,228587,DB00295,Morphine
,14722170,maturation half-life,"Metabolite clearance increased with age (maturation half-life 129 days), and appeared to be similar to that described for glomerular filtration rate maturation in infants.","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),d,129,228588,DB00295,Morphine
,14722170,steady-state serum concentration,"A mean steady-state serum concentration of 10 ng ml(-1) can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1) at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1) kg(-1) for 1- to 3-yr-old children.","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[ng] / [ml],10,228589,DB00295,Morphine
,14722170,steady-state serum concentration,"A mean steady-state serum concentration of 10 ng ml(-1) can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1) at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1) kg(-1) for 1- to 3-yr-old children.","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[μg] / [h·kg],8.5,228590,DB00295,Morphine
,14722170,steady-state serum concentration,"A mean steady-state serum concentration of 10 ng ml(-1) can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1) at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1) kg(-1) for 1- to 3-yr-old children.","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[μg] / [h·kg],13.5,228591,DB00295,Morphine
,14722170,steady-state serum concentration,"A mean steady-state serum concentration of 10 ng ml(-1) can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1) at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1) kg(-1) for 1- to 3-yr-old children.","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[μg] / [h·kg],18,228592,DB00295,Morphine
,14722170,steady-state serum concentration,"A mean steady-state serum concentration of 10 ng ml(-1) can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1) at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1) kg(-1) for 1- to 3-yr-old children.","Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722170/),[μg] / [h],16,228593,DB00295,Morphine
,2486589,peak plasma concentrations,The peak plasma concentrations of morphine were recorded at 8.0 +/- 2.6 minutes after epidural injection.,Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),min,8,229969,DB00295,Morphine
,2486589,Plasma mean residence time,"Plasma mean residence time was 84 +/- 25.7 minutes, Vdss 121 +/- 30 L, and C1 1.5 +/- 0.32 L/min.",Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),min,84,229970,DB00295,Morphine
,2486589,Vdss,"Plasma mean residence time was 84 +/- 25.7 minutes, Vdss 121 +/- 30 L, and C1 1.5 +/- 0.32 L/min.",Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),l,121,229971,DB00295,Morphine
,2486589,C1,"Plasma mean residence time was 84 +/- 25.7 minutes, Vdss 121 +/- 30 L, and C1 1.5 +/- 0.32 L/min.",Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),[l] / [min],1.5,229972,DB00295,Morphine
,2486589,MRT,"MRT (200 +/- 28 minute), Vdss (65 +/- 33.8 ml), and CL (0.32 +/- 0.15 ml/min) showed that variable fractions of morphine remained many hours in the CSF.",Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),min,200,229973,DB00295,Morphine
,2486589,Vdss,"MRT (200 +/- 28 minute), Vdss (65 +/- 33.8 ml), and CL (0.32 +/- 0.15 ml/min) showed that variable fractions of morphine remained many hours in the CSF.",Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),ml,65,229974,DB00295,Morphine
,2486589,CL,"MRT (200 +/- 28 minute), Vdss (65 +/- 33.8 ml), and CL (0.32 +/- 0.15 ml/min) showed that variable fractions of morphine remained many hours in the CSF.",Epidural morphine anesthesia for abdominal aortic surgery--pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486589/),[ml] / [min],0.32,229975,DB00295,Morphine
,3370903,Mean residence time,"Mean residence time was 137 +/- 54.9 minutes, mean initial volume of distribution 15 +/- 5.49 ml, mean volume of distribution at steady-state 42 +/- 18.25 ml and mean clearance 0.34 +/- 0.18 ml/min (0.02 +/- 0.01 L/h).",The pharmacokinetics of intradural morphine in major abdominal surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370903/),min,137,229996,DB00295,Morphine
,3370903,initial volume of distribution,"Mean residence time was 137 +/- 54.9 minutes, mean initial volume of distribution 15 +/- 5.49 ml, mean volume of distribution at steady-state 42 +/- 18.25 ml and mean clearance 0.34 +/- 0.18 ml/min (0.02 +/- 0.01 L/h).",The pharmacokinetics of intradural morphine in major abdominal surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370903/),ml,15,229997,DB00295,Morphine
,3370903,volume of distribution at steady-state,"Mean residence time was 137 +/- 54.9 minutes, mean initial volume of distribution 15 +/- 5.49 ml, mean volume of distribution at steady-state 42 +/- 18.25 ml and mean clearance 0.34 +/- 0.18 ml/min (0.02 +/- 0.01 L/h).",The pharmacokinetics of intradural morphine in major abdominal surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370903/),ml,42,229998,DB00295,Morphine
,3370903,clearance,"Mean residence time was 137 +/- 54.9 minutes, mean initial volume of distribution 15 +/- 5.49 ml, mean volume of distribution at steady-state 42 +/- 18.25 ml and mean clearance 0.34 +/- 0.18 ml/min (0.02 +/- 0.01 L/h).",The pharmacokinetics of intradural morphine in major abdominal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370903/),[ml] / [min],0.34,229999,DB00295,Morphine
,3370903,clearance,"Mean residence time was 137 +/- 54.9 minutes, mean initial volume of distribution 15 +/- 5.49 ml, mean volume of distribution at steady-state 42 +/- 18.25 ml and mean clearance 0.34 +/- 0.18 ml/min (0.02 +/- 0.01 L/h).",The pharmacokinetics of intradural morphine in major abdominal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370903/),[l] / [h],0.02,230000,DB00295,Morphine
,7340377,duration of anal,"The duration of analgesia was significantly longer, on average, with morphine (28 h) than with bupivacaine (4.3 h) when the drugs were given by the lumbar route.",A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,28,230195,DB00295,Morphine
,7340377,duration of anal,"The duration of analgesia was significantly longer, on average, with morphine (28 h) than with bupivacaine (4.3 h) when the drugs were given by the lumbar route.",A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,4.3,230196,DB00295,Morphine
,7340377,duration of pain relief,Thoracic administration of morphine also resulted in a significantly longer duration of pain relief (on average 9.8 h) than that of bupivacaine (3.8 h).,A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,9.8,230197,DB00295,Morphine
,7340377,duration of pain relief,Thoracic administration of morphine also resulted in a significantly longer duration of pain relief (on average 9.8 h) than that of bupivacaine (3.8 h).,A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,3.8,230198,DB00295,Morphine
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],32,230689,DB00295,Morphine
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],88,230690,DB00295,Morphine
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],26,230691,DB00295,Morphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],32,230692,DB00295,Morphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],88,230693,DB00295,Morphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],26,230694,DB00295,Morphine
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],316,230695,DB00295,Morphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,0.014,230696,DB00295,Morphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,1.89,230697,DB00295,Morphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,1.01,230698,DB00295,Morphine
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,7.76,230699,DB00295,Morphine
,33404848,AUC,The mean (95% CI) foetal morphine AUC in the CYP2D6 UM cohort of 0.988 (0.902 to 1.073) ng/mL.h was 1.8-fold higher than the CYP2D6 EM cohort of 0.546 (0.492 to 0.600) ng/mL.h (p < 0.001).,Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404848/),[ng] / [h·ml],0.988,230850,DB00295,Morphine
,33404848,AUC,The mean (95% CI) foetal morphine AUC in the CYP2D6 UM cohort of 0.988 (0.902 to 1.073) ng/mL.h was 1.8-fold higher than the CYP2D6 EM cohort of 0.546 (0.492 to 0.600) ng/mL.h (p < 0.001).,Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404848/),[ng] / [h·ml],0.546,230851,DB00295,Morphine
,12899973,Extraction efficiencies,"Extraction efficiencies of codeine, morphine and M-3-G from rat plasma samples were 97, 92 and 93%, respectively.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),%,97,231155,DB00295,Morphine
,12899973,Extraction efficiencies,"Extraction efficiencies of codeine, morphine and M-3-G from rat plasma samples were 97, 92 and 93%, respectively.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),%,92,231156,DB00295,Morphine
,12899973,Extraction efficiencies,"Extraction efficiencies of codeine, morphine and M-3-G from rat plasma samples were 97, 92 and 93%, respectively.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),%,93,231157,DB00295,Morphine
,12899973,detection limits,"Using native fluorescence detection (excitation at 245 nm and emission at 345 nm), the detection limits of 50 ng/ml for morphine, 25 ng/ml for codeine and 20 ng/ml for M-3-G were obtained.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),[ng] / [ml],50,231158,DB00295,Morphine
,12899973,detection limits,"Using native fluorescence detection (excitation at 245 nm and emission at 345 nm), the detection limits of 50 ng/ml for morphine, 25 ng/ml for codeine and 20 ng/ml for M-3-G were obtained.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),[ng] / [ml],25,231159,DB00295,Morphine
,12899973,detection limits,"Using native fluorescence detection (excitation at 245 nm and emission at 345 nm), the detection limits of 50 ng/ml for morphine, 25 ng/ml for codeine and 20 ng/ml for M-3-G were obtained.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),[ng] / [ml],20,231160,DB00295,Morphine
,16729270,volume of the first brain compartment,The volume of the first brain compartment was 35.4 mL with a half-life of equilibrium of 0.6 min.,Cerebral kinetics of oxycodone in conscious sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),ml,35.4,231787,DB00295,Morphine
,16729270,half-life of equilibrium,The volume of the first brain compartment was 35.4 mL with a half-life of equilibrium of 0.6 min.,Cerebral kinetics of oxycodone in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),min,0.6,231788,DB00295,Morphine
,16729270,half-life,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),min,7.2,231789,DB00295,Morphine
,16729270,deep cerebral distribution volume,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),ml,222.8,231790,DB00295,Morphine
,16729270,membrane permeability,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),[ml] / [min],54.8,231791,DB00295,Morphine
,16729270,CBF,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),[ml] / [min],40,231792,DB00295,Morphine
,16729270,Drug retention in,Drug retention in the brain was 1.3% after 45 min.,Cerebral kinetics of oxycodone in conscious sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),%,1.3,231793,DB00295,Morphine
,7704214,limits of q,"Sensitivity of the method is excellent and allows for the reproducible quantification of dihydrocodeine and dihydromorphine with limits of quantification of 2 ng/ml and 40 pg/ml serum, respectively.",Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704214/),[ng] / [ml],2,231884,DB00295,Morphine
,7704214,limits of q,"Sensitivity of the method is excellent and allows for the reproducible quantification of dihydrocodeine and dihydromorphine with limits of quantification of 2 ng/ml and 40 pg/ml serum, respectively.",Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704214/),[pg] / [ml],40,231885,DB00295,Morphine
,15652441,AUC ratio,"The AUC ratio was 100.3%, indicating equivalent absorption.","Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652441/),%,100.3,231925,DB00295,Morphine
,15652441,Fluctuation indices,"Fluctuation indices were 93.5 +/- 28.8% and 179.3 +/- 41.3% (P=0.0001) for OAD morphine and twice-daily CR morphine, respectively.","Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652441/),%,93.5,231926,DB00295,Morphine
,15652441,Fluctuation indices,"Fluctuation indices were 93.5 +/- 28.8% and 179.3 +/- 41.3% (P=0.0001) for OAD morphine and twice-daily CR morphine, respectively.","Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652441/),%,179.3,231927,DB00295,Morphine
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.14,231938,DB00295,Morphine
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.05,231939,DB00295,Morphine
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],19.50,231940,DB00295,Morphine
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],9.72,231941,DB00295,Morphine
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,22.10,231942,DB00295,Morphine
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,20.50,231943,DB00295,Morphine
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,353,231944,DB00295,Morphine
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,291,231945,DB00295,Morphine
,8364450,AUC0-6 ratios,"Although the mean AUC0-6 ratio of M-3-G to morphine after administration of a conventional suppository was three times larger than that of a hollow-type suppository containing powdered morphine, the mean AUC0-6 ratios of M-6-G to morphine after use of the three types of suppositories were all approximately 1.0.",Difference in rectal absorption of morphine from hollow-type and conventional suppositories in rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364450/),,1.0,231965,DB00295,Morphine
less,3428164,elimination half-lives,"As doses were changed and continued at static hourly rates, serum morphine concentrations were relatively constant 20 hours and beyond the time of the respective change, thus suggesting morphine elimination half-lives of less than or equal to 4 hours.",Clearance of continuous intravenous morphine for severe cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428164/),h,4,232126,DB00295,Morphine
,3812964,Concentrations,Concentrations were between 2.6 and 18.8 ng/ml depending on daily dosage and body weight.,[The pharmacokinetics of continuous peridural morphine infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3812964/),[ng] / [ml],2.6 and 18.8,232639,DB00295,Morphine
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,60,233049,DB00295,Morphine
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,300,233050,DB00295,Morphine
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,1.5 to 6,233051,DB00295,Morphine
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,15,233052,DB00295,Morphine
,6226471,total body clearance,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),[l] / [min],0.4 to over 1.5,233053,DB00295,Morphine
,6105056,plasma half-life,"Butorphanol was rapidly distributed to tissues, had a plasma half-life of about 3 hr, and was extensively metabolized prior to elimination.",Disposition of parenteral butorphanol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105056/),h,3,233176,DB00295,Morphine
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],25,234545,DB00295,Morphine
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],50,234546,DB00295,Morphine
,16044107,initial delivery rate,"For 6 patients, the initial delivery rate was 75-150 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],75-150,234547,DB00295,Morphine
,16044107,bioavailability,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),%,78,234548,DB00295,Morphine
,16044107,total clearance,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],41,234549,DB00295,Morphine
>,16044107,total clearance,"At the 2 highest doses, an increase of total clearance was observed (>60 L/h).",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],60,234550,DB00295,Morphine
,23958818,CL1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.01,234602,DB00295,Morphine
,23958818,V1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,3.35,234603,DB00295,Morphine
,23958818,CL2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.47,234604,DB00295,Morphine
,23958818,V2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,13.9,234605,DB00295,Morphine
,23958818,CL3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.41,234606,DB00295,Morphine
,23958818,V3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,145,234607,DB00295,Morphine
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,26,234608,DB00295,Morphine
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,84,234609,DB00295,Morphine
,23719682,apparent oral central volume of distribution,"The population estimates of apparent oral central volume of distribution and apparent oral linear clearance were 714 L and 64.4 L/h, respectively.",Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719682/),l,714,235282,DB00295,Morphine
,23719682,apparent oral linear clearance,"The population estimates of apparent oral central volume of distribution and apparent oral linear clearance were 714 L and 64.4 L/h, respectively.",Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719682/),[l] / [h],64.4,235283,DB00295,Morphine
,2288837,plasma clearance,The mean plasma clearance of morphine was 29 ml min-1 kg-1 and the plasma ratios of morphine-6-glucuronide to morphine were similar to those previously reported in children.,"Long term high dose morphine, ketamine and midazolam infusion in a child with burns. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288837/),[ml] / [kg·min],29,235738,DB00295,Morphine
,2288837,plasma clearance,The mean plasma clearance of ketamine was 32 ml min-1 kg-1 which is greater than that previously reported in older children and adults.,"Long term high dose morphine, ketamine and midazolam infusion in a child with burns. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288837/),[ml] / [kg·min],32,235739,DB00295,Morphine
,6517241,maximum flow rate,"34 non-intubated patients (Group I) and 14 artificially ventilated patients under intensive care conditions (Group II) received morphine solutions of 0.25% (maximum flow rate 0.31 ml/h) and 0.4% (maximum flow rate 0.5 ml/h), respectively.",[Morphine concentrations in serum in need-controlled peridural morphine infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517241/),[ml] / [h],0.31,236328,DB00295,Morphine
,6517241,maximum flow rate,"34 non-intubated patients (Group I) and 14 artificially ventilated patients under intensive care conditions (Group II) received morphine solutions of 0.25% (maximum flow rate 0.31 ml/h) and 0.4% (maximum flow rate 0.5 ml/h), respectively.",[Morphine concentrations in serum in need-controlled peridural morphine infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517241/),[ml] / [h],0.5,236329,DB00295,Morphine
,6517241,Total morphine consumption,"Total morphine consumption of the intensive care patients (Group II) until 8 p.m. on the 2nd postoperative day was 34.0 +/- 2.9 mg and was significantly higher than in non-intubated patients (Group I), with 6.4 +/- 0.4 mg (p less than 0.001).",[Morphine concentrations in serum in need-controlled peridural morphine infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517241/),mg,34.0,236330,DB00295,Morphine
,6517241,Total morphine consumption,"Total morphine consumption of the intensive care patients (Group II) until 8 p.m. on the 2nd postoperative day was 34.0 +/- 2.9 mg and was significantly higher than in non-intubated patients (Group I), with 6.4 +/- 0.4 mg (p less than 0.001).",[Morphine concentrations in serum in need-controlled peridural morphine infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517241/),mg,6.4,236331,DB00295,Morphine
,4006652,plasma concentrations,The plasma concentrations of morphine ranged from 23 to 472 ng/ml at 10 min and from 6.1 to 20.8 ng/ml at 60 min after morphine administration.,Variation in morphine pharmacokinetics in children with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006652/),[ng] / [ml],23 to 472,237732,DB00295,Morphine
,4006652,plasma concentrations,The plasma concentrations of morphine ranged from 23 to 472 ng/ml at 10 min and from 6.1 to 20.8 ng/ml at 60 min after morphine administration.,Variation in morphine pharmacokinetics in children with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006652/),[ng] / [ml],6.1 to 20.8,237733,DB00295,Morphine
,4006652,total clearance,The total clearance of morphine ranged from 9.03 to 53.4 ml/min/kg.,Variation in morphine pharmacokinetics in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006652/),[ml] / [kg·min],9.03 to 53.4,237734,DB00295,Morphine
,4006652,apparent volume of the central compartment,"The apparent volume of the central compartment and the apparent volume of distribution at steady state ranged from 0.17 to 1.10 and from 2.06 to 7.86 l/kg, respectively.",Variation in morphine pharmacokinetics in children with cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006652/),[l] / [kg],0.17 to 1.10,237735,DB00295,Morphine
,4006652,apparent volume of distribution at steady state,"The apparent volume of the central compartment and the apparent volume of distribution at steady state ranged from 0.17 to 1.10 and from 2.06 to 7.86 l/kg, respectively.",Variation in morphine pharmacokinetics in children with cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006652/),[l] / [kg],2.06 to 7.86,237736,DB00295,Morphine
,4006652,elimination half-life,The elimination half-life ranged from 0.86 to 7.55 h.,Variation in morphine pharmacokinetics in children with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006652/),h,0.86 to 7.55,237737,DB00295,Morphine
>,18360598,bioavailability,The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.,Oxycodone controlled release in cancer pain management. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),%,60,238891,DB00295,Morphine
,18360598,bioavailability,The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.,Oxycodone controlled release in cancer pain management. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),%,20,238892,DB00295,Morphine
,18360598,half-life,"There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-life of 6.2 h, which accounts for the residual 62%.",Oxycodone controlled release in cancer pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),min,37,238893,DB00295,Morphine
,18360598,half-life,"There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-life of 6.2 h, which accounts for the residual 62%.",Oxycodone controlled release in cancer pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),h,6.2,238894,DB00295,Morphine
,8926732,Peak hair codeine concentrations,"Peak hair codeine concentrations for the 5-, 10-, and 20-mg/kg groups occurred 20 days after beginning the dosing protocol and were 0.57 +/- 0.13, 0.80 +/- 0.10, and 1.95 +/- 0.35 ng/mg hair, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],0.57,239351,DB00295,Morphine
,8926732,Peak hair codeine concentrations,"Peak hair codeine concentrations for the 5-, 10-, and 20-mg/kg groups occurred 20 days after beginning the dosing protocol and were 0.57 +/- 0.13, 0.80 +/- 0.10, and 1.95 +/- 0.35 ng/mg hair, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],0.80,239352,DB00295,Morphine
,8926732,Peak hair codeine concentrations,"Peak hair codeine concentrations for the 5-, 10-, and 20-mg/kg groups occurred 20 days after beginning the dosing protocol and were 0.57 +/- 0.13, 0.80 +/- 0.10, and 1.95 +/- 0.35 ng/mg hair, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],1.95,239353,DB00295,Morphine
,8926732,peak concentrations,"Morphine peak concentrations occurred at the same time and were 1.08 +/- 0.28, 1.21 +/- 0.09, and 2.10 +/- 0.26 ng/mg hair for the 5-, 10-, and 20-mg/kg groups, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],1.08,239354,DB00295,Morphine
,8926732,peak concentrations,"Morphine peak concentrations occurred at the same time and were 1.08 +/- 0.28, 1.21 +/- 0.09, and 2.10 +/- 0.26 ng/mg hair for the 5-, 10-, and 20-mg/kg groups, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],1.21,239355,DB00295,Morphine
,8926732,peak concentrations,"Morphine peak concentrations occurred at the same time and were 1.08 +/- 0.28, 1.21 +/- 0.09, and 2.10 +/- 0.26 ng/mg hair for the 5-, 10-, and 20-mg/kg groups, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],2.10,239356,DB00295,Morphine
,18968768,detection limit,The peak current was linearly related to the morphine concentration in the range of 1.0x10(-6) M to 5.0x10(-4) M at +0.60 V (vs. Ag/AgCl) with a detection limit of 5.0x10(-7) M (S/N of 3).,Amperometric determination of morphine on cobalt hexacyanoferrate modified electrode in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968768/),M,5.0x10(-7,239876,DB00295,Morphine
,18968768,S/N,The peak current was linearly related to the morphine concentration in the range of 1.0x10(-6) M to 5.0x10(-4) M at +0.60 V (vs. Ag/AgCl) with a detection limit of 5.0x10(-7) M (S/N of 3).,Amperometric determination of morphine on cobalt hexacyanoferrate modified electrode in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968768/),,3,239877,DB00295,Morphine
,10393603,Plasma clearance,Plasma clearance of morphine was 23.1 mL/min per kg body weight.,Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10393603/),[ml] / [kg·min],23.1,240249,DB00295,Morphine
,10393603,volume of distribution,The volume of distribution was 5.2 L/kg.,Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10393603/),[l] / [kg],5.2,240250,DB00295,Morphine
,10393603,Molar ratios,"Molar ratios of M3G/morphine, M6G/morphine, and M3G/M6G were 21.1, 4.7, and 4.2, respectively.",Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10393603/),,21.1,240251,DB00295,Morphine
,10393603,Molar ratios,"Molar ratios of M3G/morphine, M6G/morphine, and M3G/M6G were 21.1, 4.7, and 4.2, respectively.",Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10393603/),,4.7,240252,DB00295,Morphine
,10393603,Molar ratios,"Molar ratios of M3G/morphine, M6G/morphine, and M3G/M6G were 21.1, 4.7, and 4.2, respectively.",Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10393603/),,4.2,240253,DB00295,Morphine
,14534521,bioavailability,"Intramuscularly administered diacetylmorphine (</=200-250 mg) exhibited linear diacetylmorphine, monoacetylmorphine, and morphine kinetics and resulted in sustained diacetylmorphine exposures (bioavailability, 380% +/- 157% [mean +/- SD]) and in lower and delayed peak monoacetylmorphine and morphine concentrations as compared with intravenous administration.",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,380,240255,DB00295,Morphine
,14534521,bioavailabilities,"Oral diacetylmorphine (</=600 mg) yielded negligible systemic diacetylmorphine and monoacetylmorphine exposures but was associated with linear kinetics and high bioavailabilities for morphine (67% +/- 19%), morphine-3-glucuronide (205% +/- 52%), and morphine-6-glucuronide (180% +/- 61%).",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,67,240256,DB00295,Morphine
,14534521,bioavailabilities,"Oral diacetylmorphine (</=600 mg) yielded negligible systemic diacetylmorphine and monoacetylmorphine exposures but was associated with linear kinetics and high bioavailabilities for morphine (67% +/- 19%), morphine-3-glucuronide (205% +/- 52%), and morphine-6-glucuronide (180% +/- 61%).",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,205,240257,DB00295,Morphine
,14534521,bioavailabilities,"Oral diacetylmorphine (</=600 mg) yielded negligible systemic diacetylmorphine and monoacetylmorphine exposures but was associated with linear kinetics and high bioavailabilities for morphine (67% +/- 19%), morphine-3-glucuronide (205% +/- 52%), and morphine-6-glucuronide (180% +/- 61%).",Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534521/),%,180,240258,DB00295,Morphine
,3774825,ED50,The ED50 values for locomotor behavior representing 5 times control activity were 7.5 mg/kg for aged mice and 17.8 mg/kg for the mature adults.,Differences in morphine-induced antinociception and locomotor activity in mature adult and aged mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774825/),[mg] / [kg],7.5,240938,DB00295,Morphine
,3774825,ED50,The ED50 values for locomotor behavior representing 5 times control activity were 7.5 mg/kg for aged mice and 17.8 mg/kg for the mature adults.,Differences in morphine-induced antinociception and locomotor activity in mature adult and aged mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774825/),[mg] / [kg],17.8,240939,DB00295,Morphine
,3774825,ED50,The ED50 values for antinociception 1 hour after morphine administration were 70 mg/kg for the aged mice and 13 mg/kg for the mature adults.,Differences in morphine-induced antinociception and locomotor activity in mature adult and aged mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774825/),[mg] / [kg],70,240940,DB00295,Morphine
,3774825,ED50,The ED50 values for antinociception 1 hour after morphine administration were 70 mg/kg for the aged mice and 13 mg/kg for the mature adults.,Differences in morphine-induced antinociception and locomotor activity in mature adult and aged mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774825/),[mg] / [kg],13,240941,DB00295,Morphine
,3528988,Terminal half-lives,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),h,30.4,241267,DB00295,Morphine
,3528988,Terminal half-lives,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),h,2.7,241268,DB00295,Morphine
,3528988,clearance,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),[l] / [min],0.19,241269,DB00295,Morphine
,3528988,clearance,Terminal half-lives (mean +/- S.D.) were 30.4 +/- 16.3 h and 2.7 +/- 1.2 h respectively for methadone and morphine while the clearance values (mean +/- S.D.) were 0.19 +/- 0.13 l/min and 1.16 +/- 0.47 l/min.,A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),[l] / [min],1.16,241270,DB00295,Morphine
,3528988,oral bioavailability,"There were pronounced differences in oral bioavailability between the two opioids: methadone, 79 +/- 11.7%, compared to morphine, 26 +/- 13% (mean +/- S.D.).",A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),%,79,241271,DB00295,Morphine
,3528988,oral bioavailability,"There were pronounced differences in oral bioavailability between the two opioids: methadone, 79 +/- 11.7%, compared to morphine, 26 +/- 13% (mean +/- S.D.).",A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3528988/),%,26,241272,DB00295,Morphine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),,240,241360,DB00295,Morphine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),,163,241361,DB00295,Morphine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),,123,241362,DB00295,Morphine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),[nM] / [l],309,241363,DB00295,Morphine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),[nM] / [l],251,241364,DB00295,Morphine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),[nM] / [l],169,241365,DB00295,Morphine
,1540490,plasma half-lives,4. In the infants the mean plasma half-lives of codeine and morphine were 2.6 and 2.5 h.,Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),h,2.6,241366,DB00295,Morphine
,1540490,plasma half-lives,4. In the infants the mean plasma half-lives of codeine and morphine were 2.6 and 2.5 h.,Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),h,2.5,241367,DB00295,Morphine
,1540490,concentration ratio,"5. The mean morphine/codeine concentration ratio was 4.3% in the infants and 1.6% in the children, suggesting impaired glucuronidation of morphine in the former group.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),%,4.3,241368,DB00295,Morphine
,1540490,concentration ratio,"5. The mean morphine/codeine concentration ratio was 4.3% in the infants and 1.6% in the children, suggesting impaired glucuronidation of morphine in the former group.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),%,1.6,241369,DB00295,Morphine
,9129563,peak serum concentration,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[pM] / [ml],13.9,242602,DB00295,Morphine
,9129563,peak serum concentration,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[pM] / [ml],0.68,242603,DB00295,Morphine
,9129563,area under the serum concentration-time curve,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[h·pM] / [ml],27.8,242604,DB00295,Morphine
,9129563,area under the serum concentration-time curve,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[h·pM] / [ml],1.9,242605,DB00295,Morphine
,9129563,total amount of morphine excreted in urine,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),μM,0.160,242606,DB00295,Morphine
,9129563,total amount of morphine excreted in urine,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),μM,0.015,242607,DB00295,Morphine
,2276388,bioavailability,The bioavailability after administration in the colostomy showed very great variation; the mean value compared to rectal bioavailability was only 43% (range 0.1-127%).,Comparative bioavailability of a morphine suppository given rectally and in a colostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2276388/),%,43,242887,DB00295,Morphine
,8520812,area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24),"Although naltrexone did not qualitatively alter the concentration-time curve for controlled-release morphine, the area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24) was significantly greater (p < 0.01) for morphine given with naltrexone (265 ng x h/ml) than for morphine given alone (215 ng x h/ml).",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[h·ng] / [ml],265,243028,DB00295,Morphine
,8520812,area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24),"Although naltrexone did not qualitatively alter the concentration-time curve for controlled-release morphine, the area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24) was significantly greater (p < 0.01) for morphine given with naltrexone (265 ng x h/ml) than for morphine given alone (215 ng x h/ml).",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[h·ng] / [ml],215,243029,DB00295,Morphine
,8520812,apparent absorption half-life,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),h,0.94-0.58,243030,DB00295,Morphine
,8520812,Cmax,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[ng] / [ml],28.17,243031,DB00295,Morphine
,8520812,Cmax,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[ng] / [ml],32.26,243032,DB00295,Morphine
,1869598,maximum morphine plasma concentration (Cmax),"At steady-state, the maximum morphine plasma concentration (Cmax) was 24.1 ng/ml at 45 mg and 18.7 ng/ml at 30 mg of controlled-release morphine sulphate tablets.",Plasma concentrations of morphine in children with chronic pain--comparison of controlled release and regular morphine sulphate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869598/),[ng] / [ml],24.1,243547,DB00295,Morphine
,1869598,maximum morphine plasma concentration (Cmax),"At steady-state, the maximum morphine plasma concentration (Cmax) was 24.1 ng/ml at 45 mg and 18.7 ng/ml at 30 mg of controlled-release morphine sulphate tablets.",Plasma concentrations of morphine in children with chronic pain--comparison of controlled release and regular morphine sulphate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869598/),[ng] / [ml],18.7,243548,DB00295,Morphine
,1869598,Cmax,The Cmax was 17.6 ng/ml at 15 mg and 31.4 ng/ml at 20 mg dose of the regular tablets.,Plasma concentrations of morphine in children with chronic pain--comparison of controlled release and regular morphine sulphate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869598/),[ng] / [ml],17.6,243549,DB00295,Morphine
,1869598,Cmax,The Cmax was 17.6 ng/ml at 15 mg and 31.4 ng/ml at 20 mg dose of the regular tablets.,Plasma concentrations of morphine in children with chronic pain--comparison of controlled release and regular morphine sulphate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869598/),[ng] / [ml],31.4,243550,DB00295,Morphine
,24236993,pKa,"It has been argued that absorption of buprenorphine through the buccal mucosa is high, in part due to its pKa of 8.24.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8.24,243813,DB00295,Morphine
,24236993,pKa,"Morphine, methadone, hydromorphone, and oxymorphone have a pKa between 8 and 9.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8 and 9,243814,DB00295,Morphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,36.6,243815,DB00295,Morphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,44.2,243816,DB00295,Morphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,22.4,243817,DB00295,Morphine
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,18.8,243818,DB00295,Morphine
,8026197,Plasma clearance rate,Plasma clearance rate of morphine increased from 0.574 +/- 0.3 L/kg/hr to 1.058 +/- 0.727 L/kg/hr after discontinuation of ECMO (p < .01).,Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8026197/),[l] / [h·kg],0.574,244377,DB00295,Morphine
,8026197,Plasma clearance rate,Plasma clearance rate of morphine increased from 0.574 +/- 0.3 L/kg/hr to 1.058 +/- 0.727 L/kg/hr after discontinuation of ECMO (p < .01).,Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8026197/),[l] / [h·kg],1.058,244378,DB00295,Morphine
,11907197,bioavailability,"Morphine administered nasally to humans as a simple solution is only absorbed to a limited degree, with a bioavailability of the order of 10% compared with intravenous administration.",Intranasal delivery of morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907197/),%,10,244728,DB00295,Morphine
,11907197,T(max),The results show that the nasal formulation was rapidly absorbed with a T(max) of 15 min or less and a bioavailability of nearly 60%.,Intranasal delivery of morphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907197/),min,15,244729,DB00295,Morphine
,11907197,bioavailability,The results show that the nasal formulation was rapidly absorbed with a T(max) of 15 min or less and a bioavailability of nearly 60%.,Intranasal delivery of morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907197/),%,60,244730,DB00295,Morphine
,16763013,CL(in),CL(in) across the BBB was estimated to 1910 microl/min x g brain.,In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763013/),[μl] / [g·min],1910,244789,DB00295,Morphine
,16763013,"K(p,uu)","K(p,uu) was estimated to 3.0, meaning that the unbound concentration of oxycodone in brain was 3 times higher than in blood, which is an indication of active influx of oxycodone at the BBB.",In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763013/),,3.0,244790,DB00295,Morphine
,21491207,Plasma concentrations,"Plasma concentrations of oxycodone and noroxycodone ranged from 1.0 to 256.0 and 0.9-269.4 μg/L, respectively.",Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491207/),[μg] / [l],1.0 to 256.0,244815,DB00295,Morphine
,21491207,Plasma concentrations,"Plasma concentrations of oxycodone and noroxycodone ranged from 1.0 to 256.0 and 0.9-269.4 μg/L, respectively.",Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491207/),[μg] / [l],0.9-269.4,244816,DB00295,Morphine
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,20,245762,DB00295,Morphine
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,6,245763,DB00295,Morphine
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,2 to 3,245764,DB00295,Morphine
,13957,half-life,The half-life of methadone averages 25 hours.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,25,245765,DB00295,Morphine
,13957,half-life,Naloxone rapidly disappears from the serum in man and the initial distribution phase has a half-life of 4 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,4,245766,DB00295,Morphine
,13957,half-life,The half-life of naloxone in serum following distribution is 64 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,64,245767,DB00295,Morphine
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,68,246405,DB00295,Morphine
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,60,246406,DB00295,Morphine
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,59,246407,DB00295,Morphine
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,63,246408,DB00295,Morphine
,16334958,vF thresholds,"The vF thresholds were significantly increased from 5 to 8 hours during the infusion phase, corresponding to targeted morphine plasma concentrations > 30 ng/mL and infusion rates > or = 0.15 +/- 0.02 mg/kg/h.",Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334958/),h,5,246454,DB00295,Morphine
,16334958,maximal effect (EMAX),"The maximal effect (EMAX) was 78 +/- 11% (percentage change from baseline), and the effective concentration to attain a 50% maximal response (EC50) was 29.5 +/- 5.4 ng/mL.",Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334958/),%,78,246455,DB00295,Morphine
,16334958,effective concentration to attain a 50% maximal response (EC50),"The maximal effect (EMAX) was 78 +/- 11% (percentage change from baseline), and the effective concentration to attain a 50% maximal response (EC50) was 29.5 +/- 5.4 ng/mL.",Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334958/),[ng] / [ml],29.5,246456,DB00295,Morphine
,16334958,EC50,"The vF thresholds were significantly increased from 1 to 7 hours during the multiple-dose phase; the EC50 and EMAX were 23.9 +/- 4.7 ng/mL and 173 +/- 58%, respectively.",Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334958/),[ng] / [ml],23.9,246457,DB00295,Morphine
,16334958,EMAX,"The vF thresholds were significantly increased from 1 to 7 hours during the multiple-dose phase; the EC50 and EMAX were 23.9 +/- 4.7 ng/mL and 173 +/- 58%, respectively.",Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334958/),%,173,246458,DB00295,Morphine
,12602585,half-life,Typical half-life of MOR in plasma was 40 to 60 minutes and related to dose.,Interactions of morphine and isoflurane in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),min,40 to 60,247028,DB00295,Morphine
,12602585,PaCO2,Mean PaCO2 increased from 70 mm Hg before MOR to 88 to 102 mm Hg for 30 to 240 minutes after the high dose of MOR.,Interactions of morphine and isoflurane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),hg·mm,70,247029,DB00295,Morphine
,12602585,PaCO2,Mean PaCO2 increased from 70 mm Hg before MOR to 88 to 102 mm Hg for 30 to 240 minutes after the high dose of MOR.,Interactions of morphine and isoflurane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),hg·mm,88,247030,DB00295,Morphine
,12602585,PaCO2,Mean PaCO2 increased from 70 mm Hg before MOR to 88 to 102 mm Hg for 30 to 240 minutes after the high dose of MOR.,Interactions of morphine and isoflurane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),hg·mm,102,247031,DB00295,Morphine
,10584978,total,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],43.0,247040,DB00295,Morphine
,10584978,clearance,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],43.0,247041,DB00295,Morphine
,10584978,clearance,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],51.0,247042,DB00295,Morphine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],7.11,247043,DB00295,Morphine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],8.60,247044,DB00295,Morphine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],11.5,247045,DB00295,Morphine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],14.0,247046,DB00295,Morphine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],4.05,247047,DB00295,Morphine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],4.94,247048,DB00295,Morphine
,10584978,half-life,Antipyrine half-life was significantly reduced (12.3 +/- 2.8 h to 9.4 +/- 2.2 h) and some patients developed clinical signs of L-methadone underdosage.,Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),h,12.3,247049,DB00295,Morphine
,10584978,half-life,Antipyrine half-life was significantly reduced (12.3 +/- 2.8 h to 9.4 +/- 2.2 h) and some patients developed clinical signs of L-methadone underdosage.,Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),h,9.4,247050,DB00295,Morphine
,10630773,Overall systemic bioavailability,Overall systemic bioavailability of morphine administered per rectum was 19.6%.,"Pharmacokinetics, pharmacodynamics, and analgesic effects of morphine after rectal, intramuscular, and intravenous administration in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630773/),%,19.6,247238,DB00295,Morphine
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],68,247242,DB00295,Morphine
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],101,247243,DB00295,Morphine
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],208,247244,DB00295,Morphine
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],304,247245,DB00295,Morphine
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],375,247246,DB00295,Morphine
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],34,247247,DB00295,Morphine
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],51,247248,DB00295,Morphine
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],104,247249,DB00295,Morphine
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],152,247250,DB00295,Morphine
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],188,247251,DB00295,Morphine
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,3.6,247252,DB00295,Morphine
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,14.9,247253,DB00295,Morphine
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,11.9,247254,DB00295,Morphine
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,31.1,247255,DB00295,Morphine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,4.1,247369,DB00295,Morphine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,0.98,247370,DB00295,Morphine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,1.55,247371,DB00295,Morphine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],41,247372,DB00295,Morphine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],"14,494",247373,DB00295,Morphine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],"7,426",247374,DB00295,Morphine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],6.3,247375,DB00295,Morphine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],616.7,247376,DB00295,Morphine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],328,247377,DB00295,Morphine
,3335120,elimination half-life,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,18.69,247486,DB00295,Morphine
,3335120,elimination half-life,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,4.04,247487,DB00295,Morphine
,3335120,mean residence time,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,12.77,247488,DB00295,Morphine
,3335120,mean residence time,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,3.90,247489,DB00295,Morphine
,2453226,elimination half-life,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),h,2.36,247787,DB00295,Morphine
,2453226,hepatic extraction ratio,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),,0.51,247788,DB00295,Morphine
,2453226,apparent volume of distribution,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),[l] / [kg],2.9,247789,DB00295,Morphine
,2453226,volume of central compartment,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),[l] / [kg],0.23,247790,DB00295,Morphine
,2453226,absolute bioavailability,"The absolute bioavailability after peroral administration was 50.7 +/- 29.8 per cent, and that after rectal administration was 33 +/- 22 per cent.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),%,50.7,247791,DB00295,Morphine
,2453226,absolute bioavailability,"The absolute bioavailability after peroral administration was 50.7 +/- 29.8 per cent, and that after rectal administration was 33 +/- 22 per cent.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),%,33,247792,DB00295,Morphine
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,3,247956,DB00295,Morphine
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,15,247957,DB00295,Morphine
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,135-190,247958,DB00295,Morphine
,31124839,peak plasma concentrations,The range of peak plasma concentrations was 0.39-2.44 µg/mL for the manual bolus atomization versus 0.25-1.07 μg/mL for the micropump nebulization.,Population Pharmacokinetics of Intraperitoneal Bupivacaine Using Manual Bolus Atomization Versus Micropump Nebulization and Morphine Requirements in Young Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31124839/),[μg] / [ml],0.39-2.44,247993,DB00295,Morphine
,31124839,peak plasma concentrations,The range of peak plasma concentrations was 0.39-2.44 µg/mL for the manual bolus atomization versus 0.25-1.07 μg/mL for the micropump nebulization.,Population Pharmacokinetics of Intraperitoneal Bupivacaine Using Manual Bolus Atomization Versus Micropump Nebulization and Morphine Requirements in Young Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31124839/),[μg] / [ml],0.25-1.07,247994,DB00295,Morphine
,12189362,metabolic transit time,"The formation of M6G from morphine was modeled as a fraction of morphine clearance of about 14%, which accounted for the formation of M6G, and a delay of the appearance of M6G in plasma modeled as a first-order process, with a mean metabolic transit time of 17.2 minutes.",Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189362/),min,17.2,248052,DB00295,Morphine
,6190484,biological half-life,"The intracerebral level of morphine was found to depend on the dose injected, and the biological half-life of the drug was estimated to be about 1 hr.",Direct correlation between level of morphine and its biochemical effect on monoamine systems in mouse brain. Evidence for involvement of dopaminergic neurons in the pharmacological action of acute morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6190484/),h,1,248070,DB00295,Morphine
,21417608,rate constant,"A rate constant of morphine disappearance from the donor phase of the in vitro model of 1.8 × 10(-2) min(-1) was calculated, independently of the different release media used.",Intra-articular injection of morphine to the horse: establishment of an in vitro-in vivo relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417608/),1/[min],1.8 × 10(-2),248172,DB00295,Morphine
,21417608,disappearance rate constants,The in vivo synovial fluid disappearance rate constants were in the range of 1.0 × 10(-2)-1.7 × 10(-2) min(-1).,Intra-articular injection of morphine to the horse: establishment of an in vitro-in vivo relationship. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417608/),1/[min],1.0 × 10(-2),248173,DB00295,Morphine
,21417608,disappearance rate constants,The in vivo synovial fluid disappearance rate constants were in the range of 1.0 × 10(-2)-1.7 × 10(-2) min(-1).,Intra-articular injection of morphine to the horse: establishment of an in vitro-in vivo relationship. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417608/),1/[min],1.7 × 10(-2),248174,DB00295,Morphine
,2795844,Onset of analgesia,"Onset of analgesia was at 15.8 +/- 4.8 mins and 24.7 +/- 3.5 mins in the excellent and fair analgesia groups, respectively.",[Post-thoracotomy analgesia and serum concentration of epidurally administered morphine; a pharmacokinetic and pharmacodynamic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795844/),min,15.8,248536,DB00295,Morphine
,2795844,Onset of analgesia,"Onset of analgesia was at 15.8 +/- 4.8 mins and 24.7 +/- 3.5 mins in the excellent and fair analgesia groups, respectively.",[Post-thoracotomy analgesia and serum concentration of epidurally administered morphine; a pharmacokinetic and pharmacodynamic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795844/),min,24.7,248537,DB00295,Morphine
,2795844,Maximal concentration (Cmax),Maximal concentration (Cmax) was calculated to be 38.5 +/- 4.2 ng.,[Post-thoracotomy analgesia and serum concentration of epidurally administered morphine; a pharmacokinetic and pharmacodynamic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795844/),ng,38.5,248538,DB00295,Morphine
,7297022,Volume of distribution,Volume of distribution ranged from 0.95 to 3.75 l/kg and serum clearance from 5.0 to 16.1 ml/min/kg.,Morphine kinetics in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297022/),[l] / [kg],0.95 to 3.75,248588,DB00295,Morphine
,7297022,serum clearance,Volume of distribution ranged from 0.95 to 3.75 l/kg and serum clearance from 5.0 to 16.1 ml/min/kg.,Morphine kinetics in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297022/),[ml] / [kg·min],5.0 to 16.1,248589,DB00295,Morphine
,7297022,oral bioavailability,There was a variation in oral bioavailability of 15% to 64% and an interindividual variation in terminal half-life from 58 to 465 min.,Morphine kinetics in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297022/),%,15,248590,DB00295,Morphine
,7297022,terminal half-life,There was a variation in oral bioavailability of 15% to 64% and an interindividual variation in terminal half-life from 58 to 465 min.,Morphine kinetics in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297022/),min,58 to 465,248591,DB00295,Morphine
,30919469,Maximal concentrations,"Maximal concentrations of M3G and M6G ranged from 55.1 to 504 and 6.2 to 28.4 ng/ml, respectively, across dose groups.",Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919469/),[ng] / [ml],55.1 to 504,248814,DB00295,Morphine
,30919469,Maximal concentrations,"Maximal concentrations of M3G and M6G ranged from 55.1 to 504 and 6.2 to 28.4 ng/ml, respectively, across dose groups.",Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919469/),[ng] / [ml],6.2 to 28.4,248815,DB00295,Morphine
,30919469,volume of distribution at steady-state,"The volume of distribution at steady-state and systemic clearance ranged from 9.40 to 16.9 L/kg and 23.3 to 32.4 ml min-1 kg-1 , respectively.",Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919469/),[l] / [kg],9.40 to 16.9,248816,DB00295,Morphine
,30919469,systemic clearance,"The volume of distribution at steady-state and systemic clearance ranged from 9.40 to 16.9 L/kg and 23.3 to 32.4 ml min-1 kg-1 , respectively.",Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919469/),[ml] / [kg·min],23.3 to 32.4,248817,DB00295,Morphine
,17471182,passive diffusion rate constant,The passive diffusion rate constant was 0.0014 min(-1).,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),1/[min],0.0014,249309,DB00295,Morphine
,17471182,active efflux rate constant,The active efflux rate constant decreased from 0.0195 min(-1) to 0.0113 min(-1) in the presence of GF120918.,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),1/[min],0.0195,249310,DB00295,Morphine
,17471182,active efflux rate constant,The active efflux rate constant decreased from 0.0195 min(-1) to 0.0113 min(-1) in the presence of GF120918.,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),1/[min],0.0113,249311,DB00295,Morphine
,17471182,maximum transport (N(max)/V(ecf)),The active influx was insensitive to GF120918 and had a maximum transport (N(max)/V(ecf)) of 0.66 ng min(-1) ml(-1) and was saturated at low concentrations of morphine (C(50)=9.9 ng ml(-1)).,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),[ng] / [min·ml],0.66,249312,DB00295,Morphine
,17471182,C(50),The active influx was insensitive to GF120918 and had a maximum transport (N(max)/V(ecf)) of 0.66 ng min(-1) ml(-1) and was saturated at low concentrations of morphine (C(50)=9.9 ng ml(-1)).,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),[ng] / [ml],9.9,249313,DB00295,Morphine
,1269215,volume of central compartment,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),[l] / [kg],0.09,250461,DB00295,Morphine
,1269215,total apparent volume of distribution,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),[l] / [kg],1.02,250462,DB00295,Morphine
,1269215,distribution T 1/2,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),min,0.90,250463,DB00295,Morphine
,1269215,apparent elimination T 1/2,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),min,137,250464,DB00295,Morphine
,1269215,total clearance,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),[ml] / [min],378,250465,DB00295,Morphine
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,2,250726,DB00295,Morphine
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,over,250727,DB00295,Morphine
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,8,250728,DB00295,Morphine
,2452249,latencies,The 50-mg/kg dose elevated latencies to approximately 5 sec after 24 hr.,Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,5,250729,DB00295,Morphine
,16631414,plasma clearance,"For example, plasma clearance was 76 mL h(-)(1) kg(-)(1) in the flounder but was almost twice as much in the trout (153 mL h(-)(1) kg(-)(1)) and mean residence time was 27.9h in the flounder but was 7.0 h in the trout.",Pharmacokinetics of morphine in fish: winter flounder (Pseudopleuronectes americanus) and seawater-acclimated rainbow trout (Oncorhynchus mykiss). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631414/),h(-)(1)·kg(-)(1)·ml,76,251040,DB00295,Morphine
,16631414,plasma clearance,"For example, plasma clearance was 76 mL h(-)(1) kg(-)(1) in the flounder but was almost twice as much in the trout (153 mL h(-)(1) kg(-)(1)) and mean residence time was 27.9h in the flounder but was 7.0 h in the trout.",Pharmacokinetics of morphine in fish: winter flounder (Pseudopleuronectes americanus) and seawater-acclimated rainbow trout (Oncorhynchus mykiss). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631414/),h(-)(1)·kg(-)(1)·ml,153,251041,DB00295,Morphine
,16631414,mean residence time,"For example, plasma clearance was 76 mL h(-)(1) kg(-)(1) in the flounder but was almost twice as much in the trout (153 mL h(-)(1) kg(-)(1)) and mean residence time was 27.9h in the flounder but was 7.0 h in the trout.",Pharmacokinetics of morphine in fish: winter flounder (Pseudopleuronectes americanus) and seawater-acclimated rainbow trout (Oncorhynchus mykiss). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631414/),h,27.9,251042,DB00295,Morphine
,16631414,mean residence time,"For example, plasma clearance was 76 mL h(-)(1) kg(-)(1) in the flounder but was almost twice as much in the trout (153 mL h(-)(1) kg(-)(1)) and mean residence time was 27.9h in the flounder but was 7.0 h in the trout.",Pharmacokinetics of morphine in fish: winter flounder (Pseudopleuronectes americanus) and seawater-acclimated rainbow trout (Oncorhynchus mykiss). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631414/),h,7.0,251043,DB00295,Morphine
,1958450,t1/2z,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),min,222,251145,DB00295,Morphine
,1958450,CL,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),[l] / [min],0.78,251146,DB00295,Morphine
,1958450,Vss,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),[l] / [kg],2.60,251147,DB00295,Morphine
,1958450,"AUC(0,12) ratio","The mean AUC(0,12) ratio of noroxycodone to oxycodone was 0.33.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),,0.33,251148,DB00295,Morphine
,10319789,Time to onset,Time to onset was 1.3 +/- 0.3 h for C0401-30; 2.6 +/- 0.6 h for C0401-10; and 0.4 +/- 0.2 h for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,1.3,251438,DB00295,Morphine
,10319789,Time to onset,Time to onset was 1.3 +/- 0.3 h for C0401-30; 2.6 +/- 0.6 h for C0401-10; and 0.4 +/- 0.2 h for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,2.6,251439,DB00295,Morphine
,10319789,Time to onset,Time to onset was 1.3 +/- 0.3 h for C0401-30; 2.6 +/- 0.6 h for C0401-10; and 0.4 +/- 0.2 h for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,0.4,251440,DB00295,Morphine
,10319789,Duration of action,Duration of action was 62 +/- 0.3 h for C0401-30; 27 +/- 2 h for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,62,251441,DB00295,Morphine
,10319789,Duration of action,Duration of action was 62 +/- 0.3 h for C0401-30; 27 +/- 2 h for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,27,251442,DB00295,Morphine
,10319789,Time to peak cerebrospinal fluid morphine concentration,Time to peak cerebrospinal fluid morphine concentration was 11 h for C0401-30; 3 h for C0401-10; and 5 min for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,11,251443,DB00295,Morphine
,10319789,Time to peak cerebrospinal fluid morphine concentration,Time to peak cerebrospinal fluid morphine concentration was 11 h for C0401-30; 3 h for C0401-10; and 5 min for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,3,251444,DB00295,Morphine
,10319789,Time to peak cerebrospinal fluid morphine concentration,Time to peak cerebrospinal fluid morphine concentration was 11 h for C0401-30; 3 h for C0401-10; and 5 min for MS-5.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),min,5,251445,DB00295,Morphine
,10319789,Peak lumbar cerebrospinal fluid level,"Peak lumbar cerebrospinal fluid level was 34,992 +/- 5,578 ng/ml for MS-5; 14,483 +/- 3,438 ng/ml for C0401-30; and 10,730 +/- 2,888 ng/ml for C0401-10.",Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),[ng] / [ml],"34,992",251446,DB00295,Morphine
,10319789,Peak lumbar cerebrospinal fluid level,"Peak lumbar cerebrospinal fluid level was 34,992 +/- 5,578 ng/ml for MS-5; 14,483 +/- 3,438 ng/ml for C0401-30; and 10,730 +/- 2,888 ng/ml for C0401-10.",Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),[ng] / [ml],"14,483",251447,DB00295,Morphine
,10319789,Peak lumbar cerebrospinal fluid level,"Peak lumbar cerebrospinal fluid level was 34,992 +/- 5,578 ng/ml for MS-5; 14,483 +/- 3,438 ng/ml for C0401-30; and 10,730 +/- 2,888 ng/ml for C0401-10.",Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),[ng] / [ml],"10,730",251448,DB00295,Morphine
,10319789,mean residence time,Morphine mean residence time in lumbar cerebrospinal fluid was 0.8 +/- 0.1 h for MS-5; 8.9 +/- 1.0 h for C0401-30.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,0.8,251449,DB00295,Morphine
,10319789,mean residence time,Morphine mean residence time in lumbar cerebrospinal fluid was 0.8 +/- 0.1 h for MS-5; 8.9 +/- 1.0 h for C0401-30.,Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319789/),h,8.9,251450,DB00295,Morphine
,9915332,elimination half life,Drug activity in the tissue revealed an elimination half life of 2.3 h and negligible concentration in the blood.,Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915332/),h,2.3,251568,DB00295,Morphine
,8357878,recoveries,"For routine analysis the procedure provides high and reproducible recoveries over a concentration range of 1.0-1000 ng ml-1 for morphine, M6G and normorphine and 20-1000 ng ml-1 for M3G.",An improved extraction method for the HPLC determination of morphine and its metabolites in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8357878/),[ng] / [ml],20-1000,251666,DB00295,Morphine
,3514045,oral bioavailability,The oral bioavailability is approximately 40% with marked patient-to-patient variations as a result of differences in presystemic elimination.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),%,40,251886,DB00295,Morphine
,3514045,volume of distribution,The reported values for the volume of distribution range from 1.0 to 4.7 L/kg.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),[l] / [kg],1.0 to 4.7,251887,DB00295,Morphine
,3514045,Plasma protein binding,Plasma protein binding is about 30%.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),%,30,251888,DB00295,Morphine
,3514045,elimination half-life,The elimination half-life varies between 0.7 and 7.8 hours.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),h,0.7 and 7.8,251889,DB00295,Morphine
,3514045,Plasma clearance,Plasma clearance is approximately 19 ml/min/kg (5 to 34 ml/min/kg) and mostly accounted for by metabolic clearance.,High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514045/),[ml] / [kg·min],19,251890,DB00295,Morphine
,3098137,onset,"The onset and the duration of analgesia were 30 +/- 12 min and 19.5 +/- 8 h, respectively (mean +/- SD).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),min,30,251965,DB00295,Morphine
,3098137,duration of,"The onset and the duration of analgesia were 30 +/- 12 min and 19.5 +/- 8 h, respectively (mean +/- SD).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),min,30,251966,DB00295,Morphine
,3098137,duration of,"The onset and the duration of analgesia were 30 +/- 12 min and 19.5 +/- 8 h, respectively (mean +/- SD).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),h,19.5,251967,DB00295,Morphine
,3098137,slope,"However, the slope of the ventilatory response to CO2 was significantly (P less than 0.05) decreased after surgery but before morphine, as compared with its preoperative control value (0.84 +/- 0.44 versus 1.51 +/- 0.72 l X min-1 X mmHg-1), and remained low for 22 h after epidural morphine (0.90 +/- 0.57 l X min-1 X mmHg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[l] / [min·mmhg],0.84,251968,DB00295,Morphine
,3098137,slope,"However, the slope of the ventilatory response to CO2 was significantly (P less than 0.05) decreased after surgery but before morphine, as compared with its preoperative control value (0.84 +/- 0.44 versus 1.51 +/- 0.72 l X min-1 X mmHg-1), and remained low for 22 h after epidural morphine (0.90 +/- 0.57 l X min-1 X mmHg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[l] / [min·mmhg],1.51,251969,DB00295,Morphine
,3098137,slope,"However, the slope of the ventilatory response to CO2 was significantly (P less than 0.05) decreased after surgery but before morphine, as compared with its preoperative control value (0.84 +/- 0.44 versus 1.51 +/- 0.72 l X min-1 X mmHg-1), and remained low for 22 h after epidural morphine (0.90 +/- 0.57 l X min-1 X mmHg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[l] / [min·mmhg],0.90,251970,DB00295,Morphine
,3098137,ventilatory response,"However, the slope of the ventilatory response to CO2 was significantly (P less than 0.05) decreased after surgery but before morphine, as compared with its preoperative control value (0.84 +/- 0.44 versus 1.51 +/- 0.72 l X min-1 X mmHg-1), and remained low for 22 h after epidural morphine (0.90 +/- 0.57 l X min-1 X mmHg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[l] / [min·mmhg],0.84,251971,DB00295,Morphine
,3098137,ventilatory response,"However, the slope of the ventilatory response to CO2 was significantly (P less than 0.05) decreased after surgery but before morphine, as compared with its preoperative control value (0.84 +/- 0.44 versus 1.51 +/- 0.72 l X min-1 X mmHg-1), and remained low for 22 h after epidural morphine (0.90 +/- 0.57 l X min-1 X mmHg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[l] / [min·mmhg],1.51,251972,DB00295,Morphine
,3098137,ventilatory response,"However, the slope of the ventilatory response to CO2 was significantly (P less than 0.05) decreased after surgery but before morphine, as compared with its preoperative control value (0.84 +/- 0.44 versus 1.51 +/- 0.72 l X min-1 X mmHg-1), and remained low for 22 h after epidural morphine (0.90 +/- 0.57 l X min-1 X mmHg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[l] / [min·mmhg],0.90,251973,DB00295,Morphine
,3098137,terminal half-life,"Pharmacokinetic parameters were similar to those observed after epidural injection of morphine in adults, except for a shorter terminal half-life (73.8 +/- 41.6 min) attributed to a greater total body clearance of morphine in the children (28.3 +/- 3.4 ml X min-1 X kg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),min,73.8,251974,DB00295,Morphine
,3098137,total body clearance,"Pharmacokinetic parameters were similar to those observed after epidural injection of morphine in adults, except for a shorter terminal half-life (73.8 +/- 41.6 min) attributed to a greater total body clearance of morphine in the children (28.3 +/- 3.4 ml X min-1 X kg-1).",Epidural morphine in children: pharmacokinetics and CO2 sensitivity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098137/),[ml] / [kg·min],28.3,251975,DB00295,Morphine
,30074252,standard curve,The standard curve ranged from 1 to 500 ng/mL.,Development of a method for the determination of hydromorphone in plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30074252/),[ng] / [ml],1 to 500,251982,DB00295,Morphine
,32654915,Cmax,"The Cmax, tmax and elimination t½ were 270.7 ± 136.0 ng mL-1, 0.438 ± 0.156 hours and 2.00 ± 0.534 hours, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],270.7,252585,DB00295,Morphine
,32654915,tmax,"The Cmax, tmax and elimination t½ were 270.7 ± 136.0 ng mL-1, 0.438 ± 0.156 hours and 2.00 ± 0.534 hours, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),h,0.438,252586,DB00295,Morphine
,32654915,elimination t½,"The Cmax, tmax and elimination t½ were 270.7 ± 136.0 ng mL-1, 0.438 ± 0.156 hours and 2.00 ± 0.534 hours, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),h,2.00,252587,DB00295,Morphine
,32654915,Cmax,"M3G was the main metabolite detected (Cmax 492.7 ± 35.5 ng mL-1), followed by C6G (Cmax 96.1 ± 33.8 ng mL-1) and M6G (Cmax 22.3 ± 4.96 ng mL-1).","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],492.7,252588,DB00295,Morphine
,32654915,Cmax,"M3G was the main metabolite detected (Cmax 492.7 ± 35.5 ng mL-1), followed by C6G (Cmax 96.1 ± 33.8 ng mL-1) and M6G (Cmax 22.3 ± 4.96 ng mL-1).","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],96.1,252589,DB00295,Morphine
,32654915,Cmax,"M3G was the main metabolite detected (Cmax 492.7 ± 35.5 ng mL-1), followed by C6G (Cmax 96.1 ± 33.8 ng mL-1) and M6G (Cmax 22.3 ± 4.96 ng mL-1).","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],22.3,252590,DB00295,Morphine
,32654915,Cmax,"Morphine and norcodeine were the least abundant metabolites with Cmax of 3.17 ± 0.95 and 1.42 ± 0.79 ng mL-1, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],3.17,252591,DB00295,Morphine
,32654915,Cmax,"Morphine and norcodeine were the least abundant metabolites with Cmax of 3.17 ± 0.95 and 1.42 ± 0.79 ng mL-1, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],1.42,252592,DB00295,Morphine
,660555,half-life,"Further, this analysis yielded 20 minutes as the half-life of naloxone.",The relationship between pharmacokinetics and pharmacodynamic action as applied to in vivo pA2: application to the analgesic effect of morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/660555/),min,20,252676,DB00295,Morphine
,6183551,ED50's,"Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively).",Receptor binding and analgesic properties of oxymorphazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183551/),[mg] / [kg],0.8,253392,DB00295,Morphine
,6183551,ED50's,"Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively).",Receptor binding and analgesic properties of oxymorphazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183551/),[mg] / [kg],0.4,253393,DB00295,Morphine
,26556729,plasma target concentrations,"Postoperatively, hydromorphone was applied intravenously during three sequential periods: (1) as TCI with plasma target concentrations of 1 to 2 ng/ml until extubation; (2) as TCI-PCA with plasma target concentrations between 0.8 and 10 ng/ml during the following 6 to 8 h; and (3) thereafter as PCA with a bolus dose of 0.2 mg until the next morning.",Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],1 to 2,253494,DB00295,Morphine
,26556729,plasma target concentrations,"Postoperatively, hydromorphone was applied intravenously during three sequential periods: (1) as TCI with plasma target concentrations of 1 to 2 ng/ml until extubation; (2) as TCI-PCA with plasma target concentrations between 0.8 and 10 ng/ml during the following 6 to 8 h; and (3) thereafter as PCA with a bolus dose of 0.2 mg until the next morning.",Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],0.8 and 10,253495,DB00295,Morphine
,26556729,maximum plasma target concentration,The maximum plasma target concentration during TCI-PCA was 2.3 ng/ml (0.9 to 7.0 ng/ml).,Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],2.3,253496,DB00295,Morphine
,26556729,EC50,The EC50 of hydromorphone for NRS of 4 or less was 4.1 ng/ml (0.6 to 12.8 ng/ml).,Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],4.1,253497,DB00295,Morphine
,3368920,elimination constant,"Plasma clearance of gentamicin was nearly halved by morphine, due primarily to lowering of the elimination constant of gentamicin from 0.03 to 0.02 min-1 (p less than 0.01).",Morphine effects on gentamicin disposition and toxicity in mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),1/[min],0.03,253553,DB00295,Morphine
,3368920,elimination constant,"Plasma clearance of gentamicin was nearly halved by morphine, due primarily to lowering of the elimination constant of gentamicin from 0.03 to 0.02 min-1 (p less than 0.01).",Morphine effects on gentamicin disposition and toxicity in mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),1/[min],0.02,253554,DB00295,Morphine
,3368920,LD50,"LD50 of acutely administered iv gentamicin was 51.6 mg/kg after saline and 45.3 mg/kg after treatment with morphine, 20 mg/kg sc.",Morphine effects on gentamicin disposition and toxicity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),[mg] / [kg],51.6,253555,DB00295,Morphine
,3368920,LD50,"LD50 of acutely administered iv gentamicin was 51.6 mg/kg after saline and 45.3 mg/kg after treatment with morphine, 20 mg/kg sc.",Morphine effects on gentamicin disposition and toxicity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),[mg] / [kg],45.3,253556,DB00295,Morphine
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],22.2,253697,DB00295,Morphine
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],27.2,253698,DB00295,Morphine
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],26.0,253699,DB00295,Morphine
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],23.4,253700,DB00295,Morphine
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],32.8,253701,DB00295,Morphine
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],23.0,253702,DB00295,Morphine
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],22.2,253703,DB00295,Morphine
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],31.1,253704,DB00295,Morphine
,8926744,hair concentration,"in female subjects, the mean (plus or minus standard error of the mean) hair concentration of codeine in the proximal, 1-cm segment from plucked hair was 2.7 ng/mg (+/- 0.55) at 12 h after the last codeine dose; 0.44 ng/mg (+/- 0.20) still remained in this segment at 5 weeks.",Disposition of codeine in female human hair after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926744/),[ng] / [mg],2.7,253905,DB00295,Morphine
,8926744,hair concentration,"in female subjects, the mean (plus or minus standard error of the mean) hair concentration of codeine in the proximal, 1-cm segment from plucked hair was 2.7 ng/mg (+/- 0.55) at 12 h after the last codeine dose; 0.44 ng/mg (+/- 0.20) still remained in this segment at 5 weeks.",Disposition of codeine in female human hair after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926744/),[ng] / [mg],0.44,253906,DB00295,Morphine
,8926744,hair concentration,"In male subjects studied previously, the mean hair concentration of codeine in the proximal, 1-cm hair segment was 2.6 ng/mg (+/- 0.34) at 12 h after the last codeine dose, and no codeine was detected at 5 weeks.",Disposition of codeine in female human hair after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926744/),[ng] / [mg],2.6,253907,DB00295,Morphine
,762653,terminal half-life of morphine elimination,The terminal half-life of morphine elimination was 5 hours.,Morphine persistence in rat brain and serum after single doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/762653/),h,5,254207,DB00295,Morphine
,16326369,apparent steady-state,The time-course of serum 17beta-estradiol and progesterone released from these capsules in the OVX rat is characterized by an initial increase in serum hormone levels followed by a decline and then an apparent steady-state that persists from 7 to 24 days postimplant.,Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326369/),d,7 to 24,254208,DB00295,Morphine
,16326369,total clearance,Both hormones have large clearance values (total clearance is 97.7 L/day for 17beta-estradiol and 20.9 L/day for progesterone).,Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326369/),[l] / [d],97.7,254209,DB00295,Morphine
,16326369,total clearance,Both hormones have large clearance values (total clearance is 97.7 L/day for 17beta-estradiol and 20.9 L/day for progesterone).,Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326369/),[l] / [d],20.9,254210,DB00295,Morphine
,23503706,time to maximum concentration (tmax),The time to maximum concentration (tmax) varied from 0.5 to 24 hours (median 12 hours) according to which peak predominated.,The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),h,12,254654,DB00295,Morphine
,23503706,maximum concentration (Cmax),"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.22,254655,DB00295,Morphine
,23503706,maximum individual Cmax,"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.44,254656,DB00295,Morphine
,11966664,"AUC(0,infinity)","After i.v. M6G the mean (+/- s.d.) AUC(0,infinity) standardized to a dose of 1 mg was 223 +/- 57 nmol l(-1) h, mean elimination half-life was 1.7 +/- 0.7 h and the mean clearance was 157 +/- 46 ml min(-1).","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),[h·nM] / [l],223,255091,DB00295,Morphine
,11966664,elimination half-life,"After i.v. M6G the mean (+/- s.d.) AUC(0,infinity) standardized to a dose of 1 mg was 223 +/- 57 nmol l(-1) h, mean elimination half-life was 1.7 +/- 0.7 h and the mean clearance was 157 +/- 46 ml min(-1).","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),h,1.7,255092,DB00295,Morphine
,11966664,clearance,"After i.v. M6G the mean (+/- s.d.) AUC(0,infinity) standardized to a dose of 1 mg was 223 +/- 57 nmol l(-1) h, mean elimination half-life was 1.7 +/- 0.7 h and the mean clearance was 157 +/- 46 ml min(-1).","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),[ml] / [min],157,255093,DB00295,Morphine
,11966664,"bioavailability (F(0,infinity))","These parameters were virtually identical after subcutaneous administration which had a bioavailability (F(0,infinity)) of 102 +/- 35% (90% CI 82, 117%) and t(max) of 0.5 +/- 0.2 h.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),%,102,255094,DB00295,Morphine
,11966664,t(max),"These parameters were virtually identical after subcutaneous administration which had a bioavailability (F(0,infinity)) of 102 +/- 35% (90% CI 82, 117%) and t(max) of 0.5 +/- 0.2 h.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),h,0.5,255095,DB00295,Morphine
,11966664,bioavailability,"The mean bioavailability of nebulized M6G was 6 +/- 2% (90% CI 4, 7%) with a t(max) of 1.2 +/- 0.8 h.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),%,6,255096,DB00295,Morphine
,11966664,t(max),"The mean bioavailability of nebulized M6G was 6 +/- 2% (90% CI 4, 7%) with a t(max) of 1.2 +/- 0.8 h.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),h,1.2,255097,DB00295,Morphine
,11966664,t(max),"Following oral M6G two plasma M6G peaks were seen in 7 of the 10 subjects, the first with a t(max) of 3.1 (+/- 0.9) h.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),h,3.1,255098,DB00295,Morphine
,11966664,t(max),"The second peak had a t(max) of 13.4 (+/-5.0) h, started approximately 4 h after dosing, and was associated with the detection of plasma M3G and morphine, suggesting that M6G was significantly hydrolysed in the gut to morphine, which was then glucuronidated following absorption.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),h,13.4,255099,DB00295,Morphine
,11966664,bioavailability,"Although the overall mean bioavailability was 11 +/- 3% (90% CI 9, 12%), confining the analysis to data from the first peak suggested a bioavailability of directly absorbed M6G of only 4 +/- 4%.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),%,11,255100,DB00295,Morphine
,11966664,bioavailability,"Although the overall mean bioavailability was 11 +/- 3% (90% CI 9, 12%), confining the analysis to data from the first peak suggested a bioavailability of directly absorbed M6G of only 4 +/- 4%.","The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966664/),%,4,255101,DB00295,Morphine
,2275236,apparent volume of distribution,Ketorolac is more than 99 percent bound to plasma proteins and has a mean apparent volume of distribution of 0.11-0.25 L/kg.,Ketorolac: a parenteral nonsteroidal antiinflammatory drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275236/),[l] / [kg],0.11-0.25,255157,DB00295,Morphine
,7734250,Apparent steady state blood propofol concentrations,Apparent steady state blood propofol concentrations were 3.41 (SD 0.69) micrograms ml-1 in the weight-corrected group and 3.46 (0.79) microgram ml-1 in the standard dose group.,Propofol administered by a manual infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734250/),[μg] / [ml],3.41,255240,DB00295,Morphine
,7734250,Apparent steady state blood propofol concentrations,Apparent steady state blood propofol concentrations were 3.41 (SD 0.69) micrograms ml-1 in the weight-corrected group and 3.46 (0.79) microgram ml-1 in the standard dose group.,Propofol administered by a manual infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734250/),[μg] / [ml],3.46,255241,DB00295,Morphine
,833758,molar ratio,"In vitro inhibition studies indicated the molar ratio of M-3-G/morphine which inhibited 3H-morphine-antimorphine binding by 50% (150) was 90 and 14 for RIA-A and RIA-B, respectively.",Pharmacokinetics of morphine by radioimmunoassay: the influence of immunochemical factors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833758/),,90,255415,DB00295,Morphine
,833758,molar ratio,"In vitro inhibition studies indicated the molar ratio of M-3-G/morphine which inhibited 3H-morphine-antimorphine binding by 50% (150) was 90 and 14 for RIA-A and RIA-B, respectively.",Pharmacokinetics of morphine by radioimmunoassay: the influence of immunochemical factors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833758/),,14,255416,DB00295,Morphine
,833758,half-life,After rapid i.v. administration of morphine (1 or 5 mg/kg) the disappearance curves obtained with RIA-B were multiphasic and contained a prolonged terminal phase with an estimated half-life of 24 hours.,Pharmacokinetics of morphine by radioimmunoassay: the influence of immunochemical factors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833758/),h,24,255417,DB00295,Morphine
,833758,serum morphine clearance,With RIA-A the mean serum morphine clearance (86 ml/min/kg) and half-life of the elimination phase (74 minutes were independent of dosage.,Pharmacokinetics of morphine by radioimmunoassay: the influence of immunochemical factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833758/),[ml] / [kg·min],86,255418,DB00295,Morphine
,833758,half-life of the elimination phase,With RIA-A the mean serum morphine clearance (86 ml/min/kg) and half-life of the elimination phase (74 minutes were independent of dosage.,Pharmacokinetics of morphine by radioimmunoassay: the influence of immunochemical factors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/833758/),min,74,255419,DB00295,Morphine
,31691978,effective permeability,"Based on experiments in Caco-2 cell monolayers, the effective permeability of dihydrocodeine in human jejunum was established as 1.28 × 10-4 cm/s.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[cm] / [s],1.28 × 10-4,255905,DB00295,Morphine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [min·pM],0.19,255906,DB00295,Morphine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [min·pM],0.066,255907,DB00295,Morphine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [mg·min],0.14,255908,DB00295,Morphine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [mg·min],0.22,255909,DB00295,Morphine
,31691978,Renal clearance,Renal clearance was calculated as 5.37 L/h on the total clearance value multiplied by the fraction recovered in urine.,Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[l] / [h],5.37,255910,DB00295,Morphine
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],48.6,256793,DB00295,Morphine
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],36.3,256794,DB00295,Morphine
,8823235,total recovered amount,"The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823235/),nM,4349,256896,DB00295,Morphine
,8823235,total recovered amount,"The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823235/),nM,2564,256897,DB00295,Morphine
,8823235,total recovered amount,"The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823235/),nM,1127,256898,DB00295,Morphine
,14659513,C(max),Single dose nasal morphine gluconate administered to 11 patients was associated with effective plasma morphine concentrations (mean C(max) 64 ng/ml; range 33.8-121 ng/ml) and low plasma morphine metabolites (morphine-6-glucuronide mean C(max) 114 ng/ml; range 46-189 ng/ml; morphine-3-glucuronide mean C(max) 572 ng/ml; range 257-990 ng/ml).,"Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14659513/),[ng] / [ml],64,257047,DB00295,Morphine
,14659513,C(max),Single dose nasal morphine gluconate administered to 11 patients was associated with effective plasma morphine concentrations (mean C(max) 64 ng/ml; range 33.8-121 ng/ml) and low plasma morphine metabolites (morphine-6-glucuronide mean C(max) 114 ng/ml; range 46-189 ng/ml; morphine-3-glucuronide mean C(max) 572 ng/ml; range 257-990 ng/ml).,"Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14659513/),[ng] / [ml],114,257048,DB00295,Morphine
,14659513,C(max),Single dose nasal morphine gluconate administered to 11 patients was associated with effective plasma morphine concentrations (mean C(max) 64 ng/ml; range 33.8-121 ng/ml) and low plasma morphine metabolites (morphine-6-glucuronide mean C(max) 114 ng/ml; range 46-189 ng/ml; morphine-3-glucuronide mean C(max) 572 ng/ml; range 257-990 ng/ml).,"Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14659513/),[ng] / [ml],572,257049,DB00295,Morphine
,14659513,time to onset,"Patients reported rapid onset of pain relief (perceptible pain relief achieved in 10/11 patients, time to onset 2.4+/-2.1 min; and meaningful pain relief, achieved in five patients, 6.8+/-7.3 min to onset, mean t(max) 0.36 h).","Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14659513/),min,2.4,257050,DB00295,Morphine
,14659513,t(max),"Patients reported rapid onset of pain relief (perceptible pain relief achieved in 10/11 patients, time to onset 2.4+/-2.1 min; and meaningful pain relief, achieved in five patients, 6.8+/-7.3 min to onset, mean t(max) 0.36 h).","Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14659513/),h,0.36,257051,DB00295,Morphine
,10648334,Maximal plasma concentrations,"Maximal plasma concentrations of 17.2 and 10.4 mg/L (P < 0.01, analysis of variance) were achieved after 4.2 and 3.6 h for the AL and AS groups, respectively.","The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10648334/),[mg] / [l],17.2,258185,DB00295,Morphine
,10648334,Maximal plasma concentrations,"Maximal plasma concentrations of 17.2 and 10.4 mg/L (P < 0.01, analysis of variance) were achieved after 4.2 and 3.6 h for the AL and AS groups, respectively.","The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10648334/),[mg] / [l],10.4,258186,DB00295,Morphine
,24243216,Peak effects,Peak effects for pharmacodynamic measures were delayed with ORF (1-2 hours) versus OC and Oxy API (0.5-1 hour).,"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243216/),h,1-2,259209,DB00295,Morphine
,24243216,Peak effects,Peak effects for pharmacodynamic measures were delayed with ORF (1-2 hours) versus OC and Oxy API (0.5-1 hour).,"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243216/),h,0.5-1,259210,DB00295,Morphine
,6470567,t1/2,"The t1/2 of morphine was significantly prolonged from 1.02 +/- 0.50 hours (mean +/- SD) to 2.46 +/- 2.68 hours (p = 0.03) after transfusion with stroma-free hemoglobin, and to 2.05 +/- 0.95 hours (p = 0.006) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),h,1.02,259836,DB00295,Morphine
,6470567,t1/2,"The t1/2 of morphine was significantly prolonged from 1.02 +/- 0.50 hours (mean +/- SD) to 2.46 +/- 2.68 hours (p = 0.03) after transfusion with stroma-free hemoglobin, and to 2.05 +/- 0.95 hours (p = 0.006) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),h,2.46,259837,DB00295,Morphine
,6470567,t1/2,"The t1/2 of morphine was significantly prolonged from 1.02 +/- 0.50 hours (mean +/- SD) to 2.46 +/- 2.68 hours (p = 0.03) after transfusion with stroma-free hemoglobin, and to 2.05 +/- 0.95 hours (p = 0.006) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),h,2.05,259838,DB00295,Morphine
,6470567,volume of distribution,The volume of distribution was increased from 1.35 +/- 0.81 L X kg-1 to 2.99 +/- 1.45 L X kg-1 (p = 0.004) after transfusion with stroma-free hemoglobin; no such difference was observed after transfusion with fluosol DA (p = 0.86).,Interaction of oxygen-carrying resuscitation fluids with morphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [kg],1.35,259839,DB00295,Morphine
,6470567,volume of distribution,The volume of distribution was increased from 1.35 +/- 0.81 L X kg-1 to 2.99 +/- 1.45 L X kg-1 (p = 0.004) after transfusion with stroma-free hemoglobin; no such difference was observed after transfusion with fluosol DA (p = 0.86).,Interaction of oxygen-carrying resuscitation fluids with morphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [kg],2.99,259840,DB00295,Morphine
,6470567,area under the time-concentration curve,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[h·mg] / [l],2.37,259841,DB00295,Morphine
,6470567,area under the time-concentration curve,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[h·mg] / [l],6.02,259842,DB00295,Morphine
,6470567,total body clearance,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [h·kg],1.02,259843,DB00295,Morphine
,6470567,total body clearance,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [h·kg],0.55,259844,DB00295,Morphine
,34228875,absorption lag time,"However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),min,11.5,259884,DB00295,Morphine
,34228875,absorption lag time,"However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),min,14,259885,DB00295,Morphine
,34228875,oral bioavailability,"Furthermore, oral bioavailability was 14.4% higher in patients compared to healthy volunteers regardless of formulation type (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),%,14.4,259886,DB00295,Morphine
,10969293,total bioavailability,"The authors found that, with administration by inhalation, the total bioavailability was 59%, of which 43% was absorbed almost instantaneously and 57% was absorbed with a half-life of 18 min.",Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),%,59,260524,DB00295,Morphine
,10969293,total bioavailability,"The authors found that, with administration by inhalation, the total bioavailability was 59%, of which 43% was absorbed almost instantaneously and 57% was absorbed with a half-life of 18 min.",Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),%,43,260525,DB00295,Morphine
,10969293,total bioavailability,"The authors found that, with administration by inhalation, the total bioavailability was 59%, of which 43% was absorbed almost instantaneously and 57% was absorbed with a half-life of 18 min.",Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),%,57,260526,DB00295,Morphine
,10969293,half-life,"The authors found that, with administration by inhalation, the total bioavailability was 59%, of which 43% was absorbed almost instantaneously and 57% was absorbed with a half-life of 18 min.",Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),min,18,260527,DB00295,Morphine
,10969293,times to the half-maximal miotic effects,"The median times to the half-maximal miotic effects of morphine were 10 and 5.5 min after inhalation and intravenous administration, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),min,10,260528,DB00295,Morphine
,10969293,times to the half-maximal miotic effects,"The median times to the half-maximal miotic effects of morphine were 10 and 5.5 min after inhalation and intravenous administration, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),min,5.5,260529,DB00295,Morphine
,10969293,ke0,The pharmacodynamic parameter ke0 was approximately 0.003 min-1.,Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),1/[min],0.003,260530,DB00295,Morphine
,10969293,bioavailability,Morphine bioavailability after such administration is 59% of the dose loaded into the dosage form.,Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969293/),%,59,260531,DB00295,Morphine
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],60,260908,DB00295,Morphine
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],52,260909,DB00295,Morphine
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],98,260910,DB00295,Morphine
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],80,260911,DB00295,Morphine
,12501913,plasma elimination half-life,"In opiate-naïve subjects, intravenous (i.v.) ACOD showed a plasma elimination half-life of 237 +/- 18 min, urine peak concentrations 2 h after administration, and a detection window of 8 h.",Acetylcodeine as a urinary marker to differentiate the use of street heroin and pharmaceutical heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501913/),min,237,260935,DB00295,Morphine
,27225747,clearance,"For a 3.5-kg neonate, morphine clearance was 0.77 L/h (CV, 48%), and the steady-state volume of distribution was 8.0 L (CV, 49%).",Decreased Morphine Clearance in Neonates With Hypoxic Ischemic Encephalopathy Receiving Hypothermia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27225747/),[l] / [h],0.77,261575,DB00295,Morphine
,27225747,steady-state volume of distribution,"For a 3.5-kg neonate, morphine clearance was 0.77 L/h (CV, 48%), and the steady-state volume of distribution was 8.0 L (CV, 49%).",Decreased Morphine Clearance in Neonates With Hypoxic Ischemic Encephalopathy Receiving Hypothermia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27225747/),l,8.0,261576,DB00295,Morphine
,1931393,total body clearance,The mean (SEM) total body clearance of morphine was 1.63 (0.21) litre min-1; this comprised 1.01 (0.10) litre min-1 clearance by the liver and 0.55 (0.06) litre min-1 by the kidneys.,Physiological disposition of i.v. morphine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931393/),[l] / [min],1.63,261616,DB00295,Morphine
,1931393,renal clearance,The kidney clearance of morphine was greater than the 0.21 (0.06) litre min-1 renal clearance determined from the product of the mean total body clearance and the 12.3 (2.4%) of the administered dose recovered as unmetabolized morphine from 48 h urine collection (P less than 0.05).,Physiological disposition of i.v. morphine in sheep. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931393/),[l] / [min],0.21,261617,DB00295,Morphine
<,7586928,metabolic ratio [MR],"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,1,261923,DB00295,Morphine
<,7586928,1,"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,20,261924,DB00295,Morphine
>,7586928,MR,"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,20,261925,DB00295,Morphine
,7586928,area under the serum concentration-time curve (AUC),"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),[h·nM] / [l],10.3,261926,DB00295,Morphine
,7586928,partial metabolic clearance,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),[ml] / [min],7.0,261927,DB00295,Morphine
,7586928,total urinary recovery,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),%,1.3,261928,DB00295,Morphine
,7586928,total urinary recovery,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),%,8.9,261929,DB00295,Morphine
,20637968,Plasma C(max),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[pg] / [ml],579,262116,DB00295,Morphine
,20637968,Plasma C(max),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[pg] / [ml],584,262117,DB00295,Morphine
,20637968,AUC(0-t),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·pg] / [ml],1811,262118,DB00295,Morphine
,20637968,AUC(0-t),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·pg] / [ml],1954,262119,DB00295,Morphine
,20637968,AUC(0-t),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·ng] / [ml],163,262120,DB00295,Morphine
,20637968,AUC(0-t),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·ng] / [ml],174,262121,DB00295,Morphine
,20637968,C(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[ng] / [ml],24.5,262122,DB00295,Morphine
,20637968,C(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[ng] / [ml],7.7,262123,DB00295,Morphine
,20637968,T(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),h,2.00,262124,DB00295,Morphine
,20637968,T(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),h,7.03,262125,DB00295,Morphine
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],125.4,262297,DB00295,Morphine
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],57.2,262298,DB00295,Morphine
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],2561,262299,DB00295,Morphine
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],1095,262300,DB00295,Morphine
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,5.0,262301,DB00295,Morphine
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,8.0,262302,DB00295,Morphine
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.8,262303,DB00295,Morphine
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.4,262304,DB00295,Morphine
,11748388,"t(1/2,ke0)","The estimated median t(1/2,ke0) of M6G was 6.4 h (range, 2.9-16.2 h), and that of morphine was 2.8 h (range, 1.8-4.4 h).",The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748388/),h,6.4,262700,DB00295,Morphine
,11748388,"t(1/2,ke0)","The estimated median t(1/2,ke0) of M6G was 6.4 h (range, 2.9-16.2 h), and that of morphine was 2.8 h (range, 1.8-4.4 h).",The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748388/),h,2.8,262701,DB00295,Morphine
,11748388,EC50,"Judged by the concentration at half-maximun effect (EC50) values of the sigmoid pupil size at maximum constriction (Emax) model describing concentration-response relation, M6G was apparently 22 times less potent than morphine (EC50 = 740.5 nm [range, 500-1,520 nm] for M6G and 36.2 nm [range, 19.7-43.3 nm] for morphine).",The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748388/),nm,740.5,262702,DB00295,Morphine
,11748388,EC50,"Judged by the concentration at half-maximun effect (EC50) values of the sigmoid pupil size at maximum constriction (Emax) model describing concentration-response relation, M6G was apparently 22 times less potent than morphine (EC50 = 740.5 nm [range, 500-1,520 nm] for M6G and 36.2 nm [range, 19.7-43.3 nm] for morphine).",The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748388/),nm,36.2,262703,DB00295,Morphine
,26352950,maximum plasma concentration,The results indicate that the plasma levels of parent tramadol are low or negligible during the first 30-45 min and then reach the predicted mean maximum plasma concentration of 358 ng/ml at 1.52 hr.,"PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE AND ITS METABOLITE O-DESMETHYLTRAMADOL FOLLOWING A SINGLE, ORALLY ADMINISTERED DOSE IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26352950/),[ng] / [ml],358,262760,DB00295,Morphine
,6496014,maximum plasma morphine concentration,"It was found that 45-120 min after administration of morphine hydrogel, a mean maximum plasma morphine concentration of 61 ng X ml-1 was obtained.",Rectal administration of morphine hydrogel: absorption and bioavailability in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6496014/),[ng] / [ml],61,263204,DB00295,Morphine
,6496014,mean,"After 8 h, the mean plasma concentration was 10 ng X ml-1.",Rectal administration of morphine hydrogel: absorption and bioavailability in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6496014/),[ng] / [ml],10,263205,DB00295,Morphine
,6496014,plasma concentration,"After 8 h, the mean plasma concentration was 10 ng X ml-1.",Rectal administration of morphine hydrogel: absorption and bioavailability in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6496014/),[ng] / [ml],10,263206,DB00295,Morphine
,6496014,biological availability,The mean biological availability of morphine hydrogel was 48% (range 31-72%).,Rectal administration of morphine hydrogel: absorption and bioavailability in women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6496014/),%,48,263207,DB00295,Morphine
,1888639,steady-state plasma morphine concentration,2. The mean steady-state plasma morphine concentration (+/- s.d.) for a diamorphine infusion rate of 15 micrograms kg-1 h-1 was 62.5 +/- 22.8 ng ml-1.,Morphine kinetics after diamorphine infusion in premature neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),[ng] / [ml],62.5,263250,DB00295,Morphine
,1888639,clearance,"3. Morphine clearance was 3.6 +/- 0.9 ml min-1 kg-1, the elimination half-life was 8.9 +/- 3.3 h and the volume of distribution was 2.7 +/- 1.01 kg-1.",Morphine kinetics after diamorphine infusion in premature neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),[ml] / [kg·min],3.6,263251,DB00295,Morphine
,1888639,elimination half-life,"3. Morphine clearance was 3.6 +/- 0.9 ml min-1 kg-1, the elimination half-life was 8.9 +/- 3.3 h and the volume of distribution was 2.7 +/- 1.01 kg-1.",Morphine kinetics after diamorphine infusion in premature neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),h,8.9,263252,DB00295,Morphine
,1888639,volume of distribution,"3. Morphine clearance was 3.6 +/- 0.9 ml min-1 kg-1, the elimination half-life was 8.9 +/- 3.3 h and the volume of distribution was 2.7 +/- 1.01 kg-1.",Morphine kinetics after diamorphine infusion in premature neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888639/),1/[kg],2.7,263253,DB00295,Morphine
,31286645,time to maximum concentration,"Plasma TRV734 maximum concentration and area under the plasma concentration-time curve generally increased with dose, while time to maximum concentration was similar across doses (0.5-1.3 h).","A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31286645/),h,0.5-1.3,263344,DB00295,Morphine
,31286645,half-life,The half-life increased with dose from 10 mg through 150 mg (0.75-2.28 h) but was similar from 150 mg through 250 mg.,"A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31286645/),h,0.75-2.28,263345,DB00295,Morphine
,6546839,duration of analgesia,"Administration of morphine at the end of the operation resulted in a highly variable duration of analgesia ranging from 1-20.5 and 1-40 h for the 0.25 and 0.50 mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),h,1-20.5,265271,DB00295,Morphine
,6546839,duration of analgesia,"Administration of morphine at the end of the operation resulted in a highly variable duration of analgesia ranging from 1-20.5 and 1-40 h for the 0.25 and 0.50 mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),h,1-40,265272,DB00295,Morphine
,6546839,CSF,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"4,228",265273,DB00295,Morphine
,6546839,CSF,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"10,447",265274,DB00295,Morphine
,6546839,concentrations,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"4,228",265275,DB00295,Morphine
,6546839,concentrations,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"10,447",265276,DB00295,Morphine
,6546839,terminal elimination half-life,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),min,175,265277,DB00295,Morphine
,6546839,terminal elimination half-life,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),min,196,265278,DB00295,Morphine
,6546839,volume of CSF distribution,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ml] / [kg],0.88,265279,DB00295,Morphine
,6546839,volume of CSF distribution,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ml] / [kg],1.06,265280,DB00295,Morphine
,6546839,clearance from CSF,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[μl] / [kg·min],2.81,265281,DB00295,Morphine
,6546839,clearance from CSF,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[μl] / [kg·min],3.41,265282,DB00295,Morphine
,3981418,sensitivities,"Sensitive reversed-phase HPLC assays with electrochemical detection, developed to quantify naltrexone, 6 beta-naltrexol, and their conjugates in biological fluids, provided assay sensitivities of 2-14 ng/mL in plasma, urine, and bile.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ng] / [ml],2-14,265314,DB00295,Morphine
,3981418,P,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,5,265315,DB00295,Morphine
,3981418,half-lives,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,5,265316,DB00295,Morphine
,3981418,half-lives,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,47,265317,DB00295,Morphine
,3981418,total,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ml] / [min],1043,265318,DB00295,Morphine
,3981418,renal clearances,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ml] / [min],72,265319,DB00295,Morphine
,3981418,renal clearance,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),,85,265320,DB00295,Morphine
,31959534,terminal half-life (t1/2),"The mean ± SD hydromorphone terminal half-life (t1/2), clearance and volume of distribution of H-IV were 19 ± 8 minutes, 79 ± 12.9 mL minute⁻1 kg⁻1 and 1125 ± 309 mL kg⁻1.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min,19,266086,DB00295,Morphine
,31959534,clearance,"The mean ± SD hydromorphone terminal half-life (t1/2), clearance and volume of distribution of H-IV were 19 ± 8 minutes, 79 ± 12.9 mL minute⁻1 kg⁻1 and 1125 ± 309 mL kg⁻1.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),kg⁻1·minute⁻1·ml,79,266087,DB00295,Morphine
,31959534,volume of distribution,"The mean ± SD hydromorphone terminal half-life (t1/2), clearance and volume of distribution of H-IV were 19 ± 8 minutes, 79 ± 12.9 mL minute⁻1 kg⁻1 and 1125 ± 309 mL kg⁻1.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),kg⁻1·ml,1125,266088,DB00295,Morphine
,31959534,t1/2,The t1/2 was 26.7 ± 9.25 minutes for H-IM.,Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min,26.7,266089,DB00295,Morphine
,31959534,Area under the curve,"Area under the curve was 518 ± 87.5 and 1128 ± 810 minute ng mL⁻1 for H-IV and H-IM, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min·ml⁻1·ng,518,266090,DB00295,Morphine
,31959534,Area under the curve,"Area under the curve was 518 ± 87.5 and 1128 ± 810 minute ng mL⁻1 for H-IV and H-IM, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min·ml⁻1·ng,1128,266091,DB00295,Morphine
,31959534,bioavailability,The IM bioavailability was 217%.,Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),%,217,266092,DB00295,Morphine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.45,266219,DB00295,Morphine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.65,266220,DB00295,Morphine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,4.80,266221,DB00295,Morphine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.40,266222,DB00295,Morphine
,1485370,plasma clearance,"After intravenous administration, the mean plasma clearance of oxycodone was 25.5 +/- 10.1 L/h and the mean volume of distribution at steady state was 2.5 +/- 0.8 L/kg.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[l] / [h],25.5,266223,DB00295,Morphine
,1485370,volume of distribution at steady state,"After intravenous administration, the mean plasma clearance of oxycodone was 25.5 +/- 10.1 L/h and the mean volume of distribution at steady state was 2.5 +/- 0.8 L/kg.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[l] / [kg],2.5,266224,DB00295,Morphine
,1485370,normalized area under the curve (AUC/D),"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],48.2,266225,DB00295,Morphine
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],19.8,266226,DB00295,Morphine
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],17.5,266227,DB00295,Morphine
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],20.3,266228,DB00295,Morphine
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.52,266229,DB00295,Morphine
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.48,266230,DB00295,Morphine
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.76,266231,DB00295,Morphine
,10670739,total chromatographic run time,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),[min] / [injection],3,266721,DB00295,Morphine
,10670739,retention times,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),min,1.5,266722,DB00295,Morphine
,10670739,retention times,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),min,1.9,266723,DB00295,Morphine
,10670739,retention times,"The total chromatographic run time was 3 min per injection, with retention times of 1.5, 1.9 and 2.4 min for MOR, M6G, and M3G, respectively.","Simultaneous assay of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma using normal-phase liquid chromatography-tandem mass spectrometry with a silica column and an aqueous organic mobile phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10670739/),min,2.4,266724,DB00295,Morphine
,24496960,total morphine rescue dose,The median (interquartile range [IQR]) total morphine rescue dose was 0 (0-20) μg/kg in younger patients versus 193 (19-362) μg/kg in older patients (p = 0.003).,Evidence-based morphine dosing for postoperative neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24496960/),[μg] / [kg],0,267237,DB00295,Morphine
,24496960,total morphine rescue dose,The median (interquartile range [IQR]) total morphine rescue dose was 0 (0-20) μg/kg in younger patients versus 193 (19-362) μg/kg in older patients (p = 0.003).,Evidence-based morphine dosing for postoperative neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24496960/),[μg] / [kg],193,267238,DB00295,Morphine
,24496960,m,The median (IQR) actual average morphine infusion rate was 4.4 (4.0-4.8) μg/kg/h in younger patients versus 14.4 (11.3-23.4) μg/kg/h in older patients (p < 0.001).,Evidence-based morphine dosing for postoperative neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24496960/),[μg] / [h·kg],4.4,267239,DB00295,Morphine
,24496960,infusion rate,The median (IQR) actual average morphine infusion rate was 4.4 (4.0-4.8) μg/kg/h in younger patients versus 14.4 (11.3-23.4) μg/kg/h in older patients (p < 0.001).,Evidence-based morphine dosing for postoperative neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24496960/),[μg] / [h·kg],4.4,267240,DB00295,Morphine
,24496960,infusion rate,The median (IQR) actual average morphine infusion rate was 4.4 (4.0-4.8) μg/kg/h in younger patients versus 14.4 (11.3-23.4) μg/kg/h in older patients (p < 0.001).,Evidence-based morphine dosing for postoperative neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24496960/),[μg] / [h·kg],14.4,267241,DB00295,Morphine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],71.7,268712,DB00295,Morphine
,27940077,t1/2,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),min,116,268713,DB00295,Morphine
,27940077,clearance,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ml] / [kg·min],6.25,268714,DB00295,Morphine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],191,268715,DB00295,Morphine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],63,268716,DB00295,Morphine
,27940077,ED50,The ED50 value of nicotine to produce discriminative stimulus effects was 0.013 mg/kg.,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.013,268717,DB00295,Morphine
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.00015,268718,DB00295,Morphine
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.031,268719,DB00295,Morphine
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.58,268720,DB00295,Morphine
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.45,268721,DB00295,Morphine
,10518075,clearance,"Morphine clearance for groups 1, 2, 3, and 4 was calculated as 2.27 +/- 1.07, 3.21 +/- 1.57, 4.51 +/- 1.97, and 7.80 +/- 2.67 mL/kg/min, respectively, and correlated with PCA (r = 0.63, P <.001).",Morphine pharmacokinetics and pain assessment in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518075/),[ml] / [kg·min],2.27,268728,DB00295,Morphine
,10518075,clearance,"Morphine clearance for groups 1, 2, 3, and 4 was calculated as 2.27 +/- 1.07, 3.21 +/- 1.57, 4.51 +/- 1.97, and 7.80 +/- 2.67 mL/kg/min, respectively, and correlated with PCA (r = 0.63, P <.001).",Morphine pharmacokinetics and pain assessment in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518075/),[ml] / [kg·min],3.21,268729,DB00295,Morphine
,10518075,clearance,"Morphine clearance for groups 1, 2, 3, and 4 was calculated as 2.27 +/- 1.07, 3.21 +/- 1.57, 4.51 +/- 1.97, and 7.80 +/- 2.67 mL/kg/min, respectively, and correlated with PCA (r = 0.63, P <.001).",Morphine pharmacokinetics and pain assessment in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518075/),[ml] / [kg·min],4.51,268730,DB00295,Morphine
,10518075,clearance,"Morphine clearance for groups 1, 2, 3, and 4 was calculated as 2.27 +/- 1.07, 3.21 +/- 1.57, 4.51 +/- 1.97, and 7.80 +/- 2.67 mL/kg/min, respectively, and correlated with PCA (r = 0.63, P <.001).",Morphine pharmacokinetics and pain assessment in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518075/),[ml] / [kg·min],7.80,268731,DB00295,Morphine
,15448532,duration of analgesia (mesor),Rhythm analysis revealed a mean ( +/- SD) duration of analgesia (mesor) of 93.0 +/- 3.8 min.,Chronopharmacology of intrathecal sufentanil for labor analgesia: daily variations in duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448532/),min,93.0,268775,DB00295,Morphine
,15448532,amplitude,The amplitude of this 12-h component was 16.1 +/- 5.5 min.,Chronopharmacology of intrathecal sufentanil for labor analgesia: daily variations in duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448532/),min,16.1,268776,DB00295,Morphine
,7654494,Cmax,"After the initial 30 mg dose on the first day of infarction, mean +/- standard deviation Cmax was 1237 +/- 284 nmol l-1 with a median tmax of 4 h (range 1 to 10 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),[nM] / [l],1237,269026,DB00295,Morphine
,7654494,tmax,"After the initial 30 mg dose on the first day of infarction, mean +/- standard deviation Cmax was 1237 +/- 284 nmol l-1 with a median tmax of 4 h (range 1 to 10 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),h,4,269027,DB00295,Morphine
,7654494,Cmax,"Following the last 60 mg dose, Cmax was 2685 +/- 497 nmol l-1 with a median tmax of 4 h (2 to 7 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),[nM] / [l],2685,269028,DB00295,Morphine
,7654494,tmax,"Following the last 60 mg dose, Cmax was 2685 +/- 497 nmol l-1 with a median tmax of 4 h (2 to 7 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),h,4,269029,DB00295,Morphine
,26108255,Tmax,Median Tmax for crushed OxyContin® was the same as IR oxycodone and 3.25 hours shorter than intact OxyContin®.,Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26108255/),h,3.25,269263,DB00295,Morphine
,10963905,mechanical thresholds,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),g,124,269313,DB00295,Morphine
,10963905,mechanical thresholds,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),g,63,269314,DB00295,Morphine
,10963905,thermal latencies,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),s,19,269315,DB00295,Morphine
,10963905,thermal latencies,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),s,4.7,269316,DB00295,Morphine
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],17,269317,DB00295,Morphine
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],>,269318,DB00295,Morphine
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],100,269319,DB00295,Morphine
,10963905,D(30),The D(30) value for SDZ NKT 343 was 3.89 mg kg(-1).,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],3.89,269320,DB00295,Morphine
,10963905,ED(50),"For comparison, morphine inhibited the carrageenan-induced mechanical and thermal hyperalgesia with an ED(50) of 1.85 and 2.51 mg kg(-1) s.c., respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],1.85,269321,DB00295,Morphine
,10963905,ED(50),"For comparison, morphine inhibited the carrageenan-induced mechanical and thermal hyperalgesia with an ED(50) of 1.85 and 2.51 mg kg(-1) s.c., respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],2.51,269322,DB00295,Morphine
,10963905,maximum reversal,RPR100893 was significantly less effective with a maximum reversal of 30% at 100 mg kg(-1).,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),%,30,269323,DB00295,Morphine
,3214449,Peak concentration,Peak concentration of morphine in serum (86 ng/ml) and in CSF (2610 ng/ml) was reached after 10 min respectively 40 min of epidural injection.,Pharmacokinetics of morphine in cerebrospinal fluid and plasma after epidural administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214449/),[ng] / [ml],86,269491,DB00295,Morphine
,3214449,Peak concentration,Peak concentration of morphine in serum (86 ng/ml) and in CSF (2610 ng/ml) was reached after 10 min respectively 40 min of epidural injection.,Pharmacokinetics of morphine in cerebrospinal fluid and plasma after epidural administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214449/),[ng] / [ml],2610,269492,DB00295,Morphine
,6743446,peak plasma morphine concentration,"Mean peak plasma morphine concentration was 14.8 ng ml-1, and occurred at a mean time of 142.5 min after ingestion.",Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743446/),[ng] / [ml],14.8,269537,DB00295,Morphine
,6743446,mean time,"Mean peak plasma morphine concentration was 14.8 ng ml-1, and occurred at a mean time of 142.5 min after ingestion.",Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743446/),min,142.5,269538,DB00295,Morphine
,6743446,systemic availability,The mean systemic availability of morphine in the first 7 h after administration of MST was 18.3%.,Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743446/),%,18.3,269539,DB00295,Morphine
,15053825,plasma clearance (CL),3. Morphine reduced plasma clearance (CL) of MTX from 0.147 +/- 0.015 to 0.061 +/- 0.009 mL/min per g bodyweight (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml] / [g·min],0.147,270319,DB00295,Morphine
,15053825,plasma clearance (CL),3. Morphine reduced plasma clearance (CL) of MTX from 0.147 +/- 0.015 to 0.061 +/- 0.009 mL/min per g bodyweight (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml] / [g·min],0.061,270320,DB00295,Morphine
,15053825,area under the plasma concentration-time curve (AUC(0- infinity )),The area under the plasma concentration-time curve (AUC(0- infinity )) was raised by morphine from 151 +/- 18 to 369 +/- 36 micro g.mL per min (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml·μg] / [min],151,270321,DB00295,Morphine
,15053825,area under the plasma concentration-time curve (AUC(0- infinity )),The area under the plasma concentration-time curve (AUC(0- infinity )) was raised by morphine from 151 +/- 18 to 369 +/- 36 micro g.mL per min (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml·μg] / [min],369,270322,DB00295,Morphine
,11903869,elimination half-life (t1/2el),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,76.3,270824,DB00295,Morphine
,11903869,elimination half-life (t1/2el),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,93.6,270825,DB00295,Morphine
,11903869,mean residence time (MRT),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,105.0,270826,DB00295,Morphine
,11903869,mean residence time (MRT),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,120.5,270827,DB00295,Morphine
,11903869,clearance (Clp),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],24.1,270828,DB00295,Morphine
,11903869,clearance (Clp),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],13.9,270829,DB00295,Morphine
,11903869,volume of distribution (V(dss)),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],2.6,270830,DB00295,Morphine
,11903869,volume of distribution (V(dss)),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],1.7,270831,DB00295,Morphine
,11903869,t1/2el,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,416.8,270832,DB00295,Morphine
,11903869,t1/2el,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,380.2,270833,DB00295,Morphine
,11903869,MRT,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,417.6,270834,DB00295,Morphine
,11903869,MRT,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,409.8,270835,DB00295,Morphine
,11903869,Clp,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],16.7,270836,DB00295,Morphine
,11903869,Clp,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],23.7,270837,DB00295,Morphine
,11903869,V(dss),Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],7.1,270838,DB00295,Morphine
,11903869,V(dss),Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],8.9,270839,DB00295,Morphine
,11903869,t1/2el,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,216.4,270840,DB00295,Morphine
,11903869,MRT,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,307.5,270841,DB00295,Morphine
,11903869,Clp,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],20.8,270842,DB00295,Morphine
,11903869,V(dss),"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],5.2,270843,DB00295,Morphine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,15,270844,DB00295,Morphine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,3,270845,DB00295,Morphine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,10,270846,DB00295,Morphine
,9663177,metabolic transit time,"The extent and time course of morphine-6-beta-glucuronide formation from morphine could be well described by a parametric model, with a fraction of morphine metabolized to morphine-6-beta-glucuronide of 7.55% +/- 1.24% and a mean metabolic transit time for morphine to morphine-6-beta-glucuronide of 0.28 +/- 0.21 hour.",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),h,0.28,270897,DB00295,Morphine
,9663177,clearance,"The underlying disposition of morphine and morphine-6-beta-glucuronide was characterized by clearance (morphine clearance, 32.7 +/- 6 ml.min-1.kg-1, morphine-6-beta-glucuronide clearance, 2.2 +/- 0.4 ml.min-1.kg-1), volume of distribution at steady state (morphine, 1.8 +/- 0.3 L.hr-1; morphine-6-beta-glucuronide, 0.12 +/- 0.02 L.hr-1), and mean disposition residence time (morphine, 1.8 +/- 0.4 hours; morphine-6-beta-glucuronide, 1.7 +/- 0.4 hours).",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),[ml] / [kg·min],32.7,270898,DB00295,Morphine
,9663177,clearance,"The underlying disposition of morphine and morphine-6-beta-glucuronide was characterized by clearance (morphine clearance, 32.7 +/- 6 ml.min-1.kg-1, morphine-6-beta-glucuronide clearance, 2.2 +/- 0.4 ml.min-1.kg-1), volume of distribution at steady state (morphine, 1.8 +/- 0.3 L.hr-1; morphine-6-beta-glucuronide, 0.12 +/- 0.02 L.hr-1), and mean disposition residence time (morphine, 1.8 +/- 0.4 hours; morphine-6-beta-glucuronide, 1.7 +/- 0.4 hours).",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),[ml] / [kg·min],2.2,270899,DB00295,Morphine
,9663177,volume of distribution at steady state,"The underlying disposition of morphine and morphine-6-beta-glucuronide was characterized by clearance (morphine clearance, 32.7 +/- 6 ml.min-1.kg-1, morphine-6-beta-glucuronide clearance, 2.2 +/- 0.4 ml.min-1.kg-1), volume of distribution at steady state (morphine, 1.8 +/- 0.3 L.hr-1; morphine-6-beta-glucuronide, 0.12 +/- 0.02 L.hr-1), and mean disposition residence time (morphine, 1.8 +/- 0.4 hours; morphine-6-beta-glucuronide, 1.7 +/- 0.4 hours).",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),[l] / [h],1.8,270900,DB00295,Morphine
,9663177,volume of distribution at steady state,"The underlying disposition of morphine and morphine-6-beta-glucuronide was characterized by clearance (morphine clearance, 32.7 +/- 6 ml.min-1.kg-1, morphine-6-beta-glucuronide clearance, 2.2 +/- 0.4 ml.min-1.kg-1), volume of distribution at steady state (morphine, 1.8 +/- 0.3 L.hr-1; morphine-6-beta-glucuronide, 0.12 +/- 0.02 L.hr-1), and mean disposition residence time (morphine, 1.8 +/- 0.4 hours; morphine-6-beta-glucuronide, 1.7 +/- 0.4 hours).",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),[l] / [h],0.12,270901,DB00295,Morphine
,9663177,disposition residence time,"The underlying disposition of morphine and morphine-6-beta-glucuronide was characterized by clearance (morphine clearance, 32.7 +/- 6 ml.min-1.kg-1, morphine-6-beta-glucuronide clearance, 2.2 +/- 0.4 ml.min-1.kg-1), volume of distribution at steady state (morphine, 1.8 +/- 0.3 L.hr-1; morphine-6-beta-glucuronide, 0.12 +/- 0.02 L.hr-1), and mean disposition residence time (morphine, 1.8 +/- 0.4 hours; morphine-6-beta-glucuronide, 1.7 +/- 0.4 hours).",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),h,1.8,270902,DB00295,Morphine
,9663177,disposition residence time,"The underlying disposition of morphine and morphine-6-beta-glucuronide was characterized by clearance (morphine clearance, 32.7 +/- 6 ml.min-1.kg-1, morphine-6-beta-glucuronide clearance, 2.2 +/- 0.4 ml.min-1.kg-1), volume of distribution at steady state (morphine, 1.8 +/- 0.3 L.hr-1; morphine-6-beta-glucuronide, 0.12 +/- 0.02 L.hr-1), and mean disposition residence time (morphine, 1.8 +/- 0.4 hours; morphine-6-beta-glucuronide, 1.7 +/- 0.4 hours).",Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9663177/),h,1.7,270903,DB00295,Morphine
,32702184,minimum effective analgesic concentration,"Monte Carlo simulations based on the final pharmacokinetic model determined optimal patient-controlled analgesia parameters to achieve a target of 20 ng/mL (as the median effective analgesic concentration), using minimum effective analgesic concentration of 4 ng/mL as a proxy for patient-controlled analgesia dose demand, and not exceeding the defined safe upper threshold of 40 ng/mL.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),[ng] / [ml],4,270978,DB00295,Morphine
,32702184,systemic clearance,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),[l] / [min],0.748,270979,DB00295,Morphine
,32702184,volume of distribution,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),l,33,270980,DB00295,Morphine
,32702184,peripheral clearance,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),[l] / [min],1.57,270981,DB00295,Morphine
,32702184,peripheral volume of distribution,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),l,146,270982,DB00295,Morphine
,30189012,clearance,The haemodialysis clearance of oxycodone based on its recovery in dialysate was (mean ± SD) 8.4 ± 2.1 L/h.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),[l] / [h],8.4,271360,DB00295,Morphine
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,3.9,271361,DB00295,Morphine
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,5.7,271362,DB00295,Morphine
,657720,volume of distribution (Vd),"Mean (+/-SE) kinetic parameters following IV morphine were: volume of distribution (Vd), 3.2 (+/- 0.3) L/kg; elimination half-life (t1/2beta), 2.9 (+/- 0.5) hr; clearance, 14.7 (+/- 0.9) ml/min/kg; extraction ratio, 0.70 (+/- 0.04).",Kinetics of intravenous and intramuscular morphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),[l] / [kg],3.2,271455,DB00295,Morphine
,657720,elimination half-life (t1/2beta),"Mean (+/-SE) kinetic parameters following IV morphine were: volume of distribution (Vd), 3.2 (+/- 0.3) L/kg; elimination half-life (t1/2beta), 2.9 (+/- 0.5) hr; clearance, 14.7 (+/- 0.9) ml/min/kg; extraction ratio, 0.70 (+/- 0.04).",Kinetics of intravenous and intramuscular morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),h,2.9,271456,DB00295,Morphine
,657720,clearance,"Mean (+/-SE) kinetic parameters following IV morphine were: volume of distribution (Vd), 3.2 (+/- 0.3) L/kg; elimination half-life (t1/2beta), 2.9 (+/- 0.5) hr; clearance, 14.7 (+/- 0.9) ml/min/kg; extraction ratio, 0.70 (+/- 0.04).",Kinetics of intravenous and intramuscular morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),[ml] / [kg·min],14.7,271457,DB00295,Morphine
,657720,extraction ratio,"Mean (+/-SE) kinetic parameters following IV morphine were: volume of distribution (Vd), 3.2 (+/- 0.3) L/kg; elimination half-life (t1/2beta), 2.9 (+/- 0.5) hr; clearance, 14.7 (+/- 0.9) ml/min/kg; extraction ratio, 0.70 (+/- 0.04).",Kinetics of intravenous and intramuscular morphine. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),,0.70,271458,DB00295,Morphine
,657720,peak plasma levels,"After IM morphine, peak plasma levels ranged from 51 to 62 ng/ml and were reached within 20 min of injection.",Kinetics of intravenous and intramuscular morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),[ng] / [ml],51 to 62,271459,DB00295,Morphine
,657720,absorption half-life,The absorption half-life averaged 7.7 (+/- 1.6) min.,Kinetics of intravenous and intramuscular morphine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),min,7.7,271460,DB00295,Morphine
,657720,Systemic availability,Systemic availability was 100% complete.,Kinetics of intravenous and intramuscular morphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),%,100,271461,DB00295,Morphine
,657720,Vd,"Kinetic variables were Vd, 4.7 (+/- 0.2) L/kg; t1/2beta, 4.5 (+/- 0.3) hr; clearance, 12.4 (+/- 1.2) ml/min/kg; extraction ratio, 0.59 (+/- 0.05).",Kinetics of intravenous and intramuscular morphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),[l] / [kg],4.7,271462,DB00295,Morphine
,657720,t1/2beta,"Kinetic variables were Vd, 4.7 (+/- 0.2) L/kg; t1/2beta, 4.5 (+/- 0.3) hr; clearance, 12.4 (+/- 1.2) ml/min/kg; extraction ratio, 0.59 (+/- 0.05).",Kinetics of intravenous and intramuscular morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),h,4.5,271463,DB00295,Morphine
,657720,clearance,"Kinetic variables were Vd, 4.7 (+/- 0.2) L/kg; t1/2beta, 4.5 (+/- 0.3) hr; clearance, 12.4 (+/- 1.2) ml/min/kg; extraction ratio, 0.59 (+/- 0.05).",Kinetics of intravenous and intramuscular morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),[ml] / [kg·min],12.4,271464,DB00295,Morphine
,657720,extraction ratio,"Kinetic variables were Vd, 4.7 (+/- 0.2) L/kg; t1/2beta, 4.5 (+/- 0.3) hr; clearance, 12.4 (+/- 1.2) ml/min/kg; extraction ratio, 0.59 (+/- 0.05).",Kinetics of intravenous and intramuscular morphine. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657720/),,0.59,271465,DB00295,Morphine
,23973378,plasma clearance,"The mean plasma clearance of methadone was 19.9 ± 8.5 mL/min (± SD) compared with 105.7 ± 8.3 mL/min for HM, a difference of 85.7 mL/min (95% confidence interval 61.9 to 109.1).",Intradialytic clearance of opioids: methadone versus hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973378/),[ml] / [min],19.9,271827,DB00295,Morphine
,23973378,plasma clearance,"The mean plasma clearance of methadone was 19.9 ± 8.5 mL/min (± SD) compared with 105.7 ± 8.3 mL/min for HM, a difference of 85.7 mL/min (95% confidence interval 61.9 to 109.1).",Intradialytic clearance of opioids: methadone versus hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973378/),[ml] / [min],105.7,271828,DB00295,Morphine
,25669174,maximum concentration (Cmax ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),nM,343,271914,DB00295,Morphine
,25669174,maximum concentration (Cmax ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),nM,225,271915,DB00295,Morphine
,25669174,area under the concentration-time curve (AUC0-last ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),min·μM,58.8,271916,DB00295,Morphine
,25669174,area under the concentration-time curve (AUC0-last ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),min·μM,37.2,271917,DB00295,Morphine
,23786198,apparent terminal half-life (t(½)),"In the clinical phase, the apparent terminal half-life (t(½)) of morphine was approximately 1.5 hours, volume of distribution per bioavailability was approximately 4.5 L/kg, and clearance per bioavailability was approximately 35 mL/kg/min.",Pharmacokinetics of intramuscularly administered morphine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23786198/),h,1.5,272086,DB00295,Morphine
,23786198,volume of distribution per bioavailability,"In the clinical phase, the apparent terminal half-life (t(½)) of morphine was approximately 1.5 hours, volume of distribution per bioavailability was approximately 4.5 L/kg, and clearance per bioavailability was approximately 35 mL/kg/min.",Pharmacokinetics of intramuscularly administered morphine in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23786198/),[l] / [kg],4.5,272087,DB00295,Morphine
,23786198,clearance per bioavailability,"In the clinical phase, the apparent terminal half-life (t(½)) of morphine was approximately 1.5 hours, volume of distribution per bioavailability was approximately 4.5 L/kg, and clearance per bioavailability was approximately 35 mL/kg/min.",Pharmacokinetics of intramuscularly administered morphine in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23786198/),[ml] / [kg·min],35,272088,DB00295,Morphine
,23786198,Peak plasma concentration,Peak plasma concentration in naïve pooled analysis was 21.6 ng/mL and occurred approximately 4 minutes after administration.,Pharmacokinetics of intramuscularly administered morphine in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23786198/),[ng] / [ml],21.6,272089,DB00295,Morphine
,7624926,absolute bioavailability,"The absolute bioavailability of morphine in both IR and in CR tablets was, 32%, and the relative bioavailability of the CR tablet versus the IR tablets was 103% (91-115%, 95% confidence interval).","Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624926/),%,32,272246,DB00295,Morphine
,7624926,relative bioavailability,"The absolute bioavailability of morphine in both IR and in CR tablets was, 32%, and the relative bioavailability of the CR tablet versus the IR tablets was 103% (91-115%, 95% confidence interval).","Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624926/),%,103,272247,DB00295,Morphine
,10201674,fraction of morphine absorbed,The fraction of morphine absorbed from the gut was 82+/-14%.,Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201674/),%,82,272382,DB00295,Morphine
,10201674,oral bioavailability,"Of this, 42+/-8% passed through the liver, resulting in an oral bioavailability of morphine of 34+/-9%.",Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201674/),%,34,272383,DB00295,Morphine
,31278694,Cmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[ng] / [ml],44.78,272649,DB00295,Morphine
,31278694,Cmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[ng] / [ml],33.30,272650,DB00295,Morphine
,31278694,Tmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),min,30,272651,DB00295,Morphine
,31278694,AUC0-∞,The overall morphine exposure (AUC0-∞) was similar for fed (440.6 ng · h/ml) vs. fasted conditions (395.1 ng · h/ml).,"A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[h·ng] / [ml],440.6,272652,DB00295,Morphine
,31278694,AUC0-∞,The overall morphine exposure (AUC0-∞) was similar for fed (440.6 ng · h/ml) vs. fasted conditions (395.1 ng · h/ml).,"A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[h·ng] / [ml],395.1,272653,DB00295,Morphine
,30930095,terminal half-life (t1/2),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,18.1,272911,DB00295,Morphine
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,34.0,272912,DB00295,Morphine
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,41.3,272913,DB00295,Morphine
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],66.6,272914,DB00295,Morphine
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],550.0,272915,DB00295,Morphine
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],92.7,272916,DB00295,Morphine
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],1118,272917,DB00295,Morphine
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],550.0,272918,DB00295,Morphine
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],92.7,272919,DB00295,Morphine
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],1118,272920,DB00295,Morphine
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],1460,272921,DB00295,Morphine
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],2242,272922,DB00295,Morphine
,30930095,HR,"HR was elevated above baseline in treatments LD, MD and HD, extending to 30, 15 and 105 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),,30,272923,DB00295,Morphine
,30930095,HR,"HR was elevated above baseline in treatments LD, MD and HD, extending to 30, 15 and 105 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),,15,272924,DB00295,Morphine
,30930095,HR,"HR was elevated above baseline in treatments LD, MD and HD, extending to 30, 15 and 105 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),,105,272925,DB00295,Morphine
,30930095,Respiratory rate,"Respiratory rate was elevated above baseline in treatments MD and HD from 30 to 195 minutes and from 45 to 480 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,30 to 195,272926,DB00295,Morphine
,30930095,Respiratory rate,"Respiratory rate was elevated above baseline in treatments MD and HD from 30 to 195 minutes and from 45 to 480 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,45 to 480,272927,DB00295,Morphine
,7975724,maximum concentrations,"Plasma concentrations of unchanged dihydrocodeine were significantly lower after oral rather than intramuscular administration; the maximum concentrations were 40 and 549 ng/ml after oral and intramuscular administration, respectively.",Metabolism and pharmacokinetics of dihydrocodeine in dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975724/),[ng] / [ml],40,273016,DB00295,Morphine
,7975724,maximum concentrations,"Plasma concentrations of unchanged dihydrocodeine were significantly lower after oral rather than intramuscular administration; the maximum concentrations were 40 and 549 ng/ml after oral and intramuscular administration, respectively.",Metabolism and pharmacokinetics of dihydrocodeine in dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975724/),[ng] / [ml],549,273017,DB00295,Morphine
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],22.4,273696,DB00295,Morphine
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],26.8,273697,DB00295,Morphine
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,33,273698,DB00295,Morphine
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,19.5,273699,DB00295,Morphine
,9706948,Tmax,The Tmax value for codeine (63.3 +/- 11.7) was greater than that for tramadol (P = 0.034).,"A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),,63.3,273700,DB00295,Morphine
,8318321,elimination half-life,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),h,2.14,273782,DB00295,Morphine
,8318321,elimination half-life,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),h,27.10,273783,DB00295,Morphine
,8318321,elimination half-life,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),h,17.33,273784,DB00295,Morphine
,8318321,clearance,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),[ml] / [min],96.0,273785,DB00295,Morphine
,8318321,clearance,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),[ml] / [min],10.57,273786,DB00295,Morphine
,8318321,clearance,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),[ml] / [min],14.3,273787,DB00295,Morphine
,8318321,volume of distribution,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),[l] / [kg],0.19,273788,DB00295,Morphine
,8318321,volume of distribution,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),[l] / [kg],0.25,273789,DB00295,Morphine
,8318321,volume of distribution,"Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination half-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0.03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1.",Morphine-6-glucuronide disposition in renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318321/),[l] / [kg],0.27,273790,DB00295,Morphine
,17456651,central volume of distribution,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),ml,1200,274021,DB00295,Morphine
,17456651,peripheral volume of distribution,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),ml,828,274022,DB00295,Morphine
,17456651,clearance from the central compartment,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),[ml] / [min],7.52,274023,DB00295,Morphine
,17456651,elimination half-life,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),min,238,274024,DB00295,Morphine
